



US007217286B2

(12) **United States Patent**
Falotico et al.

(10) **Patent No.:** **US 7,217,286 B2**

(45) **Date of Patent:** ***May 15, 2007**

(54) **LOCAL DELIVERY OF RAPAMYCIN FOR TREATMENT OF PROLIFERATIVE SEQUELAE ASSOCIATED WITH PTCA PROCEDURES, INCLUDING DELIVERY USING A MODIFIED STENT**

(75) Inventors: **Robert Falotico**, Bell Mead, NJ (US);
Gerard H. Llanos, Stewartsville, NJ (US)

(73) Assignee: **Cordis Corporation**, Miami Lakes, FL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **11/467,035**

(22) Filed: **Aug. 24, 2006**

(65) **Prior Publication Data**

US 2007/0021825 A1 Jan. 25, 2007

Related U.S. Application Data

(63) Continuation of application No. 10/951,385, filed on Sep. 28, 2004, which is a continuation of application No. 10/408,328, filed on Apr. 7, 2003, now Pat. No. 6,808,536, which is a continuation of application No. 09/874,117, filed on Jun. 4, 2001, now Pat. No. 6,585,764, which is a continuation of application No. 09/061,568, filed on Apr. 16, 1998, now Pat. No. 6,273,913.

(60) Provisional application No. 60/044,692, filed on Apr. 18, 1997.

(51) **Int. Cl.**
A61F 2/06 (2006.01)

(52) **U.S. Cl.** 623/1.42

(58) **Field of Classification Search** 623/1.45–1.48;
427/2.1–2.31
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

861,659 A	7/1907	Johnston	464/147
3,051,677 A	8/1962	Rexford	522/156
3,279,996 A	10/1966	Long et al.	424/424
3,526,005 A	9/1970	Bokros	623/11.11
3,599,641 A	8/1971	Sheridan	604/256
3,657,744 A	4/1972	Ersek	128/898
3,744,596 A	7/1973	Sander	188/203
3,779,805 A	12/1973	Alsberg	427/105

(Continued)

FOREIGN PATENT DOCUMENTS

DE 3205942 A1 9/1983

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 07/819,314, filed Jan. 9, 1992, Morris.

(Continued)


Primary Examiner—Suzette Gherbi

(74) *Attorney, Agent, or Firm*—Woodcock Washburn LLP

(57) **ABSTRACT**

Methods of preparing intravascular stents with a polymeric coating containing macrocyclic lactone (such as rapamycin or its analogs), stents and stent graphs with such coatings, and methods of treating a coronary artery with such devices. The macrocyclic lactone-based polymeric coating facilitates the performance of such devices in inhibiting restenosis.

5 Claims, 2 Drawing Sheets



U.S. PATENT DOCUMENTS

3,929,992 A	12/1975	Sehgal et al.	424/122	5,049,403 A	9/1991	Larm et al.	427/2.1
3,932,627 A	1/1976	Margraf	514/56	5,053,048 A	10/1991	Pinchuk	623/1.43
3,948,254 A	4/1976	Zaffaroni	128/833	5,059,166 A	10/1991	Fischell et al.	600/3
3,952,334 A	4/1976	Bokros et al.	623/11.11	5,061,275 A	10/1991	Wallsten et al.	623/1.22
3,968,800 A	7/1976	Vilasi	606/198	5,061,750 A	10/1991	Feijen et al.	525/54.1
4,069,307 A	1/1978	Higuchi et al.	424/432	5,064,435 A	11/1991	Porter	623/23.7
4,076,285 A	2/1978	Martinez	285/332	5,092,877 A	3/1992	Pinchuk	128/898
4,292,965 A	10/1981	Nash et al.	128/833	5,102,417 A	4/1992	Palmaz	606/195
4,299,226 A	11/1981	Banka	604/509	5,104,404 A	4/1992	Wolff	623/1.16
4,300,244 A	11/1981	Bokros	623/1.13	5,116,365 A	5/1992	Hillstead	623/1.15
4,312,920 A	1/1982	Pierce et al.	428/425.5	5,122,154 A	6/1992	Rhodes	623/1.13
4,321,711 A	3/1982	Mano	623/1.43	5,131,908 A	7/1992	Dardik et al.	600/36
4,323,071 A	4/1982	Simpson et al.	606/194	5,133,732 A	7/1992	Wiktor	623/1.22
4,390,599 A	6/1983	Broyles	428/597	5,134,192 A	7/1992	Feijen et al.	525/54.1
4,413,359 A	11/1983	Akiyama et al.	623/23.72	5,135,536 A	8/1992	Hillstead	606/195
4,423,183 A	12/1983	Close	524/546	5,163,952 A	11/1992	Froix	623/1.18
4,441,216 A	4/1984	Ionescu et al.	623/2.19	5,163,958 A	11/1992	Pinchuk	623/23.49
4,503,569 A	3/1985	Dotter	623/1.19	5,171,217 A	12/1992	March et al.	604/507
4,512,338 A	4/1985	Balko et al.	606/108	5,171,262 A	12/1992	MacGregor	623/1.15
4,550,447 A	11/1985	Seiler, Jr. et al.	623/1.32	5,176,660 A	1/1993	Truckai	604/527
4,553,545 A	11/1985	Maass et al.	606/198	5,176,972 A	1/1993	Bloom et al.	430/14
4,560,374 A	12/1985	Hammerslag	604/509	5,178,618 A	1/1993	Kandarpa	606/28
4,562,596 A	1/1986	Kronberg	623/1.32	5,180,366 A	1/1993	Woods	604/96.01
4,565,740 A	1/1986	Golander et al.	428/409	5,182,317 A	1/1993	Winters et al.	523/112
4,580,568 A	4/1986	Gianturco	606/198	5,185,408 A	2/1993	Tang et al.	525/415
4,613,665 A	9/1986	Larm	536/20	5,192,307 A	3/1993	Wall	623/1.2
4,642,111 A	2/1987	Sakamoto et al.	424/492	5,195,984 A	3/1993	Schalz	623/1.2
4,655,771 A	4/1987	Wallsten	623/1.22	5,213,576 A	5/1993	Abiuso et al.	604/103.01
4,656,083 A	4/1987	Hoffman et al.	442/123	5,213,898 A	5/1993	Larm et al.	428/422
4,676,241 A	6/1987	Webb et al.	128/207.14	5,217,483 A	6/1993	Tower	623/1.15
4,678,466 A	7/1987	Rosenwald	424/427	5,222,971 A	6/1993	Willard et al.	606/198
4,687,482 A	8/1987	Hanson	623/1.49	5,226,913 A	7/1993	Pinchuk	140/71 R
4,689,046 A	8/1987	Bokros	623/2.31	5,234,456 A	8/1993	Silvestrini	623/1.2
4,731,054 A	3/1988	Billeter et al.	604/93.01	5,246,445 A	9/1993	Yachia et al.	623/1.2
4,733,665 A	3/1988	Palmaz	606/108	5,258,020 A	11/1993	Froix	128/898
4,733,665 A	3/1988	Palmaz	606/108	5,258,021 A	11/1993	Duran	623/2.3
4,739,762 A	4/1988	Palmaz	623/1.11	5,262,451 A	11/1993	Winters et al.	523/112
4,740,207 A	4/1988	Kreamer	623/1.15	5,266,073 A	11/1993	Wall	623/1.2
4,749,585 A	6/1988	Greco et al.	428/422	5,272,012 A	12/1993	Opolski	428/423.1
4,753,652 A	6/1988	Langer et al.	623/1.42	5,275,622 A	1/1994	Lazarus et al.	623/1.11
4,760,849 A	8/1988	Kropf	606/191	5,282,823 A	2/1994	Schwartz et al.	623/1.22
4,768,507 A	9/1988	Fischell et al.	623/1.11	5,282,824 A	2/1994	Gianturco	623/1.13
4,776,337 A	10/1988	Palmaz	623/1.11	5,283,257 A	2/1994	Gregory et al.	514/458
4,786,500 A	11/1988	Wong	424/422	5,288,711 A	2/1994	Mitchell et al.	424/122
4,787,899 A	11/1988	Lazarus	623/1.11	5,290,305 A	3/1994	Inoue	623/1.2
4,800,882 A	1/1989	Gianturco	606/194	5,292,331 A	3/1994	Boneau	623/1.16
4,810,784 A	3/1989	Larm	536/20	5,292,802 A	3/1994	Rhee et al.	525/54.1
4,856,516 A	8/1989	Hillstead	606/194	5,304,121 A	4/1994	Sahatjian	604/509
4,871,357 A	10/1989	Hsu et al.	604/266	5,304,200 A	4/1994	Spaulding	623/1.16
4,872,867 A	10/1989	Joh	604/269	5,306,250 A	4/1994	March et al.	604/104
4,876,109 A	10/1989	Mayer et al.	604/269	5,308,862 A	5/1994	Ohlstein	514/411
4,886,062 A	12/1989	Wiktor	606/194	5,308,889 A	5/1994	Rhee et al.	523/113
4,907,336 A	3/1990	Gianturco	29/515	5,314,444 A	5/1994	Gianturco	606/195
4,916,193 A	4/1990	Tang et al.	525/413	5,314,472 A	5/1994	Fontaine	623/1.22
4,954,126 A	9/1990	Wallsten	600/36	5,328,471 A	7/1994	Slepian	604/101.03
4,969,458 A	11/1990	Wiktor	623/1.11	5,334,301 A	8/1994	Heinke et al.	204/267
4,990,131 A	2/1991	Dardik et al.	600/36	5,336,518 A	8/1994	Narayanan et al.	427/470
4,990,155 A	2/1991	Wilkoft	606/191	5,338,770 A	8/1994	Winters et al.	523/112
4,994,071 A	2/1991	MacGregor	606/194	5,342,348 A	8/1994	Kaplan	604/891.1
4,994,298 A	2/1991	Yasuda	427/490	5,342,387 A	8/1994	Summers	606/198
4,998,923 A	3/1991	Samson et al.	606/194	5,342,621 A	8/1994	Eury	606/198
5,015,253 A	5/1991	MacGregor	623/1.15	5,354,308 A	10/1994	Simon et al.	623/1.15
5,019,090 A	5/1991	Pinchuk	623/1.15	5,356,433 A	10/1994	Rowland et al.	424/422
5,019,096 A	5/1991	Fox, Jr. et al.	600/36	5,366,504 A	11/1994	Andersen et al.	623/1.5
5,029,877 A	7/1991	Fedeli	277/354	5,368,566 A	11/1994	Crocker	604/101.02
5,034,265 A	7/1991	Hoffman et al.	442/126	5,370,683 A	12/1994	Fontaine	623/1.22
5,035,706 A	7/1991	Gianturco et al.	606/198	5,370,691 A	12/1994	Samson	623/1.22
5,041,100 A	8/1991	Rowland et al.	604/265	5,375,612 A	12/1994	Cottenceau et al.	128/899
5,041,126 A	8/1991	Gianturco	623/1.15	5,376,112 A	12/1994	Duran	623/1.26
5,047,020 A	9/1991	Hsu	604/266	5,378,475 A	1/1995	Smith et al.	424/473
5,049,132 A	9/1991	Shaffer et al.	604/101.02	5,380,299 A	1/1995	Fearnot et al.	604/265
				5,382,261 A	1/1995	Palmaz	606/158
				5,383,853 A	1/1995	Jung et al.	604/103.04

US 7,217,286 B2

Page 3

5,383,928 A	1/1995	Scott et al.	623/1.12	5,609,629 A	3/1997	Fearnott et al.	623/1.42
5,387,235 A	2/1995	Chuter	623/1.11	5,616,608 A	4/1997	Kinsella et al.	514/449
5,389,106 A	2/1995	Tower	623/1.15	5,620,984 A	4/1997	Bianco et al.	514/263.36
5,393,772 A	2/1995	Yue et al.	514/410	5,621,102 A	4/1997	Bianco et al.	544/267
5,395,390 A	3/1995	Simon et al.	623/1.18	5,622,975 A	4/1997	Singh et al.	514/324
5,397,355 A	3/1995	Marin et al.	623/1.2	5,624,411 A	4/1997	Tuch	604/265
5,399,352 A	3/1995	Hanson	424/423	5,628,785 A	5/1997	Schwartz et al.	128/898
5,403,341 A	4/1995	Solar	606/198	5,629,077 A	5/1997	Turnlund et al.	623/1.15
5,405,377 A	4/1995	Cragg	623/1.2	5,629,315 A	5/1997	Bianco et al.	514/263.36
5,409,696 A	4/1995	Narayanan et al.	424/78.17	5,632,763 A	5/1997	Glastra	623/1.15
5,411,549 A	5/1995	Peters	623/1.15	5,632,771 A	5/1997	Boatman et al.	623/1.15
5,415,619 A	5/1995	Lee et al.	600/36	5,632,776 A	5/1997	Kurumatani et al.	424/423
5,417,969 A	5/1995	Hsu et al.	424/78.27	5,632,840 A	5/1997	Campbell	156/196
5,419,760 A	5/1995	Narciso, Jr.	604/8	5,635,201 A	6/1997	Fabo	424/443
D359,802 S	6/1995	Fontaine	D24/155	5,637,113 A	6/1997	Tartaglia et al.	623/1.42
5,421,955 A	6/1995	Lau et al.	216/48	5,643,312 A	7/1997	Fischell et al.	623/1.15
5,423,885 A	6/1995	Williams	623/1.17	5,643,939 A	7/1997	Ohlstein	514/411
5,429,618 A	7/1995	Keogh	604/266	5,646,160 A	7/1997	Morris et al.	514/291
5,429,634 A	7/1995	Narciso, Jr.	604/890.1	5,648,357 A	7/1997	Bianco et al.	514/263.36
5,439,446 A	8/1995	Barry	604/103.01	5,649,952 A	7/1997	Lam	623/1.15
5,441,515 A	8/1995	Khosravi et al.	606/194	5,649,977 A	7/1997	Campbell	623/1.15
5,441,516 A	8/1995	Wang et al.	606/198	5,651,174 A	7/1997	Schwartz et al.	29/527.2
5,441,947 A	8/1995	Dodge et al.	514/179	5,652,243 A	7/1997	Bianco et al.	514/263.36
5,443,458 A	8/1995	Evry	604/891.1	5,653,747 A	8/1997	Dereume	623/1.54
5,443,477 A	8/1995	Marin et al.	606/198	5,653,992 A	8/1997	Bezwada et al.	424/426
5,443,496 A	8/1995	Schwartz et al.	623/1.16	5,662,609 A	9/1997	Slepian	604/101.03
5,443,498 A	8/1995	Fontaine	623/1.17	5,665,591 A	9/1997	Sonenshein et al.	435/375
5,443,500 A	8/1995	Sigwart	623/1.17	5,665,728 A	9/1997	Morris et al.	424/122
5,447,724 A	9/1995	Helmus et al.	424/426	5,667,764 A	9/1997	Kopia et al.	424/1.45
5,449,372 A	9/1995	Schmaltz et al.	606/198	5,669,924 A	9/1997	Shaknovich	623/1.11
5,449,373 A	9/1995	Pinchasik et al.	606/198	5,670,506 A	9/1997	Leigh et al.	514/141
5,449,382 A	9/1995	Dayton	623/1.15	5,672,638 A	9/1997	Verhoeven et al.	523/112
5,464,450 A	11/1995	Buscemi et al.	632/1.2	5,674,242 A	10/1997	Phan et al.	606/198
5,464,540 A	11/1995	Friesen et al.	210/640	5,679,400 A	10/1997	Tuch	427/2.14
5,464,650 A	11/1995	Berg et al.	427/2.3	5,679,659 A	10/1997	Verhoeven et al.	514/56
5,474,563 A	12/1995	Myler et al.	606/108	5,684,061 A	11/1997	Ohnishi et al.	523/114
5,486,357 A	1/1996	Narayanan	424/78.17	5,691,311 A	11/1997	Maraganore et al.	514/12
5,496,365 A	3/1996	Sgro	623/1.2	5,693,085 A	12/1997	Buirge et al.	623/1.13
5,500,013 A	3/1996	Buscemi et al.	623/1.22	5,697,967 A	12/1997	Dinh et al.	128/898
5,510,077 A	4/1996	Dinh et al.	264/485	5,697,971 A	12/1997	Fischell et al.	623/1.15
5,512,055 A	4/1996	Domb et al.	604/265	5,700,286 A	12/1997	Tartaglia et al.	623/1.15
5,516,781 A	5/1996	Morris et al.	514/291	5,707,385 A	1/1998	Williams	606/192
5,519,042 A	5/1996	Morris et al.	514/378	5,709,874 A	1/1998	Hanson et al.	424/423
5,523,092 A	6/1996	Hanson et al.	424/423	5,713,949 A	2/1998	Jayaraman	623/1.12
5,527,354 A	6/1996	Fontaine et al.	623/1.17	5,716,981 A	2/1998	Hunter et al.	514/449
5,545,208 A	8/1996	Wolff et al.	623/1.22	5,725,549 A	3/1998	Lam	623/1.15
5,551,954 A	9/1996	Buscemi et al.	623/1.15	5,725,567 A	3/1998	Wolff et al.	623/1.42
5,554,182 A	9/1996	Dinh et al.	600/36	5,728,150 A	3/1998	McDonald et al.	623/1.15
5,554,954 A	9/1996	Takahashi	327/546	5,728,420 A	3/1998	Keogh	427/2.12
5,556,413 A	9/1996	Lam	623/1.2	5,731,326 A	3/1998	Hart et al.	514/323
5,562,922 A	10/1996	Lambert	424/486	5,733,327 A	3/1998	Igaki et al.	623/1.5
5,563,146 A	10/1996	Morris	514/291	5,733,920 A	3/1998	Mansuri et al.	514/337
5,569,197 A	10/1996	Helmus	604/102.02	5,733,925 A	3/1998	Kunz et al.	514/449
5,569,295 A	10/1996	Lam	606/198	5,735,897 A	4/1998	Buirge	623/1.15
5,569,462 A	10/1996	Martinson et al.	424/423	5,739,138 A	4/1998	Bianco et al.	514/263.36
5,569,463 A	10/1996	Helmus et al.	424/426	5,755,734 A	5/1998	Richter et al.	606/194
5,571,089 A	11/1996	Crocker	604/103.01	5,755,772 A	5/1998	Evans et al.	128/898
5,571,166 A	11/1996	Dinh et al.	128/898	5,759,205 A	6/1998	Valentini	438/173
5,574,059 A	11/1996	Regunathan et al.	514/397	5,769,883 A	6/1998	Buscemi et al.	623/1.42
5,575,818 A	11/1996	Pinchuk	623/1.15	5,776,184 A	7/1998	Tuch	623/1.11
5,578,075 A	11/1996	Dayton	623/1.15	5,780,476 A	7/1998	Underiner et al.	514/263.36
5,580,873 A	12/1996	Bianco et al.	514/263.36	5,782,908 A	7/1998	Cahalan et al.	623/1.13
5,580,874 A	12/1996	Bianco et al.	514/263.36	5,788,979 A	8/1998	Alt et al.	424/426
5,591,140 A	1/1997	Narayanan et al.	604/269	5,792,106 A	8/1998	Mische	604/103.01
5,591,197 A	1/1997	Orth et al.	623/1.16	5,792,772 A	8/1998	Bianco et al.	514/263.36
5,591,224 A	1/1997	Schwartz et al.	623/1.22	5,798,372 A	8/1998	Davies et al.	514/356
5,591,227 A	1/1997	Dinh et al.	623/1.22	5,799,384 A	9/1998	Schwartz et al.	29/458
5,599,352 A	2/1997	Dinh et al.	128/898	5,800,507 A	9/1998	Schwartz	623/1.11
5,603,722 A	2/1997	Phan et al.	623/1.18	5,800,508 A	9/1998	Goicoechea et al.	623/1.15
5,604,283 A	2/1997	Wada et al.	524/236	5,807,861 A	9/1998	Klein et al.	514/263.35
5,605,696 A	2/1997	Eury et al.	424/423	5,811,447 A	9/1998	Kunz et al.	514/411
5,607,463 A	3/1997	Schwartz et al.	623/1.44	5,820,917 A	10/1998	Tuch	427/2.1
5,607,475 A	3/1997	Cahalan et al.	424/423	5,820,918 A	10/1998	Ronan et al.	427/2.1

US 7,217,286 B2

Page 4

5,824,048 A	10/1998	Tuch	128/898	6,284,305 B1	9/2001	Ding et al.	427/2.28
5,824,049 A	10/1998	Ragheb et al.	623/1.44	6,287,320 B1	9/2001	Slepian	606/194
5,827,587 A	10/1998	Fukushi	428/36.6	6,287,628 B1	9/2001	Hossainy et al.	427/2.3
5,833,651 A	11/1998	Donovan et al.	604/509	6,299,604 B1	10/2001	Ragheb et al.	604/265
5,837,008 A	11/1998	Berg et al.	128/898	6,306,144 B1	10/2001	Sydney et al.	606/108
5,837,313 A	11/1998	Ding et al.	427/2.21	6,306,166 B1	10/2001	Barry et al.	623/1.46
5,843,120 A	12/1998	Israel et al.	623/1.15	6,306,176 B1	10/2001	Whitbourne	623/23.59
5,843,166 A	12/1998	Lentz et al.	623/1.13	6,306,421 B1	10/2001	Kunz et al.	424/423
5,843,172 A	12/1998	Yan	623/1.42	6,309,380 B1	10/2001	Larson et al.	604/502
5,849,034 A	12/1998	Schwartz	606/36	6,309,660 B1	10/2001	Hsu et al.	424/425
5,851,217 A	12/1998	Wolff et al.	606/191	6,313,264 B1	11/2001	Caggiano et al.	530/350
5,851,231 A	12/1998	Wolff et al.	623/1.42	6,316,018 B1	11/2001	Ding et al.	424/423
5,858,990 A	1/1999	Walsh	514/44	6,335,029 B1	1/2002	Kamath et al.	424/423
5,861,027 A	1/1999	Trapp	623/1.15	6,358,556 B1	3/2002	Ding et al.	427/2.24
5,865,814 A	2/1999	Tuch	623/1.15	6,369,039 B1	4/2002	Palasis et al.	423/9.2
5,871,535 A	2/1999	Wolff et al.	128/898	6,379,382 B1	4/2002	Yang	623/1.42
5,873,904 A	2/1999	Ragheb et al.	623/1.13	6,387,121 B1	5/2002	Alt	623/1.15
5,876,433 A	3/1999	Lunn	623/1.15	6,403,635 B1	6/2002	Kinsella et al.	514/449
5,877,224 A	3/1999	Brocchini et al.	514/772.2	6,407,067 B1	6/2002	Schafer	514/19
5,879,697 A	3/1999	Ding et al.	424/422	6,517,858 B1	2/2003	Le Moel et al.	424/424
5,882,335 A	3/1999	Leone et al.	604/103.02	6,517,889 B1	2/2003	Jayaraman	427/2.24
5,891,108 A	4/1999	Leone et al.	604/264	6,545,097 B2	4/2003	Pinchuk et al.	525/240
5,893,840 A	4/1999	Hull et al.	604/103.02	6,585,764 B2	7/2003	Wright et al.	623/1.42
5,897,911 A	4/1999	Loeffler	427/2.25	6,620,194 B2	9/2003	Ding et al.	623/1.43
5,900,246 A	5/1999	Lambert	424/429	6,746,773 B2	6/2004	Llanos et al.	428/421
5,902,266 A	5/1999	Leone et al.	604/509	6,776,796 B2	8/2004	Llanos et al.	623/1.46
5,916,910 A	6/1999	Lai	514/423	6,808,536 B2	10/2004	Wright et al.	623/1.42
5,922,393 A	7/1999	Jayaraman	427/2.3	2001/0007083 A1	7/2001	Roorda	623/1.15
5,932,243 A	8/1999	Fricker et al.	424/450	2001/0029351 A1	10/2001	Falotico et al.	604/103.02
5,932,299 A	8/1999	Katoot	427/508	2001/0029660 A1	10/2001	Johnson	29/557
5,932,580 A	8/1999	Levitzi et al.	181/152	2001/0032014 A1	10/2001	Yang et al.	623/1.15
5,951,586 A	9/1999	Berg et al.	606/198	2001/0034363 A1	10/2001	Li et al.	514/449
5,957,971 A	9/1999	Schwartz	623/1.15	2001/0037145 A1	11/2001	Guruwaiya et al.	623/1.15
5,968,091 A	10/1999	Pinchuk et al.	623/1.16	2002/0010418 A1	1/2002	Lary et al.	604/101.04
5,972,027 A	10/1999	Johnson	623/1.42	2002/0032477 A1	3/2002	Helmus et al.	623/1.2
5,976,534 A	11/1999	Hart et al.	424/145.1	2002/0041899 A1	4/2002	Chudzik et al.	424/487
5,977,163 A	11/1999	Li et al.	514/449	2002/0061326 A1	5/2002	Li et al.	424/424
5,980,553 A	11/1999	Gray et al.	623/1.15	2002/0068969 A1	6/2002	Shanley et al.	623/1.16
5,980,566 A	11/1999	Alt et al.	623/23.7	2002/0071902 A1	6/2002	Ding et al.	427/2.24
5,980,972 A	11/1999	Ding	427/2.24	2002/0082680 A1	6/2002	Shanley et al.	623/1.16
5,981,568 A	11/1999	Kunz et al.	514/411	2002/0082685 A1	6/2002	Sirhan et al.	623/1.42
5,985,307 A	11/1999	Hanson et al.	424/423	2002/0091433 A1	7/2002	Ding et al.	623/1.2
5,997,468 A	12/1999	Wolff et al.	606/36	2002/0095114 A1	7/2002	Palasis	604/96.01
6,004,346 A	12/1999	Wolff et al.	623/23.71	2002/0099438 A1	7/2002	Furst	623/1.16
6,015,432 A	1/2000	Rakos et al.	623/1.13	2002/0103526 A1	8/2002	Steinke	623/1.11
6,039,721 A	3/2000	Johnson et al.	604/508	2002/0119178 A1	8/2002	Levesque et al.	424/423
6,059,813 A	5/2000	Vrba et al.	606/198	2002/0123505 A1	9/2002	Mollison et al.	514/291
6,071,305 A	6/2000	Brown et al.	623/1.43	2002/0127327 A1	9/2002	Schwartz et al.	427/2.15
6,074,659 A	6/2000	Kunz et al.	424/423	2002/0133222 A1	9/2002	Das	623/1.16
6,080,190 A	6/2000	Schwartz et al.	623/1.22	2002/0133224 A1	9/2002	Bajgar et al.	623/1.39
6,096,070 A	8/2000	Ragheb et al.	623/1.39	2002/0165608 A1	11/2002	Llanos	604/500
6,120,536 A	9/2000	Ding et al.	623/1.43	2002/0193475 A1	12/2002	Hossainy et al.	524/113
6,120,847 A	9/2000	Yang et al.	427/335	2003/0065377 A1	4/2003	Davila et al.	604/265
6,136,798 A	10/2000	Cody et al.	514/141	2003/0216699 A1	11/2003	Falotico	604/265
6,140,127 A	10/2000	Sprague	435/395	2004/0049265 A1	3/2004	Ding et al.	623/1.42
6,146,358 A	11/2000	Rowe	604/103	2004/0243097 A1	12/2004	Falotico et al.	604/500
6,153,252 A *	11/2000	Hossainy et al.	427/2.3	2004/0260268 A1	12/2004	Falotico et al.	604/500
6,159,488 A	12/2000	Nagier et al.	424/423	2005/0002986 A1	1/2005	Falotico et al.	424/426
6,171,232 B1	1/2001	Papandreou et al.	600/36	2005/0004663 A1	1/2005	Llanos et al.	623/1.46
6,171,609 B1	1/2001	Kunz	424/422	2005/0033261 A1	2/2005	Falotico et al.	604/500
6,177,272 B1	1/2001	Nabel et al.	435/320.1	2005/0106210 A1	5/2005	Ding et al.	424/423
6,179,817 B1	1/2001	Zhong	604/265	2005/0187611 A1	8/2005	Ding et al.	623/1.15
6,193,746 B1	2/2001	Strecker	623/1.13	2005/0208200 A1	9/2005	Ding et al.	427/2.25
6,214,901 B1	4/2001	Chudzik et al.	523/113	2006/0088654 A1	4/2006	Ding et al.	427/2.21
6,225,346 B1	5/2001	Tang et al.	514/523	2006/0089705 A1	4/2006	Ding et al.	623/1.15
6,240,616 B1	6/2001	Yan	29/527.2				
6,245,537 B1	6/2001	Williams et al.	435/135				
6,251,920 B1	6/2001	Grainger et al.	514/319				
6,254,632 B1	7/2001	Wu et al.	623/1.15	DE	19723723 A1	12/1998	
6,254,634 B1	7/2001	Anderson et al.	623/1.42	EP	0 145 166 A2	6/1985	
6,258,121 B1	7/2001	Yang et al.	623/1.46	EP	0 177 330 A2	4/1986	
6,268,390 B1	7/2001	Kunz	514/411	EP	0 183 372 A1	6/1986	
6,273,913 B1	8/2001	Wright et al.	623/1.42	EP	0 221 570 A2	5/1987	

FOREIGN PATENT DOCUMENTS

EP 0 421 729 A2 4/1991
 EP 0 540 290 A2 5/1993
 EP 0 568 310 A1 11/1993
 EP 0 604 022 A1 6/1994
 EP 0 621 015 A1 10/1994
 EP 0 623 354 A1 11/1994
 EP 0 734 698 A2 3/1996
 EP 0 712 615 A1 5/1996
 EP 0 716 836 A1 6/1996
 EP 0 734 721 A2 10/1996
 EP 0 747 069 A2 12/1996
 EP 0 761 251 A1 3/1997
 EP 0 800 801 A1 10/1997
 EP 0 540 290 B1 1/1998
 EP 0 830 853 A1 3/1998
 EP 0 815 803 A1 7/1998
 EP 0 850 651 A2 7/1998
 EP 0 938 878 A2 9/1999
 EP 0 938 878 A3 9/1999
 EP 0 950 386 A2 10/1999
 EP 0 968 688 A1 1/2000
 EP 0 633 032 B1 2/2001
 EP 1 192 957 A2 4/2002
 EP 1 588 726 A1 10/2005
 EP 1 588 727 A1 10/2005
 FR 566 807 A1 4/1992
 GB 0 662 307 A2 12/1951
 GB 1 205 743 A 9/1970
 GB 2 135 585 A 9/1984
 SU 660689 5/1979
 SU 1457921 2/1989
 WO 89/03232 A1 4/1989
 WO 91/12779 A1 9/1991
 WO 92/15286 A1 9/1992
 WO 94/01056 A1 1/1994
 WO 94/21308 A1 9/1994
 WO 94/21309 A1 9/1994
 WO 94/24961 A1 11/1994
 WO 96/00272 A1 1/1996
 WO 96/26689 A1 9/1996
 WO 96/32907 A1 10/1996
 WO 96/34580 A1 11/1996
 WO 97/25000 A1 7/1997
 WO 97/33534 A1 9/1997
 WO 98/08463 A1 3/1998
 WO 98/13344 A1 4/1998
 WO 98/19628 A1 5/1998
 WO 98/23228 A1 6/1998
 WO 98/23244 A1 6/1998
 WO 98/34669 A1 8/1998
 WO 98/36784 A1 8/1998
 WO 98/47447 A1 10/1998
 WO 98/56312 A1 12/1998
 WO 00/21584 A1 4/2000
 WO 00/27445 A1 5/2000
 WO 00/27455 A1 5/2000
 WO 00/32255 A1 6/2000
 WO 00/38754 A1 7/2000
 WO 01/87342 A2 11/2001
 WO 01/87372 A1 11/2001
 WO 01/87373 A1 11/2001
 WO 01/87376 A1 11/2001
 WO 02/26139 A1 4/2002
 WO 02/26271 A1 4/2002
 WO 02/26280 A1 4/2002
 WO 02/26281 A1 4/2002
 WO 03/015664 A1 2/2003
 WO 03/057218 A1 7/2003

OTHER PUBLICATIONS

U.S. Appl. No. 08/424,884, filed Apr. 19, 1995, Helmus et al.
 U.S. Appl. No. 08/526,273, filed Sep. 11, 1995, Ding.

U.S. Appl. No. 08/730,542, filed Oct. 11, 1996, Helmus.
 U.S. Appl. No. 09/575,480, filed May 19, 2000, Kopia.
 U.S. Appl. No. 10/431,059, filed May 7, 2003, Falotico.
 U.S. Appl. No. 10/829,074, filed Apr. 21, 2004, Falotico et al.
 U.S. Appl. No. 10/833,200, filed Apr. 27, 2004, Falotico et al.
 U.S. Appl. No. 10/852,517, filed May 24, 2004, Falotico et al.
 Abraham, R. T., "Mammalian target of rapamycin: Immunosuppressive drugs offer new insight into cell growth regulation," *Progress in Inflammation Research*, 2000, Switzerland.
 Alvarado, R. et al., "Evaluation of Polymer-coated Balloon-expandable Stents in Bile Ducts," *Radiology*, 1989, 170, 975-978.
 Badimon, J. J. et al., "Inhibitory Effects of Rapamycin on Intimal Hyperplasia After PTCA," *JACC*, Mar. 1998.
 Bailey et al., "Polymer Coating of Palmaz-Schatz Stent Attenuates Vascular Spasm after Stent Placement," *Circulation*, 82:III-541 (1990).
 Berk, B. C. et al., "Pharmacologic Roles of Heparin and Glucocorticoids to Prevent Restenosis After Coronary Angioplasty," *JACC*, May 1991, 17(6), 111B-117B.
 Bertram, P. G. et al., "The 14-3-3 proteins positively regulate rapamycin-sensitive signaling," *Current Biology*, 1998, 8, 1259-1267.
 Biomaterials Science (B.D. Ratner, Ed.), Academic Press, New York, NY, pp. 228-238, 1996.
 Campbell, G. R. et al., "Phenotypic Modulation of Smooth Muscle Cells in Primary Culture, Vascular Smooth Muscle Cells in Culture," *CRC Press*, 1987, 39-55.
 Chang, M. W. et al., "Adenovirus-mediated Over-expression of the Cyclin/Cyclin-dependent Kinase inhibitor, p21 inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat Carotid Artery Model of Balloon Angioplasty," *J. Clin. Invest.*, 1995, 96, 2260-2268.
 Chung, J. et al., "Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases," *Cell*, Jun. 26, 1992, 69(7), 1227-1236.
 Clowes, A. W. et al., "Kinetics of cellular proliferation after arterial injury. IV. Heparin inhibits rat smooth muscle mitogenesis and migration," *Circ. Res.*, 1986, 58(6), 839-845.
 Clowes, A. W. et al., Kinetics of Cellular Proliferation after Arterial Injury, *Laboratory Investigation*, 1985, 52(6), 611-616.
 Clowes, A. W. et al., "Significance of quiescent smooth muscle migration in the injured rat carotid artery," *Circ Res.* 1985, 56(1), 139-145.
 Clowes, A. W., "Suppression by heparin of smooth muscle cell proliferation in injured arteries," *Nature*, 1977, 265(5595), 625-626.
 Colburn, M. D. et al., "Dose responsive suppression of myointimal hyperplasia by dexamethasone," *J. Vasc. Surg.*, 1992, 15, 510-518.
 Currier, J. W. et al., "Colchicine Inhibits Restenosis After Iliac Angioplasty in the Atherosclerotic Rabbit," *Circ.*, 1989, 80(4), 11-66 (Abstract No. 0263).
 Encyclopedia of Polymer Science and Engineering, vol. 7, Fluorocarbon Elastomers, p. 257-267, Mar. 1989.
 Farb, A. et al., "Vascular smooth muscle cell cytotoxicity and sustained inhibition of neointimal formation by fibroblast growth factor 2-saporin fusion protein," *Circ. Res.*, 1997, 80, 542-550.
 Ferns, G. A. A. et al., "Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF," *Science*, 1991, 253, 1129-1132.
 Fischman, D. L. et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease," *N. Eng. J. Med.*, 1994 Aug. 25, 331(8), 496-501.
 Franklin, S. M. et al., "Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials," *Coronary Artery Disease* Mar. 1993, 4(3), 232-242.
 Fukuyama, J. et al., "Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet," *Eur. J. Pharmacol.*, 1996, 318, 327-332.
 Gregory, C. R. et al., "Rapamycin Inhibits Arterial Intimal Thickening Caused by Both Alloimmune and Mechanical Injury," *Transplantation*, Jun. 1993, 55(6), 1409-1418.

- Gregory, C. R. et al., "Treatment with Rapamycin and Mycophenolic Acid Reduces Arterial Intimal Thickening Produced by Mechanical Injury and Allows Endothelial Replacement," *Transplantation*, Mar. 15, 1995, 59(5), 655-661.
- Guyton, J. R. et al., "Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin," *Circ. Res.*, 1980, 46, 625-634.
- Hansson, G. K. et al., "Interferon- γ Inhibits Arterial Stenosis After Injury," *Circ.*, 1991, 84, 1266-1272.
- Hashemolhosseini, S. et al., "Rapamycin Inhibition of the G1 to S Transition Is Mediated by Effects on Cyclin D1 mRNA and Protein Stability," *J Biol Chem*, Jun. 5, 1998, 273, 14424-14429.
- Jonasson, J. et al., "Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury," *Proc. Natl. Acad. Sci.*, 1988, 85, 2303-2306.
- Kuhnt, M. et al., "Microbial Conversion of Rapamycin," *Enzyme and Microbial Technology*, 1997, 21, 405-412.
- Lange, R. A. MD et al., "Restenosis After Coronary Balloon Angioplasty," *Annu. Rev. Med.*, 1991, 42, 127-132.
- Liu, M. W. et al., "Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit," *Circ.*, 1990, 81, 1089-1093.
- Liu, M. W., MD et al., "Restenosis After Coronary Angioplasty Potential Biologic Determinants and Role of Intimal Hyperplasia," *Circulation*, 1989, 79, 1374-1387.
- Lundergan, C. F. et al., "Peptide inhibition of Myointimal Proliferation by Angiopeptin, a Somatostatin Analogue," *JACC*, May 1991, 17(6), 132B-136B.
- Majesky, M. W. et al., "Heparin regulates smooth muscle S phase entry in the injured rat carotid artery," *Circ. Res.*, 1987, 61, 296-300.
- Marx, S. O. et al., "Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells," *Circ. Res.*, 1995, 76, 412-417.
- Nemecek, G. M. et al., "Terbinafine Inhibits the Mitogenic Response to Platelet-Derived Growth Factor in Vitro and Neointimal Proliferation in Vivo," *J. Pharmacol. Exp. Thera.*, 1989, 248, 1167-1174.
- Okada, T. et al., "Localized Release of Perivascular Heparin Inhibits Intimal Proliferation after Endothelial Injury without Systemic Anticoagulation," *Neurosurgery*, 1989, 25, 892-898.
- Poon, M. et al., "Rapamycin Inhibits Vascular Smooth Muscle Cell Migration," *J. Clin Invest.*, Nov. 1996, 98(10), 2277-2283.
- Popma, J. J. et al., "Clinical trials of restenosis after coronary angioplasty," *Circulation*, Sep. 1991, 84(3), 1426-1436.
- Powell, J. S. et al., "Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury," *Science*, 1989, 245, 186-188.
- Rensing, B. J. et al., Coronary restenosis elimination with a sirolimus eluting stent, *European Heart Journal*, 2001, 22, 2125-2130.
- Rodeck, C. et al., "Methods for the Transcervical Collection of Fetal Cells During the First Trimester of Pregnancy," *Prenatal Diagnosis*, 1995, 15, 933-942.
- Ruef, J. MD, et al., "Flavopiridol Inhibits Muscle Cell Proliferation In Vitro and Neointimal Formation In Vivo After Carotid Injury in the Rat," From the Division of Cardiology and Sealy Center for Molecular Cardiology, University of Texas Medical Branch, Galveston; Accepted Apr. 9, 1999; *Circulation* Aug. 10, 1999, pp. 659-665.
- Serruys, P. W. et al., "A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease," *N Engl J Med*, Aug. 25, 1994; 331(8), 489-495.
- Serruys, P. W. et al., "Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial," *Circulation*. Oct. 1993; 88(4 Pt 1), 1588-1601.
- Serruys, P. W. et al., "Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study," *Circulation*, Feb. 1, 1996; 93(3), 412-422.
- Siekierka, J. J., "Probing T-Cell Signal Transduction Pathways with the Immunosuppressive Drugs, FK-506 and Rapamycin," *Immunologic Research*, 1994, 13, 110-116.
- Sigwart, et al., "Intravascular Stents to Prevent Occlusion and Restenosis After Transluminal Angioplasty," *N. Engl. J. Med.*, Mar. 19, 1987, 316, 701-706.
- Simons, M. et al., "Antisense *c-myc* oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo," *Nature*, 1992, 359, 67-70.
- Snow, A. D. et al., "Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells," *Am. J. Pathol.*, 1990, 137, 313-330.
- Sollott, S. J. et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat," *J. Clin. Invest.*, 1995, 95, 1869-1876.
- van Der Giessen, et al., "Self-expandable Mesh Stents: an Experimental Study Comparing Polymer Coated and Uncoated Wallstent Stents in the Coronary Circulation of Pigs," *Circulation* 1990, 82(suppl. III):III-542.
- van Der Giessen, W. J. et al., "Coronary stenting with polymer-coated and uncoated self-expanding endoprostheses in pigs," *Coron. Art. Disease* 1992; 3, 631-640.
- Vasey, C. G. et al., "Clinical Cardiology: Stress Echo and Coronary Flow", *Circulation*, Oct. 1989, 80(4) Supplement II, II-66.
- Verweire, E. et al., "Evaluation of Fluorinated Polymers As Coronary Stent Coating," *Journal of Materials Science: Materials in Medicine*, Apr. 2000.
- Weinberger, J. et al., "Intracoronary irradiation: dose response for the prevention of restenosis in swine," *Int. J. Rad. Onc. Biol. Phys.*, 1996, 36, 767-775.
- Preliminary Amendment in U.S. Appl. No. 07/258,189, May 22, 1989.
- Trial Transcript from Nov. 6, 2000 at 185-90 and 235-36 (Attorneys' opening remarks regarding '984 patent).
- Trial Transcript from Nov. 7, 2000 at 274-301, 307-315, 320-28 and 332 (Cordis expert testimony regarding the Palmaz-Schatz stent); 370-379, 480-496 (J. Palmaz testimony regarding the Palmaz-Schatz stent, the '984 patent and the connected z-stent art).
- Trial Transcript from Nov. 8, 2000 at 547-63, 657-63, 674-722, 782-85 (Cordis expert testimony regarding the Palmaz-Schatz stent, the '984 patent and the connected z-stent art).
- Trial Transcript from Nov. 9, 2000 at 819-23, 921 (Cordis expert testimony regarding the '984 patent); 926-941. (R. Croce testimony re Palmaz-Schatz stent); 1033-1053. (R. Schatz testimony).
- Trial Transcript from Nov. 13, 2000 at 1086-1 134. (R. Schatz testimony); 1275-1305 (Cordis expert testimony regarding the '984 patent).
- Trial Transcript from Nov. 14, 2000 at 1390-1404, 1448-1454, 1486-1500 (Cordis expert testimony regarding the '984 patent).
- Trial Transcript from Nov. 15, 2000 at 1686-87, 1724-42, 1828-34, 1850-54, 1887-92 (AVE expert testimony regarding the '984 patent).
- Trial Transcript from Nov. 16, 2000 at 2077-198 (AVE expert testimony regarding the alleged obviousness of the '984 patent).
- Trial Transcript from Nov. 17, 2000 at 2331-34 (jury instructions as to the meaning of the limitations of the claims of the '984 patent).
- Trial Transcript from Nov. 20, 2000 at 2441-48, 2499-2500, 2546-50, 2552-56 (Attorneys' closing arguments regarding the '984 patent).
- Trial Transcript from Nov. 21, 2000 at 2592-94 (reading of jury verdict).
- Trial Transcript from Dec. 18, 2000 at 2750-95 (Cordis expert testimony regarding the Palmaz-Schatz stent during the damages phase).
- Trial Transcript from Dec. 20, 2000 at 3421-88)AVE expert testimony regarding the Palmaz-Schatz stent during the damages phase).
- Jury verdict, dated Nov. 21, 2000.
- District Court decisions on post-trial motions (194 F. Supp. 2d 323).
- Court of Appeal for the Federal Circuit decision (339 F.3d 1352).
- Trial Transcript from Mar. 4, 2005 at 133-135, 171-173 and 192-96 (Attorney's opening remarks regarding '984 validity).
- Trial Transcript from Mar. 7, 2005 at 275-31 1 (Cordis expert testimony regarding the Palmaz-Schatz stent); 342-46, 353-59, 416-425 (J. Palmaz testimony regarding the Palmaz-Schatz stent, the '984 patent and the connected z-stent art); 430-449, 452-58,

462-492 (R. Croce testimony regarding the Palmaz-Schatz stent); 500-507 (Cordis expert testimony regarding the '984 patent).

Trial Transcript from Mar. 8, 2005 at 609 (Cordis expert testimony regarding the '984 patent); 628-73, 724-740, 773, 801-839 (Cordis expert testimony regarding the '984 patent, the prior art and the Palmaz-Schatz stent).

Trial Transcript from Mar. 9, 2005 at 936-49, 968-69 (Cordis expert testimony regarding the '984 patent, the prior art and the Palmaz-Schatz stent).

Trial Transcript from Mar. 10, 2005 at 1427-74, 178-1509, 1514-23 (AVE expert testimony regarding the alleged obviousness of the '984 patent); 1566-93 (AVE expert testimony regarding Palmaz-Schatz stent); 1634-49 (R. Schatz testimony).

Trial Transcript from Mar. 11, 2005 at 1846-47, 1891-1900, 1919 (Attorneys' closing arguments regarding '984 obviousness).

Trial Transcript from Mar. 14, 2005 at 1964-67 (reading of jury verdict).

Jury verdict dated Mar. 14, 2005.

Medtronic Vascular Inc.'s Opening Brief in Support of Its Motion for Judgment As A Infringement Claim dated Apr. 19, 2005.

Medtronic Vascular Inc.'s Opening Brief in Support of Its Motion for a New Trial dated Apr. 19, 2005.

D.I. 1407, Cordis' Combined Answering Brief In Opposition to AVE's Motion for JMOL on Infringement of the Palmaz '762 and Schatz '984 Patents and Its Motion for a New Trial dated May 5, 2005.

D.I. 1414, Medtronic Vascular Inc.'s Combined Reply Brief In Support of Its Motion for Judgment as a Matter of Law on Cordis Corp.'s Patent Infringement Claims and Its Motion for a New Trial dated May 19, 2005.

Trial Transcript from Feb. 8, 2001 at 372-412, 449-469 (B. Tobor testimony regarding the prosecution of the '417, '984 and '332 patents); 510-13 (J. Milnamow testimony regarding the prosecution of the '332 patent); 558-604 (J. Palmaz testimony regarding the prosecution of the '417, '984 and '332 patents and the prior art).

Trial Transcript from Feb. 9, 2001 at 637-45, 662-672, 682-85 (J. Palmaz testimony regarding the prior art); 699-742 (R. Schatz testimony); 769-770, 790-95 (Cordis expert testimony regarding prior art).

D.I. 1067, Medtronic AVE, Inc.'s Post-Trial Brief Relating to the Unenforceability of the '762 and '984 Patents Due to Inequitable Conduct.

D.I. 1077, Cordis' Combined Answering Brief in Opposition to AVE's BSC's Post-Hearing Briefs on Alleged Inequitable Conduct Concerning the '762, '984 and '332 Patents.

D.I. 1089, Reply Brief In Support of Medtronic AVE, Inc.'s Contention that the '762 and '984 Patents are Unenforceable Due to Inequitable Conduct dated May 7, 2001.

C.A. No. 00-886-SLR, Answer and Counterclaims of Def. Medtronic AVE, Inc. To First Amended Complaint of Plaintiff Cordis Corp.

BSC's Opening Post-Trial Brief in Support of Its Defense That the Patents in Suit Are Unenforceable, dated Mar. 16, 2001.

Reply Brief in Support of BSC's Defense That the Patents in Suit Are Unenforceable, dated May 7, 2001.

Court's Decision on allegations of inequitable conduct (194 F. Supp. 2d 323) Mar. 28, 2002.

Trial Transcript from Nov. 21, 2000 at 155-57 and 180-84 (Attorneys' opening remarks regarding '332 patent).

Trial Transcript from Nov. 27, 2000 at 227-51, 260-300 (Cordis expert testimony regarding the Palmaz-Schatz stent); 343-60, 363-67, 424-33 (J. Palmaz testimony regarding the Palmaz-Schatz stent and the '332 patent).

Trial Transcript from Nov. 28, 2000 at 649-71.

Trial Transcript from Nov. 29, 2000 at 791-816, 859-870, 953-62 (Cordis expert testimony regarding the '332 patent and the Palmaz-Schatz stent).

Trial Transcript from Nov. 30, 2000 at 1018 (Cordis expert testimony regarding the '332 patent); 1062-80, 1108-1111 (R. Croce testimony regarding the Palmaz-Schatz stent); 1169-70, 1205-17, 1236-45 (Cordis expert testimony regarding the '332 patent).

Trial Transcript from Dec. 1, 2000 at 1352-54 (Cordis expert testimony regarding the '332 patent); 1364-1442 (R. Schatz testi-

mony); 1493-1508, 1552-69 (BSC expert testimony regarding the '332 patent and the Palmaz-Schatz stent).

Trial Transcript from Dec. 4, 2000 at 1602-12, 1638-51, 1713-14, 1730-61, 1811-14, 1823-36 (BSC expert testimony regarding the alleged obviousness of the '332 patent, the prior art and the Palmaz-Schatz stent).

Trial Transcript from Dec. 6, 2000 at 2318-27, 2342-58 (BSC expert testimony regarding the '332 patent).

Trial Transcript from Dec. 7, 2000 at 2549-52 (Cordis expert testimony regarding the '332 patent); 2575-2579, 2591-92, 2630-31, 2649, 2669-71, 2684-85, 2688, 2708-10, 2725-27 (Attorney closing argument regarding '332 patent); 2742-46 Q'ury instructions as to the meaning of the limitations of the claims of the '332 patent).

Trial Transcript from Dec. 11, 2000 at 2817-22 (reading of jury verdict).

Jury verdict, dated Dec. 11, 2000.

D.I. 699, Motion by Defendant BSC and Scimed Life Systems, Inc. For Summary Judgment of Invalidity of U. S. Appl. No. 5,902,332 dated Apr. 4, 2000.

D.I.896, Order Denying Motion for Summary Judgment of Invalidity and Unenforceability of Claims 1, 3, and 5 of the U.S. Appl. No. 5,902,332 Denying {699-1} Motion for Summary Judgment of Invalidity of U.S. Appl. No. 5,902,332 dated Oct. 12, 2000.

Wright et al., Percutaneous Endovascular Stent: An Experimental Study (Abstract), RSNA Meeting (Nov. 28, 1984).

Hearing Transcript from Feb. 10, 1998 at 122-32, 146-80 (Attorneys' opening remarks regarding '417 patent); 180-312 (R. Schatz testimony) [Portions of This Transcript Have Been Removed as Confidential].

Hearing Transcript from Feb. 11, 1998 at 427-575, 577-651 (Cordis expert testimony regarding the '417 patent, the prior art and the Palmaz-Schatz stent).

Hearing Transcript from Feb. 13, 1998 at 1121-1261 (Guidant expert testimony regarding the alleged obviousness of the '417 patent, the prior art and the Palmaz-Schatz stent). [Portions of This Transcript Have Been Removed as Confidential].

Order by J. Robinson denying Cordis' Motion for a Preliminary Injunction Against ACS dated Jul. 17, 1998.

ACS, Inc.'s and Guidant Corp.'s Opening Brief in Support of Their Motion for Summary Judgment of Invalidity of U.S. Appl. No. 5,102,417 dated Aug. 27, 1998.

Plaintiff's Answering Brief in Opposition to ACS' and BSC's Motion for Summary Judgment on Obviousness dated Sep. 24, 1998.

Order dated Mar. 31, 2000.

Schatz Deposition Testimony; May 15, 1996: 79-83, 89-92, 105-107 and 153-161.

Schatz Deposition Testimony; May 16, 1996: 555-564, 569-572.

Schatz Deposition Testimony; Jan. 8, 1998: 67-73, 108-110.

Schatz Deposition Testimony; Jul. 14, 1998: 69-77, 108-112, 119-123.

Schatz Deposition Testimony; Jul. 12, 1999: 88-91, 132-135, 144-149, 218-223, 231-242.

Schatz Deposition Testimony; Jul. 13, 1999: 251-334, 339-345, 374-416.

Schatz Deposition Testimony; Jul. 14, 1999: 454-550.

Schatz Deposition Testimony; Jul. 15, 1999: 560-614.

Schatz Deposition Testimony; Dec. 2, 1999: 906-911, 928-942, 945-963, 976-978, 1029-1034, 1038-1042.

Palmaz Deposition Testimony, Nov. 5, 1991: 160-172.

Palmaz Deposition Testimony, Feb. 5, 1995: 710-727.

Palmaz Deposition Testimony, Jul. 16, 1998: 55-56, 81-82.

Palmaz Deposition Testimony, Jul. 28, 1999: 560-568, 570-579.

Palmaz Deposition Testimony, Jul. 29, 1999: 778-785.

Palmaz Deposition Testimony, Aug. 31, 1999: 1403-1452.

Palmaz Deposition Testimony, Sep. 2, 1999: 1953-1960.

Palmaz Deposition Testimony, Oct. 14, 1999: 2201-2209; 2275-2342; 2371-2411.

Palmaz Deposition Testimony, Oct. 15, 1999: 2424-2497; 2508-2589.

Palmaz Deposition Testimony, Oct. 16, 1999: 2853-2860.

Tobor Deposition Testimony, Jun. 17, 1999: 837-958.

- Tobor Deposition Testimony, Jun. 18, 1999: 1095-1184.
 Tobor Deposition Testimony, Dec. 1, 1999: 1217-1371.
 Tobor Deposition Testimony, Dec. 2, 1999: 1398-1414; 1444-1508; 1532-1548.
 Tobor Deposition Testimony, Dec. 3, 1999: 1652-1653; 1662-1672; 1683-1694.
 Kula Deposition Testimony, Apr. 20, 1999: 268-169.
 Kula Deposition Testimony, Nov. 16, 1999: 660-675; 680-694; 7-8-755; 774-821.
 Kula Deposition Testimony, Nov. 18, 1999: 176-223.
 Expert Report of Dr. Rodney S. Badger on Behalf of Medtronic AVE, Inc. (Jan. 31, 2000).
 Expert Report of Dr. Joseph Bonn on Behalf of Medtronic AVE, Inc. (Jan. 31, 2000).
 Deposition of Dr. Joseph Bonn dated Mar. 14, 2000.
 Rebuttal Expert Report of Nigel Buller, B.Sc., M.B., F.R.C.P. (Mar. 2000).
 Second Supplemental Rebuttal Expert Report of Nigel Buller, B.Sc., M.B., F.R.C.P. (Aug. 17, 2004).
 Rebuttal Expert Report of John M. Collins, PH.D. (Feb. 2000).
 Expert Report of David C. Cumberland, M.D. (Jan. 24, 2000).
 Expert Report of John T. Goolkasian (Feb. 2000).
 Deposition of Richard R. Heuser, M.D. (Sep. 7, 2004).
 Deposition of Henry R. Piehler (Sep. 10, 2004).
 Deposition of Ronald J. Solar (Mar. 22, 2000).
 Deposition of Ronald J. Solar (Mar. 23, 2000).
 Deposition of Ronald J. Solar (Apr. 12, 2000).
 Expert Report of Dr. Arina Van Breda on Behalf of Medtronic AVE, Inc. (Jan. 31, 2000).
 Deposition of Anna Van Breda (Mar. 24, 2000).
 Deposition of Arina Van Breda (Aug. 21, 2004).
 Expert Report of John F. Witherspoon (Jan. 24, 2000).
 Supplemental Expert Report of John F. Witherspoon (Oct. 27, 2000).
 Deposition of John F. Witherspoon (Mar. 8, 2000).
 Palmaz et al., Article: "Normal and Stenotic Renal Arteries: Experimental Balloon Expandable Intraluminal Stenting", Radiology, Sep. 1987. (AVE 84).
 Julio C. Palmaz, Article: "Expandable vascular endoprosthesis." (AVE 132).
 Duprat et al., Article: Flexible Balloon-Expandable Stent for Small Vessels Duprat et al. Radiology, vol. 162, pp. 276-278, 1987. (AVE 134).
 Coons et al., Article: "Large-Bore, Long Biliary Endoprosthesis (Biliary Stents) for Improved Drainage," Radiology, vol. 148, pp. 89-94, 1983. (AVE 143).
 Honickman et al., Article: "Malpositioned Biliary Endoprosthesis, Technical Developments And Instrumentation," vol. 144, No. 2., 1982. (AVE 144).
 Harries-Jones, et al., Article: "Repositioning of Biliary Endoprosthesis with Gruntzig Balloon Catheters," AJR, vol. 138, pp. 771-772, 1982. (AVE 153).
 Charnsangavej et al., Article "Stenosis of the Vena Cava: Preliminary Assessment of Treatment with Expandable Metallic Stents," Radiology, vol. 161, pp. 295-298, 1986. (AVE 359).
 Wallace, M. J. et al., Article "Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications," Radiology, vol. 158, pp. 309-312, 1986. (AVE 364).
 T. Yoshioka, et al., AIR Article: "Self-Expanding Endovascular Graft: An Experimental Study in Dogs", vol. 151, pp. 673-676, 1988. (AVE 438).
 Palmaz, J. C. et al., Article: "Expandable Intraluminal Vascular Graft: A Feasibility Study," Surgery, vol. 99, pp. 199-205, 1986. (AVE 461).
 Lawrence et al., Article: "Percutaneous Endovascular Graft: Experimental Evaluation," Radiology, vol. 163, pp. 357-360, 1987. (AVE 671).
 Palmaz et al., Article: Expandable Intraluminal Graft: A Preliminary Study, 1 Jan. 17-22, 1985, Radiology, vol. 156, pp. 73-77, 1985. (AVE 1224).
 Fallone et al., "Elastic Characteristics of the Self-Expanding Metallic Stents," Investigative Radiology, vol. 23, pp. 370-376, 1988. (AVE 1953).
 Palmaz Paper Entitled "Research Project Expandable Vascular Endoprosthesis" May 18, 1983.
 Rousseau, et al., Publication: "Percutaneous Vascular Stent: Experimental Studies & Preliminary Clinical Results in Peripheral Arterial Diseases," in Inter. Angio, vol. 6, 153-161, 1987. (AVE 3301).
 Rousseau, et al., Publication: "Self-Expanding Endovascular Prosthesis: An Experimental Study," Radiology, vol. 164, pp. 709-714, 1987. (AVE 3303).
 Wallace, et al., Article: "Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications," Radiology, vol. 58, pp. 309-312, 1986. (DBX 2938).
 Palmaz et al., Article: "Expandable Intraluminal Graft: A Preliminary Study," Radiology, vol. 156, pp. 73-77, Nov. 17-22, 1985 (DBX 4595).
 Program for the 12th Annual Course on Diagnostic Angiography and Interventional Radiology Mar. 23-26, 1987 sponsored by The Society of Cardiovascular and Interventional Radiology (DBX 6235).
 Preliminary Motion for Judgment re: Wolff claims 1, 2-8, 10, 15 and 19 (DBX6759).
 Palmaz Declaration (DBX 7069).
 Letter from Gaterud to Dr. Palmaz dated Jul. 5, 1988 with attached document entitled: "Segmented, balloon-expandable stents." (DBX 7160).
 Duprat et al., Article: "Flexible Balloon-Expandable Stent For Small Vessels," Radiology, vol. 168, pp. 276-278, 1987 (PX 82).
 Drawing Sent to Bodic on Mar. 17, 1986 (PX 374).
 Letter from Dr. Palmaz to R. Bowman enclosing a model of the flexible coronary graft dated Mar. 17, 1986 (PX 337).
 Lab Notebook pages dated Jul. 30, 1987 from Rodney Wolff (COR 185596-597) (PX621A).
 Charnsangavej, et al., Article: "Stenosis of The Vena Cava Preliminary Assessment of Treatment with expandable Metallic Stents," Radiology, vol. 161, No. 2, pp. 295-298 with attached photographs, 1986. (API 72).
 J. Palmaz: The Current Status of Vascular Prostheses, published by SCIR in the Twelfth Annual Course on Diagnostic Angiography And Interventional Radiology Mar. 23-26, 1987. (API 73).
 Amendment in Response to Office Action of Oct. 18, 1998 in re: Application of Julio Palmaz S/N 174,246. (API 152).
 Article: Wallace, et al., Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications Work In Progress, Radiology, vol. 158, pp. 309-312. (API 295).
 Reply of Senior Party Schatz To Patentee Wolff's Opposition To The Belated Motion For Judgment Of Applicant Schatz With Regard To Wolff Claims 1, 2-8, 10, 11, 13-17, And 19 (COR 186450-455) (API 310).
 Brief Of Senior Party Schatz At Final Hearing (API 313).
 Letter from Ron Sickles to Ben Tobor dated Feb. 10, 1988 (Exhibit 42).
 Letter from R.O. Sickles to Mike Tatlow dated May 12, 1988 (Exhibit 43).
 Letter from R. O. Sickles to Richard Schatz dated Jun. 2, 1988 (Exhibit 44).
 Letter from Richard Schatz to Raimund Erbel dated Jun. 3, 1988 (Exhibit 45).
 Letter from Richard Schatz to Mike Schuler dated Aug. 29, 1991 (Exhibit 48).
 Minutes of J&J Stent Project Review Meeting dated Jan. 21, 1988 (Exhibit 7).
 Preliminary Motion for Judgment with Regard to Wolff Claims 1, 2-8, 10, 11, 13-17, and 19. (Exhibit 67).
 Declaration of Richard A Schatz. (Exhibit 75).
 Belated Motion for Judgment with Regard to Wolff Claims 1, 2-8, 10, 11, 13-17 and 19. (Schatz-Exhibit 77).
 Letter from Dr. Schatz to Mr. Tobor, dated Jun. 3, 1988. (Exhibit 122).
 Letter from Dr. Schatz to Mr. Romano, dated Nov. 28, 1988. (Exhibit 131).
 Letter from Mr. Sickles to Mr. Tobor, dated Feb. 10, 1988 (Exhibit 145).
 Richard A. Schatz, Article titled: "A View of Vascular Stents" Circulation, vol. 79, No. 2, pp. 445-457, 1989. (Exhibit 194).

- Senior Party Schatz's reply to Patentee Wolff's Opposition to the Preliminary Motion Of Applicant Schatz for judgment with regard to Wolff Claims 1, 2-8, 10, 11, and 13-17. (Exhibit 69).
- Wallace, et al., Article: "Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications" Work In Progress," Radiology, vol. 158, pp. 309-312, 1986. (Exhibit 165).
- Charnsangavej, et al., Article: "Stenosis of The Vena Cava Preliminary Assessment of Treatment with expandable Metallic Stents," Radiology, vol. 161, No. 2, pp. 295-298 with attached photographs, 1986! (Exhibit 167).
- David D. Lawrence et al., Publication: Percutaneous Endovascular Graft: Experimental Evaluation¹, Radiology, pp. 163, 357-360, 1987. (Exhibit 173).
- Charles E. Putnam, M.D., Cover and article from "Investigative Radiology", vol. 23, No. 5, May 1988. (Exhibit 177).
- Robert N. Berk, Cover and article from "American Journal of Roentology", pp. 673-676, 1988. (Exhibit 178).
- Declaration of John S. Kula Under 37 CFR § 1.672. (Kula-Exhibit 77).
- Yoshioka et al., Article: "Self-Expanding Endovascular Graft: An Experimental Study in Dogs" AJR, vol. 151, pp. 673-676, 1988. (PX 100).
- Palmaz, et al., Article: Expandable Intraluminal Graft: A Preliminary Study Work in Progress¹, Radiology, vol. 156, No. 1, pp. 73-77, 1985. (PX 101).
- Declaration of Richard Schatz Under 37 C.F.R. § 1.672. (PX 106).
- Charnsangavej et al., Article: "Stenosis of the Vena Cave: Preliminary Assessment of Treatment with Expandable Metallic Stents," Radiology, vol. 161, pp. 295-298, 1986. (PX 143).
- Wallace, et al., Article: Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications Work in Progress¹, Radiology, vol. 158, pp. 309-312, 1986. (PX 144).
- Gina Kolata, News Article: NY Times, "Devices That Opens Clogged Arteries Gets a Falling Grade in a New Study", pp. 16-18, Jan. 3, 1991. (PX 186).
- Duprat, et al., Article: "Flexible Balloon- Expanded Stent for Small Vessels Work in Progress"¹, Radiology, vol. 162, pp. 276-278, 1987. (PX 207).
- Letter from Palmaz to Bowman dated Mar. 17, 1986. (PX 350).
- Memo re: Minutes of Stent Project Review- San Antonio- Mar. 15, 1988. (PX 651).
- Kuntz, et al., Article: Clinical Cardiology Frontiers: "Defining Coronary Restenosis, Newer Clinical and Angiographic Paradigms", Circulation, Sep. 1993, vol. 88, No. 3, pp. 1310-1323. (PX 854).
- Belated Motion for Judgment with regard to Wolff Claims¹, 2-8, 10, 11, 13-17, and 19. (PX 1410).
- Drawing of Spiral Stent (sent to Bodic Mar. 17, 1986). (PX2933).
- Wright et al., Article: "Percutaneous Endovascular Stents: An Experimental Evaluation," Radiology, vol. 156, pp. 69-72, 1985. (PX 3093).
- Charnsangavej et al., Article: "A New Expandable Metallic Stent for Dilation of Stenotic Tubular Structures: Experimental and Clinical Evaluation," Houston Medical Journal, vol. 3, pp. 41-51, Jun. 1987. (PX 3207).
- In re Application of Wiktor, Appln. No. 69,636, Response to Office Action dated Mar. 17, 1988. (PX3236).
- Transmittal Letter of Response to First Office Action in '417 patent. (PX 3993).
- Letter from B. Tobor to R. Schatz dated Jul. 23, 1991. (PX 3996).
- Mullins et al., Article: "Implication of balloon-expandable intravascular grafts by catheterization in pulmonary arteries and systemic veins," Circulation, vol. 77, No. 1, pp. 188-189, 1988. (PX4049).
- Schatz et al., Article: "Intravascular Stents for Angioplasty," Cardio, 1997. (PX 4050).
- Schatz et al., Article: "New Technology in Angioplasty Balloon-Expandable Intravascular Stents, New Developments in Medicine," vol. 2, No. 2 pp. 59-75, 1987. (PX4051).
- Richard A. Schatz, Article: "Introduction to Intravascular Stents," Cardiology Clinics, vol. 6, No. 3, pp. 357-372, 1988. (PX 4052).
- Richard A. Schatz, Article: "A View of Vascular Stents," Circulation, vol. 79, No. 2, pp. 445-457, 1989. (PX4053).
- Wang et al., Article: "An Update on Coronary Stents," Cardio, pp. 177-186, 1992. (PX 4054).
- Richard A. Schatz, Article: "New Technology in Angioplasty: Balloon-Expandable Starts," Medicamundi, vol. 33, No. 3, pp. 12-126, 1988. (PX 4055).
- Letter from Tobor to Schatz dated Sep. 29, 1988. (PX 1395).
- Verified Statement of Facts by Unnamed Inventor R.A. Schatz document filed in U. S. Patent and Trademark Office on Sep. 8, 1989. (PX 3677).
- Declaration of John S. Kula Under 37 CFR § 1.672 (Exhibit 329).
- Letter to Mike Schular from R.A. Schatz dated Aug. 29, 1991. (Exhibit 402).
- Articulated, Balloon-Expandable Stents, (DBX 7159).
- J. Rosch et al., Experimental Intrahepatic Portacaval Anastomosis: Use of Expandable Gianturco Stents, Radiology, vol. 162, pp. 481-485, 1987.
- J. Rosch et al., Modified Gianturco Expandable Wire Stents In Experimental and Clinical Use, Ann Radiol, vol. 31, No. 2, pp. 100-103, 1987.
- J. Rosch et al., Gianturco Expandable Stents In the Treatment of Superior Vena Cava Syndrome Recurring After Vena Cava Syndrome Recurring After Maximum-Tolerance Radiation, Cancer, vol. 60, pp. 1243-1246, 1987.
- I.E. Gordon, Structures or Why Things Don't Fall Down, Penguin Books, pp. 45-59, 132-148, 210-244, 377-383.
- Maass et al., Radiological Follow-up of Transluminally Inserted Vascular Endoprostheses: An Experimental Study Using Expanding Spirals, Radiology, vol. 152, pp. 659-663, 1984.
- Argument submitted re EP 861 15473 dated Jan. 20, 1995. (AVE 2478).
- Verified Statement of Facts by Julio C. Palmaz dated Aug. 4, 1989. (PX 3662).
- Papanicolaou et al., Insertion of a Biliary Endoprosthesis Using A Balloon Dilatation Catheter, Gastrointest Radiology, vol. 10, pp. 394-396, 1985.
- Palmaz et al., Atherosclerotic Rabbit Aortas: Expandable Intraluminal Grafting, Radiology, vol. 168, pp. 723-726, 1986.
- Palmaz, The Current Status of Vascular Prostheses; Rosch et al., Gianturco, Expandable Stents in Experimental and Clinical Use, SCIVR, pp. 118-124, 1987.
- Rosch et al., Abstract: Modified Gianturco Expandable Wire Stents in Experimental and Clinical Use, CIRSE, Porto Cervo, Sardinia, May 25-29, 1987.
- Rosch et al., Gianturco Expandable Wire Stents in the Treatment of Superior Vena Cava Syndrome Recurring After Maximum-Tolerance Radiation, Cancer, vol. 60, pp. 1243-1246, 1987.
- Mirich et al., Percutaneously Placed Endovascular Grafts for Aortic Aneurysms: Feasibility Study, Radiology, vol. 170, pp. 1033-1037, 1989.
- Dotter, Transluminally-placed Coilspring Endarterial Tube Grafts, Investigative Radiology, vol. 4, Sep.-Oct., pp. 329-332, 1969.
- Palmaz et al., Abstract: Expandable Intraluminal Graft: A Preliminary Study, Radiology, vol. 153 (P), Nov. 1983: 70th Scientific Assembly and Annual Meeting.
- Cragg et al, Nonsurgical Placement of Arterial Endoprostheses: A New Technique Using Nitinol Wire, Radiology, vol. 147, pp. 261-263, Apr. 1983.
- J. Rosch et al., Gianturco Expandable Stents in Experimental and Clinical Use, Program: "Twelfth Annual Course on Diagnostic Angiography and Interventional Radiology" (Society of Cardiovascular and Interventional Radiology, Pittsburgh, PA), Mar. 23-26, 1987 (the second Monofilament Article).
- Uchida et al., Modifications of Gianturco Expandable Wire Stents, AIR, vol. 150, pp. 1185-1187, 1988.
- Palmaz, Balloon-Expandable Intravascular Stent, AJR, vol. 1510, pp. 1263-1269.
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, Guidant Corporation, Arterial Vascular Engineering, Inc., Boston Scientific Corporation and SCMED Life Systems, Inc., Plaintiffs Complaint, Oct. 23, 1997 (Case No. 97-550-SLR).
- Arterial Vascular Engineering, Inc. v. Cordis Corporation*, Johnson & Johnson and Expandable-Grafts Partnership, Plaintiffs First Amended Complaint for Declaratory Relief of Patent Validity,

Unenforceability, Noninfringement, and for Antitrust Violations, Jan. 27, 1998 (Civil Action No. 97-700).

Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership, Cordis Corporation and Johnson & Johnson's Answer and Counterclaim, Feb. 27, 1998 (Civil Action No. 97-700-SLR).

Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership, Expandable-Graft Partnership's Answer, Feb. 27, 1998 (Civil Action No. 97-700-SLR).

Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership, Reply of Plaintiff Arterial Vascular Engineering, Inc. To Counterclaims of Defendant Cordis Corporation, Mar. 31, 1998 (Civil Action No. 97-700-SLR).

Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership, Reply of Plaintiff Arterial Vascular Engineering, Inc. To Counterclaims of Defendant Expandable Grafts Partnership, Mar. 31, 1998 (Civil Action No. 97-700-SLR).

Cordis Corporation v. Advanced Cardiovascular Systems, Inc. and Guidant Corporation, Cordis Corporation's Motion for a Preliminary Injunction, Oct. 8, 1997 (Civil Action No. 97-550).

Cordis Corporation v. Advanced Cardiovascular Systems, Inc., Guidant Corporation Arterial Vascular Engineering, Inc., Boston Scientific Corporation and SCJVID, Inc., Cordis's Motion for Preliminary Injunction Against Arterial Vascular Engineering, Inc., Dec. 29, 1997 (Case No. 97-550-SLR).

Deposition of R. Schatz, M.D. in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, taken on Jan. 8, 1998 (Civil Action No. 97-550 SLR).

Deposition of Lee P. Bendel in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, taken on Jan. 22, 1998 (Civil Action No. 97-550 SLR).

Deposition of Julio Cesar Palmaz in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, taken on Dec. 29, 1997 (Civil Action No. 97-550 SLR).

Deposition of Richard A. Bowman in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, taken on Jan. 9, 1998 (Civil Action No. 97-550 SLR).

Deposition of Gary Schneiderman in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, taken on Jan. 16, 1998 (Civil Action No. 97-550 SLR).

Deposition of David Pearle, M.D. in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, taken on Jul. 10, 1998 (Civil Action No. 97-550 SLR).

Preliminary Injunction hearing testimony taken on Feb. 9-13, 1998 (Civil Action No. 97-550 SLR).

Cordis Corporation v. Advanced Cardiovascular Systems, Inc., et al., (Civil Action No. 97-550 SLR) and *Cordis Corporation v. Advanced Cardiovascular Systems, Inc. Et al.* (Civil Action No. 98-65-SLR), Opening Post Hearing Brief of Plaintiff Cordis Corporation in Support of Motion for Preliminary Injunction, Mar. 6, 1998 (Portions relevant to patent claim construction and patent validity issues).

Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc. et al., Post-Hearing Reply Brief of Plaintiff Cordis Corporation in Support of Its Motion for Preliminary Injunction, Apr. 10, 1998 (Case No. 97-550 SLR) (Portions relevant to patent validity issues).

Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc. et al., Plaintiffs Motion for a Preliminary Injunction Against Boston Scientific Corporation and SCLMED Life Systems, Inc. And Memorandum in Support, Apr. 13, 1998 (Case No. 97-550-SLR).

Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc., et al., Judge Robinson's Order Denying Plaintiffs Motion for a Preliminary Injunction, Jul. 17, 1998 (Civil Action No. 97-550 SLR).

Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc., et al., Defendant Boston Scientific Corporation and SCLMED Life Systems, Inc.'s Motion for Summary Judgment of Invalidity of U.S. Appl. No. 5,102,417, filed Aug. 27, 1998 (Civil Action No. 97-550- SLR).

Boston Scientific Limited, et al. v. Expandable Grafts Partnership, Plaintiffs' Statement of Claim, Mar. 13, 1997 (UK Action No. 1493).

Boston Scientific Limited, et al. v. Expandable Grafts Partnership, Defendant's Amended Defense and Counterclaim, Aug. 14, 1997 (UK Action No. 1493).

Boston Scientific Limited, et al. v. Expandable Grafts Partnership, Petition for Revocation, Mar. 13, 1997 (UK Action No. 1497).

Boston Scientific Limited, et al. v. Expandable Grafts Partnership, Particulars of Objections, Mar. 13, 1997 (UK Action No. 1497).

Boston Scientific Limited, et al. v. Expandable Grafts Partnership and Boston Scientific Limited et al., v. Julio C. Palmaz, Boston's Skeleton Argument (UK Action Nos. 1493, 1495, 1496, and 1497).

Boston Scientific Limited, et al. v. Julio C. Palmaz and Expandable Grafts Partnership, Skeleton Argument of Palmaz/EGP, Mar. 19, 1998 (UK Action Nos. 1493, 1495, 1496 and 1497).

Boston Scientific Limited, et al. v. Julio C. Palmaz and Expandable Grafts Partnership, EGP's Final Submissions, Apr. 2, 1998 (UK Action Nos. 1493, 1495, 1496 and 1497).

Boston Scientific Limited, et al. v. Julio C. Palmaz and Expandable Grafts Partnership, Judgment, Jun. 26, 1998 (UK Action Nos. 1493, 1495, 1496 and 1497).

Rosch, Modified Gianturco Expandable Wire Stents in Experimental and Clinical Use, CJJRSE 1987 Presentation: see Witness Statement of Josef Rosch from U.K. Proceeding.

Statement of Claim by Boston Scientific et al. against Expandable Grafts Partnership et al., in *EPG et al., v. Boston Scientific et al.* in Netherlands (Mar. 13, 1997).

Motion for Joinder of Actions, Change of Claim and Statement of Claim filed by Expandable Grafts Partnership et al. in *EPG et al. v. Boston Scientific et al.* In Netherlands (Apr. 22, 1997).

Opinion of K.J. Merman filed *EPG et al. v. Boston Scientific et al.* in Netherlands (Aug. 29, 1997).

Expert report of Dr. Nigel Buller in *EPG et al. v. Boston Scientific et al.* in Netherlands (Aug. 28, 1997).

Expert report of Lee P. Bendel in *EPG et al. v. Boston Scientific et al.* in Netherlands (Aug. 28, 1997).

Memorandum of Oral Pleading in *EPG et al. v. Boston Scientific et al.* in Netherlands (Sep. 12, 1997).

Plea Notes of P. A.M. in *EPG et al. v. Boston Scientific et al.* in Netherlands (Mar. 10, 1998).

Decision of Court of Appeals in *EPG et al. v. Boston Scientific et al.* in Netherlands (Apr. 23, 1998).

Translation of Nullity Action Against EPO 0 364 787 by Biotronik in Germany.

Translation of Nullity Action Against EPO 0 335 341 by Biotronik in Germany.

Translation of EPG Response to Nullity Action Against EP 0 364 787 by Biotronik in Germany.

Translation of EPG Response to Nullity Action EP 0 335 341 by Biotronik in Germany.

Nullity Suit Against EP-B1-0 335 341 Brought by Boston Scientific in Germany.

Translation of Opposition filed by Terumo Corp. Against Japan Patent No. 2680901.

Translation of Decision on Opposition Against Japan Patent No. 2680901.

Memorandum Order of the Court dated Sep. 7, 2000, concerning disputed claim construction.

Translation of Judgment in Nullity Action Against EP 0 364 787 by Biotronik in Germany.

Translation of Judgment in Nullity Action Against EP 0 335 341 by Biotronik in Germany.

Trial transcript from Mar. 17, 2005 at 171-172, 191-192.

Trial transcript from Mar. 18, 2005 at 282-285, 325-327, 349-351.

Trial transcript from Mar. 21, 2005 at 721-726.

Trial transcript from Mar. 24, 2005 at 1387.

Trial transcript from Jul. 26, 2005.

BSC's Opening Brief in Support of Its Motion for Judgment as a Matter of Law or, in the Alternative, for a New Trial, dated Mar. 16, 2001.

- Cordis' Answering Brief in Opposition to BSC's Motion for JMOL or a New Trial on the Palmaz '762 Patent and the Schatz '332 Patents, dated Apr. 17, 2001.
- BSC's Reply Brief in Support of Its Motion for Judgment as a Matter of Law or, in the Alternative, for a New Trial, dated May 11, 2001.
- J. Rosch et al., Abstract, Expandable Gianturco-Type Wire Stents in Experimental Intrahepatic Portacaval Shunts, Program: "72nd Scientific Assembly and Annual Meeting of the Radiological Society of North America", Nov. 30-Dec. 5, 1986, *Radiology*, vol. 161, pp. 40-41, 1986.
- Cordis Corporation v. Boston Scientific*, Order Dated Mar. 27, 2006 (97-550-SLR).
- Cordis Corporation v. Boston Scientific*, Judgment in a Civil Case Dated Mar. 27, 2006 (97-550-SLR).
- Cordis Corporation v. Boston Scientific*, Memorandum Opinion Dated Mar. 27, 2006 (97-550-SLR).
- Cordis Corporation v. Boston Scientific*, Order Dated Mar. 27, 2006 (97-550-SLR).
- Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc., Guidant Corporation, Arterial Vascular Engineering, Inc., Boston Scientific Corporation and SCIMED Life Systems, Inc.*, Answer and Counterclaims of Defendant Advanced Cardiovascular Systems, Inc., Apr. 8, 1998 (Case No. 97-550-SLR).
- Boston Scientific Limited et al. v. Expandable Grafts Partnership and Boston Scientific Limited et al. v. Julio C. Palmaz*, Boston's Closing Submissions (UK Action Nos. 1493, 1495, 1496 and 1497).
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc., Guidant Corporation, Arterial Vascular Engineering, Inc., Boston Scientific Corporation and SCIMED Life Systems, Inc.*, Defendants' Answer, Nov. 12, 1997 (Case No. 97-550-SLR).
- Statement of Rejoinder in the Action on the Merits, Also Including an Amendment of Defendant's Final Position in the Principal Action, as Well as the Provisional Statement of Rejoinder in the Action on the Counterclaim in *EPG et al. v. Boston Scientific et al.* in Netherlands (Feb. 10, 1998).
- Statement of Answer in the Ancillary Appeal in *EPG et al. v. Boston Scientific et al.* in Netherlands (Mar. 10, 1998).
- Appeal filed by Expandable Grafts Partnership et al. in *EPG et al. v. Boston Scientific et al.* in Netherlands (Nov. 12, 1997).
- Title filed by Boston Scientific et al. in *EPG et al. v. Boston Scientific et al.* in Netherlands (Jan. 22, 1998).
- Deposition of Richard Schatz, M.D. in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.* taken on Jul. 14, 1998 (Civil Action No. 97-550-SLR).
- Jury Verdict form from the *Cordis Corporation et al. v. Boston Scientific Corporation, et al.* liability trial, undated.
- Trial testimony transcripts from the *Cordis Corporation et al. v. Boston Scientific Corporation et al.* liability trial dated Nov. 21, Nov. 27-Dec. 1, Dec. 4-8 and Dec. 11, 2000.
- Boston Scientific SCIMED, Inc. and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.*, Opening Expert Report of Stephen R. Hanson, Ph.D. (Civil Action No. 03-283-SLR).
- Boston Scientific SCIMED, Inc. and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.*, Opening Expert Report of Robson F. Storey, Ph.D. (Civil Action No. 03-283-SLR).
- Boston Scientific SCIMED, Inc. and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.*, Rebuttal Expert Report of Kinam Park, Ph.D. (Civil Action No. 03-283-SLR).
- Cordis Corporation v. Boston Scientific Corporation and SCIMED Life Systems, Inc.* (C.A. No. 03-027-SLR) and *Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.* (C.A. No. 03-283-SLR) Combined Post-Hearing Brief In Support Of Cordis Corporation's Motion For Preliminary Injunction in C.A. No. 03-027-SLR, And In Opposition to Plaintiffs' Motion For Preliminary Injunction in C.A. No. 03-283-SLR.
- Cordis Corporation v. Boston Scientific Corporation and SCIMED Life Systems, Inc.* (C.A. No. 03-027-SLR) *Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.* (C.A. No. 03-283-SLR), Boston Scientific's Opening Post-Hearing Brief.
- Wu et al., Silicone-covered self-expanding metallic stents for the palliation of malignant esophageal obstruction and esophagorespiratory fistulas: experience in 32 patients and a review of the literature, *Gastrointestinal Endoscopy*, 1994, pp. 22-33, vol. 40, No. 1, Portland Oregon.
- Binmoeller, et al., Silicone-Covered Expandable Metallic Stents in the Esophagus: An Experimental Study, *Endoscopy*, 1992, pp. 416-420, vol. 24, Georg Thieme Verlag Stuttgart New York.
- Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.*, Answering Memorandum in Opposition to Plaintiffs Motion for a Preliminary Injunction and Appendix thereto (Civil Action No. 03-283-SLR).
- Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.*, Plaintiff's Reply Brief in Support of Their Motion for Preliminary Injunction.
- Rhine, Polymers for Sustained Macromolecule Release: Procedures to Fabricate Reproducible Delivery Systems and Control Release Kinetics, *Journal of Pharmaceutical Sciences*, 1980, pp. 265-270, vol. 69, No. 3.
- Langer et al., Controlled Release of Macromolecules From Polymers, *Biomedical Polymers Polymeric Materials and Pharmaceuticals for Biomedical Use*, 1980, pp. 112-137, Academic Press, Inc., New York, NY.
- Langer et al., Applications of Polymeric Delivery Systems for Macromolecules and Factors Controlling Release Kinetics.
- Rhine et al., A Method to Achieve Zero-Order Release Kinetics From Polymer Matric Drug Delivery Systems, pp. 67-72.
- Langer et al., Polymers for the Sustained Release of Macromolecules: Controlled and Magnetically Modulated Systems, *Better Therapy With Existing Drugs: New Uses and Delivery Systems*; 1981, pp. 179-216, Merck Sharp & Dohme International, Rahway, NJ.
- Hsieh, et al., Zero-Order Controlled-Release Polymer Matrices for Micro-and-Macromolecules, *Journal of Pharmaceutical Sciences*, 1983 pp. 17-22, vol. 72, No. 1.
- Brown et al., In Vivo and In Vitro Release of Macromolecules from Polymeric Drug Delivery Systems, *Journal of Pharmaceutical Sciences*, 1983, pp. 1181-1185, vol. 72, No. 10.
- Langer, Implantable Controlled Release Systems, *Pharmac. Ther.*, 1983, pp. 35-51, vol. 21, printed in Great Britain.
- Kost et al., Controlled Release of Bioactive Agents, *Trends in Biotechnology*, 1984, pp. 47-51, vol. 2, No. 2, Elsevier BV Amsterdam.
- Bawa et al., An Explanation for the Controlled Release of Macromolecules from Polymers, *Journal of Controlled Release*, 1985, pp. 259-267, vol. 1 Elsevier Science BV Amsterdam.
- Leong et al., Polymeric controlled drug delivery, 1987, pp. 199-233, vol. 1/3, Elsevier Science Publishers BV Amsterdam.
- Langer, Polymeric Delivery Systems, *Targeting of Drugs 2 Optimization Strategies*, 1989, pp. 165-174, Plenum Press, New York and London.
- Langer, Biomaterials in Controlled Drug Delivery; New Perspectives from Biotechnological Advances; *Pharmaceutical Technology*, 1989, pp. 18, 23-24, 26, 28, 30.
- Langer, Controlled Release Systems, pp. 115-124.
- Laurencin et al., Polymeric Controlled Release Systems: New Methods for Drug Delivery, *Clinics in Laboratory Medicine*, 1987, pp. 301-323, vol. 7, No. 2, WB Saunders Company, Philadelphia.
- Langer, Biopolymers in Controlled Release Systems, *Polymeric Biomaterials*, pp. 161-169.
- Tsong-Pin Hsu et al., Polymers for the Controlled Release of Macromolecules: Effect of Molecular Weight of Ethylene-vinyl Acetate Copolymer, *Journal of Biomedical Materials Research*, 1985, pp. 445-460, vol. 19.
- Langer, Polymers and Drug Delivery Systems, *Long-Acting Contraceptive Delivery Systems*, 1983, pp. 23-32, Harper & Row, Philadelphia, PA.
- Langer, New Drug Delivery Systems: What the Clinician Can Expect, *Drug Therapy*, 1983, pp. 217-231.

- Langer, et al., Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review, *Rev. Macromol. Chem. Phys.*, 1983, pp. 61-126.
- Langer, Polymeric Delivery Systems for Controlled Drug Release, *Chem. Eng. Commun.* 1980, pp. 1-48-vol. 6, Gordon and Breach Science Publishers, Inc. USA.
- Langer, et al., Biocompatibility of Polymeric Delivery Systems for Macromolecules, *Journal of Biomedical Materials Research*, 1981, pp. 267-277, vol. 15.
- Langer, Controlled Release: A New Approach to Drug Delivery, *Technology Review*, 1981, pp. 26-34.
- Langer, et al., Sustained Release of Macromolecules from Polymers, *Polymeric Delivery Systems*, pp. 175-176, Gordon and Breach Science Publishers, New York.
- Langer, Polymers for the Sustained Release of Proteins and other Macromolecules, *Nature*, 1976, pp. 797, 263, 799-800, vol. 263, No. 5580.
- Baker, et al., Controlled Release: Mechanisms and Rates (1974).
- Hanson, et al., In Vivo Evaluation of Artificial Surfaces with a Nonhuman Primate Model of Arterial Thrombosis, *Lab Clin. Med.*, Feb. 1980, pp. 289-304.
- Baker, Controlled Release of Biologically Active Agents (1987) pp. 1-275.
- Cordis Corporation v. Boston Scientific Corporation* (CA. No. 03-27-SLR) and *Boston Scientific Scimed, Inc., v. Cordis Corporation and Johnson & Johnson, Incorporated* (CA. No. 03-283-SLR) Hearing Transcripts for Jul. 21, 2003, Jul. 22, 2003, Jul. 23, 2003.
- Cordis Corporation v. Boston Scientific Corporation et al.* (CA. No. 03-027-SLR), and *Boston Scientific Scimed, Inc. et al. v. Cordis Corporation et al.* (CA. No. 03-283-SLR), Boston Scientific's Post-Hearing Reply Brief and Exhibits Thereto, Sep. 12, 2003.
- Cordis Corporation v. Boston Scientific Corporation et al.* (CA. No. 03-027-SLR), and *Boston Scientific Scimed, Inc. et al. v. Cordis Corporation et al.* (CA. 03-283-SLR), Memorandum Order, Nov. 21, 2003.
- Cordis Corporation v. Boston Scientific Corporation et al.* (CA. No. 03-027-SLR), and *Boston Scientific Scimed, Inc. et al. v. Cordis Corporation et al.* (CA. No. 03-283-SLR), Deposition Transcript of Julio C. Palmaz.
- Plea Notes in *EPG et al. v. Boston Scientific et al.* in Netherlands (Sep. 12, 1997).
- Provisional Judgment *EPG et al. v. Boston Scientific et al.* in Netherlands (Oct. 29, 1997).
- Trial testimony transcripts from the *Cordis Corporation et al. v. Medtronic AVE Inc., et al.* liability trial dated Nov. 6-9, 13-17 and 20-21, 2000.
- Jury verdict form from the *Cordis Corporation et al. v. Medtronic AVE, Inc. et al.* liability trial.
- Hearing testimony transcript from the consolidated *Cordis Corporation et al. v. Medtronic AVE, Inc. et al.* and Boston Scientific Corporation et al. inequitable conduct hearing dated Feb. 7-9 and 12, 2001.
- Cordis Corporation v. Medtronic Ave., Inc. et al.* OPINION, 97-550-SLR, dated Mar. 28, 2002.
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc. et al.* (CA. No. 97-550-SLR), *Medtronic AVE, Inc. v. Cordis Corporation et al.* (CA. No. 97-700-SLR), *Boston Scientific Corporation v. Athicon, Inc. et al.* (CA. No. 98-19-SLR), Expert Report of John T. Goolkasian, Esq.
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc. et al.* (CA. No. 97-550-SLR), *Medtronic AVE, Inc. v. Cordis Corporation et al.* (CA. No. 97-700-SLR), *Boston Scientific Corporation v. Athicon, Inc. et al.* (CA. 98-19-SLR), Expert Report to John F. Witherspoon.

* cited by examiner

FIG. 1




FIG. 1a




FIG. 2a




FIG. 2b




FIG. 3a





FIG. 3b



FIG. 4



1

LOCAL DELIVERY OF RAPAMYCIN FOR TREATMENT OF PROLIFERATIVE SEQUELAE ASSOCIATED WITH PTCA PROCEDURES, INCLUDING DELIVERY USING A MODIFIED STENT

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of Ser. No. 10/951,385, filed Sep. 28, 2004, now pending, which in turn is a continuation of Ser. No. 10/408,328, filed Apr. 7, 2003, now issued as U.S. Pat. No. 6,808,536, which in turn is a continuation of application Ser. No. 09/874,117, filed Jun. 4, 2001, now issued as U.S. Pat. No. 6,585,764, which is a continuation of application Ser. No. 09/061,568, filed Apr. 16, 1998, now issued as U.S. Pat. No. 6,273,913, which in turn claims benefit of provisional application Ser. No. 60/044,692, filed Apr. 18, 1997. The disclosures of these prior applications are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

Delivery of rapamycin locally, particularly from an intravascular stent, directly from micropores in the stent body or mixed or bound to a polymer coating applied on stent, to inhibit neointimal tissue proliferation and thereby prevent restenosis. This invention also facilitates the performance of the stent in inhibiting restenosis.

BACKGROUND OF THE INVENTION

Re-narrowing (restenosis) of an arteriosclerotic coronary artery after percutaneous transluminal coronary angioplasty (PTCA) occurs in 10–50% of patients undergoing this procedure and subsequently requires either further angioplasty or coronary artery bypass graft. While the exact hormonal and cellular processes promoting restenosis are still being determined, our present understanding is that the process of PTCA, besides opening the arteriosclerotically obstructed artery, also injures resident coronary arterial smooth muscle cells (SMC). In response to this injury, adhering platelets, infiltrating macrophages, leukocytes, or the smooth muscle cells (SMC) themselves release cell derived growth factors with subsequent proliferation and migration of medial SMC through the internal elastic lamina to the area of the vessel intima. Further proliferation and hyperplasia of intimal SMC and, most significantly, production of large amounts of extracellular matrix over a period of 3–6 months results in the filling in and narrowing of the vascular space sufficient to significantly obstruct coronary blood flow.

Several recent experimental approaches to preventing SMC proliferation have shown promise although the mechanisms for most agents employed are still unclear. Heparin is the best known and characterized agent causing inhibition of SMC proliferation both in vitro and in animal models of balloon angioplasty-mediated injury. The mechanism of SMC inhibition with heparin is still not known but may be due to any or all of the following: 1) reduced expression of the growth regulatory protooncogenes c-fos and c-myc, 2) reduced cellular production of tissue plasminogen activator; are 3) binding and dequstration of growth regulatory factors such as fibrovalent growth factor (FGF).

Other agents which have demonstrated the ability to reduce myointimal thickening in animal models of balloon

2

vascular injury are angiopeptin (a somatostatin analog), calcium channel blockers, angiotensin converting enzyme inhibitors (captopril, cilazapril), cyclosporin A, trapidil (an antianginal, antiplatelet agent), terbinafine (antifungal), colchicine and taxol (antitubulin antiproliferatives), and c-myc and c-myb antisense oligonucleotides.

Additionally, a goat antibody to the SMC mitogen platelet derived growth factor (PDGF) has been shown to be effective in reducing myointimal thickening in a rat model of balloon angioplasty injury, thereby implicating PDGF directly in the etiology of restenosis. Thus, while no therapy has as yet proven successful clinically in preventing restenosis after angioplasty, the in vivo experimental success of several agents known to inhibit SMC growth suggests that these agents as a class have the capacity to prevent clinical restenosis and deserve careful evaluation in humans.

Coronary heart disease is the major cause of death in men over the age of 40 and in women over the age of fifty in the western world. Most coronary artery-related deaths are due to atherosclerosis. Atherosclerotic lesions which limit or obstruct coronary blood flow are the major cause of ischemic heart disease related mortality and result in 500,000–600,000 deaths in the United States annually. To arrest the disease process and prevent the more advanced disease states in which the cardiac muscle itself is compromised, direct intervention has been employed via percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) PTCA is a procedure in which a small balloon-tipped catheter is passed down a narrowed coronary artery and then expanded to re-open the artery. It is currently performed in approximately 250,000–300,000 patients each year. The major advantage of this therapy is that patients in which the procedure is successful need not undergo the more invasive surgical procedure of coronary artery bypass graft. A major difficulty with PTCA is the problem of post-angioplasty closure of the vessel, both immediately after PTCA (acute reocclusion) and in the long term (restenosis).

The mechanism of acute reocclusion appears to involve several factors and may result from vascular recoil with resultant closure of the artery and/or deposition of blood platelets along the damaged length of the newly opened blood vessel followed by formation of a fibrin/red blood cell thrombus. Recently, intravascular stents have been examined as a means of preventing acute reclosure after PTCA.

Restenosis (chronic reclosure) after angioplasty is a more gradual process than acute reocclusion: 30% of patients with subtotal lesions and 50% of patients with chronic total lesions will go on to restenosis after angioplasty. While the exact mechanism for restenosis is still under active investigation, the general aspects of the restenosis process have been identified.

In the normal arterial wall, smooth muscle cells (SMC) proliferate at a low rate (<0.1%/day; ref). SMC in vessel wall exists in a *contractile* phenotype characterized by 80–90% of the cell cytoplasmic volume occupied with the contractile apparatus. Endoplasmic reticulum, golgi bodies, and free ribosomes are few and located in the perinuclear region. Extracellular matrix surrounds SMC and is rich in heparin-like glycosylaminoglycans which are believed to be responsible for maintaining SMC in the contractile phenotypic state.

Upon pressure expansion of an intracoronary balloon catheter during angioplasty, smooth muscle cells within the arterial wall become injured. Cell derived growth factors such as platelet derived growth factor (PDGF), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF),

etc. released from platelets (i.e., PDGF) adhering to the damaged arterial luminal surface, invading macrophages and/or leukocytes, or directly from SMC (i.e., BFGF) provoke a proliferation and migratory response in medial SMC. These cells undergo a phenotypic change from the contractile phenotype to a synthetic phenotype characterized by only few contractile filament bundles but extensive rough endoplasmic reticulum, golgi and free ribosomes. Proliferation/migration usually begins within 1–2 days post-injury and peaks at 2 days in the media, rapidly declining thereafter (Campbell et al., In: Vascular Smooth Muscle Cells in Culture, Campbell, J. H. and Campbell, G. R., Eds, CRC Press, Boca Raton, 1987, pp. 39–55); Clowes, A. W. and Schwartz, S. M., Circ. Res. 56:139–145, 1985).

Finally, daughter synthetic cells migrate to the intimal layer of arterial smooth muscle and continue to proliferate. Proliferation and migration continues until the damaged luminal endothelial layer regenerates at which time proliferation ceases within the intima, usually within 7–14 days postinjury. The remaining increase in intimal thickening which occurs over the next 3–6 months is due to an increase in extracellular matrix rather than cell number. Thus, SMC migration and proliferation is an acute response to vessel injury while intimal hyperplasia is a more chronic response. (Liu et al., Circulation, 79:1374–1387, 1989).

Patients with symptomatic reocclusion require either repeat PTCA or CABG. Because 30–50% of patients undergoing PTCA will experience restenosis, restenosis has clearly limited the success of PTCA as a therapeutic approach to coronary artery disease. Because SMC proliferation and migration are intimately involved with the pathophysiological response to arterial injury, prevention of SMC proliferation and migration represents a target for pharmacological intervention in the prevention of restenosis.

SUMMARY OF THE INVENTION

Novel Features and Applications to Stent Technology
Currently, attempts to improve the clinical performance of stents have involved some variation of either applying a coating to the metal, attaching a covering or membrane, or embedding material on the surface via ion bombardment. A stent designed to include reservoirs is a new approach which offers several important advantages over existing technologies.

Local Drug Delivery from a Stent to Inhibit Restenosis

In this application, it is desired to deliver a therapeutic agent to the site of arterial injury. The conventional approach has been to incorporate the therapeutic agent into a polymer material which is then coated on the stent. The ideal coating material must be able to adhere strongly to the metal stent both before and after expansion, be capable of retaining the drug at a sufficient load level to obtain the required dose, be able to release the drug in a controlled way over a period of several weeks, and be as thin as possible so as to minimize the increase in profile. In addition, the coating material should not contribute to any adverse response by the body (i.e., should be non-thrombogenic, non-inflammatory, etc.). To date, the ideal coating material has not been developed for this application.

An alternative would be to design the stent to contain reservoirs which could be loaded with the drug. A coating or membrane of biocompatible material could be applied over the reservoirs which would control the diffusion of the drug from the reservoirs to the artery wall.

One advantage of this system is that the properties of the coating can be optimized for achieving superior biocompat-

ibility and adhesion properties, without the addition requirement of being able to load and release the drug. The size, shape, position, and number of reservoirs can be used to control the amount of drug, and therefore the dose delivered.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will be better understood in connection with the following figures in which FIGS. 1 and 1A are top views and section views of a stent containing reservoirs as described in the present invention;

FIGS. 2a and 2b are similar views of an alternate embodiment of the stent with open ends;

FIGS. 3a and 3b are further alternate figures of a device containing a grooved reservoir; and

FIG. 4 is a layout view of a device containing a reservoir as in FIG. 3.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

Pharmacological attempts to prevent restenosis by pharmacologic means have thus far been unsuccessful and all involve systemic administration of the trial agents. Neither aspirin-dipyridamole, ticlopidine, acute heparin administration, chronic warfarin (6 months) nor methylprednisolone have been effective in preventing restenosis although platelet inhibitors have been effective in preventing acute reocclusion after angioplasty. The calcium antagonists have also been unsuccessful in preventing restenosis, although they are still under study. Other agents currently under study include thromboxane inhibitors, prostacyclin mimetics, platelet membrane receptor blockers, thrombin inhibitors and angiotensin converting enzyme inhibitors. These agents must be given systemically, however, and attainment of a therapeutically effective dose may not be possible; antiproliferative (or anti-restenosis) concentrations may exceed the known toxic concentrations of these agents so that levels sufficient to produce smooth muscle inhibition may not be reached (Lang et al., 42 Ann. Rev. Med., 127–132 (1991); Popma et al., 84 Circulation, 1426–1436 (1991)).

Additional clinical trials in which the effectiveness for preventing restenosis of dietary fish oil supplements, thromboxane receptor antagonists, cholesterol lowering agents, and serotonin antagonists has been examined have shown either conflicting or negative results so that no pharmacological agents are as yet clinically available to prevent post-angioplasty restenosis (Franklin, S. M. and Faxon, D. P., 4 Coronary Artery Disease, 2-32-242 (1993); Serruys, P. W. et al., 88 Circulation, (part 1) 1588–1601, (1993).

Conversely, stents have proven useful in preventing reducing the proliferation of restenosis. Stents, such as the stent 10 seen in layout in FIG. 4, balloon-expandable slotted metal tubes (usually but not limited to stainless steel), which when expanded within the lumen of an angioplastied coronary artery, provide structural support to the arterial wall. This support is helpful in maintaining an open path for blood flow. In two randomized clinical trials, stents were shown to increase angiographic success after PTCA, increase the stenosed blood vessel lumen and to reduce the lesion recurrence at 6 months (Serruys et al., 331 New Eng Jour. Med, 495, (1994); Fischman et al., 331 New Eng Jour. Med, 496–501 (1994). Additionally, in a preliminary trial, heparin coated stents appear to possess the same benefit of reduction in stenosis diameter at follow-up as was observed with non-heparin coated stents. Additionally, heparin coating appears to have the added benefit of producing a reduction

in sub-acute thrombosis after stent implantation (Serruys et al., 93 *Circulation*, 412-422, (1996). Thus, 1) sustained mechanical expansion of a stenosed coronary artery has been shown to provide some measure of restenosis prevention, and 2) coating of stents with heparin has demonstrated both the feasibility and the clinical usefulness of delivering drugs to local, injured tissue off the surface of the stent.

Numerous agents are being actively studied as antiproliferative agents for use in restenosis and have shown some activity in experimental animal models. These include: heparin and heparin fragments (Clowes and Karnovsky, 265 *Nature*, 25-626, (1977); Guyton, J. R. et al. 46 *Circ. Res.*, 625-634, (1980); Clowes, A. W. and Clowes, M. M., 52 *Lab. Invest.*, 611-616, (1985); Clowes, A. W. and Clowes, M. M., 58 *Circ. Res.*, 839-845 (1986); Majesky et al., 61 *Circ Res.*, 296-300, (1987); Snow et al., 137 *Am. J. Pathol.*, 313-330 (1990); Okada, T. et al., 25 *Neurosurgery*, 92-898, (1989) colchicine (Currier, J. W. et al., 80 *Circulation*, 11-66, (1989), taxol (ref), angiotensin converting enzyme (ACE) inhibitors (Powell, J. S. et al., 245 *Science*, 186-188 (1989), angiopeptin (Lundergan, C. F. et al., 17 *Am. J. Cardiol. (Suppl. B)*; 132B-136B (1991), Cyclosporin A (Jonasson, L. et al., 85 *Proc. Natl. Acad. Sci.*, 2303 (1988), goat-anti-rabbit PDGF antibody (Ferns, G. A. A., et al., 253 *Science*, 1129-1132 (1991), terbinafine (Nemecek, G. M. et al., 248 *J. Pharmacol. Exp. Thera.*, 1167-11747 (1989), trapidil (Liu, M. W. et al., 81 *Circulation*, 1089-1093 (1990), interferon-gamma (Hansson, G. K. and Holm, 84 *J. Circulation*, 1266-1272 (1991), steroids (Colburn, M. D. et al., 15 *J. Vasc. Surg.*, 510-518 (1992), see also Berk, B. C. et al., 17 *J. Am. Coll. Cardiol.*, 111B-117B (1991), ionizing radiation (ref), fusion toxins (ref) antisense oligonucleotides (ref), gene vectors (ref), and rapamycin (see below).

Of particular interest in rapamycin. Rapamycin is a macrolide antibiotic which blocks IL-2-mediated T-cell proliferation and possesses antiinflammatory activity. While the precise mechanism of rapamycin is still under active investigation, rapamycin has been shown to prevent the G.sub.1 to 5 phase progression of T-cells through the cell cycle by inhibiting specific cell cyclins and cyclin-dependent protein kinases (Siekierka, *Immunol. Res.* 13: 110-116, 1994). The antiproliferative action of rapamycin is not limited to T-cells; Marx et al. (*Circ Res* 76:412-417, 1995) have demonstrated that rapamycin prevents proliferation of both rat and human SMC in vitro while Poon et al. have shown the rat, porcine, and human SMC migratin can also be inhibited by rapamycin (*J Clin Invest* 98: 2277-2283, 1996). Thus, rapamycin is capable of inhibiting both the inflammatory response known to occur after arterial injury and stent implantation, as well as the SMC hyperproliferative response. In fact, the combined effects of rapamycin have been demonstrated to result in a diminished SMC hyperproliferative response in a rat femoral artery graft model and in both rat and porcine arterial balloon injury models (Gregory et al., *Transplantation* 55:1409-1418, 1993; Gallo et al., in press, (1997)). These observations clearly support the potential use of rapamycin in the clinical setting of post-angioplasty restenosis.

Although the ideal agent for restenosis has not yet been identified, some desired properties are clear: inhibition of local thrombosis without the risk systemic bleeding complications and continuous and prevention of the dequale of arterial injury, including local inflammation and sustained prevention smooth muscle proliferation at the site of angioplasty without serious systemic complications. Inasmuch as stents prevent at least a portion of the restenosis process, an agent which prevents inflammation and the proliferation of

SMC combined with a stent may provide the most efficacious treatment for post-angioplasty restenosis.

Experiments

Agents: Rapamycin (sirolimus) structural analogs (macrocyclic lactones) and inhibitors of cell-cycle progression.

Delivery Methods: These can vary:

Local delivery of such agents (rapamycin) from the struts of a stent, from a stent graft, grafts, stent cover or sheath.

Involving comixture with polymers (both degradable and nondegrading) to hold the drug to the stent or graft.

or entrapping the drug into the metal of the stent or graft body which has been modified to contain micropores or channels, as will be explained further herein.

or including covalent binding of the drug to the stent via solution chemistry techniques (such as via the Carmeda process) or dry chemistry techniques (e.g. vapour deposition methods such as rf-plasma polymerization) and combinations thereof.

Catheter delivery intravascularly from a tandem balloon or a porous balloon for intramural uptake.

Extravascular delivery by the pericardial route.

Extravascular delivery by the advential application of sustained release formulations.

Uses:

for inhibition of cell proliferation to prevent neointimal proliferation and restenosis.

prevention of tumor expansion from stents.

preventing growth of tissue into catheters and shunts inducing their failure.

1. Experimental Stent Delivery Method—Delivery from Polymer Matrix:

Solution of Rapamycin, prepared in a solvent miscible with polymer carrier solution, is mixed with solution of polymer at final concentration range 0.001 weight % to 30 weight % of drug. Polymers are biocompatible (i.e., not elicit any negative tissue reaction or promote mural thrombus formation) and degradable, such as lactone-based polyesters or copolyesters, e.g., polylactide, polycaprolactone-glycolide, polyorthoesters, polyanhydrides; poly-amino acids; polysaccharides; polyphosphazenes; poly(ether-ester) copolymers, e.g., PEO-PLLA, or blends thereof. Nonabsorbable biocompatible polymers are also suitable candidates. Polymers such as polydimethylsiloxane; poly(ethylene-vinylacetate); acrylate based polymers or copolymers, e.g., poly(hydroxyethyl methacrylate, polyvinyl pyrrolidinone; fluorinated polymers such as polytetrafluoroethylene; cellulose esters.

Polymer/drug mixture is applied to the surfaces of the stent by either dip-coating, or spray coating, or brush coating or dip/spin coating or combinations thereof, and the solvent allowed to evaporate to leave a film with entrapped rapamycin.

2. Experimental Stent Delivery Method—Delivery from Microporous Depots in Stent Through a Polymer Membrane Coating:

Stent, whose body has been modified to contain micropores or channels is dipped into a solution of Rapamycin, range 0.001 wt % to saturated, in organic solvent such as acetone or methylene chloride, for sufficient time to allow solution to permeate into the pores. (The dipping solution can also be compressed to improve the loading efficiency.) After solvent has been allowed to evaporate, the stent is dipped briefly in fresh solvent to remove excess surface bound drug. A solution of polymer, chosen from any identified in the first experimental method, is applied to the

stent as detailed above. This outer layer of polymer will act as diffusion-controller for release of drug.

3. Experimental Stent Delivery Method—Delivery Via Lysis of a Covalent Drug Tether:

Rapamycin is modified to contain a hydrolytically or enzymatically labile covalent bond for attaching to the surface of the stent which itself has been chemically derivatized to allow covalent immobilization. Covalent bonds such as ester, amides or anhydrides may be suitable for this.

4. Experimental Method—Pericardial Delivery:

A: Polymeric Sheet

Rapamycin is combined at concentration range previously highlighted, with a degradable polymer such as poly(caprolactone-glycolid-e) or non-degradable polymer, e.g., polydimethylsiloxane, and mixture cast as a thin sheet, thickness range 10.mu. to 1000.mu. The resulting sheet can be wrapped perivascularly on the target vessel. Preference would be for the absorbable polymer.

B: Conformal Coating:

Rapamycin is combined with a polymer that has a melting temperature just above 37° C., range 40°–45° C. Mixture is applied in a molten state to the external side of the target vessel. Upon cooling to body temperature the mixture solidifies conformably to the vessel wall. Both non-degradable and absorbable biocompatible polymers are suitable.

As seen in the figures it is also possible to modify currently manufactured stents in order to adequately provide the drug dosages such as rapamycin. As seen in FIGS. 1a, 2a and 3a, any stent strut 10, 20, 30 can be modified to have a certain reservoir or channel 11, 21, 31. Each of these reservoirs can be open or closed as desired. These reservoirs can hold the drug to be delivered. FIG. 4 shows a stent 40 with a reservoir 45 created at the apex of a flexible strut. Of course, this reservoir 45 is intended to be useful to deliver rapamycin or any other drug at a specific point of flexibility of the stent. Accordingly, this concept can be useful for “second generation” type stents.

In any of the foregoing devices, however, it is useful to have the drug dosage applied with enough specificity and

enough concentration to provide an effective dosage in the lesion area. In this regard, the reservoir size in the stent struts must be kept at a size of about 0.0005" to about 0.003". Then, it should be possible to adequately apply the drug dosage at the desired location and in the desired amount.

These and other concepts will be disclosed herein. It would be apparent to the reader that modifications are possible to the stent or the drug dosage applied. In any event, however, the any obvious modifications should be perceived to fall within the scope of the invention which is to be realized from the attached claims and their equivalents.

What is claimed:

1. A device comprising a metallic stent, a biocompatible, nonabsorbable polymeric carrier, and a therapeutic agent, wherein:

said polymeric carrier comprises an acrylate-based polymer or copolymer, a fluorinated polymer, or a mixture thereof, and

said therapeutic agent is rapamycin, or a macrocyclic lactone analog thereof, and is present in an amount effective to inhibit neointimal proliferation.

2. The device according to claim 1 wherein said therapeutic agent is a macrocyclic lactone analog of rapamycin.

3. The device according to claim 1 that provides a controlled release of said therapeutic agent over a period of several weeks.

4. The device according to claim 2 that provides a controlled release of said therapeutic agent over a period of several weeks.

5. A method of inhibiting neointimal proliferation in a coronary artery resulting from percutaneous transluminal coronary angioplasty comprising implanting a device according to any one of claims 1 to 4 in the lumen of said coronary artery.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,217,286 B2
APPLICATION NO. : 11/467035
DATED : May 15, 2007
INVENTOR(S) : Robert Falotico et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title Page.
Item (56) **References Cited,**

U.S. PATENT DOCUMENTS

Page 2, "5,195,984 A" reference, delete "Schalz" and insert -- Schatz --.

Page 2, insert missing reference -- 5,354,257 10/94 Roubin, et al. --.

OTHER PUBLICATIONS

Page 7, "D.I. 699, Motion by Defendant BSC and Scimed Life Systems, Inc." reference, delete "U.S. Appl. No. 5,902,332" and insert -- U.S. Patent No. 5,902,332 --.

Page 7, "D.I. 896, Order Denying Motion for Summary Judgement" reference, delete "U.S. Appl. No. 5,902,332" and insert -- U.S. Patent No. 5,902,332 -- (both occurrences).

Page 7, "ACS, Inc.'s and Guidant Corp.'s Opening Brief in Support" reference, delete "U.S. Appl. No. 5,102,417" and insert -- U.S. Appl. No. 5,102,417" and insert -- U.S. Patent No. 5,102,417 --.

Page 9, "Letter from B. Tobor to R. Schatz" reference, delete "Implication" and insert -- Implantation --.

Page 9, "Richard A. Schatz, Article: "New Technology in Angioplasty:" reference, delete "12-1 26," and insert -- 12-1 16, --.

Page 10, "Boston Scientific Limited et al. v. Expandable Grafts Partnership" reference, delete "Limted" and insert -- Limited --.

Page 12, "Hearing testimony transcript from the consolidated Cordis Corporation et al." reference, delete "trascript" and insert -- transcript --.

Column 2,

Line 53, delete "arterial will," and insert -- arterial wall, --.

Column 5,

Line 22, delete "(Suppi. B);" and insert -- (Suppl. B); --.

Line 23, delete "Nati," and insert -- Natl. --.

Line 46, delete "migratin" and insert -- migration --.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,217,286 B2
APPLICATION NO. : 11/467035
DATED : May 15, 2007
INVENTOR(S) : Robert Falotico et al.

Page 2 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 6,

Line 30, delete "preventingrowth" and insert -- prevent ingrowth --.

Signed and Sealed this

Seventeenth Day of June, 2008

A handwritten signature in black ink, reading "Jon W. Dudas". The signature is stylized, with a large loop for the "J" and a cursive "Dudas".

JON W. DUDAS
Director of the United States Patent and Trademark Office



US007223286B2

(12) **United States Patent**
Wright et al.

(10) **Patent No.:** **US 7,223,286 B2**

(45) **Date of Patent:** ***May 29, 2007**

(54) **LOCAL DELIVERY OF RAPAMYCIN FOR TREATMENT OF PROLIFERATIVE SEQUELAE ASSOCIATED WITH PTCA PROCEDURES, INCLUDING DELIVERY USING A MODIFIED STENT**

(58) **Field of Classification Search** 623/1.42–1.48;
427/2.1–2.31
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

861,659 A	7/1907	Johnston	464/147
3,051,677 A	8/1962	Rexford	522/156
3,279,996 A	10/1966	Long et al.	424/424
3,526,005 A	9/1970	Bokros	623/11.11
3,599,641 A	8/1971	Sheridan	604/256
3,657,744 A	4/1972	Ersek	128/898

(75) Inventors: **Carol Wright**, Somerset, NJ (US);
Gerard H. Llanos, Stewartsville, NJ (US); **Ronald Rakos**, Neshanic Station, NJ (US); **Kristin King**, Mahwah, NJ (US); **Robert Falotico**, Bell Mead, NJ (US)

(73) Assignee: **Cordis Corporation**, Miami Lakes, FL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 265 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **10/951,385**

(22) Filed: **Sep. 28, 2004**

(65) **Prior Publication Data**

US 2005/0085902 A1 Apr. 21, 2005

Related U.S. Application Data

(63) Continuation of application No. 10/408,328, filed on Apr. 7, 2003, now Pat. No. 6,808,536, which is a continuation of application No. 09/874,117, filed on Jun. 4, 2001, now Pat. No. 6,585,764, which is a continuation of application No. 09/061,568, filed on Apr. 16, 1998, now Pat. No. 6,273,913.

(60) Provisional application No. 60/044,692, filed on Apr. 18, 1997.

(51) **Int. Cl.**
A61F 2/06 (2006.01)

(52) **U.S. Cl.** 623/1.42

(Continued)

FOREIGN PATENT DOCUMENTS

DE 3205942 A1 9/1983

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 07/819,314, filed Jan. 9, 1992, Morris.

(Continued)


Primary Examiner—Suzette Gherbi

(74) *Attorney, Agent, or Firm*—Woodcock Washburn LLP

(57) **ABSTRACT**

Methods of preparing intravascular stents with a polymeric coating containing macrocyclic lactone (such as rapamycin or its analogs), stents and stent graphs with such coatings, and methods of treating a coronary artery with such devices. The macrocyclic lactone-based polymeric coating facilitates the performance of such devices in inhibiting restenosis.

77 Claims, 2 Drawing Sheets



U.S. PATENT DOCUMENTS

3,744,596 A	7/1973	Sander	188/203	5,049,132 A	9/1991	Shaffer et al.	604/101.02
3,779,805 A	12/1973	Alsberg	427/105	5,049,403 A	9/1991	Larm et al.	427/2.1
3,929,992 A	12/1975	Sehgal et al.	424/122	5,053,048 A	10/1991	Pinchuk	623/1.43
3,932,627 A	1/1976	Margraf	514/56	5,059,166 A	10/1991	Fischell et al.	600/3
3,948,254 A	4/1976	Zaffaroni	128/833	5,061,275 A	10/1991	Wallsten et al.	623/1.22
3,952,334 A	4/1976	Bokros et al.	623/11.11	5,061,750 A	10/1991	Feijen et al.	525/54.1
3,968,800 A	7/1976	Vilasi	606/198	5,064,435 A	11/1991	Porter	623/23.7
4,069,307 A	1/1978	Higuchi et al.	424/432	5,092,877 A	3/1992	Pinchuk	128/898
4,076,285 A	2/1978	Martinez	285/332	5,102,417 A	4/1992	Palmaz	606/195
4,292,965 A	10/1981	Nash et al.	128/833	5,104,404 A	4/1992	Wolff	623/1.16
4,299,226 A	11/1981	Banka	604/509	5,116,365 A	5/1992	Hillstead	623/1.15
4,300,244 A	11/1981	Bokros	623/1.13	5,122,154 A	6/1992	Rhodes	623/1.13
4,312,920 A	1/1982	Pierce et al.	428/425.5	5,131,908 A	7/1992	Dardik et al.	600/36
4,321,711 A	3/1982	Mano	623/1.43	5,133,732 A	7/1992	Wiktor	623/1.22
4,323,071 A	4/1982	Simpson et al.	606/194	5,134,192 A	7/1992	Feijen et al.	525/54.1
4,390,599 A	6/1983	Broyles	428/597	5,135,536 A	8/1992	Hillstead	606/195
4,413,359 A	11/1983	Akiyama et al.	623/23.72	5,163,952 A	11/1992	Froix	623/1.18
4,423,183 A	12/1983	Close	524/546	5,163,958 A	11/1992	Pinchuk	623/23.49
4,441,216 A	4/1984	Ionescu et al.	623/2.19	5,171,217 A	12/1992	March et al.	604/507
4,503,569 A	3/1985	Dotter	623/1.19	5,171,262 A	12/1992	MacGregor	623/1.15
4,512,338 A	4/1985	Balko et al.	606/108	5,176,660 A	1/1993	Truckai	604/527
4,550,447 A	11/1985	Seiler, Jr. et al.	623/1.32	5,176,972 A	1/1993	Bloom et al.	430/14
4,553,545 A	11/1985	Maass et al.	606/198	5,178,618 A	1/1993	Kandarpa	606/28
4,560,374 A	12/1985	Hammerslag	604/509	5,180,366 A	1/1993	Woods	604/96.01
4,562,596 A	1/1986	Kornberg	623/1.32	5,182,317 A	1/1993	Winters et al.	523/112
4,565,740 A	1/1986	Golander et al.	428/409	5,185,408 A	2/1993	Tang et al.	525/415
4,580,568 A	4/1986	Gianturco	606/198	5,192,307 A	3/1993	Wall	623/1.2
4,613,665 A	9/1986	Larm	536/20	5,195,984 A	3/1993	Schatz	623/1.2
4,642,111 A	2/1987	Sakamoto et al.	424/492	5,213,576 A	5/1993	Abiuso et al.	604/103.01
4,655,771 A	4/1987	Wallsten	623/1.22	5,213,898 A	5/1993	Larm et al.	428/422
4,656,083 A	4/1987	Hoffman et al.	442/123	5,217,483 A	6/1993	Tower	623/1.15
4,676,241 A	6/1987	Webb et al.	128/207.14	5,222,971 A	6/1993	Willard et al.	606/198
4,678,466 A	7/1987	Rosenwald	424/427	5,226,913 A	7/1993	Pinchuk	140/71 R
4,687,482 A	8/1987	Hanson	623/1.49	5,234,456 A	8/1993	Silvestrini	623/1.2
4,689,046 A	8/1987	Bokros	623/2.31	5,246,445 A	9/1993	Yachia et al.	623/1.2
4,731,054 A	3/1988	Billeter et al.	604/93.01	5,258,020 A	11/1993	Froix	128/898
4,733,665 A	3/1988	Palmaz	606/108	5,258,021 A	11/1993	Duran	623/2.3
4,739,762 A	4/1988	Palmaz	623/1.11	5,262,451 A	11/1993	Winters et al.	523/112
4,740,207 A	4/1988	Kreamer	623/1.15	5,266,073 A	11/1993	Wall	623/1.2
4,749,585 A	6/1988	Greco et al.	428/422	5,272,012 A	12/1993	Opolski	428/423.1
4,753,652 A	6/1988	Langer et al.	623/1.42	4,733,665 A	1/1994	Palmaz	606/108
4,760,849 A	8/1988	Kropf	606/191	5,275,622 A	1/1994	Lazarus et al.	623/1.11
4,768,507 A	9/1988	Fischell et al.	623/1.11	5,282,823 A	2/1994	Schwartz et al.	623/1.22
4,776,337 A	10/1988	Palmaz	623/1.11	5,282,824 A	2/1994	Gianturco	623/1.13
4,786,500 A	11/1988	Wong	424/422	5,283,257 A	2/1994	Gregory et al.	514/458
4,787,899 A	11/1988	Lazarus	623/1.11	5,288,711 A	2/1994	Mitchell et al.	424/122
4,800,882 A	1/1989	Gianturco	606/194	5,290,305 A	3/1994	Inoue	623/1.2
4,810,784 A	3/1989	Larm	536/20	5,292,331 A	3/1994	Boneau	623/1.16
4,856,516 A	8/1989	Hillstead	606/194	5,292,802 A	3/1994	Rhee et al.	525/54.1
4,871,357 A	10/1989	Hsu et al.	604/266	5,304,121 A	4/1994	Sahatjian	604/509
4,872,867 A	10/1989	Joh	604/269	5,304,200 A	4/1994	Spaulding	623/1.16
4,876,109 A	10/1989	Mayer et al.	604/269	5,306,250 A	4/1994	March et al.	604/104
4,886,062 A	12/1989	Wiktor	606/194	5,308,862 A	5/1994	Ohlstein	514/411
4,907,336 A	3/1990	Gianturco	29/515	5,308,889 A	5/1994	Rhee et al.	523/113
4,916,193 A	4/1990	Tang et al.	525/413	5,314,444 A	5/1994	Gianturco	606/195
4,954,126 A	9/1990	Wallsten	600/36	5,314,472 A	5/1994	Fontaine	623/1.22
4,969,458 A	11/1990	Wiktor	623/1.11	5,328,471 A	7/1994	Slepian	604/101.03
4,990,131 A	2/1991	Dardik et al.	600/36	5,334,301 A	8/1994	Heinke et al.	204/267
4,990,155 A	2/1991	Wilkoff	606/191	5,336,518 A	8/1994	Narayanan et al.	427/470
4,994,071 A	2/1991	MacGregor	606/194	5,338,770 A	8/1994	Winters et al.	523/112
4,994,298 A	2/1991	Yasuda	427/490	5,342,348 A	8/1994	Kaplan	604/891.1
4,998,923 A	3/1991	Samson et al.	606/194	5,342,387 A	8/1994	Summers	606/198
5,015,253 A	5/1991	MacGregor	623/1.15	5,342,621 A	8/1994	Eury	606/198
5,019,090 A	5/1991	Pinchuk	623/1.15	5,354,257 A	10/1994	Roubin et al.	600/7
5,019,096 A	5/1991	Fox, Jr. et al.	600/36	5,354,308 A	10/1994	Simon et al.	623/1.15
5,029,877 A	7/1991	Fedeli	277/354	5,356,433 A	10/1994	Rowland et al.	424/422
5,034,265 A	7/1991	Hoffman et al.	442/126	5,366,504 A	11/1994	Andersen et al.	623/1.5
5,035,706 A	7/1991	Giantureo et al.	606/198	5,368,566 A	11/1994	Crocker	604/101.02
5,041,100 A	8/1991	Rowland et al.	604/265	5,370,683 A	12/1994	Fontaine	623/1.22
5,041,126 A	8/1991	Gianturco	623/1.15	5,370,691 A	12/1994	Samson	623/1.22
5,047,020 A	9/1991	Hsu	604/266	5,375,612 A	12/1994	Cottenceau et al.	128/899
				5,376,112 A	12/1994	Duran	623/1.26
				5,378,475 A	1/1995	Smith et al.	424/473

5,380,299 A	1/1995	Fearnot et al.	604/265	5,605,696 A	2/1997	Eury et al.	424/423
5,382,261 A	1/1995	Palmaz	606/158	5,607,463 A	3/1997	Schwartz et al.	623/1.44
5,383,853 A	1/1995	Jung et al.	604/103.04	5,607,475 A	3/1997	Cahalan et al.	424/423
5,383,928 A	1/1995	Scott et al.	623/1.12	5,609,629 A	3/1997	Fearnot et al.	623/1.42
5,387,235 A	2/1995	Chuter	623/1.11	5,616,608 A	4/1997	Kinsella et al.	514/449
5,389,106 A	2/1995	Tower	623/1.15	5,620,984 A	4/1997	Bianco et al.	514/263.36
5,393,772 A	2/1995	Yue et al.	514/410	5,621,102 A	4/1997	Bianco et al.	544/267
5,395,390 A	3/1995	Simon et al.	623/1.18	5,622,975 A	4/1997	Singh et al.	514/324
5,397,355 A	3/1995	Marin et al.	623/1.2	5,624,411 A	4/1997	Tuch	604/265
5,399,352 A	3/1995	Hanson	424/423	5,628,785 A	5/1997	Schwartz et al.	128/898
5,403,341 A	4/1995	Solar	606/198	5,629,077 A	5/1997	Turnlund et al.	623/1.15
5,405,377 A	4/1995	Cragg	623/1.2	5,629,315 A	5/1997	Bianco et al.	514/263.36
5,409,696 A	4/1995	Narayanan et al.	424/78.17	5,632,763 A	5/1997	Glastra	623/1.15
5,411,549 A	5/1995	Peters	623/1.15	5,632,771 A	5/1997	Boatman et al.	623/1.15
5,415,619 A	5/1995	Lee et al.	600/36	5,632,776 A	5/1997	Kurumatani et al.	424/423
5,417,969 A	5/1995	Hsu et al.	424/78.27	5,632,840 A	5/1997	Campbell	156/196
5,419,760 A	5/1995	Narciso, Jr.	604/8	5,635,201 A	6/1997	Fabo	424/443
D359,802 S	6/1995	Fontaine	D24/155	5,637,113 A	6/1997	Tartaglia et al.	623/1.42
5,421,955 A	6/1995	Lau et al.	216/48	5,643,312 A	7/1997	Fischell et al.	623/1.15
5,423,885 A	6/1995	Williams	623/1.17	5,643,939 A	7/1997	Ohlstein	514/411
5,429,618 A	7/1995	Keogh	604/266	5,646,160 A	7/1997	Morris et al.	514/291
5,429,634 A	7/1995	Narciso, Jr.	604/890.1	5,648,357 A	7/1997	Bianco et al.	514/263.36
5,439,446 A	8/1995	Barry	604/103.01	5,649,952 A	7/1997	Lam	623/1.15
5,441,515 A	8/1995	Khosravi et al.	606/194	5,649,977 A	7/1997	Campbell	623/1.15
5,441,516 A	8/1995	Wang et al.	606/198	5,651,174 A	7/1997	Schwartz et al.	29/527.2
5,441,947 A	8/1995	Dodge et al.	514/179	5,652,243 A	7/1997	Bianco et al.	514/263.36
5,443,458 A	8/1995	Evry	604/891.1	5,653,747 A	8/1997	Dereume	623/1.54
5,443,477 A	8/1995	Marin et al.	606/198	5,653,992 A	8/1997	Bezwada et al.	424/426
5,443,496 A	8/1995	Schwartz et al.	623/1.16	5,662,609 A	9/1997	Slepian	604/101.03
5,443,498 A	8/1995	Fontaine	623/1.17	5,665,591 A *	9/1997	Sonenshein et al.	435/375
5,443,500 A	8/1995	Sigwart	623/1.17	5,665,728 A	9/1997	Morris et al.	424/122
5,447,724 A	9/1995	Helmus et al.	424/426	5,667,764 A	9/1997	Kopia et al.	424/1.45
5,449,372 A	9/1995	Schmaltz et al.	606/198	5,669,924 A	9/1997	Shaknovich	623/1.11
5,449,373 A	9/1995	Pinchasik et al.	606/198	5,670,506 A	9/1997	Leigh et al.	514/141
5,449,382 A	9/1995	Dayton	623/1.15	5,672,638 A	9/1997	Verhoeven et al.	523/112
5,464,450 A	11/1995	Buscemi et al.	632/1.2	5,674,242 A	10/1997	Phan et al.	606/198
5,464,540 A	11/1995	Friesen et al.	210/640	5,679,400 A	10/1997	Tuch	427/2.14
5,464,650 A	11/1995	Berg et al.	427/2.3	5,679,659 A	10/1997	Verhoeven et al.	514/56
5,474,563 A	12/1995	Myler et al.	606/108	5,684,061 A	11/1997	Ohnishi et al.	523/114
5,486,357 A	1/1996	Narayanan	424/78.17	5,691,311 A	11/1997	Maraganore et al.	514/12
5,496,365 A	3/1996	Sgro	623/1.2	5,693,085 A	12/1997	Buirge et al.	623/1.13
5,500,013 A	3/1996	Buscemi et al.	623/1.22	5,697,967 A	12/1997	Dinh et al.	128/898
5,510,077 A	4/1996	Dinh et al.	264/485	5,697,971 A	12/1997	Fischell et al.	623/1.15
5,512,055 A	4/1996	Domb et al.	604/265	5,700,286 A	12/1997	Tartaglia et al.	623/1.15
5,516,781 A	5/1996	Morris et al.	514/291	5,707,385 A	1/1998	Williams	606/192
5,519,042 A	5/1996	Morris et al.	514/378	5,709,874 A	1/1998	Hanson et al.	424/423
5,523,092 A	6/1996	Hanson et al.	424/423	5,713,949 A	2/1998	Jayaraman	623/1.12
5,527,354 A	6/1996	Fontaine et al.	623/1.17	5,716,981 A	2/1998	Hunter et al.	514/449
5,545,208 A	8/1996	Wolff et al.	623/1.22	5,725,549 A	3/1998	Lam	623/1.15
5,551,954 A	9/1996	Buscemi et al.	623/1.15	5,725,567 A	3/1998	Wolff et al.	623/1.42
5,554,182 A	9/1996	Dinh et al.	600/36	5,728,150 A	3/1998	McDonald et al.	623/1.15
5,554,954 A	9/1996	Takahashi	327/546	5,728,420 A	3/1998	Keogh	427/2.12
5,556,413 A	9/1996	Lam	623/1.2	5,731,326 A	3/1998	Hart et al.	514/323
5,562,922 A	10/1996	Lambert	424/486	5,733,327 A	3/1998	Igaki et al.	623/1.5
5,563,146 A	10/1996	Morris	514/291	5,733,920 A	3/1998	Mansuri et al.	514/337
5,569,197 A	10/1996	Helmus	604/102.02	5,733,925 A	3/1998	Kunz et al.	514/449
5,569,295 A	10/1996	Lam	606/198	5,735,897 A	4/1998	Buirge	623/1.15
5,569,462 A	10/1996	Martinson et al.	424/423	5,739,138 A	4/1998	Bianco et al.	514/263.36
5,569,463 A	10/1996	Helmus et al.	424/426	5,755,734 A	5/1998	Richter et al.	606/194
5,571,089 A	11/1996	Crocker		5,755,772 A	5/1998	Evans et al.	128/898
5,571,166 A	11/1996	Dinh et al.	128/898	5,759,205 A	6/1998	Valentini	433/173
5,574,059 A	11/1996	Regunathan et al.	514/397	5,769,883 A	6/1998	Buscemi et al.	623/1.42
5,575,818 A	11/1996	Pinchuk	623/1.15	5,776,184 A	7/1998	Tuch	623/1.11
5,578,075 A	11/1996	Dayton	623/1.15	5,780,476 A	7/1998	Underiner et al.	514/263.36
5,580,873 A	12/1996	Bianco et al.	514/263.36	5,782,908 A	7/1998	Cahalan et al.	623/1.13
5,580,874 A	12/1996	Bianco et al.	514/263.36	5,788,979 A	8/1998	Alt et al.	424/426
5,591,140 A	1/1997	Narayanan et al.	604/269	5,792,106 A	8/1998	Mische	604/103.01
5,591,197 A	1/1997	Orth et al.		5,792,772 A	8/1998	Bianco et al.	514/263.36
5,591,224 A	1/1997	Schwartz et al.	623/1.22	5,798,372 A	8/1998	Davies et al.	514/356
5,591,227 A	1/1997	Dinh et al.	623/1.22	5,799,384 A	9/1998	Schwartz et al.	29/458
5,599,352 A	2/1997	Dinh et al.	128/898	5,800,507 A	9/1998	Schwartz	623/1.11
5,603,722 A	2/1997	Phan et al.	623/1.18	5,800,508 A	9/1998	Goicoechea et al.	623/1.15
5,604,283 A	2/1997	Wada et al.	524/236	5,807,861 A	9/1998	Klein et al.	514/263.35

5,811,447 A	9/1998	Kunz et al.	514/411	6,258,121 B1	7/2001	Yang et al.	623/1.46
5,820,917 A	10/1998	Tuch	427/2.1	6,268,390 B1	7/2001	Kunz	514/411
5,820,918 A	10/1998	Ronan et al.	427/2.1	6,273,913 B1	8/2001	Wright et al.	623/1.42
5,824,048 A	10/1998	Tuch	128/898	6,284,305 B1	9/2001	Ding et al.	427/2.28
5,824,049 A	10/1998	Ragheb et al.	623/1.44	6,287,320 B1	9/2001	Slepian	606/194
5,827,587 A	10/1998	Fukushi	428/36.6	6,287,628 B1	9/2001	Hossainy et al.	427/2.3
5,833,651 A	11/1998	Donovan et al.	604/509	6,299,604 B1	10/2001	Ragheb et al.	604/265
5,837,008 A	11/1998	Berg et al.	427/2.21	6,306,144 B1	10/2001	Sydney et al.	606/108
5,837,313 A	11/1998	Ding et al.	427/2.21	6,306,166 B1	10/2001	Barry et al.	623/1.46
5,843,120 A	12/1998	Israel et al.		6,306,176 B1	10/2001	Whitbourne	623/23.59
5,843,166 A	12/1998	Lentz et al.		6,306,421 B1	10/2001	Kunz et al.	424/423
5,843,172 A	12/1998	Yan	623/1.42	6,309,380 B1	10/2001	Larson et al.	604/502
5,849,034 A	12/1998	Schwartz	606/36	6,309,660 B1	10/2001	Hsu et al.	424/425
5,851,217 A	12/1998	Wolff et al.	606/191	6,313,264 B1	11/2001	Caggiano et al.	530/350
5,851,231 A	12/1998	Wolff et al.	623/1.42	6,316,018 B1	11/2001	Ding et al.	424/423
5,858,990 A	1/1999	Walsh	514/44	6,335,029 B1	1/2002	Kamath et al.	424/423
5,861,027 A	1/1999	Trapp	623/1.15	6,358,556 B1	3/2002	Ding et al.	427/2.24
5,865,814 A	2/1999	Tuch	623/1.15	6,369,039 B1	4/2002	Palasis et al.	424/93.2
5,871,535 A	2/1999	Wolff et al.	128/898	6,379,382 B1	4/2002	Yang	623/1.42
5,873,904 A	2/1999	Ragheb et al.	623/1.13	6,387,121 B1	5/2002	Alt	623/1.15
5,876,433 A	3/1999	Lunn	623/1.15	6,403,635 B1	6/2002	Kinsella et al.	514/449
5,877,224 A	3/1999	Brocchini et al.	514/772.2	6,407,067 B1	6/2002	Schafer	514/19
5,879,697 A	3/1999	Ding et al.	424/422	6,517,858 B1	2/2003	Haberbosch et al.	424/424
5,882,335 A	3/1999	Leone et al.	604/103.02	6,517,889 B1	2/2003	Jayaraman	427/2.24
5,891,108 A	4/1999	Leone et al.		6,545,097 B2	4/2003	Pinchuk et al.	525/240
5,893,840 A	4/1999	Hull et al.	604/103.02	6,585,764 B2	7/2003	Wright et al.	623/1.42
5,897,911 A	4/1999	Loeffler	427/2.25	6,620,194 B2	9/2003	Ding et al.	623/1.43
5,900,246 A	5/1999	Lambert	424/429	6,746,773 B2	6/2004	Llanos et al.	428/421
5,902,266 A	5/1999	Leone et al.	604/509	6,776,796 B2	8/2004	Llanos et al.	623/1.46
5,916,910 A	6/1999	Lai	514/423	6,808,536 B2	10/2004	Wright et al.	623/1.42
5,922,393 A	7/1999	Jayaraman	427/2.3	2001/0007083 A1	7/2001	Roorda	623/1.15
5,932,243 A	8/1999	Fricker et al.		2001/0029351 A1	10/2001	Falotico et al.	604/103.02
5,932,299 A	8/1999	Katoot	427/508	2001/0029660 A1	10/2001	Johnson	29/557
5,932,580 A	8/1999	Levitzi et al.	181/152	2001/0032014 A1	10/2001	Yang et al.	623/1.15
5,951,586 A	9/1999	Berg et al.	606/198	2001/0034363 A1	10/2001	Li et al.	514/449
5,957,971 A	9/1999	Schwartz	623/1.15	2001/0037145 A1	11/2001	Guruwaiya et al.	623/1.15
5,968,091 A	10/1999	Pinchuk et al.	623/1.16	2002/0010418 A1	1/2002	Lary et al.	604/101.04
5,972,027 A	10/1999	Johnson		2002/0032477 A1	3/2002	Helmus et al.	623/1.2
5,976,534 A	11/1999	Hart et al.	424/145.1	2002/0041899 A1	4/2002	Chudzik et al.	424/487
5,977,163 A	11/1999	Li et al.	514/449	2002/0061326 A1	5/2002	Li et al.	424/424
5,980,553 A	11/1999	Gray et al.	623/1.15	2002/0068969 A1	6/2002	Shanley et al.	623/1.16
5,980,566 A	11/1999	Alt et al.	623/23.7	2002/0071902 A1	6/2002	Ding et al.	427/2.24
5,980,972 A	11/1999	Ding	427/2.24	2002/0082680 A1	6/2002	Shanley et al.	623/1.16
5,981,568 A	11/1999	Kunz et al.	514/411	2002/0082685 A1	6/2002	Sirhan et al.	623/1.42
5,985,307 A	11/1999	Hanson et al.	424/423	2002/0091433 A1	7/2002	Ding et al.	623/1.2
5,997,468 A	12/1999	Wolff et al.	606/36	2002/0095114 A1	7/2002	Palasis	604/96.01
6,004,346 A	12/1999	Wolff et al.	623/23.71	2002/0099438 A1	7/2002	Furst	623/1.16
6,015,432 A	1/2000	Rakos et al.	623/1.13	2002/0103526 A1	8/2002	Steinke	623/1.11
6,039,721 A	3/2000	Johnson et al.	604/508	2002/0119178 A1	8/2002	Levesque et al.	424/423
6,059,813 A	5/2000	Vrba et al.	606/198	2002/0123505 A1	9/2002	Molliston et al.	514/291
6,071,305 A	6/2000	Brown et al.	623/1.43	2002/0127327 A1	9/2002	Schwartz et al.	427/2.15
6,074,659 A	6/2000	Kunz et al.	424/423	2002/0133222 A1	9/2002	Das	623/1.16
6,080,190 A	6/2000	Schwartz	623/1.22	2002/0133224 A1	9/2002	Bajgar et al.	623/1.39
6,096,070 A	8/2000	Ragheb et al.	623/1.39	2002/0165608 A1	11/2002	Llanos	604/500
6,120,536 A	9/2000	Ding et al.	623/1.43	2002/0193475 A1	12/2002	Hossainy et al.	524/113
6,120,847 A	9/2000	Yang et al.		2003/0065377 A1	4/2003	Davila et al.	604/265
6,136,798 A	10/2000	Cody et al.	514/141	2003/0216699 A1	11/2003	Falotico	604/265
6,140,127 A	10/2000	Sprague	435/395	2004/0049265 A1	3/2004	Ding et al.	623/1.42
6,146,358 A	11/2000	Rowe	604/103	2004/0243097 A1	12/2004	Falotico et al.	604/500
6,153,252 A	11/2000	Hossainy et al.	427/2.3	2004/0260268 A1	12/2004	Falotico et al.	604/500
6,159,488 A	12/2000	Nagler et al.	424/423	2005/0002986 A1	1/2005	Falotico et al.	424/426
6,171,232 B1	1/2001	Papandreou et al.	600/36	2005/0004663 A1	1/2005	Llanos et al.	623/1.46
6,171,609 B1	1/2001	Kunz	424/422	2005/0033261 A1	2/2005	Falotico et al.	604/500
6,177,272 B1	1/2001	Nabel et al.	435/320.1	2005/0106210 A1	5/2005	Ding et al.	424/423
6,179,817 B1	1/2001	Zhong	604/265	2005/0187611 A1	8/2005	Ding et al.	623/1.15
6,193,746 B1	2/2001	Strecker	623/1.13	2005/0208200 A1	9/2005	Ding et al.	427/2.25
6,214,901 B1	4/2001	Chudzik et al.	523/113	2006/0088654 A1	4/2006	Ding et al.	427/2.21
6,225,346 B1	5/2001	Tang et al.	514/523	2006/0089705 A1	4/2006	Ding et al.	623/1.15
6,240,616 B1	6/2001	Yan	29/527.2				
6,245,537 B1	6/2001	Williams et al.	435/135				
6,251,920 B1	6/2001	Grainger et al.	514/319				
6,254,632 B1	7/2001	Wu et al.	623/1.15				
6,254,634 B1	7/2001	Anderson et al.	623/1.42				

FOREIGN PATENT DOCUMENTS

DE	19723723 A1	12/1998
EP	0 145 166 A2	6/1985

EP	0 177 330 A2	4/1986
EP	0 183 372 A1	6/1986
EP	0 221 570 A2	5/1987
EP	0 421 729 A2	4/1991
EP	0 540 290 A2	5/1993
EP	0 568 310 A1	11/1993
EP	0 604 022 A1	6/1994
EP	0 621 015 A1	10/1994
EP	0 623 354 A1	11/1994
EP	0 734 698 A2	3/1996
EP	0 712 615 A1	5/1996
EP	0 716 836 A1	6/1996
EP	0 734 721 A2	10/1996
EP	0 747 069 A2	12/1996
EP	0 761 251 A1	3/1997
EP	0 800 801 A1	10/1997
EP	0 540 290 B1	1/1998
EP	0 830 853 A1	3/1998
EP	0 815 803 A1	7/1998
EP	0 850 651 A2	7/1998
EP	0 938 878 A2	9/1999
EP	0 938 878 A3	9/1999
EP	0 950 386 A2	10/1999
EP	0 968 688 A1	1/2000
EP	0 633 032 B1	2/2001
EP	1 192 957 A2	4/2002
EP	1 588 726 A1	10/2005
EP	1 588 727 A1	10/2005
FR	566 807 A1	4/1992
GB	0 662 307 A2	12/1951
GB	1 205 743 A	9/1970
GB	2 135 585 A	9/1984
SU	660689	5/1979
SU	1457921	2/1989
WO	89/03232 A1	4/1989
WO	91/12779 A1	9/1991
WO	92/15286 A1	9/1992
WO	94/01056 A1	1/1994
WO	94/21308 A1	9/1994
WO	94/21309 A1	9/1994
WO	94/24961 A1	11/1994
WO	96/00272 A1	1/1996
WO	96/26689 A1	9/1996
WO	96/32907 A1	10/1996
WO	96/34580 A1	11/1996
WO	97/25000 A1	7/1997
WO	97/33534 A1	9/1997
WO	98/08463 A1	3/1998
WO	98/13344 A1	4/1998
WO	98/19628 A1	5/1998
WO	98/23228 A1	6/1998
WO	98/23244 A1	6/1998
WO	98/34669 A1	8/1998
WO	98/36784 A1	8/1998
WO	98/47447 A1	10/1998
WO	98/56312 A1	12/1998
WO	00/21584 A1	4/2000
WO	00/27445 A1	5/2000
WO	00/27455 A1	5/2000
WO	00/32255 A1	6/2000
WO	00/38754 A1	7/2000
WO	01/87342 A2	11/2001
WO	01/87372 A1	11/2001
WO	01/87373 A1	11/2001
WO	01/87376 A1	11/2001
WO	02/26139 A1	4/2002
WO	02/26271 A1	4/2002
WO	02/26280 A1	4/2002
WO	02/26281 A1	4/2002
WO	03/015664 A1	2/2003

WO 03/057218 A1 7/2003

OTHER PUBLICATIONS

U.S. Appl. No. 08/424,884, filed Apr. 19, 1995, Helmus et al.
U.S. Appl. No. 08/526,273, filed Sep. 11, 1995, Ding.
U.S. Appl. No. 08/730,542, filed Oct. 11, 1996, Helmus.
U.S. Appl. No. 09/575,480, filed May 19, 2000, Kopia.
U.S. Appl. No. 10/431,059, filed May 7, 2003, Falotico
Abraham, R. T., "Mammalian target of rapamycin: Immunosuppressive drugs offer new insight into cell growth regulation," *Progress in Inflammation Research*, 2000, Switzerland.
Alvarado, R. et al., "Evaluation of Polymer-coated Balloon-expandable Stents in Bile Ducts," *Radiology*, 1989, 170, 975-978.
Bailey et al., "Polymer Coating of Palmaz-Schatz Stent Attenuates Vascular Spasm after Stent Placement," *Circulation*, 82:III-541 (1990).
Berk, B. C. et al., "Pharmacologic Roles of Heparin and Glucocorticoids to Prevent Restenosis After Coronary Angioplasty," *JACC*, May 1991, 17(6), 111B-117B.
Bertram, P. G. et al., "The 14-3-3 proteins positively regulate rapamycin-sensitive signaling," *Current Biology*, 1998, 8, 1259-1267.
Biomaterials Science (B.D. Ratner, Ed.), Academic Press, New York, NY, pp. 228-238, 1996.
Campbell, G. R. et al., "Phenotypic Modulation of Smooth Muscle Cells in Primary Culture, Vascular Smooth Muscle Cells in Culture," *CRC Press*, 1987, 39-55.
Chang, M. W. et al., "Adenovirus-mediated Over-expression of the Cyclin/Cyclin-dependent Kinase inhibitor, p21 inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat Carotid Artery Model of Balloon Angioplasty," *J. Clin. Invest.*, 1995, 96, 2260-2268.
Chung, J. et al., "Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases," *Cell*, Jun. 26, 1992, 69(7), 1227-1236.
Clowes, A. W. et al., "Kinetics of cellular proliferation after arterial injury. IV. Heparin inhibits rat smooth muscle mitogenesis and migration," *Circ. Res.*, 1986, 58(6), 839-845.
Clowes, A. W. et al., Kinetics of Cellular Proliferation after Arterial Injury, *Laboratory Investigation*, 1985, 52(6), 611-616.
Clowes, A. W. et al., "Significance of quiescent smooth muscle migration in the injured rat carotid artery," *Circ. Res.* 1985, 56(1), 139-145.
Clowes, A. W., "Suppression by heparin of smooth muscle cell proliferation in injured arteries," *Nature*, 1977, 265(5595), 625-626.
Colburn, M. D. et al., "Dose responsive suppression of myointimal hyperplasia by dexamethasone," *J. Vasc. Surg.*, 1992, 15, 510-518.
Curier, J. W. et al., "Colchicine Inhibits Restenosis After Iliac Angioplasty in the Artherosclerotic Rabbit," *Circ.*, 1989, 80(4), 11-66 (Abstract No. 0263).
Encyclopedia of Polymer Science and Engineering, vol. 7, Fluorocarbon Elastomers, p. 257-267, Mar. 1989.
Farb, A. et al., "Vascular smooth muscle cell cytotoxicity and sustained inhibition of neointimal formation by fibroblast growth factor 2-saporin fusion protein," *Circ. Res.*, 1997, 80, 542-550.
Ferns, G. A. et al., "Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF," *Science*, 1991, 253, 1129-1132.
Fischman, D. L. et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease," *N. Eng. J. Med.*, Aug. 25, 1994, 331(8), 496-501.
Franklin, S. M. et al., "Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials," *Coronary Artery Disease* Mar. 1993, 4(3), 232-242.
Fukuyama, J. et al., "Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet," *Eur. J. Pharmacol.*, 1996, 318, 327-332.
Gregory, C. R. et al., "Rapamycin Inhibits Arterial Intimal Thickening Caused by Both Alloimmune and Mechanical Injury," *Transplantation*, Jun. 1993, 55(6), 1409-1418.

- Gregory, C. R. et al., "Treatment with Repamycin and Mycophenolic Acid Reduces Arterial Intimal Thickening Produced by Mechanical Injury and Allows Endothelial Replacement," *Transplantation*, Mar. 15, 1995, 59(5), 655-661.
- Guyton, J. R. et al., "Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin," *Circ. Res.*, 1980, 46, 625-634.
- Hansson, G. K. et al., "Interferon- γ Inhibits Arterial Stenosis After Injury," *Circ.*, 1991, 84, 1266-1272.
- Hashemolhosseini, S. et al., "Rapamycin Inhibition of the G1 to S Transition Is Mediated by Effects on Cyclin D1 mRNA and Protein Stability," *J Biol Chem*, Jun. 5, 1998, 273, 14424-14429.
- Jonasson, J. et al., "Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury," *Proc. Natl. Acad. Sci.*, 1988, 85, 2303-2306.
- Lange, R. A. MD et al., "Restenosis After Coronary Balloon Angioplasty," *Annu. Rev. Med.*, 1991, 42, 127-132.
- Liu, M. W. et al., "Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit," *Circ.*, 1990, 81, 1089-1093.
- Liu, M. W., MD et al., "Restenosis After Coronary Angioplasty Potential Biologic Determinants and Role of Intimal Hyperplasia," *Circulation*, 1989, 79, 1374-1387.
- Lundergan, C. F. et al., "Peptide inhibition of Myointimal Proliferation by Angiopeptin, a Somatostatin Analogue," *JACC*, May 1991, 17(6), 132B-136B.
- Majesky, M. W. et al., "Heparin regulates smooth muscle S phase entry in the injured rat carotid artery," *Circ. Res.*, 1987, 61, 296-300.
- Marx, S. O. et al., "Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells," *Circ. Res.*, 1995, 76, 412-417.
- Nemecsek, G. M. et al., "Terbinafine Inhibits the Mitogenic Response to Platelet-Derived Growth Factor in Vitro and Neoinimal Proliferation in Vivo," *J. Pharmacol. Exp. Ther.*, 1989, 248, 1167-1174.
- Okada, T. et al., "Localized Release of Perivascular Heparin Inhibits Intimal Proliferation after Endothelial Injury without Systemic Anticoagulation," *Neurosurgery*, 1989, 25, 892-898.
- Poon, M. et al., "Rapamycin Inhibits Vascular Smooth Muscle Cell Migration," *J. Clin. Invest.*, Nov. 1996, 98(10), 2277-2283.
- Popma, J. J. et al., "Clinical trials of restenosis after coronary angioplasty," *Circulation*, Sep. 1991, 84(3), 1426-1436.
- Powell, J. S. et al., "Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury," *Science*, 1989, 245, 186-188.
- Rensing, B. J. et al., Coronary restenosis elimination with a sirolimus eluting stent, *European Heart Journal*, 2001, 22, 2125-2130.
- Rodeck, C. et al., "Methods for the Transcervical Collection of Fetal Cells During the First Trimester of Pregnancy," *Prenatal Diagnosis*, 1995, 15, 933-942.
- Ruef, J. MD, et al., "Flavopiridol Inhibits Muscle Cell Proliferation In Vitro and Neointimal Formation In Vivo After Carotid Injury in the Rat," From the Division of Cardiology and Sealy for Molecular Cardiology, University of Texas Medical Branch, Galveston; Accepted Apr. 9, 1999; *Circulation* Aug. 10, 1999, pp. 659-665.
- Serruys, P. W. et al., "A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease," *N Engl J Med*, Aug. 25, 1994; 331(8), 489-495.
- Serruys, P. W. et al., "Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial," *Circulation*, Oct. 1993; 88(4 Pt 1), 1588-1601.
- Serruys, P. W. et al., "Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study," *Circulation*, Feb. 1, 1996; 93(3), 412-422.
- Siekierka, J. J., "Probing T-Cell Signal Transduction Pathways with the Immunosuppressive Drugs, FK-506 and Rapamycin," *Immunologic Research*, 1994, 13, 110-116.
- Sigwart, et al., "Intravascular Stents to Prevent Occlusion and Restenosis After Transluminal Angioplasty," *N. Engl. J. Med.*, Mar. 19, 1987, 316, 701-706.
- Simons, M. et al., "Antisense *c-myc* oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo," *Nature*, 1992, 359, 67-70.
- Snow, A. D. et al., "Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells," *Am. J. Pathol.*, 1990, 137, 313-330.
- Sollott, S. J. et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat," *J. Clin. Invest.*, 1995, 95, 1869-1876.
- van Der Giessen, et al., "Self-expandable Mesh Stents: an Experimental Study Comparing Polymer Coated and Uncoated Wallstent Stents in the Coronary Circulation of Pigs," *Circulation* 1990, 82(suppl. III):III-542.
- van Der Giessen, W. J. et al., "Coronary stenting with polymer-coated and uncoated self-expanding endoprosthesis in pigs," *Coron. Art. Disease* 1992; 3, 631-640.
- Vasey, C. G. et al., "Clinical Cardiology: Stress Echo and Coronary Flow", *Circulation*, Oct. 1989, 80(4) Supplement II, II-66.
- Verweire, E. et al., "Evaluation of Fluorinated Polymers As Coronary Stent Coating," *Journal of Materials Science: Materials in Medicine*, Apr. 2000.
- Weinberger, J. et al., "Intracoronary irradiation: dose response for the prevention of restenosis in swine," *Int. J. Rad. Onc. Biol. Phys.*, 1996, 36, 767-775.
- Preliminary Amendment in U.S. Appl. No. 07/258,189, May 22, 1989.
- Trial Transcript from Nov. 6, 2000 at 185-90 and 235-36 (Attorneys' opening remarks regarding '984 patent).
- Trial Transcript from Nov. 7, 2000 at 274-301, 307-315, 320-28 and 332 (Cordis expert testimony regarding the Palmaz-Schatz stent); 370-379, 480-496 (J. Palmaz testimony regarding the Palmaz-Schatz stent, the '984 patent and the connected z-stent art).
- Trial Transcript from Nov. 8, 2000 at 547-63, 657-63, 674-722, 782-85 (Cordis expert testimony regarding the Palmaz-Schatz stent, the '984 patent and the connected z-stent art).
- Trial Transcript from Nov. 9, 2000 at 819-23, 921 (Cordis expert testimony regarding the '984 patent); 926-941. (R. Croce testimony re Palmaz-Schatz stent); 1033-1053. (R. Schatz testimony).
- Trial Transcript from Nov. 13, 2000 at 1086-1 134. (R. Schatz testimony); 1275-1305 (Cordis expert testimony regarding the '984 patent).
- Trial Transcript from Nov. 14, 2000 at 1390-1404, 1448-1454, 1486-1500 (Cordis expert testimony regarding the '984 patent).
- Trial Transcript from Nov. 15, 2000 at 1686-87, 1724-42, 1828-34, 1850-54, 1887-92 (AVE expert testimony regarding the '984 patent).
- Trial Transcript from Nov. 16, 2000 at 2077-198 (AVE expert testimony regarding the alleged obviousness of the '984 patent).
- Trial Transcript from Nov. 17, 2000 at 2331-34 (jury instructions as to the meaning of the limitations of the claims of the '984 patent).
- Trial Transcript from Nov. 20, 2000 at 2441-48, 2499-2500, 2546-50, 2552-56 (Attorneys' closing arguments regarding the '984 patent).
- Trial Transcript from Nov. 21, 2000 at 2592-94 (reading of jury verdict).
- Trial Transcript from Dec. 18, 2000 at 2750-95 (Cordis expert testimony regarding the Palmaz-Schatz stent during the damages phase).
- Trial Transcript from Dec. 20, 2000 at 3421-88 (AVE expert testimony regarding the Palmaz-Schatz stent during the damages phase).
- Jury verdict, dated Nov. 21, 2000.
- District Court decisions on post-trial motions (194 F. Supp. 2d 323).
- Court of Appeal for the Federal Circuit decision (339 F.3d 1352).
- Trial Transcript from Mar. 4, 2005 at 133-135, 171-173 and 192-96 (Attorney's opening remarks regarding '984 validity).
- Trial Transcript from Mar. 7, 2005 at 275-31 1 (Cordis expert testimony regarding the Palmaz-Schatz stent); 342-46, 353-59, 416-425 (J. Palmaz testimony regarding the Palmaz-Schatz stent, the '984 patent and the connected z-stent art); 430-449, 452-58, 462-492 (R. Croce testimony regarding the Palmaz-Schatz stent); 500-507 (Cordis expert testimony regarding the '984 patent).

Trial Transcript from Mar. 8, 2005 at 609 (Cordis expert testimony regarding the '984 patent); 628-73, 724-740, 773, 801-839 (Cordis expert testimony regarding the '984 patent), the prior art and the Palmaz-Schatz stent).

Trial Transcript from Mar. 9, 2005 at 936-49, 968-69 (Cordis expert testimony regarding the '984 patent, the prior art and the Palmaz-Schatz stent).

Trial Transcript from Mar. 10, 2005 at 1427-74, 178-1509, 1514-23 (AVE expert testimony regarding the alleged obviousness of the '984 patent); 1566-93 (AVE expert testimony regarding Palmaz-Schatz stent); 1634-49 (R. Schatz testimony).

Trial Transcript from Mar. 11, 2005 at 1846-47, 1891-1900, 1919 (Attorneys' closing arguments regarding '984 obviousness).

Trial Transcript from Mar. 14, 2005 at 1964-67 (reading of jury verdict).

Jury verdict dated Mar. 14, 2005.

Medtronic Vascular Inc.'s Opening Brief in Support of Its Motion for Judgement As A Infringement Claim dated Apr. 19, 2005.

Medtronic Vascular Inc.'s Opening Brief in Support of Its Motion for a New Trial dated Apr. 9, 2005.

D.I. 1407, Cordis' Combined Answering Brief In Opposition to AVE's Motion for JMOL on Infringement of the Palmaz '762 and Schatz '984 Patents and Its Motion for a New Trial dated May 5, 2005.

D.I. 1414, Medtronic Vascular Inc.'s Combined Reply Brief In Support of Its Motion for Judgement as a Matter of Law on Cordis Corp.'s Patent Infringement Claims and Its Motion for a New Trial dated May 19, 2005.

Trial Transcript from Feb. 8, 2001 at 372-412, 449-469 (B. Tobor testimony regarding the prosecution of the '417, '984 and '332 patents); 510-13 (J. Milnamow testimony regarding the prosecution of the '332 patent); 558-604 (J. Palmaz testimony regarding the prosecution of the '417, '984 and '332 patents and the prior art).

Trial Transcript from Feb. 9, 2001 at 637-45, 662-672, 682-85 (J. Palmaz testimony regarding the prior art); 699-742 (R. Schatz testimony); 769-770, 790-95 (Cordis expert testimony regarding prior art).

D.I. 1067, Medtronic AVE, Inc.'s Post-Trial Brief Relating to the Unenforceability of the '762 and '984 Patents Due to Inequitable Conduct.

D.I. 1077, Cordis' Combined Answering Brief in Opposition to AVE's BSC's Post-Hearing Briefs on Alleged Inequitable Conduct Concerning the '762, '984 and '332 Patents.

D.I. 1089, Reply Brief In Support of Medtronic AVE, Inc.'s Contention that the '762 and '984 Patents are Unenforceable Due to Inequitable Conduct dated May 7, 2001.

C.A. No. 00-886-SLR, Answer and Counterclaims of Def. Medtronic AVE, Inc. To First Amended Complaint of Plaintiff Cordis Corp.

BSC's Opening Post-Trial Brief in Support of Its Defense That the Patents in Suit Are Unenforceable, dated Mar. 16, 2001.

Reply Brief in Support of BSC's Defense That the Patents in Suit Are Unenforceable, dated May 7, 2001.

Court's Decision on allegations of inequitable conduct (194 F. Supp. 2d 323) Mar. 28, 2002.

Trial Transcript from Nov. 21, 2000 at 155-57 and 180-84 (Attorneys' opening remarks regarding '332 patent).

Trial Transcript from Nov. 27, 2000 at 227-51, 260-300 (Cordis expert testimony regarding the Palmaz-Schatz stent); 343-60, 363-67, 424-33 (J. Palmaz testimony regarding the Palmaz-Schatz stent and the '332 patent).

Trial Transcript from Nov. 28, 2000 at 649-71.

Trial Transcript from Nov. 29, 2000 at 791-816, 859-870, 953-62 (Cordis expert testimony regarding the '332 patent and the Palmaz-Schatz stent).

Trial Transcript from Nov. 30, 2000 at 1018 (Cordis expert testimony regarding the '332 patent); 1062-80, 1108-1111 (R. Croce testimony regarding the Palmaz-Schatz stent); 1169-70, 1205-17, 1236-45 (Cordis expert testimony regarding the '332 patent).

Trial Transcript from Dec. 1, 2000 at 1352-54 (Cordis expert testimony regarding the '332 patent); 1364-1442 (R. Schatz testimony); 1493-1508, 1552-69 (BSC expert testimony regarding the '332 patent and the Palmaz-Schatz stent).

Trial Transcript from Dec. 4, 2000 at 1602-12, 1638-51, 1713-14, 1730-61, 1811-14, 1823-36 (BSC expert testimony regarding the alleged obviousness of the '332 patent, the prior art and the Palmaz-Schatz stent).

Trial Transcript from Dec. 6, 2000 at 2318-27, 2342-58 (BSC expert testimony regarding the '332 patent).

Trial Transcript from Dec. 7, 2000 at 2549-52 (Cordis expert testimony regarding the '332 patent); 2575-2579, 2591-92, 2630-31, 2649, 2669-71, 2684-85, 2688, 2708-10, 2725-27 (Attorney closing argument regarding '332 patent); 2742-46 Q'ury instructions as to the meaning of the limitations of the claims of the '332 patent).

Trial Transcript from Dec. 11, 2000 at 2817-22 (reading of jury verdict).

Jury verdict, dated Dec. 11, 2000.

D.I. 699, Motion by Defendant BSC and Scimed Life Systems, Inc. For Summary Judgment of Invalidity of U.S. Appl. No. 5,902,332 dated Apr. 4, 2000.

D.I.896, Order Denying Motion for Summary Judgment of Invalidity and Unenforceability of Claims 1, 2, and 5 of the U.S. Appl. No. 5,902,332 Denying {699-1} Motion for Summary Judgment of Invalidity of U.S. Appl. No. 5,902,332 dated Oct. 12, 2000.

Wright et al., Percutaneous Endovascular Stent: An Experimental Study (Abstract), RSNA Meeting (Nov. 28, 1984).

Hearing Transcript from Feb. 10, 1998 at 122-32, 146-80 (Attorneys' opening remarks regarding '417 patent); 180-312 (R. Schatz testimony) [Portions of This Transcript Have Been Removed as Confidential].

Hearing Transcript from Feb. 11, 1998 at 427-575, 577-651 (Cordis expert testimony regarding the '417 patent, the prior art and the Palmaz-Schatz stent).

Hearing Transcript from Feb. 13, 1998 at 1121-1261 (Guidant expert testimony regarding the alleged obviousness of the '417 patent, the prior art and the Palmaz-Schatz stent). [Portions of This Transcript Have Been Removed as Confidential].

Order by J. Robinson denying Cordis' Motion for a Preliminary Injunction Against ACS dated Jul. 17, 1998.

ACS, Inc.'s and Guidant Corp.'s Opening Brief in Support of Their Motion for Summary Judgment of Invalidity of U.S. Appl. No. 5,102,417 dated Aug. 27, 1998.

Plaintiffs's Answering Brief in Opposition to ACS' and BSC's Motion for Summary Judgment on Obviousness dated Sep. 24, 1998.

Order dated Mar. 31, 2000.

Schatz Deposition Testimony; May 15, 1996: 79-83, 89-92, 105-107 and 153-161.

Schatz Deposition Testimony; May 16, 1996: 555-564, 569-572.

Schatz Deposition Testimony; Jan. 8, 1998: 67-73, 108-110.

Schatz Deposition Testimony; Jul. 14, 1998: 69-77, 108-112, 119-123.

Schatz Deposition Testimony; Jul. 12, 1999: 88-91, 132-135, 144-149, 218-223, 231-242.

Schatz Deposition Testimony; Jul. 13, 1999: 251-334, 339-345, 374-416.

Schatz Deposition Testimony; Jul. 14, 1999: 454-550.

Schatz Deposition Testimony; Jul. 15, 1999: 560-614.

Schatz Deposition Testimony; Dec. 2, 1999: 906-911, 928-942, 945-963, 976-978, 1029-1034, 1038-1042.

Palmaz Deposition Testimony, Nov. 5, 1991: 160-172.

Palmaz Deposition Testimony, Feb. 5, 1995: 710-727.

Palmaz Deposition Testimony, Jul. 16, 1998: 55-56; 81-82.

Palmaz Deposition Testimony, Jul. 28, 1999: 560-568, 570-579.

Palmaz Deposition Testimony, Jul. 29, 1999: 778-785.

Palmaz Deposition Testimony, Aug. 31, 1999: 1403-1452.

Palmaz Deposition Testimony, Sep. 2, 1999: 1953-1960.

Palmaz Deposition Testimony, Oct. 14, 1999: 2201-2209; 2275-2342; 2371-2411.

Palmaz Deposition Testimony, Oct. 15, 1999: 2424-2497; 2508-2589.

Palmaz Deposition Testimony, Oct. 16, 1999: 2853-2860.

Tobor Deposition Testimony, Jun. 17, 1999: 837-958.

Tobor Deposition Testimony, Jun. 18, 1999: 1095-1184.

Tobor Deposition Testimony, Dec. 1, 1999: 1217-1371.

- Tobor Deposition Testimony, Dec. 2, 1999: 1398-1414; 1444-1508; 1532-1548.
- Tobor Deposition Testimony, Dec. 3, 1999: 1652-1653; 1662-1672; 1683-1694.
- Kula Deposition Testimony, Apr. 20, 1999: 268-169.
- Kula Deposition Testimony, Nov. 16, 1999: 660-675; 680-694; 7-8-755; 774-821.
- Kula Deposition Testimony, Nov. 18, 1999; 176-223.
- Expert Report of Dr. Rodney S. Badger on Behalf of Medtronic AVE, Inc. (Jan. 31, 2000).
- Expert Report of Dr. Joseph Bonn on Behalf of Medtronic AVE, Inc. (Jan. 31, 2000).
- Deposition of Dr. Joseph Bonn dated Mar. 14, 2000.
- Rebuttal Expert Report of Nigel Buller, B.Sc., M.B., F.R.C.P. (Mar. 2000).
- Second Supplemental Rebuttal Expert Report of Nigel Buller, B.Sc., M.B., F.R.C.P. (Aug. 17, 2004).
- Rebuttal Expert Report of John M. Collins, PH.D. (Feb. 2000).
- Expert Report of David C. Cumberland, M.D. (Jan. 24, 2000).
- Expert Report of John T. Goolkasian (Feb. 2000).
- Deposition of Richard R. Heuser, M.D. (Sep. 7, 2004).
- Deposition of Henry R. Piehler (Sep. 10, 2004).
- Deposition of Ronald J. Solar (Mar. 22, 2000).
- Deposition of Ronald J. Solar (Mar. 23, 2000).
- Deposition of Ronald J. Solar (Apr. 12, 2000).
- Expert Report of Dr. Arina Van Breda on Behalf of Medtronic AVE, Inc. (Jan. 31, 2000).
- Deposition of Anna Van Breda (Mar. 24, 2000).
- Deposition of Arina Van Breda (Aug. 21, 2004).
- Expert Report of John F. Witherspoon (Jan. 24, 2000).
- Supplemental Expert Report of John F. Witherspoon (Oct. 27, 2000).
- Deposition of John F. Witherspoon (Mar. 8, 2000).
- Palmaz et al., Article: "Normal and Stenotic Renal Arteries: Experimental Balloon Expandable Intraluminal Stenting", Radiology, Sep. 1987. (AVE 84).
- Julio C. Palmaz, Article: "Expandable vascular endoprosthesis." (AVE 132).
- Duprat et al., Article: Flexible Balloon-Expandable Stent for Small Vessels Duprat et al. Radiology, vol. 162, pp. 276-278, 1987. (AVE 134).
- Coons et al., Article: "Large-Bore, Long Biliary Endoprosthesis (Biliary Stents) for Improved Drainage," Radiology, vol. 148, pp. 89-94, 1983. (AVE 143).
- Honickman et al., Article: "Malpositioned Biliary Endoprosthesis, Technical Developments And Instrumentation," vol. 144, No. 2., 1982. (AVE 144).
- Harries-Jones, et al., Article: "Repositioning of Biliary Endoprosthesis with Gruntzig Balloon Catheters," AJR, vol. 138, pp. 771-772, 1982. (AVE 153).
- Charnsangavej et al., Article "Stenosis of the Vena Cava: Preliminary Assessment of Treatment with Expandable Metallic Stents," Radiology, vol. 161, pp. 295-298, 1986. (AVE 359).
- Wallace, M. J. et al., Article "Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications," Radiology, vol. 158, pp. 309-312, 1986. (AVE 364).
- T. Yoshioka, et al., AIR Article: "Self-Expanding Endovascular Graft: An Experimental Study in Dogs", vol. 151, pp. 673-676, 1988. (AVE 438).
- Palmaz, J. C. et al., Article: "Expandable Intraluminal Vascular Graft: A Feasibility Study," Surgery, vol. 99, pp. 199-205, 1986. (AVE 461).
- Lawrence et al., Article: "Percutaneous Endovascular Graft: Experimental Evaluation," Radiology, vol. 163, pp. 357-360, 1987. (AVE 671).
- Palmaz et al., Article: Expandable Intraluminal Graft: A Preliminary Study, Nov. 17-22, 1985, Radiology, vol. 156, pp. 73-77, 1985. (AVE 1224).
- Fallone et al., "Elastic Characteristics of the Self-Expanding Metallic Stents," Investigative Radiology, vol. 23, pp. 370-376, 1988. (AVE 1953).
- Palmaz Paper Entitled "Research Project Expandable Vascular Endoprosthesis" May 18, 1983.
- Rousseau, et al., Publication: "Percutaneous Vascular Stent: Experimental Studies & Preliminary Clinical Results in Peripheral Arterial Diseases," in Inter. Angio, vol. 6, 153-161, 1987. (AVE 3301).
- Rousseau, et al., Publication: "Self-Expanding Endovascular Prosthesis: An Experimental Study," Radiology, vol. 164, pp. 709-714, 1987. (AVE 3303).
- Wallace, et al., Article: "Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications," Radiology, vol. 58, pp. 309-312, 1986. (DBX 2938).
- Palmaz et al., Article: "Expandable Intraluminal Graft: A Preliminary Study," Radiology, vol. 156, pp. 73-77, Nov. 17-22, 1985 (DBX 4595).
- Program for the 12th Annual Course on Diagnostic Angiography and Interventional Radiology Mar. 23-26, 1987 sponsored by The Society of Cardiovascular and Interventional Radiology (DBX 6235).
- Preliminary Motion for Judgment re: Wolff claims 1, 2-8, 10, 15 and 19 (DBX6759).
- Palmaz Declaration (DBX 7069).
- Letter from Gaterud to Dr. Palmaz dated Jul. 5, 1988 with attached document entitled: "Segmented, balloon-expandable stents." (DBX 7160).
- Duprat et al., Article: "Flexible Balloon-Expandable Stent For Small Vessels," Radiology, vol. 168, pp. 276-278, 1987 (PX 82).
- Drawing Sent to Bodic on Mar. 17, 1986 (PX 374).
- Letter from Dr. Palmaz to R. Bowman enclosing a model of the flexible coronary graft dated Mar. 17, 1986 (PX 337).
- Lab Notebook pages dated Jul. 30, 1987 from Rodney Wolff (COR 185596-597) (PX621A).
- Charnsangavej, et al., Article: "Stenosis of The Vena Cava Preliminary Assessment of Treatment with expandable Metallic Stents," Radiology, vol. 161, No. 2, pp. 295-298 with attached photographs, 1986. (API 72).
- J. Palmaz: The Current Status of Vascular Prosthesis, published by SCIR in the Twelfth Annual Course on Diagnostic Angiography And Interventional Radiology Mar. 23-26, 1987. (API 73).
- Amendment in Response to Office Action of Oct. 18, 1998 in re: Application of Julio Palmaz U.S. Appl. No. 174,246. (API 152).
- Article: Wallace, et al., Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications Work In Progress, Radiology, vol. 158, pp. 309-312. (API 295).
- Reply of Senior Party Schatz To Patentee Wolffs Opposition To The Belated Motion For Judgment Of Applicant Schatz With Regard To Wolff Claims 1, 2-8, 10, 11, 13-17, And 19 (COR 186450-455) (API 310).
- Brief Of Senior Party Schatz At Final Hearing (API 313).
- Copy of Letter from Ron Sickles to Ben Tobor dated Feb. 10, 1988 (Exhibit 42).
- Copy of Letter from R.O. Sickles to Mike Tatlow dated May 12, 1988 (Exhibit 43).
- Copy of Letter from R. O. Sickles to Richard Schatz dated Jun. 2, 1988 (Exhibit 44).
- Copy of Letter from Richard Schatz to Raimund Erbel dated Jun. 3, 1988 (Exhibit 45).
- Copy of Letter from Richard Schatz to Mike Schuler dated Aug. 29, 1991 (Exhibit 48).
- Minutes of J&J Stent Project Review Meeting datd Jan. 21, 1988 (Exhibit 7).
- Preliminary Motion for Judgment with Regard to Wolff Claims 1, 2-8, 10, 11, 13-17, and 19. (Exhibit 67).
- Declaration of Richard A. Schatz. (Exhibit 75).
- Belated Motion for Judgement with Regard to Wolff Claims 1, 2-8, 10, 11, 13-17 and 19. (Schatz—Exhibit 77).
- Letter from Dr. Schatz to Mr. Tobor, dated Jun. 3, 1988. (Exhibit 122).
- Letter from Dr. Schatz to Mr. Romano, dated Nov. 28, 1988. (Exhibit 131).
- Letter from Mr. Sickles to Mr. Tobor, dated Feb. 10, 1988 (Exhibit 145).
- Richard A. Schatz, Article title: "A View of Vascular Stents" Circulation, vol. 79, No. 2, pp. 445-457, 1989. (Exhibit 194).

- Senior Party Schatz's reply to Patentee Wolff's Opposition to the Preliminary Motion Of Application Schatz for judgment with regard to Wolff Claims 1, 2-8, 10, 11, and 13-17. (Exhibit 69).
- Wallace, et al., Article: "Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications' Work In Progress," Radiology, vol. 158, pp. 309-312, 1986. (Exhibit 165).
- Charnsangavej, et al., Article: "Stenosis of The Vena Cava Preliminary Assessment of Treatment with expandable Metallic Stents," Radiology, vol. 161, No. 2, pp. 295-298 with attached photographs, 1986! (Exhibit 167).
- David D. Lawrence et al., Publication: Percutaneous Endovascular Graft: Experimental Evaluation¹, Radiology, pp. 163, 357-360, 1987. (Exhibit 173).
- Charles E. Putnam, M.D., Cover and article from "Investigative Radiology", vol. 23, No. 5, May 1988. (Exhibit 177).
- Robert N. Berk, Cover and article from "American Journal of Roentology", pp. 673-676, 1988. (Exhibit 178).
- Declaration of John S. Kula Under 37 CFR § 1.672. (Kula—Exhibit 77).
- Yoshioka et al., Article: "Self-Expanding Endovascular Graft: An Experimental Study in Dogs" AJR, vol. 151, pp. 673-676, 1988. (PX 100).
- Palmaz, et al., Article: Expandable Intraluminal Graft: A Preliminary Study Work in Progress¹, Radiology, vol. 156, No. 1, pp. 73-77, 1985. (PX 101).
- Declaration of Richard Schatz Under 37 C.F.R. § 1.672. (PX 106).
- Charnsangavej et al., Article: "Stenosis of the Vena Cava: Preliminary Assessment of Treatment with Expandable Metallic Stents," Radiology, vol. 161, pp. 295-298, 1986. (PX 143).
- Wallace, et al., Article: Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications Work in Progress¹, Radiology, vol. 158, pp. 309-312, 1986. (PX 144).
- Gina Kolata, News Article: NY Times, "Devices That Opens Clogged Arteries Gets a Falling Grade in a New Study", pp. 16-18, Jan. 3, 1991. (PX 186).
- Duprat, et al., Article: "Flexible Balloon-Expanded Stent for Small Vessels Work in Progress", Radiology, vol. 162, pp. 276-278, 1987. (PX 207).
- Letter from Palmaz to Bowman dated Mar. 17, 1986. (PX 350).
- Memo re: Minutes of Stent Project Review- San Antonio- Mar. 15, 1988. (PX 651).
- Kuntz, et al., Article: Clinical Cardiology Frontiers: "Defining Coronary Restenosis, Newer Clinical and Angiographic Paradigms", Circulation, Sep. 1993, vol. 88, No. 3, pp. 1310-1323. (PX 854).
- Belated Motion for Judgment with regard to Wolff Claims 1, 2-8, 10, 11, 13-17, and 19. (PX 1410).
- Drawing of Spiral Stent (sent to Bodic Mar. 17, 1986). (PX2933).
- Wright et al., Article: "Percutaneous Endovascular Stents: An Experimental Evaluation," Radiology, vol. 156, pp. 69-72, 1985. (PX 3093).
- Charnsangavej et al., Article: "A New Expandable Metallic Stent for Dilation of Stenotic Tubular Structures: Experimental and Clinical Evaluation," Houston Medical Journal, vol. 3, pp. 41-51, Jun. 1987. (PX 3207).
- In re Application of Wiktor, U.S. Appl. No. 69,636, Response to Office Action dated Mar. 17, 1988. (PX3236).
- Transmittal Letter of Response to First Office Action in '417 patent. (PX 3993).
- Letter from B. Tobor to R. Schatz dated Jul. 23, 1991. (PX 3996).
- Mullins et al., Article: "Implantation of balloon-expandable intravascular grafts by catheterization in pulmonary arteries and systemic veins," Circulation, vol. 77, No. 1, pp. 188-189, 1988. (PX4049).
- Schatz et al., Article: "Intravascular Stents for Angioplasty," Cardio, 1997. (PX 4050).
- Schatz et al., Article: "New Technology in Angioplasty Balloon-Expandable Intravascular Stents, New Developments in Medicine," vol. 2, No. 2, pp. 59-75, 1987. (PX4051).
- Richard A. Schatz, Article: "Introduction to Intravascular Stents," Cardiology Clinics, vol. 6, No. 3, pp. 357-372, 1988. (PX 4052).
- Richard A. Schatz, Article: "A View of Vascular Stents," Circulation, vol. 79, No. 2, pp. 445-457, 1989. (PX4053).
- Wang et al., Article: "An Update on Coronary Stents," Cardio, pp. 177-186, 1992. (PX 4054).
- Richard A. Schatz, Article: "New Technology in Angioplasty: Balloon-Expandable Starts," Medicamundi, vol. 33, No. 3, pp. 1121-1116, 1988. (PX 4055).
- Letter from Tobor to Schatz dated Sep. 29, 1988. (PX 1395).
- Verified Statement of Facts by Innamed Inventor R.A. Schatz document filed in U.S. Patent and Trademark Office on Sep. 8, 1989. (PX 3677).
- Declaration of John S. Kula Under 37 CFR § 1.672 (Exhibit 329).
- Letter to Mike Schular from R.A. Schatz dated Aug. 29, 1991. (Exhibit 402).
- Articulated, Balloon—Expandable Stents, (DBX 7159).
- J. Rosch et al., Experimental Intrahepatic Portacaval Anastomosis: Use of Expandable Gianturco Stents, Radiology, vol. 162, pp. 481-485, 1987.
- J. Rosch et al., Modified Gianturco Expandable Wire Stents In Experimental and Clinical Use, Ann Radiol, vol. 31, No. 2, pp. 100-103, 1987.
- J. Rosch et al., Gianturco Expandable Stents In the Treatment of Superior Vena Cava Syndrome Recurring After Vena Cava Syndrome Recurring After Maximum-Tolerance Radiation, Cancer, vol. 60, pp. 1243-1246, 1987.
- I.E. Gordon, Structures or Why Things Don't Fall Down, Penguin Books, pp. 45-59, 132-148, 210-244, 377-383.
- Maass et al., Radiological Follow-up of Transluminally Inserted Vascular Endoprostheses: An Experimental Study Using Expanding Spirals, Radiology, vol. 152, pp. 659-663, 1984.
- Argument submitted re EP 861 15473 dated Jan. 20, 1995. (AVE 2478).
- Verified Statement of Facts by Julio C. Palmaz dated Aug. 4, 1989. (PX 3662).
- Papanicolaou et al., Insertion of a Biliary Endoprosthesis Using A Balloon Dilatation Catheter, Gastrointest Radiology, vol. 10, pp. 394-396, 1985.
- Palmaz et al., Atherosclerotic Rabbit Aortas: Expandable Intraluminal Grafting, Radiology, vol. 168, pp. 723-726, 1986.
- Palmaz, The Current Status of Vascular Prostheses; Rosch et al., Gianturco, Expandable Stents in Experimental and Clinical Use, SCIVR, pp. 118-124, 1987.
- Rosch et al., Abstract: Modified Gianturco Expandable Wire Stents in Experimental and Clinical Use, CIRSE, Porto Cervo, Sardinia, May 25-29, 1987.
- Rosch et al., Gianturco Expandable Wire Stents in the Treatment of Superior Vena Cava Syndrome Recurring After Maximum-Tolerance Radiation, Cancer, vol. 60, pp. 1243-1246, 1987.
- Mirich et al., Percutaneously Placed Endovascular Grafts for Aortic Aneurysms: Feasibility Study, Radiology, vol. 170, pp. 1033-1037, 1989.
- Dotter, Transluminally-placed Coilspring Endarterial Tube Grafts, Investigative Radiology, vol. 4, Sep.-Oct., pp. 329-332, 1969.
- Palmaz et al., Abstract: Expandable Intraluminal Graft: A Preliminary Study, Radiology, vol. 153 (P), Nov. 1983: 70th Scientific Assembly and Annual Meeting.
- Cragg et al, Nonsurgical Placement of Arterial Endoprosthesis: A New Technique Using Nitinol Wire, Radiology, vol. 147, pp. 261-263, Apr. 1983.
- J. Rosch et al., Gianturco Expandable Stents in Experimental and Clinical Use, Program: "Twelfth Annual Course on Diagnostic Angiography and Interventional Radiology" (Society of Cardiovascular and Interventional Radiology, Pittsburgh, PA), Mar. 23-26, 1987 (the second Monofilament Article).
- Uchida et al., Modifications of Gianturco Expandable Wire Stents, AIR, vol. 150, pp. 1185-1187, 1988.
- Palmaz, Balloon-Expandable Intravascular Stent, AJR, vol. 1510, pp. 1263-1269.
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc., Guidant Corporation, Arterial Vascular Engineering, Inc., Boston Scientific Corporation and SCMED Life Systems, Inc., Plaintiffs Complaint, Oct. 23, 1997 (Case No. 97-550-SLR).
- Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership, Plaintiffs First Amended Complaint for Declaratory Relief of Patent Validity,

Unenforceability, Noninfringement, and for Antitrust Violations, Jan. 27, 1998 (Civil Action No. 97-700).

Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership, Cordis Corporation and Johnson & Johnson's Answer and Counterclaim, Feb. 27, 1998 (Civil Action No. 97-700-SLR).

Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership, Expandable-Graft Partnership's Answer, Feb. 27, 1998 (Civil Action No. 97-700-SLR).

Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership, Reply of Plaintiff Arterial Vascular Engineering, Inc. To Counterclaims of Defendant Cordis Corporation, Mar. 31, 1998 (Civil Action No. 97-700-SLR). Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership, Reply of Plaintiff Arterial Vascular Engineering, Inc. To Counterclaims of Defendant Expandable Grafts Partnership, Mar. 31, 1998 (Civil Action No. 97-700-SLR).

Cordis Corporation v. Advanced Cardiovascular Systems, Inc. and Guidant Corporation, Cordis Corporation's Motion for a Preliminary Injunction, Oct. 8, 1997 (Civil Action No. 97-550.).

Cordis Corporation v. Advanced Cardiovascular Systems, Inc., Guidant Corporation Arterial Vascular Engineering, Inc., Boston Scientific Corporation and SCJJVIED, Inc., Cordis's Motion for Preliminary Injunction Against Arterial Vascular Engineering, Inc., Dec. 29, 1997 (Case No. 97-550-SLR).

Deposition of R. Schatz, M.D. in Cordis Corporation v. Advanced Cardiovascular Systems, Inc., taken on Jan. 8, 1998 (Civil Action No. 97-550 SLR).

Deposition of Lee P. Bendel in Cordis Corporation v. Advanced Cardiovascular Systems, Inc., taken on Jan. 22, 1998 (Civil Action No. 97-550 SLR).

Deposition of Julio Cesar Palmaz in Cordis Corporation v. Advanced Cardiovascular Systems, Inc., taken on Dec. 29, 1997 (Civil Action No. 97-550 SLR).

Deposition of Richard A. Bowman in Cordis Corporation v. Advanced Cardiovascular Systems, Inc., taken on Jan. 9, 1998 (Civil Action No. 97-550 SLR).

Deposition of Gary Schneiderman in Cordis Corporation v. Advanced Cardiovascular Systems, Inc., taken on Jan. 16, 1998 (Civil Action No. 97-550 SLR).

Deposition of David Pearle, M.D. in Cordis Corporation v. Advanced Cardiovascular Systems, Inc., taken on Jul. 10, 1998 (Civil Action No. 97-550 SLR).

Preliminary Injunction hearing testimony taken on Feb. 9-13, 1998 (Civil Action No. 97-550 SLR).

Cordis Corporation v. Advanced Cardiovascular Systems, Inc., et al., (Civil Action No. 97-550 SLR) and Cordis Corporation v. Advanced Cardiovascular Systems, Inc. Et al. (Civil Action No. 98-65-SLR), Opening Post Hearing Brief of Plaintiff Cordis Corporation in Support of Motion for Preliminary Injunction, Mar. 6, 1998 (Portions relevant to patent claim construction and patent validity issues).

Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc. et al., Post-Hearing Reply Brief of Plaintiff Cordis Corporation in Support of Its Motion for Preliminary Injunction, Apr. 10, 1998 (Case No. 97-550 SLR) (Portions relevant to patent validity issues).

Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc. et al., Plaintiffs Motion for a Preliminary Injunction Against Boston Scientific Corporation and SCLMED Life Systems, Inc. And Memorandum in Support, Apr. 13, 1998 (Case No. 97-550-SLR).

Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc., et al., Judge Robinson's Order Denying Plaintiffs Motion for a Preliminary Injunction, Jul. 17, 1998 (Civil Action No. 97-550 SLR).

Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc., et al., Defendant Boston Scientific Corporation and SCTMED Life Systems, Inc.'s Motion for Summary Judgment of Invalidity of U.S. Appl. No. 5,102,417, Aug. 27, 1998 (Civil Action No. 97-550-SLR).

Boston Scientific Limited, et al. v. Expandable Grafts Partnership, Plaintiffs' Statement of Claim, Mar. 13, 1997 (UK Action No. 1493).

Boston Scientific Limited, et al. v. Expandable Grafts Partnership, Defendant's Amended Defense and Counterclaim, Aug. 14, 1997 (UK Action No. 1493).

Boston Scientific Limited, et al. v. Expandable Grafts Partnership, Petition for Revocation, Mar. 13, 1997 (UK Action No. 1497).

Boston Scientific Limited, et al. v. Expandable Grafts Partnership, Particulars of Objections, Mar. 13, 1997 (UK Action No. 1497).

Boston Scientific Limited, et al. v. Expandable Grafts Partnership and Boston Scientific Limited et al., v. Julio C. Palmaz, Boston's Skeleton Argument (UK Action Nos. 1493, 1495, 1496, and 1497). Boston Scientific Limited, et al. v. Julio C. Palmaz and Expandable Grafts Partnership, Skeleton Argument of Palmaz/EGP, Mar. 19, 1998 (UK Action Nos. 1493, 1495, 1496 and 1497).

Boston Scientific Limited, et al. v. Julio C. Palmaz and Expandable Grafts Partnership, EGP's Final Submissions, Apr. 2, 1998 (UK Action Nos. 1493, 1495, 1496 and 1497).

Boston Scientific Limited, et al. v. Julio C. Palmaz and Expandable Grafts Partnership, Judgment, Jun. 26, 1998 (UK Action Nos. 1493, 1495, 1496 and 1497).

Rosch, Modified Gianturco Expandable Wire Stents in Experimental and Clinical Use, CJJRSE 1987 Presentation: see Witness Statement of Josef Rosch from U.K. Proceeding.

Statement of Claim by Boston Scientific et al. against Expandable Grafts Partnership et al., in EPG et al., v. Boston Scientific et al. in Netherlands (Mar. 13, 1997).

Motion for Joinder of Actions, Change of Claim and Statement of Claim filed by Expandable Grafts Partnership et al. in EPG et al. v. Boston Scientific et al. In Netherlands (Apr. 22, 1997).

Opinion of K.J. Merman filed in EPG et al. v. Boston Scientific et al. in Netherlands (Aug. 29, 1997).

Expert report of Dr. Nigel Buller in EPG et al. v. Boston Scientific et al. in Netherlands (Aug. 28, 1997).

Expert report of Lee P. Bendel in EPG et al. v. Boston Scientific et al. in Netherlands (Aug. 28, 1997).

Memorandum of Oral Pleading in EPG et al. v. Boston Scientific et al. in Netherlands (Sep. 12, 1997).

Plea Notes of P. A.M. in EPG et al. v. Boston Scientific et al. in Netherlands (Mar. 10, 1998).

Decision of Court of Appeals in EPG et al. v. Boston Scientific et al. in Netherlands (Apr. 23, 1998).

Translation of Nullity Action Against EPO 0 364 787 by Biotronik in Germany.

Translation of Nullity Action Against EPO 0 335 341 by Biotronik in Germany.

Translation of EPG Response to Nullity Action Against EP 0 364 787 by Biotronik in Germany.

Translation of EPG Response to Nullity Action EP 0 335 341 by Biotronik in Germany.

Nullity Suit Against EP-B1-0 335 341 Brought by Boston Scientific in Germany.

Translation of Opposition filed by Terumo Corp. Against Japan Patent No. 2680901.

Translation of Decision on Opposition Against Japan Patent No. 2680901.

Memorandum Order of the Court dated Sep. 7, 2000, concerning disputed claim construction.

Translation of Judgment in Nullity Action Against EP 0 364 787 by Biotronik in Germany.

Translation of Judgment in Nullity Action Against EP 0 335 341 by Biotronik in Germany.

Trial transcript from Mar. 17, 2005 at 171-172, 191-192.

Trial transcript from Mar. 18, 2005 at 282-285, 325-327, 349-351.

Trial transcript from Mar. 21, 2005 at 721-726.

Trial transcript from Mar. 24, 2005 at 1387.

Trial transcript from Jul. 26, 2005.

BSC's Opening Brief in Support of Its Motion for Judgment as a Matter of Law or, in the Alternative, for a New Trial, dated Mar. 16, 2001.

- Cordis' Answering Brief in Opposition to BSC's Motion for JMOL or a New Trial on the Palmaz '762 Patent and the Schatz '332 Patents, dated Apr. 17, 2001.
- BSC's Reply Brief in Support of Its Motion for Judgment as a Matter of Law or, in the Alternative, for a New Trial, dated May 11, 2001.
- J. Rosch et al., Abstract, Expandable Gianturco-Type Wire Stents in Experimental Intrahepatic Portacaval Shunts, Program: "72nd Scientific Assembly and Annual Meeting of the Radiological Society of North America", Nov. 30-Dec. 5, 1986m Radiology, vol. 161, pp. 40-41, 1986.
- Cordis Corporation v. Boston Scientific, Order Dated Mar. 27, 2006 (97-550-SLR).
- Cordis Corporation v. Boston Scientific, Judgment in a Civil Case Dated Mar. 27, 2006 (97-550-SLR).
- Cordis Corporation v. Boston Scientific, Memorandum Opinion Dated Mar. 27, 2006 (97-550-SLR).
- Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc., Guidant Corporation, Arterial Vascular Engineering, Inc., Boston Scientific Corporation and SCIMED Life Systems, Inc.*, Answer and Counterclaims of Defendant Advanced Cardiovascular Systems, Inc., Apr. 8, 1998 (Case No. 97-550-SLR).
- Boston Scientific Limited et al. v. Expandable Grafts Partnership and Boston Scientific Limited et al. v. Julio C. Palmaz*, Boston's Closing Submissions (UK Action Nos. 1493, 1495, 1496 and 1497).
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc., Guidant Corporation, Arterial Vascular Engineering, Inc., Boston Scientific Corporation and SCIMED Life Systems, Inc.*, Defendants' Answer, Nov. 12, 1997 (Case No. 97-550-SLR).
- Statement of Rejoinder in the Action on the Merits, Also Including an Amendment of Defendant's Final Position in the Principal Action, as Well as the Provisional Statement of Rejoinder in the Action on the Counterclaim in *EPG et al. v. Boston Scientific et al.* in Netherlands (Feb. 10, 1998).
- Statement of Answer in the Ancillary Appeal in *EPG et al. v. Boston Scientific et al.* in Netherlands (Mar. 10, 1998).
- Appeal filed by Expandable Grafts Partnership et al. in *EPG et al. v. Boston Scientific et al.* in Netherlands (Nov. 12, 1997).
- Title filed by Boston Scientific et al. in *EPG et al. v. Boston Scientific et al.* in Netherlands (Jan. 22, 1998).
- Deposition of Richard Schatz, M.D. in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.* taken on Jul. 14, 1998 (Civil Action No. 97-550-SLR).
- Jury Verdict form from the *Cordis Corporation et al. v. Boston Scientific Corporation, et al.* liability trial, undated.
- Trial testimony transcripts from the *Cordis Corporation et al. v. Boston Scientific Corporation et al.* liability trial dated Nov. 21, Nov. 27-Dec. 1, Dec. 4-8 and Dec. 11, 2000.
- Boston Scientific SCIMED, Inc. and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.*, Opening Expert Report of Stephen R. Hanson, Ph.D. (Civil Action No. 03-328-SLR).
- Boston Scientific SCIMED, Inc. and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.*, Opening Expert Report of Robson F. Storey, Ph.D. (Civil Action No. 03-283-SLR).
- Boston Scientific SCIMED, Inc. and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.*, Rebuttal Expert Report of Kinam Park, Ph.D. (Civil Action No. 03-283-SLR).
- Cordis Corporation v. Boston Scientific Corporation and SCIMED Life Systems, Inc.* (C.A. No. 03-027-SLR) and *Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.* (C.A. No. 03-283-SLR) Combined Post-Hearing Brief In Support Of Cordis Corporation's Motion For Preliminary Injunction in C.A. No. 03-027-SLR, And In Opposition to Plaintiffs' Motion For Preliminary Injunction in C.A. No. 03-283-SLR.
- Cordis Corporation v. Boston Scientific Corporation and SCIMED Life Systems, Inc.* (C.A. No. 03-027-SLR) *Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.* (C.A. No. 03-283-SLR), Boston Scientific's Opening Post-Hearing Brief.
- Cordis Corporation v. Boston Scientific Corporation and SCIMED Life Systems, Inc.* (C.A. No. 03-027-SLR) *Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.* (C.A. No. 03-283-SLR), Combined Post-Hearing Answering Brief In Support of Cordis Corporation's Motion For Preliminary Injunction In C.A. No. 03-027-SLR, And In Opposition To Plaintiffs Motion For Preliminary Injunction in C.A. No. 03-283-SLR.
- Wu et al., Silicone-covered self-expanding metallic stents for the palliation of malignant esophageal obstruction and esophagorespiratory fistulas: experience in 32 patients and a review of the literature, *Gastrointestinal Endoscopy*, 1994, pp. 22-33, vol. 40, No. 1, Portland Oregon.
- Binmoeller, et al., Silicone-Covered Expandable Metallic Stents in the Esophagus: An Experimental Study, *Endoscopy*, 1992, pp. 416-420, vol. 24, Georg Thieme Verlag Stuttgart New York.
- Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.*, Answering Memorandum in Opposition to Plaintiffs Motion for a Preliminary Injunction and Appendix thereto (Civil Action No. 03-283-SLR).
- Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.*, Answering Memorandum in Opposition to Plaintiffs Motion for a Preliminary Injunction and Appendix thereto (Civil Action No. 03-283-SLR).
- Rhine, Polymers for Sustained Macromolecule Release: Procedures to Fabricate Reproducible Delivery Systems and Control Release Kinetics, *Journal of Pharmaceutical Sciences*, 1980, pp. 265-270, vol. 69, No. 3.
- Langer et al., Controlled Release of Macromolecules From Polymers, *Biomedical Polymers Polymeric Materials and Pharmaceuticals for Biomedical Use*, 1980, pp. 112-137, Academic Press, Inc., New York, NY.
- Langer et al., Applications of Polymeric Delivery Systems for Macromolecules and Factors Controlling Release Kinetics.
- Rhine et al., A Method to Achieve Zero-Order Release Kinetics From Polymer Matrix Drug Delivery Systems, pp. 67-72.
- Langer et al., Polymers for the Sustained Release of Macromolecules: Controlled and Magnetically Modulated Systems, *Better Therapy With Existing Drugs: New Uses and Delivery Systems*, 1981, pp. 179-216, Merck Sharp & Dohme International, Rahway, NJ.
- Hsieh, et al., Zero-Order Controlled-Release Polymer Matrices for Micro-and-Macromolecules, *Journal of Pharmaceutical Sciences*, 1983 pp. 17-22, vol. 72, No. 1.
- Brown et al., In Vivo and In Vitro Release of Macromolecules from Polymeric Drug Delivery Systems, *Journal of Pharmaceutical Sciences*, 1983, pp. 1181-1185, vol. 72, No. 10.
- Langer, Implantable Controlled Release Systems, *Pharmac. Ther.*, 1983, pp. 35-51, vol. 21, printed in Great Britain.
- Kost et al., Controlled Release of Bioactive Agents, *Trends in Biotechnology*, 1984, pp. 47-51, vol. 2, No. 2, Elsevier BV Amsterdam.
- Bawa et al., An Explanation for the Controlled Release of Macromolecules from Polymers, *Journal of Controlled Release*, 1985, pp. 259-267, vol. 1 Elsevier Science BV Amsterdam.
- Leong et al., Polymeric controlled drug delivery, 1987, pp. 199-233, vol. 1/3, Elsevier Science Publishers BV Amsterdam.
- Langer, Polymeric Delivery Systems, *Targeting of Drugs 2 Optimization Strategies*, 1989, pp. 165-174, Plenum Press, New York and London.
- Langer, Biomaterials in Controlled Drug Delivery: New Perspective from Biotechnological Advances; *Pharmaceutical Technology*, 1989, pp. 18, 23-24, 26, 28, 30.
- Langer, Controlled Release Systems, pp. 115-124.
- Laurencin et al., Polymeric Controlled Release Systems: New Methods for Drug Delivery, *Clinics in Laboratory Medicine*, 1987, pp. 301-323, vol. 7, No. 2, WB Saunders Company, Philadelphia.
- Langer, Biopolymers in Controlled Release Systems, *Polymeric Biomaterials*, pp. 161-169.

- Tsong-Pin Hsu et al., Polymers for the Controlled Release of Macromolecules: Effect of Molecular Weight of Ethylene-vinyl Acetate Copolymer, *Journal of Biomedical Materials Research*, 1985, pp. 445-460, vol. 19.
- Langer, Polymers and Drug Delivery Systems, *Long-Acting Contraceptive Delivery Systems*, 1983, pp. 23-32, Harper & Row, Philadelphia, PA.
- Langer, New Drug Delivery Systems: What the Clinician Can Expect, *Drug Therapy*, 1983, pp. 217-231.
- Langer, et al., Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review, *Rev. Macromol. Chem. Phys.*, 1983, pp. 61-126.
- Langer, Polymeric Delivery Systems for Controlled Drug Release, *Chem. Eng. Commun.* 1980, pp. 1-48-vol. 6, Gordon and Breach Science Publishers, Inc. USA.
- Langer, et al., Biocompatibility of Polymer Delivery Systems for Macromolecules, *Journal of Biomedical Materials Research*, 1981, pp. 267-277, vol. 15.
- Langer, Controlled Release: A New Approach to Drug Delivery, *Technology Review*, 1981, pp. 26-34.
- Langer, et al., Sustained Release of Macromolecules from Polymers, *Polymeric Delivery Systems*, PGS. 175-176, Gordon and Breach Science Publishers, New York.
- Langer, Polymers for the Sustained Release of Proteins and other Macromolecules, *Nature*, 1976, pp. 797, 263, 799-800, vol. 263, No. 5580.
- Baker, et al., Controlled Release: Mechanisms and Rates (1974).
- Hanson, et al., In Vivo Evaluation of Artificial Surfaces with a Nonhuman Primate Model of Arterial Thrombosis, *Lab Clin. Med.*, Feb. 1980, pp. 289-304.
- Baker, Controlled Release of Biologically Active Agents (1987) pp. 1-275.
- Cordis Corporation v. Boston Scientific Corporation* (CA. No. 03-027-SLR) and *Boston Scientific Scimed, Inc., v. Cordis Corporation and Johnson & Johnson, Incorporated* (CA. No. 03-283-SLR) Hearing Transcripts for Jul. 21, 2003, Jul. 22, 2003, Jul. 23, 2003.
- Cordis Corporation v. Boston Scientific Corporation et al.* (CA. No. 03-027-SLR), and *Boston Scientific Scimed, Inc. et al. v. Cordis Corporation et al.* (CA. No. 03-283-SLR), Boston Scientific's Post-Hearing Reply Brief and Exhibits Thereto, Sep. 12, 2003.
- Cordis Corporation v. Boston Scientific Corporation et al.* (CA. No. 03-027-SLR), and *Boston Scientific Scimed, Inc. et al. v. Cordis Corporation et al.* (CA. 03-283-SLR), Memorandum Order, Nov. 21, 2003.
- Cordis Corporation v. Boston Scientific Corporation et al.* (CA. No. 03-027-SLR), and *Boston Scientific Scimed, Inc. et al. v. Cordis Corporation et al.* (CA. No. 03-283-SLR), Deposition Transcript of Julio C. Palmaz.
- Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable Grafts Partnership*, Cordis Corporation and Johnson & Johnson's Answer and Counterclaim, Feb. 27, 1998 (Civil Action No. 97-700-SLR).
- Plea Notes in *EPG et al. v. Boston Scientific et al.* in Netherlands (Sep. 12, 1997).
- Provisional Judgment *EPG et al. v. Boston Scientific et al.* in Netherlands (Oct. 29, 1997).
- Trial testimony transcripts from the Cordis Corporation et al. v. Medtronic AVE Inc., et al. liability trial dated Nov. 6-9, 13-17 and 20-21, 2000.
- Jury verdict form from the Cordis Corporation et al. v. Medtronic AVE, Inc. et al. liability trial.
- Hearing testimony transcript from the consolidated Cordis Corporation et al. v. Medtronic AVE, Inc. et al. and Boston Scientific Corporation et al. inequitable conduct hearing dated Feb. 7-9 and 12, 2001.
- Cordis Corporation v. Medtronic Ave., Inc. et al.* OPINION, 97-550-SLR, dated Mar. 28, 2002.
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc. et al.* (CA. No. 97-550-SLR), *Medtronic Ave, Inc. v. Cordis Corporation et al.* (CA. No. 97-700-SLR), *Boston Scientific Corporation v. Athicon, Inc. et al.* (CA. No. 98-19-SLR), Expert Report of John T. Goolkasian, Esq.
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc. et al.* (CA. No. 97-550-SLR), *Medtronic AVE, Inc. v. Cordis Corporation et al.* (CA. No. 97-700-SLR), *Boston Scientific Corporation v. Athicon, Inc. et al.* (CA. 98-19-SLR), Expert Report of John F. Witherspoon.
- "Microbial Conversion of Rapamycin," Kuhnt et al., *Enzyme and Microbial Technology*, vol. 21, pp. 405-412, 1997.
- "Inhibitory Effects of Rapamycin on Intimal Hyperplasia After PTCA," Badimon et al., *JACC*, Mar. 1998.

* cited by examiner

FIG. 1




FIG. 1a




FIG. 2a




FIG. 2b




FIG. 3a




FIG. 3b





FIG. 4



1

LOCAL DELIVERY OF RAPAMYCIN FOR TREATMENT OF PROLIFERATIVE SEQUELAE ASSOCIATED WITH PTCA PROCEDURES, INCLUDING DELIVERY USING A MODIFIED STENT

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of Ser. No. 10/408,328, filed Apr. 7, 2003, now issued as U.S. Pat. No. 6,808,536, which in turn is a continuation of application Ser. No. 09/874,117, filed Jun. 4, 2001, now issued as U.S. Pat. No. 6,585,764, which is a continuation of application Ser. No. 09/061,568, filed Apr. 16, 1998, now issued as U.S. Pat. No. 6,273,913, which in turn claims benefit of provisional application Ser. No. 60/044,692, filed Apr. 18, 1997.

FIELD OF THE INVENTION

Delivery of rapamycin locally, particularly from an intravascular stent, directly from micropores in the stent body or mixed or bound to a polymer coating applied on stent, to inhibit neointimal tissue proliferation and thereby prevent restenosis. This invention also facilitates the performance of the stent in inhibiting restenosis.

BACKGROUND OF THE INVENTION

Re-narrowing (restenosis) of an arteriosclerotic coronary artery after percutaneous transluminal coronary angioplasty (PTCA) occurs in 10–50% of patients undergoing this procedure and subsequently requires either further angioplasty or coronary artery bypass graft. While the exact hormonal and cellular processes promoting restenosis are still being determined, our present understanding is that the process of PTCA, besides opening the arteriosclerotically obstructed artery, also injures resident coronary arterial smooth muscle cells (SMC). In response to this injury, adhering platelets, infiltrating macrophages, leukocytes, or the smooth muscle cells (SMC) themselves release cell derived growth factors with subsequent proliferation and migration of medial SMC through the internal elastic lamina to the area of the vessel intima. Further proliferation and hyperplasia of intimal SMC and, most significantly, production of large amounts of extracellular matrix over a period of 3–6 months results in the filling in and narrowing of the vascular space sufficient to significantly obstruct coronary blood flow.

Several recent experimental approaches to preventing SMC proliferation have shown promise although the mechanisms for most agents employed are still unclear. Heparin is the best known and characterized agent causing inhibition of SMC proliferation both in vitro and in animal models of balloon angioplasty-mediated injury. The mechanism of SMC inhibition with heparin is still not known but may be due to any or all of the following: 1) reduced expression of the growth regulatory protooncogenes c-fos and c-myc, 2) reduced cellular production of tissue plasminogen activator; are 3) binding and dequstration of growth regulatory factors such as fibrovalent growth factor (FGF).

Other agents which have demonstrated the ability to reduce myointimal thickening in animal models of balloon vascular injury are angiopeptin (a somatostatin analog), calcium channel blockers, angiotensin converting enzyme inhibitors (captopril, cilazapril), cyclosporin A, trapidil (an antianginal, antiplatelet agent), terbinafine (antifungal),

2

colchicine and taxol (antitubulin antiproliferatives), and c-myc and c-myb antisense oligonucleotides.

Additionally, a goat antibody to the SMC mitogen platelet derived growth factor (PDGF) has been shown to be effective in reducing myointimal thickening in a rat model of balloon angioplasty injury, thereby implicating PDGF directly in the etiology of restenosis. Thus, while no therapy has as yet proven successful clinically in preventing restenosis after angioplasty, the in vivo experimental success of several agents known to inhibit SMC growth suggests that these agents as a class have the capacity to prevent clinical restenosis and deserve careful evaluation in humans.

Coronary heart disease is the major cause of death in men over the age of 40 and in women over the age of fifty in the western world. Most coronary artery-related deaths are due to atherosclerosis. Atherosclerotic lesions which limit or obstruct coronary blood flow are the major cause of ischemic heart disease related mortality and result in 500,000–600,000 deaths in the United States annually. To arrest the disease process and prevent the more advanced disease states in which the cardiac muscle itself is compromised, direct intervention has been employed via percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG).

PTCA is a procedure in which a small balloon-tipped catheter is passed down a narrowed coronary artery and then expanded to re-open the artery. It is currently performed in approximately 250,000–300,000 patients each year. The major advantage of this therapy is that patients in which the procedure is successful need not undergo the more invasive surgical procedure of coronary artery bypass graft. A major difficulty with PTCA is the problem of post-angioplasty closure of the vessel, both immediately after PTCA (acute reocclusion) and in the long term (restenosis).

The mechanism of acute reocclusion appears to involve several factors and may result from vascular recoil with resultant closure of the artery and/or deposition of blood platelets along the damaged length of the newly opened blood vessel followed by formation of a fibrin/red blood cell thrombus. Recently, intravascular stents have been examined as a means of preventing acute reclosure after PTCA.

Restenosis (chronic reclosure) after angioplasty is a more gradual process than acute reocclusion: 30% of patients with subtotal lesions and 50% of patients with chronic total lesions will go on to restenosis after angioplasty. While the exact mechanism for restenosis is still under active investigation, the general aspects of the restenosis process have been identified.

In the normal arterial wall, smooth muscle cells (SMC) proliferate at a low rate (<0.1%/day; ref). SMC in vessel wall exists in a 'contractile' phenotype characterized by 80–90% of the cell cytoplasmic volume occupied with the contractile apparatus. Endoplasmic reticulum, golgi bodies, and free ribosomes are few and located in the perinuclear region. Extracellular matrix surrounds SMC and is rich in heparin-like glycosaminoglycans which are believed to be responsible for maintaining SMC in the contractile phenotypic state.

Upon pressure expansion of an intracoronary balloon catheter during angioplasty, smooth muscle cells within the arterial wall become injured. Cell derived growth factors such as platelet derived growth factor (PDGF), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), etc. released from platelets (i.e., PDGF) adhering to the damaged arterial luminal surface, invading macrophages and/or leukocytes, or directly from SMC (i.e., bFGF) provoke a proliferation and migratory response in medial SMC.

3

These cells undergo a phenotypic change from the contractile phenotype to a 'synthetic' phenotype characterized by only few contractile filament bundles but extensive rough endoplasmic reticulum, golgi and free ribosomes. Proliferation/migration usually begins within 1–2 days post-injury and peaks at 2 days in the media, rapidly declining thereafter (Campbell et al., In: *Vascular Smooth Muscle Cells in Culture*, Campbell, J. H. and Campbell, G. R., Eds, CRC Press, Boca Ration, 1987, pp. 39–55); Clowes, A. W. and Schwartz, S. M., *Circ. Res.* 56:139–145, 1985).

Finally, daughter synthetic cells migrate to the intimal layer of arterial smooth muscle and continue to proliferate. Proliferation and migration continues until the damaged luminal endothelial layer regenerates at which time proliferation ceases within the intima, usually within 7–14 days postinjury. The remaining increase in intimal thickening which occurs over the next 3–6 months is due to an increase in extracellular matrix rather than cell number. Thus, SMC migration and proliferation is an acute response to vessel injury while intimal hyperplasia is a more chronic response. (Liu et al., *Circulation*, 79:1374–1387, 1989).

Patients with symptomatic reocclusion require either repeat PTCA or CABG. Because 30–50% of patients undergoing PTCA will experience restenosis, restenosis has clearly limited the success of PTCA as a therapeutic approach to coronary artery disease. Because SMC proliferation and migration are intimately involved with the pathophysiological response to arterial injury, prevention of SMC proliferation and migration represents a target for pharmacological intervention in the prevention of restenosis.

SUMMARY OF THE INVENTION

Novel Features and Applications to Stent Technology

Currently, attempts to improve the clinical performance of stents have involved some variation of either applying a coating to the metal, attaching a covering or membrane, or embedding material on the surface via ion bombardment. A stent designed to include reservoirs is a new approach which offers several important advantages over existing technologies.

Local Drug Delivery from a Stent to Inhibit Restenosis

In this application, it is desired to deliver a therapeutic agent to the site of arterial injury. The conventional approach has been to incorporate the therapeutic agent into a polymer material which is then coated on the stent. The ideal coating material must be able to adhere strongly to the metal stent both before and after expansion, be capable of retaining the drug at a sufficient load level to obtain the required dose, be able to release the drug in a controlled way over a period of several weeks, and be as thin as possible so as to minimize the increase in profile. In addition, the coating material should not contribute to any adverse response by the body (i.e., should be non-thrombogenic, non-inflammatory, etc.). To date, the ideal coating material has not been developed for this application.

An alternative would be to design the stent to contain reservoirs which could be loaded with the drug. A coating or membrane of biocompatible material could be applied over the reservoirs which would control the diffusion of the drug from the reservoirs to the artery wall.

One advantage of this system is that the properties of the coating can be optimized for achieving superior biocompatibility and adhesion properties, without the addition requirement of being able to load and release the drug. The size,

4

shape, position, and number of reservoirs can be used to control the amount of drug, and therefore the dose delivered.

DESCRIPTION OF THE DRAWINGS

The invention will be better understood in connection with the following figures in which FIGS. 1 and 1A are top views and section views of a stent containing reservoirs as described in the present invention;

FIGS. 2a and 2b are similar views of an alternate embodiment of the stent with open ends;

FIGS. 3a and 3b are further alternate figures of a device containing a grooved reservoir; and

FIG. 4 is a layout view of a device containing a reservoir as in FIG. 3.

DETAILED DESCRIPTION OF THE INVENTION

Pharmacological attempts to prevent restenosis by pharmacologic means have thus far been unsuccessful and all involve systemic administration of the trial agents. Neither aspirin-dipyridamole, ticlopidine, acute heparin administration, chronic warfarin (6 months) nor methylprednisolone have been effective in preventing restenosis although platelet inhibitors have been effective in preventing acute reocclusion after angioplasty. The calcium antagonists have also been unsuccessful in preventing restenosis, although they are still under study. Other agents currently under study include thromboxane inhibitors, prostacyclin mimetics, platelet membrane receptor blockers, thrombin inhibitors and angiotensin converting enzyme inhibitors. These agents must be given systemically, however, and attainment of a therapeutically effective dose may not be possible; antiproliferative (or anti-restenosis) concentrations may exceed the known toxic concentrations of these agents so that levels sufficient to produce smooth muscle inhibition may not be reached (Lang et al., 42 *Ann. Rev. Med.*, 127–132 (1991); Popma et al., 84 *Circulation*, 1426–1436 (1991)).

Additional clinical trials in which the effectiveness for preventing restenosis of dietary fish oil supplements, thromboxane receptor antagonists, cholesterol lowering agents, and serotonin antagonists has been examined have shown either conflicting or negative results so that no pharmacological agents are as yet clinically available to prevent post-angioplasty restenosis (Franklin, S. M. and Faxon, D. P., 4 *Coronary Artery Disease*, 232–242 (1993); Serruys, P. W. et al., 88 *Circulation*, (part 1) 1588–1601, (1993)).

Conversely, stents have proven useful in preventing reducing the proliferation of restenosis. Stents, such as the stent 10 seen in layout in FIG. 4, balloon-expandable slotted metal tubes (usually but not limited to stainless steel), which when expanded within the lumen of an angioplastied coronary artery, provide structural support to the arterial wall. This support is helpful in maintaining an open path for blood flow. In two randomized clinical trials, stents were shown to increase angiographic success after PTCA, increase the stenosed blood vessel lumen and to reduce the lesion recurrence at 6 months (Serruys et al., 331 *New Eng Jour. Med.*, 495, (1994); Fischman et al., 331 *New Eng Jour. Med.*, 496–501 (1994). Additionally, in a preliminary trial, heparin coated stents appear to possess the same benefit of reduction in stenosis diameter at follow-up as was observed with non-heparin coated stents. Additionally, heparin coating appears to have the added benefit of producing a reduction in sub-acute thrombosis after stent implantation (Serruys et al., 93 *Circulation*, 412–422, (1996). Thus, 1) sustained

mechanical expansion of a stenosed coronary artery has been shown to provide some measure of restenosis prevention, and 2) coating of stents with heparin has demonstrated both the feasibility and the clinical usefulness of delivering drugs to local, injured tissue off the surface of the stent.

Numerous agents are being actively studied as antiproliferative agents for use in restenosis and have shown some activity in experimental animal models. These include: heparin and heparin fragments (Clowes and Karnovsky, 265 *Nature*, 25–626, (1977); Guyton, J. R. et al. 46 *Circ. Res.*, 625–634, (1980); Clowes, A. W. and Clowes, M. M., 52 *Lab. Invest.*, 611–616, (1985); Clowes, A. W. and Clowes, M. M., 58 *Circ. Res.*, 839–845 (1986); Majesky et al., 61 *Circ Res.*, 296–300, (1987); Snow et al., 137 *Am. J. Pathol.*, 313–330 (1990); Okada, T. et al., 25 *Neurosurgery*, 92–898, (1989) 15 colchicine (Currier, J. W. et al., 80 *Circulation*, 11–66, (1989), taxol (ref), angiotensin converting enzyme (ACE) inhibitors (Powell, J. S. et al., 245 *Science*, 186–188 (1989), angiopeptin (Lundergan, C. F. et al., 17 *Am. J. Cardiol. (Suppl. B)*; 132B–136B (1991), Cyclosporin A (Jonasson, L. et al., 85 *Proc. Natl. Acad. Sci.*, 2303 (1988), goat-anti-rabbit PDGF antibody (Ferns, G. A. A., et al., 253 *Science*, 1129–1132 (1991), terbinafine (Nemecek, G. M. et al., 248 *J. Pharmacol. Exp. Thera.*, 1167–11747 (1989), trapidil (Liu, M. W. et al., 81 *Circulation*, 1089–1093 (1990), interferon- 25 gamma (Hansson, G. K. and Holm, 84 *J. Circulation*, 1266–1272 (1991), steroids (Colburn, M. D. et al., 15 *J. Vasc. Surg.*, 510–518 (1992), see also Berk, B. C. et al., 17 *J. Am. Coll. Cardiol.*, 111B–117B (1991), ionizing radiation (ref), fusion toxins (ref) antisense oligonucleotides (ref), gene vectors (ref), and rapamycin (see below).

Of particular interest in rapamycin. Rapamycin is a macrolide antibiotic which blocks IL-2-mediated T-cell proliferation and possesses antiinflammatory activity. While the precise mechanism of rapamycin is still under active investigation, rapamycin has been shown to prevent the G₁ to S phase progression of T-cells through the cell cycle by inhibiting specific cell cyclins and cyclin-dependent protein kinases (Siekierka, *Immunol. Res.* 13: 110–116, 1994). The antiproliferative action of rapamycin is not limited to T-cells; Marx et al. (*Circ Res* 76:412–417, 1995) have demonstrated that rapamycin prevents proliferation of both rat and human SMC in vitro while Poon et al. have shown the rat, porcine, and human SMC migratin can also be inhibited by rapamycin (*J Clin Invest* 98: 2277–2283, 1996). 45 Thus, rapamycin is capable of inhibiting both the inflammatory response known to occur after arterial injury and stent implantation, as well as the SMC hyperproliferative response. In fact, the combined effects of rapamycin have been demonstrated to result in a diminished SMC hyperproliferative response in a rat femoral artery graft model and in both rat and porcine arterial balloon injury models (Gregory et al., *Transplantation* 55:1409–1418, 1993; Gallo et al., in press, (1997)). These observations clearly support the potential use of rapamycin in the clinical setting of post-angioplasty restenosis.

Although the ideal agent for restenosis has not yet been identified, some desired properties are clear: inhibition of local thrombosis without the risk systemic bleeding complications and continuous and prevention of the dequale of arterial injury, including local inflammation and sustained prevention smooth muscle proliferation at the site of angioplasty without serious systemic complications. Inasmuch as stents prevent at least a portion of the restenosis process, an agent which prevents inflammation and the proliferation of SMC combined with a stent may provide the most efficacious treatment for post-angioplasty restenosis.

Experiments

Agents: Rapamycin (sirolimus) structural analogs (macrocyclic lactones) and inhibitors of cell-cycle progression.

Delivery Methods:

These can vary:

Local delivery of such agents (rapamycin) from the struts of a stent, from a stent graft, grafts, stent cover or sheath.

Involving comixture with polymers (both degradable and nondegrading) to hold the drug to the stent or graft.

or entrapping the drug into the metal of the stent or graft body which has been modified to contain micropores or channels, as will be explained further herein.

or including covalent binding of the drug to the stent via solution chemistry techniques (such as via the Carmeda process) or dry chemistry techniques (e.g. vapour deposition methods such as rf-plasma polymerization) and combinations thereof.

Catheter delivery intravascularly from a tandem balloon or a porous balloon for intramural uptake

Extravascular delivery by the pericardial route

Extravascular delivery by the advential application of sustained release formulations.

Uses: for inhibition of cell proliferation to prevent neointimal proliferation and restenosis.

prevention of tumor expansion from stents

prevent ingrowth of tissue into catheters and shunts inducing their failure.

1. Experimental Stent Delivery Method—Delivery from Polymer Matrix:

Solution of Rapamycin, prepared in a solvent miscible with polymer carrier solution, is mixed with solution of polymer at final concentration range 0.001 weight % to 30 weight % of drug. Polymers are biocompatible (i.e., not elicit any negative tissue reaction or promote mural thrombus formation) and degradable, such as lactone-based polyesters or copolyesters, e.g., polylactide, polycaprolactone-glycolide, polyorthoesters, polyanhydrides; poly-amino acids; polysaccharides; polyphosphazenes; poly(ether-ester) copolymers, e.g., PEO-PLLA, or blends thereof. Nonabsorbable biocompatible polymers are also suitable candidates. Polymers such as polydimethylsiloxane; poly(ethylene-vinylacetate); acrylate based polymers or copolymers, e.g., poly(hydroxyethyl methylmethacrylate, polyvinyl pyrrolidinone; fluorinated polymers such as polytetrafluoroethylene; cellulose esters.

Polymer/drug mixture is applied to the surfaces of the stent by either dip-coating, or spray coating, or brush coating or dip/spin coating or combinations thereof, and the solvent allowed to evaporate to leave a film with entrapped rapamycin.

2. Experimental Stent Delivery Method—Delivery from Microporous Depots in Stent Through a Polymer Membrane Coating:

Stent, whose body has been modified to contain micropores or channels is dipped into a solution of Rapamycin, range 0.001 wt % to saturated, in organic solvent such as acetone or methylene chloride, for sufficient time to allow solution to permeate into the pores. (The dipping solution can also be compressed to improve the loading efficiency.) After solvent has been allowed to evaporate, the stent is dipped briefly in fresh solvent to remove excess surface bound drug. A solution of polymer, chosen from any identified in the first experimental method, is applied to the stent as detailed above. This outer layer of polymer will act as diffusion-controller for release of drug.

3. Experimental Stent Delivery Method—Delivery via Lysis of a Covalent Drug Tether

Rapamycin is modified to contain a hydrolytically or enzymatically labile covalent bond for attaching to the surface of the stent which itself has been chemically derivatized to allow covalent immobilization. Covalent bonds such as ester, amides or anhydrides may be suitable for this.

4. Experimental Method—Pericardial Delivery

A: Polymeric Sheet Rapamycin is combined at concentration range previously highlighted, with a degradable polymer such as poly(caprolactone-glycolide) or non-degradable polymer, e.g., polydimethylsiloxane, and mixture cast as a thin sheet, thickness range 10 μ to 1000 μ . The resulting sheet can be wrapped perivascularly on the target vessel. Preference would be for the absorbable polymer.

B: Conformal Coating: Rapamycin is combined with a polymer that has a melting temperature just above 37° C., range 40°–45° C. Mixture is applied in a molten state to the external side of the target vessel. Upon cooling to body temperature the mixture solidifies conformably to the vessel wall. Both non-degradable and absorbable biocompatible polymers are suitable.

As seen in the figures it is also possible to modify currently manufactured stents in order to adequately provide the drug dosages such as rapamycin. As seen in FIGS. 1a, 2a and 3a, any stent strut 10, 20, 30 can be modified to have a certain reservoir or channel 11, 21, 31. Each of these reservoirs can be open or closed as desired. These reservoirs can hold the drug to be delivered. FIG. 4 shows a stent 40 with a reservoir 45 created at the apex of a flexible strut. Of course, this reservoir 45 is intended to be useful to deliver rapamycin or any other drug at a specific point of flexibility of the stent. Accordingly, this concept can be useful for “second generation” type stents.

In any of the foregoing devices, however, it is useful to have the drug dosage applied with enough specificity and enough concentration to provide an effective dosage in the lesion area. In this regard, the reservoir size in the stent struts must be kept at a size of about 0.0005" to about 0.003". Then, it should be possible to adequately apply the drug dosage at the desired location and in the desired amount.

These and other concepts will be disclosed herein. It would be apparent to the reader that modifications are possible to the stent or the drug dosage applied. In any event, however, the any obvious modifications should be perceived to fall within the scope of the invention which is to be realized from the attached claims and their equivalents.

What is claimed is:

1. A stent having a coating applied thereto, wherein said coating comprises a biocompatible polymer/drug mixture and said drug is rapamycin or a macrocyclic lactone analog thereof.

2. A stent according to claim 1 comprising a generally thin walled cylinder containing a plurality of generally solid struts to which said coating is applied.

3. A stent according to claim 2 further comprising a channel formed in at least one of said struts.

4. A stent according to claim 3, wherein said channel has a closed perimeter on all sides, an open top and a generally rectangular perimeter, and said channel is smaller in all dimensions than said strut.

5. A stent according to claim 1 wherein the coating is dip-coated onto the stent.

6. A stent according to claim 1 wherein the coating is spray-coated onto the stent.

7. A stent according to claim 1 wherein said rapamycin or macrocyclic lactone analog thereof is contained in the coating at a weight percentage of about 30%.

8. A stent according to claim 1 wherein the coating comprises a degradable polymer.

9. A stent according to claim 1 wherein the coating comprises a nonabsorbable polymer.

10. A stent according to claim 1 wherein the coating comprises a lactone-based polyester; a lactone-based copolyester; a polyanhydride; a polyaminoacid; a polysaccharide; a polyphosphazene; a poly(ether-ester) copolymer; a polydimethylsiloxane; a poly(ethylene)vinylacetate; a poly(hydroxy)ethylmethacrylate; an acrylate based polymer; an acrylate based copolymer; a polyvinyl pyrrolidone; a cellulose ester; a fluorinated polymer; or a blend thereof.

11. A stent according to claim 10 wherein the coating comprises a lactone-based polyester.

12. A stent according to claim 10 wherein the coating comprises a lactone-based copolyester.

13. A stent according to claim 10 wherein the coating comprises a polyanhydride.

14. A stent according to claim 10 wherein the coating comprises a polyaminoacid.

15. A stent according to claim 10 wherein the coating comprises a polysaccharide.

16. A stent according to claim 10 wherein the coating comprises a polyphosphazene.

17. A stent according to claim 10 wherein the coating comprises a poly(ether-ester) copolymer.

18. A stent according to claim 10 wherein the coating comprises a polydimethylsiloxane.

19. A stent according to claim 10 wherein the coating comprises a poly(ethylene)vinylacetate.

20. A stent according to claim 10 wherein the coating comprises a poly(hydroxy)ethylmethacrylate.

21. A stent according to claim 10 wherein the coating comprises an acrylate based polymer.

22. A stent according to claim 10 wherein the coating comprises an acrylate based copolymer.

23. A stent according to claim 10 wherein the coating comprises a polyvinyl pyrrolidone.

24. A stent according to claim 10 wherein the coating comprises a cellulose ester.

25. A stent according to claim 10 wherein the coating comprises a fluorinated polymer.

26. A stent according to claim 10 wherein the fluorinated polymer is polytetrafluoroethylene.

27. A stent according to any one of claims 1 to 26 wherein said drug is a macrocyclic lactone analog of rapamycin.

28. A stent according to any one of claims 1 to 26 that provides a controlled release of said rapamycin or macrocyclic lactone analog thereof over a period of several weeks.

29. A stent according to claim 28 wherein said drug is a macrocyclic lactone analog of rapamycin.

30. A stent according to any one of claims 1 to 26 that releases said rapamycin or macrocyclic lactone analog thereof over a period of at least 14 days.

31. A stent according to claim 30 wherein said drug is a macrocyclic lactone analog of rapamycin.

32. A stent according to any one of claims 1 to 26 wherein said rapamycin or macrocyclic lactone analog thereof is present in a therapeutically beneficial amount to inhibit neointimal proliferation.

33. A stent according to claim 32 wherein said drug is a macrocyclic lactone analog of rapamycin.

34. A stent according to claim 33 that releases said macrocyclic lactone analog of rapamycin over a period of at least 14 days.

35. A stent according to claim 34 wherein the coating comprises a fluorinated polymer.

36. A stent according to claim 35 wherein the coating further comprises an acrylate based polymer or copolymer.

37. A stent according to claim 33 that provides a controlled release of said rapamycin or macrocyclic lactone analog thereof over a period of several weeks.

38. A stent according to claim 37 wherein the coating comprises a fluorinated polymer.

39. A stent according to claim 38 wherein the coating further comprises an acrylate based polymer or copolymer.

40. A device comprising a metallic stent, a biocompatible polymeric carrier and a drug, wherein said drug is rapamycin or a macrocyclic lactone analog thereof and is present in an amount effective to inhibit neointimal proliferation.

41. A device according to claim 40 wherein said polymeric carrier and drug are mixed together.

42. A device according to claim 40 wherein said polymeric carrier is bound to the drug.

43. A device according to claim 40 wherein the drug is entrapped on the surface of the stent by said polymeric carrier.

44. A device according to claim 40 wherein said stent comprises a generally thin walled cylinder containing a plurality of generally solid struts to which said polymeric carrier and drug are applied.

45. A device according to claim 44 further comprising a channel formed in at least one of said struts.

46. A device according to claim 45, wherein said channel has a closed perimeter on all sides, an open top and a generally rectangular perimeter, and said channel is smaller in all dimensions than said strut.

47. A device according to claim 40 wherein the polymeric carrier and drug are dip-coated onto the stent.

48. A device according to claim 40 wherein the polymeric carrier and drug are spray-coated onto the stent.

49. A device according to claim 40 wherein the weight ratio of drug to polymeric carrier is about 3:7.

50. A device according to claim 40 wherein the polymeric carrier comprises a degradable polymer.

51. A device according to claim 40 wherein the polymeric carrier comprises a nonabsorbable polymer.

52. A device according to claim 40 wherein the polymeric carrier comprises a lactone-based polyester; a lactone-based copolyester; a polyanhydride; a polyaminoacid; a polysaccharide; a polyphosphazene; a poly(ether-ester) copolymer; a polydimethylsiloxane; a poly(ethylene)vinylacetate; a poly(hydroxy)ethylmethacrylate; an acrylate based polymer; an acrylate based copolymer; a polyvinyl pyrrolidone; a cellulose ester; a fluorinated polymer; or a blend thereof.

53. A device according to claim 52 wherein the polymeric carrier comprises a lactone-based polyester.

54. A device according to claim 52 wherein the polymeric carrier comprises a lactone-based copolyester.

55. A device according to claim 52 wherein the polymeric carrier comprises a polyanhydride.

56. A device according to claim 52 wherein the polymeric carrier comprises a polyaminoacid.

57. A device according to claim 52 wherein the polymeric carrier comprises a polysaccharide.

58. A device according to claim 52 wherein the polymeric carrier comprises a polyphosphazene.

59. A device according to claim 52 wherein the polymeric carrier comprises a poly(ether-ester) copolymer.

60. A device according to claim 52 wherein the polymeric carrier comprises a polydimethylsiloxane.

61. A device according to claim 52 wherein the polymeric carrier comprises a poly(ethylene)vinylacetate.

62. A device according to claim 52 wherein the polymeric carrier comprises a poly(hydroxy)ethylmethacrylate.

63. A device according to claim 52 wherein the polymeric carrier comprises an acrylate based polymer.

64. A device according to claim 52 wherein the polymeric carrier comprises an acrylate based copolymer.

65. A device according to claim 52 wherein the polymeric carrier comprises a polyvinyl pyrrolidone.

66. A device according to claim 52 wherein the polymeric carrier comprises a cellulose ester.

67. A device according to claim 52 wherein the polymeric carrier comprises a fluorinated polymer.

68. A device according to claim 67 wherein the fluorinated polymer is polytetrafluoroethylene.

69. A device according to any one of claims 40 to 68 wherein said drug is a macrocyclic lactone analog of rapamycin.

70. A device according to any one of claims 40 to 68 that provides a controlled release of said rapamycin or macrocyclic lactone analog thereof over a period of several weeks.

71. A device according to claim 70 wherein said drug is a macrocyclic lactone analog of rapamycin.

72. A device according to claim 71 wherein the polymeric carrier comprises a fluorinated polymer.

73. A device according to claim 72 wherein the polymeric carrier further comprises an acrylate based polymer or copolymer.

74. A device according to any one of claims 40 to 68 that releases said drug over a period of at least 14 days.

75. A device according to claim 74 wherein said drug is a macrocyclic lactone analog of rapamycin.

76. A device according to claim 75 wherein the polymeric carrier comprises a fluorinated polymer.

77. A device according to claim 76 wherein the polymeric carrier further comprises an acrylate based polymer or copolymer.

* * * * *



US007229473B2

(12) **United States Patent**
Falotico et al.

(10) **Patent No.:** **US 7,229,473 B2**

(45) **Date of Patent:** ***Jun. 12, 2007**

(54) **LOCAL DELIVERY OF RAPAMYCIN FOR TREATMENT OF PROLIFERATIVE SEQUELAE ASSOCIATED WITH PTCA PROCEDURES, INCLUDING DELIVERY USING A MODIFIED STENT**

(75) Inventors: **Robert Falotico**, Bell Mead, NJ (US);
Gerard H. Llanos, Stewartsville, NJ (US)

(73) Assignee: **Cordis Corporation**, Miami Lakes, FL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **11/466,983**

(22) Filed: **Aug. 24, 2006**

(65) **Prior Publication Data**

US 2006/0282160 A1 Dec. 14, 2006

Related U.S. Application Data

(63) Continuation of application No. 10/951,385, filed on Sep. 28, 2004, which is a continuation of application No. 10/408,328, filed on Apr. 7, 2003, now Pat. No. 6,808,536, which is a continuation of application No. 09/874,117, filed on Jun. 4, 2001, now Pat. No. 6,585,764, which is a continuation of application No. 09/061,586, filed on Apr. 16, 1998, now Pat. No. 6,273,913.

(60) Provisional application No. 60/044,692, filed on Apr. 18, 1997.

(51) **Int. Cl.**
A61F 2/06 (2006.01)

(52) **U.S. Cl.** **623/1.42**

(58) **Field of Classification Search** 623/1.42–1.48
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

861,659 A	7/1907	Johnston	464/147
3,051,677 A	8/1962	Rexford	522/156
3,279,996 A	10/1966	Long et al.	424/424
3,526,005 A	9/1970	Bokros	623/11.11
3,599,641 A	8/1971	Sheridan	604/256
3,657,744 A	4/1972	Ersek	128/898
3,744,596 A	7/1973	Sander	188/203
3,779,805 A	12/1973	Alsberg	427/105

(Continued)

FOREIGN PATENT DOCUMENTS

DE 3205942 A1 9/1983

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 07/819,314, filed Jan. 9, 1992, Morris.

(Continued)


Primary Examiner—Suzette Gherbi

(74) *Attorney, Agent, or Firm*—Woodcock Washburn LLP

(57) **ABSTRACT**

Methods of preparing intravascular stents with a polymeric coating containing macrocyclic lactone (such as rapamycin or its analogs), stents and stent graphs with such coatings, and methods of treating a coronary artery with such devices. The macrocyclic lactone-based polymeric coating facilitates the performance of such devices in inhibiting restenosis.

5 Claims, 2 Drawing Sheets



US 7,229,473 B2

Page 2

U.S. PATENT DOCUMENTS

3,929,992 A	12/1975	Sehgal et al.	424/122	5,053,048 A	10/1991	Pinchuk	623/1.43
3,932,627 A	1/1976	Margraf	514/56	5,059,166 A	10/1991	Fischell et al.	600/3
3,948,254 A	4/1976	Zaffaroni	128/833	5,061,275 A	10/1991	Wallsten et al.	623/1.22
3,952,334 A	4/1976	Bokros et al.	623/11.11	5,061,750 A	10/1991	Feijen et al.	525/54.1
3,968,800 A	7/1976	Vilasi	606/198	5,064,435 A	11/1991	Porter	623/23.7
4,069,307 A	1/1978	Higuchi et al.	424/432	5,092,877 A	3/1992	Pinchuk	128/898
4,076,285 A	2/1978	Martinez	285/332	5,102,417 A	4/1992	Palma	606/195
4,292,965 A	10/1981	Nash et al.	128/833	5,104,404 A	4/1992	Wolff	623/1.16
4,299,226 A	11/1981	Banka	604/509	5,116,365 A	5/1992	Hillstead	623/1.15
4,300,244 A	11/1981	Bokros	623/1.13	5,122,154 A	6/1992	Rhodes	623/1.13
4,312,920 A	1/1982	Pierce et al.	428/425.5	5,131,908 A	7/1992	Dardik et al.	600/36
4,321,711 A	3/1982	Mano	623/1.43	5,133,732 A	7/1992	Wiktor	623/1.22
4,323,071 A	4/1982	Simpson et al.	606/194	5,134,192 A	7/1992	Feijen et al.	525/54.1
4,390,599 A	6/1983	Broyles	428/597	5,135,536 A	8/1992	Hillstead	606/195
4,413,359 A	11/1983	Akiyama et al.	623/23.72	5,163,952 A	11/1992	Froix	623/1.18
4,423,183 A	12/1983	Close	524/546	5,163,958 A	11/1992	Pinchuk	623/23.49
4,441,216 A	4/1984	Ionescu et al.	623/2.19	5,171,217 A	12/1992	March et al.	604/507
4,503,569 A	3/1985	Dotter	623/1.19	5,171,262 A	12/1992	MacGregor	623/1.15
4,512,338 A	4/1985	Balko et al.	606/108	5,176,660 A	1/1993	Truckai	604/527
4,550,447 A	11/1985	Seiler, Jr. et al.	623/1.32	5,176,972 A	1/1993	Bloom et al.	430/14
4,553,545 A	11/1985	Maass et al.	606/198	5,178,618 A	1/1993	Kandarpa	606/28
4,560,374 A	12/1985	Hammerslag	604/509	5,180,366 A	1/1993	Woods	604/96.01
4,562,596 A	1/1986	Kornberg	623/1.32	5,182,317 A	1/1993	Winters et al.	523/112
4,565,740 A	1/1986	Golander et al.	428/409	5,185,408 A	2/1993	Tang et al.	525/415
4,580,568 A	4/1986	Gianturco	606/198	5,192,307 A	3/1993	Wall	623/1.2
4,613,665 A	9/1986	Larm	536/20	5,195,984 A	3/1993	Schalz	623/1.2
4,642,111 A	2/1987	Sakamoto et al.	424/492	5,213,576 A	5/1993	Abiuso et al.	604/103.01
4,655,771 A	4/1987	Wallsten	623/1.22	5,213,898 A	5/1993	Larm et al.	428/422
4,656,083 A	4/1987	Hoffman et al.	442/123	5,217,483 A	6/1993	Tower	623/1.15
4,676,241 A	6/1987	Webb et al.	128/207.14	5,222,971 A	6/1993	Willard et al.	606/198
4,678,466 A	7/1987	Rosenwald	424/427	5,226,913 A	7/1993	Pinchuk	140/71 R
4,687,482 A	8/1987	Hanson	623/1.49	5,234,456 A	8/1993	Silvestrini	623/1.2
4,689,046 A	8/1987	Bokros	623/2.31	5,246,445 A	9/1993	Yachia et al.	623/1.2
4,731,054 A	3/1988	Billeter et al.	604/93.01	5,258,020 A	11/1993	Froix	128/898
4,733,665 A	3/1988	Palma	606/108	5,258,021 A	11/1993	Duran	623/2.3
4,739,762 A	4/1988	Palma	623/1.11	5,262,451 A	11/1993	Winters et al.	523/112
4,740,207 A	4/1988	Kreamer	623/1.15	5,266,073 A	11/1993	Wall	623/1.2
4,749,585 A	6/1988	Greco et al.	428/422	5,272,012 A	12/1993	Opolski	428/423.1
4,753,652 A	6/1988	Langer et al.	623/1.42	4,733,665 A	1/1994	Palma	606/108
4,760,849 A	8/1988	Kropf	606/191	5,275,622 A	1/1994	Lazarus et al.	623/1.11
4,768,507 A	9/1988	Fischell et al.	623/1.11	5,282,823 A	2/1994	Schwartz et al.	623/1.22
4,776,337 A	10/1988	Palma	623/1.11	5,282,824 A	2/1994	Gianturco	623/1.13
4,786,500 A	11/1988	Wong	424/422	5,283,257 A	2/1994	Gregory et al.	514/458
4,787,899 A	11/1988	Lazarus	623/1.11	5,288,711 A	2/1994	Mitchell et al.	424/122
4,800,882 A	1/1989	Gianturco	606/194	5,290,305 A	3/1994	Inoue	623/1.2
4,810,784 A	3/1989	Larm	536/20	5,292,331 A	3/1994	Boneau	623/1.16
4,856,516 A	8/1989	Hillstead	606/194	5,292,802 A	3/1994	Rhee et al.	525/54.1
4,871,357 A	10/1989	Hsu et al.	604/266	5,304,121 A	4/1994	Sahatjian	604/509
4,872,867 A	10/1989	Joh	604/269	5,304,200 A	4/1994	Spaulding	623/1.16
4,876,109 A	10/1989	Mayer et al.	604/269	5,306,250 A	4/1994	March et al.	604/104
4,886,062 A	12/1989	Wiktor	606/194	5,308,862 A	5/1994	Ohlstein	514/411
4,907,336 A	3/1990	Gianturco	29/515	5,308,889 A	5/1994	Rhee et al.	523/113
4,916,193 A	4/1990	Tang et al.	525/413	5,314,444 A	5/1994	Gianturco	606/195
4,954,126 A	9/1990	Wallsten	600/36	5,314,472 A	5/1994	Fontaine	623/1.22
4,969,458 A	11/1990	Wiktor	623/1.11	5,328,471 A	7/1994	Slepian	604/101.03
4,990,131 A	2/1991	Dardik et al.	600/36	5,334,301 A	8/1994	Heinke et al.	204/267
4,990,155 A	2/1991	Wilkoff	606/191	5,336,518 A	8/1994	Narayanan et al.	427/470
4,994,071 A	2/1991	MacGregor	606/194	5,338,770 A	8/1994	Winters et al.	523/112
4,994,298 A	2/1991	Yasuda	427/490	5,342,348 A	8/1994	Kaplan	604/891.1
4,998,923 A	3/1991	Samson et al.	606/194	5,342,387 A	8/1994	Summers	606/198
5,015,253 A	5/1991	MacGregor	623/1.15	5,342,621 A	8/1994	Eury	606/198
5,019,090 A	5/1991	Pinchuk	623/1.15	5,354,257 A	10/1994	Roubin et al.	600/7
5,019,096 A	5/1991	Fox, Jr. et al.	600/36	5,354,308 A	10/1994	Simon et al.	623/1.15
5,029,877 A	7/1991	Fedeli	277/354	5,356,433 A	10/1994	Rowland et al.	424/422
5,034,265 A	7/1991	Hoffman et al.	442/126	5,366,504 A	11/1994	Andersen et al.	623/1.5
5,035,706 A	7/1991	Gianturco et al.	606/198	5,368,566 A	11/1994	Crocker	604/101.02
5,041,100 A	8/1991	Rowland et al.	604/265	5,370,683 A	12/1994	Fontaine	623/1.22
5,041,126 A	8/1991	Gianturco	623/1.15	5,370,691 A	12/1994	Samson	623/1.22
5,047,020 A	9/1991	Hsu	604/266	5,375,612 A	12/1994	Cottenceau et al.	128/899
5,049,132 A	9/1991	Shaffer et al.	604/101.02	5,376,112 A	12/1994	Duran	623/1.26
5,049,403 A	9/1991	Larm et al.	427/2.1	5,378,475 A	1/1995	Smith et al.	424/473
				5,380,299 A	1/1995	Fearnott et al.	604/265
				5,382,261 A	1/1995	Palma	606/158

US 7,229,473 B2

Page 3

5,383,853 A	1/1995	Jung et al.	604/103.04	5,607,475 A	3/1997	Cahalan et al.	424/423
5,383,928 A	1/1995	Scott et al.	623/1.12	5,609,629 A	3/1997	Fearnott et al.	623/1.42
5,387,235 A	2/1995	Chuter	623/1.11	5,616,608 A	4/1997	Kinsella et al.	514/449
5,389,106 A	2/1995	Tower	623/1.15	5,620,984 A	4/1997	Bianco et al.	514/263.36
5,393,772 A	2/1995	Yue et al.	514/410	5,621,102 A	4/1997	Bianco et al.	544/267
5,395,390 A	3/1995	Simon et al.	623/1.18	5,622,975 A	4/1997	Singh et al.	514/324
5,397,355 A	3/1995	Marin et al.	623/1.2	5,624,411 A	4/1997	Tuch	604/265
5,399,352 A	3/1995	Hanson	424/423	5,628,785 A	5/1997	Schwartz et al.	128/898
5,403,341 A	4/1995	Solar	606/198	5,629,077 A	5/1997	Turnlund et al.	623/1.15
5,405,377 A	4/1995	Cragg	623/1.2	5,629,315 A	5/1997	Bianco et al.	514/263.36
5,409,696 A	4/1995	Narayanan et al.	424/78.17	5,632,763 A	5/1997	Glastra	623/1.15
5,411,549 A	5/1995	Peters	623/1.15	5,632,771 A	5/1997	Boatman et al.	623/1.15
5,415,619 A	5/1995	Lee et al.	600/36	5,632,776 A	5/1997	Kurumatani et al.	424/423
5,417,969 A	5/1995	Hsu et al.	424/78.27	5,632,840 A	5/1997	Campbell	156/196
5,419,760 A	5/1995	Narciso, Jr.	604/8	5,635,201 A	6/1997	Fabo	424/443
D359,802 S	6/1995	Fontaine	D24/155	5,637,113 A	6/1997	Tartaglia et al.	623/1.42
5,421,955 A	6/1995	Lau et al.	216/48	5,643,312 A	7/1997	Fischell et al.	623/1.15
5,423,885 A	6/1995	Williams	623/1.17	5,643,939 A	7/1997	Ohlstein	514/411
5,429,618 A	7/1995	Keogh	604/266	5,646,160 A	7/1997	Morris et al.	514/291
5,429,634 A	7/1995	Narciso, Jr.	604/890.1	5,648,357 A	7/1997	Bianco et al.	514/263.36
5,439,446 A	8/1995	Barry	604/103.01	5,649,952 A	7/1997	Lam	623/1.15
5,441,515 A	8/1995	Khosravi et al.	606/194	5,649,977 A	7/1997	Campbell	623/1.15
5,441,516 A	8/1995	Wang et al.	606/198	5,651,174 A	7/1997	Schwartz et al.	29/527.2
5,441,947 A	8/1995	Dodge et al.	514/179	5,652,243 A	7/1997	Bianco et al.	514/263.36
5,443,458 A	8/1995	Evry	604/891.1	5,653,747 A	8/1997	Dereume	623/1.54
5,443,477 A	8/1995	Marin et al.	606/198	5,653,992 A	8/1997	Bezwada et al.	424/426
5,443,496 A	8/1995	Schwartz et al.	623/1.16	5,662,609 A	9/1997	Slepian	604/101.03
5,443,498 A	8/1995	Fontaine	623/1.17	5,665,591 A	9/1997	Sonenshein et al.	435/375
5,443,500 A	8/1995	Sigwart	623/1.17	5,665,728 A	9/1997	Morris et al.	424/122
5,447,724 A	9/1995	Helmus et al.	424/426	5,667,764 A	9/1997	Kopia et al.	424/1.45
5,449,372 A	9/1995	Schmaltz et al.	606/198	5,669,924 A	9/1997	Shaknovich	623/1.11
5,449,373 A	9/1995	Pinchasik et al.	606/198	5,670,506 A	9/1997	Leigh et al.	514/141
5,449,382 A	9/1995	Dayton	623/1.15	5,672,638 A	9/1997	Verhoeven et al.	523/112
5,464,450 A	11/1995	Buscemi et al.	632/1.2	5,674,242 A	10/1997	Phan et al.	606/198
5,464,540 A	11/1995	Friesen et al.	210/640	5,679,400 A	10/1997	Tuch	427/2.14
5,464,650 A	11/1995	Berg et al.	427/2.3	5,679,659 A	10/1997	Verhoeven et al.	514/56
5,474,563 A	12/1995	Mylar et al.	606/108	5,684,061 A	11/1997	Ohnishi et al.	523/114
5,486,357 A	1/1996	Narayanan	424/78.17	5,691,311 A	11/1997	Maraganore et al.	514/12
5,496,365 A	3/1996	Sgro	623/1.2	5,693,085 A	12/1997	Buirge et al.	623/1.13
5,500,013 A	3/1996	Buscemi et al.	623/1.22	5,697,967 A	12/1997	Dinh et al.	128/898
5,510,077 A	4/1996	Dinh et al.	264/485	5,697,971 A	12/1997	Fischell et al.	623/1.15
5,512,055 A	4/1996	Domb et al.	604/265	5,700,286 A	12/1997	Tartaglia et al.	623/1.15
5,516,781 A	5/1996	Morris et al.	514/291	5,707,385 A	1/1998	Williams	606/192
5,519,042 A	5/1996	Morris et al.	514/378	5,709,874 A	1/1998	Hanson et al.	424/423
5,523,092 A	6/1996	Hanson et al.	424/423	5,713,949 A	2/1998	Jayaraman	623/1.12
5,527,354 A	6/1996	Fontaine et al.	623/1.17	5,716,981 A	2/1998	Hunter et al.	514/449
5,545,208 A	8/1996	Wolff et al.	623/1.22	5,725,549 A	3/1998	Lam	623/1.15
5,551,954 A	9/1996	Buscemi et al.	623/1.15	5,725,567 A	3/1998	Wolff et al.	623/1.42
5,554,182 A	9/1996	Dinh et al.	600/36	5,728,150 A	3/1998	McDonald et al.	623/1.15
5,554,954 A	9/1996	Takahashi	327/546	5,728,420 A	3/1998	Keogh	427/2.12
5,556,413 A	9/1996	Lam	623/1.2	5,731,326 A	3/1998	Hart et al.	514/323
5,562,922 A	10/1996	Lambert	424/486	5,733,327 A	3/1998	Igaki et al.	623/1.5
5,563,146 A	10/1996	Morris	514/291	5,733,920 A	3/1998	Mansuri et al.	514/337
5,569,197 A	10/1996	Helmus	604/102.02	5,733,925 A	3/1998	Kunz et al.	514/449
5,569,295 A	10/1996	Lam	606/198	5,735,897 A	4/1998	Buirge	623/1.15
5,569,462 A	10/1996	Martinson et al.	424/423	5,739,138 A	4/1998	Bianco et al.	514/263.36
5,569,463 A	10/1996	Helmus et al.	424/426	5,755,734 A	5/1998	Richter et al.	606/194
5,571,089 A	11/1996	Crocker	604/103.01	5,755,772 A	5/1998	Evans et al.	128/898
5,571,166 A	11/1996	Dinh et al.	128/898	5,759,205 A	6/1998	Valentini	433/173
5,574,059 A	11/1996	Regunathan et al.	514/397	5,769,883 A	6/1998	Buscemi et al.	623/1.42
5,575,818 A	11/1996	Pinchuk	623/1.15	5,776,184 A	7/1998	Tuch	623/1.11
5,578,075 A	11/1996	Dayton	623/1.15	5,780,476 A	7/1998	Underiner et al.	514/263.36
5,580,873 A	12/1996	Bianco et al.	514/263.36	5,782,908 A	7/1998	Cahalan et al.	623/1.13
5,580,874 A	12/1996	Bianco et al.	514/263.36	5,788,979 A	8/1998	Alt et al.	424/426
5,591,140 A	1/1997	Narayanan et al.	604/269	5,792,106 A	8/1998	Mische	604/103.01
5,591,197 A	1/1997	Orth et al.	623/1.16	5,792,772 A	8/1998	Bianco et al.	514/263.36
5,591,224 A	1/1997	Schwartz et al.	623/1.22	5,798,372 A	8/1998	Davies et al.	514/356
5,591,227 A	1/1997	Dinh et al.	623/1.22	5,799,384 A	9/1998	Schwartz et al.	29/458
5,599,352 A	2/1997	Dinh et al.	128/898	5,800,507 A	9/1998	Schwartz	623/1.11
5,603,722 A	2/1997	Phan et al.	623/1.18	5,800,508 A	9/1998	Goicoechea et al.	623/1.15
5,604,283 A	2/1997	Wada et al.	524/236	5,807,861 A	9/1998	Klein et al.	514/263.35
5,605,696 A	2/1997	Eury et al.	424/423	5,811,447 A	9/1998	Kunz et al.	514/411
5,607,463 A	3/1997	Schwartz et al.	623/1.44	5,820,917 A	10/1998	Tuch	427/2.1

5,820,918 A	10/1998	Ronan et al.	427/2.1	6,273,913 B1	8/2001	Wright et al.	623/1.42
5,824,048 A	10/1998	Tuch	128/898	6,284,305 B1	9/2001	Ding et al.	427/2.28
5,824,049 A	10/1998	Ragheb et al.	623/1.44	6,287,320 B1	9/2001	Slepian	606/194
5,827,587 A	10/1998	Fukushi	428/36.6	6,287,628 B1	9/2001	Hossainy et al.	427/2.3
5,833,651 A	11/1998	Donovan et al.	604/509	6,299,604 B1	10/2001	Ragheb et al.	604/265
5,837,008 A	11/1998	Berg et al.	128/898	6,306,144 B1	10/2001	Sydney et al.	606/108
5,837,313 A	11/1998	Ding et al.	427/2.21	6,306,166 B1	10/2001	Barry et al.	623/1.46
5,843,120 A	12/1998	Israel et al.	623/1.15	6,306,176 B1	10/2001	Whitbourne	623/23.59
5,843,166 A	12/1998	Lentz et al.	623/1.13	6,306,421 B1	10/2001	Kunz et al.	424/423
5,843,172 A	12/1998	Yan	623/1.42	6,309,380 B1	10/2001	Larson et al.	604/502
5,849,034 A	12/1998	Schwartz	606/36	6,309,660 B1	10/2001	Hsu et al.	424/425
5,851,217 A	12/1998	Wolff et al.	606/191	6,313,264 B1	11/2001	Caggiano et al.	530/350
5,851,231 A	12/1998	Wolff et al.	623/1.42	6,316,018 B1	11/2001	Ding et al.	424/423
5,858,990 A	1/1999	Walsh	514/44	6,335,029 B1	1/2002	Kamath et al.	424/423
5,861,027 A	1/1999	Trapp	623/1.15	6,348,556 B1	3/2002	Ding et al.	427/2.24
5,865,814 A	2/1999	Tuch	623/1.15	6,369,039 B1	4/2002	Palasis et al.	424/93.2
5,871,535 A	2/1999	Wolff et al.	128/898	6,379,382 B1	4/2002	Yang	623/1.42
5,873,904 A	2/1999	Ragheb et al.	623/1.13	6,387,121 B1	5/2002	Alt	623/1.15
5,876,433 A	3/1999	Lunn	623/1.15	6,403,635 B1	6/2002	Kinsella et al.	514/449
5,877,224 A	3/1999	Brocchini et al.	514/772.2	6,407,067 B1	6/2002	Schafer	514/19
5,879,697 A	3/1999	Ding et al.	424/422	6,517,858 B1	2/2003	Le Moel et al.	424/424
5,882,335 A	3/1999	Leone et al.	604/103.02	6,517,889 B1	2/2003	Jayaraman	427/2.24
5,891,108 A	4/1999	Leone et al.	604/264	6,545,097 B2	4/2003	Pinchuk et al.	525/240
5,893,840 A	4/1999	Hull et al.	604/103.02	6,585,764 B2	7/2003	Wright et al.	623/1.42
5,897,911 A	4/1999	Loeffler	427/2.25	6,620,194 B2	9/2003	Ding et al.	623/1.43
5,900,246 A	5/1999	Lambert	424/429	6,746,773 B2	6/2004	Llanos et al.	428/421
5,902,266 A	5/1999	Leone et al.	604/509	6,776,796 B2	8/2004	Falotico et al.	623/1.46
5,916,910 A	6/1999	Lai	514/423	6,808,536 B2	10/2004	Wright et al.	623/1.42
5,922,393 A	7/1999	Jayaraman	427/2.3	2001/0007083 A1	7/2001	Roorda	623/1.15
5,932,243 A	8/1999	Fricker et al.	424/450	2001/0029351 A1	10/2001	Falotico et al.	604/103.02
5,932,299 A	8/1999	Katoot	427/508	2001/0029660 A1	10/2001	Johnson	29/557
5,932,580 A	8/1999	Levitzi et al.	181/152	2001/0032014 A1	10/2001	Yang et al.	623/1.15
5,951,586 A	9/1999	Berg et al.	606/198	2001/0034363 A1	10/2001	Li et al.	514/449
5,957,971 A	9/1999	Schwartz	623/1.15	2001/0037145 A1	11/2001	Guruwaiya et al.	623/1.15
5,968,091 A	10/1999	Pinchuk et al.	623/1.16	2002/0010418 A1	1/2002	Lary et al.	604/101.04
5,972,027 A	10/1999	Johnson	623/1.42	2002/0032477 A1	3/2002	Helmus et al.	623/1.2
5,976,534 A	11/1999	Hart et al.	424/145.1	2002/0041899 A1	4/2002	Chudzik et al.	424/487
5,977,163 A	11/1999	Li et al.	514/449	2002/0061326 A1	5/2002	Li et al.	424/424
5,980,553 A	11/1999	Gray et al.	623/1.15	2002/0068969 A1	6/2002	Shanley et al.	623/1.16
5,980,566 A	11/1999	Alt et al.	623/23.7	2002/0071902 A1	6/2002	Ding et al.	427/2.24
5,980,972 A	11/1999	Ding	427/2.24	2002/0082680 A1	6/2002	Shanley et al.	623/1.16
5,981,568 A	11/1999	Kunz et al.	514/411	2002/0082685 A1	6/2002	Sirhan et al.	623/1.42
5,985,307 A	11/1999	Hanson et al.	424/423	2002/0091433 A1	7/2002	Ding et al.	623/1.2
5,997,468 A	12/1999	Wolff et al.	606/36	2002/0095114 A1	7/2002	Palasis	604/96.01
6,004,346 A	12/1999	Wolff et al.	623/23.71	2002/0099438 A1	7/2002	Furst	623/1.16
6,015,432 A	1/2000	Rakos et al.	623/1.13	2002/0103526 A1	8/2002	Steinke	623/1.11
6,039,721 A	3/2000	Johnson et al.	604/508	2002/0119178 A1	8/2002	Levesque et al.	424/423
6,059,813 A	5/2000	Vrba et al.	606/198	2002/0123505 A1	9/2002	Mollison et al.	514/291
6,071,305 A	6/2000	Brown et al.	623/1.43	2002/0127327 A1	9/2002	Schwartz et al.	427/2.15
6,074,659 A	6/2000	Kunz et al.	424/423	2002/0133222 A1	9/2002	Das	623/1.16
6,080,190 A	6/2000	Schwartz	623/1.22	2002/0133224 A1	9/2002	Bajgar et al.	623/1.39
6,096,070 A	8/2000	Ragheb et al.	623/1.39	2002/0165608 A1	11/2002	Llanos	604/500
6,120,536 A	9/2000	Ding et al.	623/1.43	2002/0193475 A1	12/2002	Hossainy et al.	524/113
6,120,847 A	9/2000	Yang et al.	427/335	2003/0065377 A1	4/2003	Davila et al.	604/265
6,136,798 A	10/2000	Cody et al.	514/141	2003/0216699 A1	11/2003	Falotico	604/265
6,140,127 A	10/2000	Sprague	435/395	2004/0049265 A1	3/2004	Ding et al.	623/1.42
6,146,358 A	11/2000	Rowe	604/103	2004/0243097 A1	12/2004	Falotico et al.	604/500
6,153,252 A	11/2000	Hossainy et al.	427/2.3	2004/0260268 A1	12/2004	Falotico et al.	604/500
6,159,488 A	12/2000	Nagier et al.	424/423	2005/0002986 A1	1/2005	Falotico et al.	424/426
6,171,232 B1	1/2001	Papandreou et al.	600/36	2005/0004663 A1	1/2005	Llanos et al.	623/1.46
6,171,609 B1	1/2001	Kunz	424/422	2005/0033261 A1	2/2005	Falotico et al.	604/500
6,177,272 B1	1/2001	Nabel et al.	435/320.1	2005/0106210 A1	5/2005	Ding et al.	424/423
6,179,817 B1	1/2001	Zhong	604/265	2005/0187611 A1	8/2005	Ding et al.	623/1.15
6,193,746 B1	2/2001	Strecker	623/1.13	2005/0208200 A1	9/2005	Ding et al.	427/2.25
6,214,901 B1	4/2001	Chudzik et al.	623/113	2006/0088654 A1	4/2006	Ding et al.	427/2.21
6,225,346 B1	5/2001	Tang et al.	514/623	2006/0089705 A1	4/2006	Ding et al.	623/1.15
6,240,616 B1	6/2001	Yan	29/527.2				
6,245,537 B1	6/2001	Williams et al.	435/135				
6,251,920 B1	6/2001	Grainger et al.	514/319				
6,254,632 B1	7/2001	Wu et al.	623/1.15				
6,254,634 B1	7/2001	Anderson et al.	623/1.42				
6,258,121 B1	7/2001	Yang et al.	623/1.46				
6,268,390 B1	7/2001	Kunz	514/411				

FOREIGN PATENT DOCUMENTS

DE	19723723 A1	12/1998
EP	0 145 166 A2	6/1985
EP	0 177 330 A2	4/1986
EP	0 183 372 A1	6/1986

EP	0 221 570 A2	5/1987
EP	0 421 729 A2	4/1991
EP	0 540 290 A2	5/1993
EP	0 568 310 A1	11/1993
EP	0 604 022 A1	6/1994
EP	0 621 015 A1	10/1994
EP	0 623 354 A1	11/1994
EP	0 712 615 A1	5/1996
EP	0 716 836 A1	6/1996
EP	0 734 721 A2	10/1996
EP	0 747 069 A2	12/1996
EP	0 761 251 A1	3/1997
EP	0 800 801 A1	10/1997
EP	0 540 290 B1	1/1998
EP	0 830 853 A1	3/1998
EP	0 815 803 A1	7/1998
EP	0 850 651 A2	7/1998
EP	0 938 878 A2	9/1999
EP	0 938 878 A3	9/1999
EP	0 950 386 A2	10/1999
EP	0 968 688 A1	1/2000
EP	0 633 032 B1	2/2001
EP	1 192 957 A2	4/2002
EP	1 588 726 A1	10/2005
EP	1 588 727 A1	10/2005
FR	566 807 A1	4/1992
GB	0 662 307 A2	12/1951
GB	1 205 743 A	9/1970
GB	2 135 585 A	9/1984
JP	0 734 698 A2	3/1996
SU	660689	5/1979
SU	1457921	2/1989
WO	89/03232 A1	4/1989
WO	91/12779 A1	9/1991
WO	92/15286 A1	9/1992
WO	94/01056 A1	1/1994
WO	94/21308 A1	9/1994
WO	94/21309 A1	9/1994
WO	94/24961 A1	11/1994
WO	96/00272 A1	1/1996
WO	96/26689 A1	9/1996
WO	96/32907 A1	10/1996
WO	96/34580 A1	11/1996
WO	97/25000 A1	7/1997
WO	97/33534 A1	9/1997
WO	98/08463 A1	3/1998
WO	98/13344 A1	4/1998
WO	98/19628 A1	5/1998
WO	98/23228 A1	6/1998
WO	98/23244 A1	6/1998
WO	98/34669 A1	8/1998
WO	98/36784 A1	8/1998
WO	98/47447 A1	10/1998
WO	98/56312 A1	12/1998
WO	00/21584 A1	4/2000
WO	00/27445 A1	5/2000
WO	00/27455 A1	5/2000
WO	00/32255 A1	6/2000
WO	00/38754 A1	7/2000
WO	01/87342 A2	11/2001
WO	01/87372 A1	11/2001
WO	01/87373 A1	11/2001
WO	01/87376 A1	11/2001
WO	02/26139 A1	4/2002
WO	02/26271 A1	4/2002
WO	02/26280 A1	4/2002
WO	02/26281 A1	4/2002
WO	03/015664 A1	2/2003

WO 03/057218 A1 7/2003

OTHER PUBLICATIONS

U.S. Appl. No. 08/424,884, filed Apr. 19, 1995, Helmus et al.
U.S. Appl. No. 08/526,273, filed Sep. 11, 1995, Ding.
U.S. Appl. No. 08/730,542, filed Oct. 11, 1996, Helmus.
U.S. Appl. No. 09/575,480, filed May 19, 2000, Kopia.
U.S. Appl. No. 10/431,059, filed May 7, 2003, Falotico.
U.S. Appl. No. 10/829,074, filed Apr. 21, 2004, Falotico et al.
U.S. Appl. No. 10/833,200, filed Apr. 27, 2004, Falotico et al.
U.S. Appl. No. 10/852,517, filed May 24, 2004, Falotico et al.
Abraham, R. T., "Mammalian target of rapamycin: Immunosuppressive drugs offer new insight into cell growth regulation," *Progress in Inflammation Research*, 2000, Switzerland.
Alvarado, R. et al., "Evaluation of Polymer-coated Balloon-expandable Stents in Bile Ducts," *Radiology*, 1989, 170, 975-978.
Badimon, J. J. et al., "Inhibitory Effects of Rapamycin on Intimal Hyperplasia After PTCA," *JACC*, Mar. 1998.
Bailey et al., "Polymer Coating of Palmaz-Schatz Stent Attenuates Vascular Spasm after Stent Placement," *Circulation*, 82:III-541 (1990).
Berk, B. C. et al., "Pharmacologic Roles of Heparin and Glucocorticoids to Prevent Restenosis After Coronary Angioplasty," *JACC*, May 1991, 17(6), 111B-117B.
Bertram, P. G. et al., "The 14-3-3 proteins positively regulate rapamycin-sensitive signaling," *Current Biology*, 1998, 8, 1259-1267.
Biomaterials Science (B.D. Ratner, Ed.), Academic Press, New York, NY, pp. 228-238, 1996.
Campbell, G. R. et al., "Phenotypic Modulation of Smooth Muscle Cells in Primary Culture, Vascular Smooth Muscle Cells in Culture," *CRC Press*, 1987, 39-55.
Chang, M. W. et al., "Adenovirus-mediated Over-expression of the Cyclin/Cyclin-dependent Kinase inhibitor, p. 21 inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat Carotid Artery Model of Balloon Angioplasty," *J. Clin. Invest.*, 1995, 96, 2260-2268.
Chung, J. et al., "Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases," *Cell*, Jun. 26, 1992, 69(7), 1227-1236.
Clowes, A. W. et al., "Kinetics of cellular proliferation after arterial injury. IV. Heparin inhibits rat smooth muscle mitogenesis and migration," *Circ. Res.*, 1986, 58(6), 839-845.
Clowes, A. W. et al., Kinetics of Cellular Proliferation after Arterial Injury, *Laboratory Investigation*, 1985, 52(6), 611-616.
Clowes, A. W. et al., "Significance of quiescent smooth muscle migration in the injured rat carotid artery," *Circ Res.* 1985, 56(1), 139-145.
Clowes, A. W., "Suppression by heparin of smooth muscle cell proliferation in injured arteries," *Nature*, 1977, 265(5595), 625-626.
Colburn, M. D. et al., "Dose responsive suppression of myointimal hyperplasia by dexamethasone," *J. Vasc. Surg.*, 1992, 15, 510-518.
Currier, J. W. et al., "Colchicine Inhibits Restenosis After Iliac Angioplasty in the Atherosclerotic Rabbit," *Circ.*, 1989, 80(4), 11-66 (Abstract No. 0263).
Encyclopedia of Polymer Science and Engineering, vol. 7, Fluorocarbon Elastomers, p. 257-267, Mar. 1989.
Farb, A. et al., "Vascular smooth muscle cell cytotoxicity and sustained inhibition of neointimal formation by fibroblast growth factor 2-saporin fusion protein," *Circ. Res.*, 1997, 80, 542-550.
Ferns, G. A. A. et al., "Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF," *Science*, 1991, 253, 1129-1132.
Fischman, D. L. et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease," *N. Eng. J. Med.*, Aug. 25, 1994, 331(8), 496-501.
Franklin, S. M. et al., "Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials," *Coronary Artery Disease* Mar. 1993, 4(3), 232-242.

- Fukuyama, J. et al., "Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet," *Eur. J. Pharmacol.*, 1996, 318, 327-332.
- Gregory, C. R. et al., "Rapamycin Inhibits Arterial Intimal Thickening Caused by Both Alloimmune and Mechanical Injury," *Transplantation*, Jun. 1993, 55(6), 1409-1418.
- Gregory, C. R. et al., "Treatment with Rapamycin and Mycophenolic Acid Reduces Arterial Intimal Thickening Produced by Mechanical Injury and Allows Endothelial Replacement," *Transplantation*, Mar. 15, 1995, 59(5), 655-661.
- Guyton, J. R. et al., "Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin," *Circ. Res.*, 1980, 46, 625-634.
- Hansson, G. K. et al., "Interferon- γ Inhibits Arterial Stenosis After Injury," *Circ.*, 1991, 84, 1266-1272.
- Hashemolhosseini, S. et al., "Rapamycin Inhibition of the G1 to S Transition Is Mediated by Effects on Cyclin D1 mRNA and Protein Stability," *J Biol Chem*, Jun. 5, 1998, 273, 14424-14429.
- Jonasson, J. et al., "Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury," *Proc. Natl. Acad. Sci.*, 1988, 85, 2303-2306.
- Kuhnt, M. et al., "Microbial Conversion of Rapamycin," *Enzyme and Microbial Technology*, 1997, 21, 405-412.
- Lange, R. A. MD et al., "Restenosis After Coronary Balloon Angioplasty," *Annu. Rev. Med.*, 1991, 42, 127-132.
- Liu, M. W. et al., "Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit," *Circ.*, 1990, 81, 1089-1093.
- Liu, M. W., MD et al., "Restenosis After Coronary Angioplasty Potential Biologic Determinants and Role of Intimal Hyperplasia," *Circulation*, 1989, 79, 1374-1387.
- Lundergan, C. F. et al., "Peptide inhibition of Myointimal Proliferation by Angiopeptin, a Somatostatin Analogue," *JACC*, May 1991, 17(6), 132B-136B.
- Majesky, M. W. et al., "Heparin regulates smooth muscle S phase entry in the injured rat carotid artery," *Circ. Res.*, 1987, 61, 296-300.
- Marx, S. O. et al., "Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells," *Circ. Res.*, 1995, 76, 412-417.
- Nemecek, G. M. et al., "Terbinafine Inhibits the Mitogenic Response to Platelet-Derived Growth Factor in Vitro and Neointimal Proliferation in Vivo," *J. Pharmacol. Exp. Ther.*, 1989, 248, 1167-1174.
- Okada, T. et al., "Localized Release of Perivascular Heparin Inhibits Intimal Proliferation after Endothelial Injury without Systemic Anticoagulation," *Neurosurgery*, 1989, 25, 892-898.
- Poon, M. et al., "Rapamycin Inhibits Vascular Smooth Muscle Cell Migration," *J. Clin Invest.*, Nov. 1996, 98(10), 2277-2283.
- Popma, J. J. et al., "Clinical trials of restenosis after coronary angioplasty," *Circulation*, Sep. 1991, 84(3), 1426-1436.
- Powell, J. S. et al., "Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury," *Science*, 1989, 245, 186-188.
- Rensing, B. J. et al., Coronary restenosis elimination with a sirolimus eluting stent, *European Heart Journal*, 2001, 22, 2125-2130.
- Rodeck, C. et al., "Methods for the Transcervical Collection of Fetal Cells During the First Trimester of Pregnancy," *Prenatal Diagnosis*, 1995, 15, 933-942.
- Ruef, J. MD, et al., "Flavopiridol Inhibits Muscle Cell Proliferation In Vitro and Neointimal Formation In Vitro After Carotid Injury in the Rat," From the Division of Cardiology and Sealy Center for Molecular Cardiology, University of Texas Medical Branch, Galveston; Accepted Apr. 9, 1999; *Circulation* Aug. 10, 1999, pp. 659-665.
- Serruys, P. W. et al., "A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease," *N Engl J Med*, Aug. 25, 1994; 331(8), 489-495.
- Serruys, P. W. et al., "Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial," *Circulation*, Oct. 1993; 88(4 Pt 1), 1588-1601.
- Serruys, P. W. et al., "Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study," *Circulation*, Feb. 1, 1996; 93(3), 412-422.
- Siekierka, J. J., "Probing T-Cell Signal Transduction Pathways with the Immunosuppressive Drugs, FK-506 and Rapamycin," *Immunologic Research*, 1994, 13, 110-116.
- Sigwart, et al., "Intravascular Stents to Prevent Occlusion and Restenosis After Transluminal Angioplasty," *N. Engl. J. Med.*, Mar. 19, 1987, 316, 701-706.
- Simons, M. et al., "Antisense c-myc oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo," *Nature*, 1992, 359, 67-70.
- Snow, A. D. et al., "Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells," *Am. J. Pathol.*, 1990, 137, 313-330.
- Sollott, S. J. et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat," *J. Clin. Invest.*, 1995, 95, 1869-1876.
- van Der Giessen, et al., "Self-expandable Mesh Stents: an Experimental Study Comparing Polymer Coated and Uncoated Wallstent Stents in the Coronary Circulation of Pigs," *Circulation* 1990, 82(suppl. III):III-542
- van Der Giessen, W. J. et al., "Coronary stenting with polymer-coated and uncoated self-expanding endoprostheses in pigs," *Coron. Art. Disease* 1992; 3, 631-640.
- Vasey, C. G. et al., "Clinical Cardiology: Stress Echo and Coronary Flow", *Circulation*, Oct. 1989, 80(4) Supplement II, II-66.
- Verweire, E. et al., "Evaluation of Fluorinated Polymers As Coronary Stent Coating," *Journal of Materials Science: Materials in Medicine*, Apr. 2000.
- Weinberger, J. et al., "Intracoronary irradiation: dose response for the prevention of restenosis in swine," *Int. J. Rad. Onc. Biol. Phys.*, 1996, 36, 767-775.
- Preliminary Amendment in U.S. Appl. No. 07/258,189, May 22, 1989.
- Trial Transcript from Nov. 6, 2000 at 185-90 and 235-36 (Attorneys' opening remarks regarding '984 patent).
- Trial Transcript from Nov. 7, 2000 at 274-301, 307-315, 320-28 and 332 (Cordis expert testimony regarding the Palmaz-Schatz stent); 370-379, 480-496 (J. Palmaz testimony regarding the Palmaz-Schatz stent, the '984 patent and the connected z-stent art).
- Trial Transcript from Nov. 8, 2000 at 547-63, 657-63, 674-722, 782-85 (Cordis expert testimony regarding the Palmaz-Schatz stent, the '984 patent and the connected z-stent art).
- Trial Transcript from Nov. 9, 2000 at 819-23, 921 (Cordis expert testimony regarding the '984 patent); 926-941. (R. Croce testimony re Palmaz-Schatz stent); 1033-1053. (R. Schatz testimony).
- Trial Transcript from Nov. 13, 2000 at 1089-1134. (R. Schatz testimony); 1275-1305 (Cordis expert testimony regarding the '984 patent).
- Trial Transcript from Nov. 14, 2000 at 1390-1404, 1448-1454, 1486-1500 (Cordis expert testimony regarding the '984 patent).
- Trial Transcript from Nov. 15, 2000 at 1686-87, 1724-42, 1828-34, 1850-54, 1887-92 (AVE expert testimony regarding the '984 patent).
- Trial Transcript from Nov. 16, 2000 at 2077-198 (AVE expert testimony regarding the alleged obviousness of the '984 patent).
- Trial Transcript from Nov. 17, 2000 at 2331-34 (jury instructions as to the meaning of the limitations of the claims of the '984 patent).
- Trial Transcript from Nov. 20, 2000 at 2441-48, 2499-2500, 2546-50, 2552-56 (Attorneys' closing arguments regarding the '984 patent).
- Trial Transcript from Nov. 21, 2000 at 2592-94 (reading of jury verdict).
- Trial Transcript from Dec. 18, 2000 at 2750-95 (Cordis expert testimony regarding the Palmaz-Schatz stent during the damages phase).
- Trial Transcript from Dec. 20, 2000 at 3421-88 (AVE expert testimony regarding the Palmaz-Schatz stent during the damages phase).
- Jury verdict, dated Nov. 21, 2000.
- District Court decisions on post-trial motions (194 F. Supp. 2d 323).
- Court of Appeal for the Federal Circuit decision (339 F.3d 1352).

Trial Transcript from Mar. 4, 2005 at 133-135, 171-173 and 192-96 (Attorney's opening remarks regarding '984 validity).

Trial Transcript from Mar. 7, 2005 at 275-311 (Cordis expert testimony regarding the Palmaz-Schatz stent); 342-46, 353-59, 416-425 (J. Palmaz testimony regarding the Palmaz-Schatz stent, the '984 patent and the connected z-stent art); 430-449, 452-58, 462-492 (R. Croce testimony regarding the Palmaz-Schatz stent); 500-507 (Cordis expert testimony regarding the '984 patent).

Trial Transcript from Mar. 8, 2005 at 609 (Cordis expert testimony regarding the '984 patent); 628-73, 724-740, 773, 801-839 (Cordis expert testimony regarding the '984 patent, the prior art and the Palmaz-Schatz stent).

Trial Transcript from Mar. 9, 2005 at 936-49, 968-69 (Cordis expert testimony regarding the '984 patent, the prior art and the Palmaz-Schatz stent).

Trial Transcript from Mar. 10, 2005 at 1427-74, 178-1509, 1514-23 (AVE expert testimony regarding the alleged obviousness of the '984 patent); 1566-93 (AVE expert testimony regarding Palmaz-Schatz stent); 1634-49 (R. Schatz testimony).

Trial Transcript from Mar. 11, 2005 at 1846-47, 1891-1900, 1919 (Attorneys' closing arguments regarding '984 obviousness).

Trial Transcript from Mar. 14, 2005 at 1964-67 (reading of jury verdict).

Jury verdict dated Mar. 14, 2005.

Medtronic Vascular Inc.'s Opening Brief in Support of Its Motion for Judgment As a Infringement Claim dated Apr. 19, 2005.

Medtronic Vascular Inc.'s Opening Brief in Support of Its Motion for a New Trial dated Apr. 19, 2005.

D.I. 1407, Cordis' Combined Answering Brief In Opposition to AVE's Motion for JMOL on Infringement of the Palmaz '762 and Schatz '984 Patents and Its Motion for a New Trial dated May 5, 2005.

D.I. 1414, Medtronic Vascular Inc.'s Combined Reply Brief In Support of Its Motion for Judgment as a Matter of Law on Cordis Corp.'s Patent Infringement Claims and Its Motion for a New Trial dated May 19, 2005.

Trial Transcript from Feb. 8, 2001 at 372-412, 449-469 (B. Tobor testimony regarding the prosecution of the '417, '984 and '332 patents); 510-13 (J. Milnamow testimony regarding the prosecution of the '332 patent); 558-604 (J. Palmaz testimony regarding the prosecution of the '417, '984 and '332 patents and the prior art).

Trial Transcript from Feb. 9, 2001 at 637-45, 662-672, 682-85 (J. Palmaz testimony regarding the prior art); 699-742 (R. Schatz testimony); 769-770, 790-95 (Cordis expert testimony regarding prior art).

D.I. 1067, Medtronic AVE, Inc.'s Post-Trial Brief Relating to the Unenforceability of the '762 and '984 Patents Due to Inequitable Conduct.

D.I. 1077, Cordis' Combined Answering Brief in Opposition to AVE's BSC's Post-Hearing Briefs on Alleged Inequitable Conduct Concerning the '762, '984 and '332 Patents.

D.I. 1089, Reply Brief In Support of Medtronic AVE, Inc.'s Contention that the '762 and '984 Patents are Unenforceable Due to Inequitable Conduct dated May 7, 2001.

C.A. No. 00-886-SLR, Answer and Counterclaims of Def. Medtronic AVE, Inc. To First Amended Complaint of Plaintiff Cordis Corp.

BSC's Opening Post-Trial Brief in Support of Its Defense That the Patents in Suit Are Unenforceable, dated Mar. 16, 2001.

Reply Brief in Support of BSC's Defense That the Patents in Suit Are Unenforceable, dated May 7, 2001.

Court's Decision on allegations of inequitable conduct (194 F. Supp. 2d 323) Mar. 28, 2002.

Trial Transcript from Nov. 21, 2000 at 155-57 and 180-84 (Attorneys' opening remarks regarding '332 patent).

Trial Transcript from Nov. 27, 2000 at 227-51, 260-300 (Cordis expert testimony regarding the Palmaz-Schatz stent); 343-60, 363-67, 424-33 (J. Palmaz testimony regarding the Palmaz-Schatz stent and the '332 patent).

Trial Transcript from Nov. 28, 2000 at 649-71.

Trial Transcript from Nov. 29, 2000 at 791-816, 859-870, 953-62 (Cordis expert testimony regarding the '332 patent and the Palmaz-Schatz stent).

Trial Transcript from Nov. 30, 2000 at 1018 (Cordis expert testimony regarding the '332 patent); 1062-80, 1108-1111 (R. Croce testimony regarding the Palmaz-Schatz stent); 1169-70, 1205-17, 1236-45 (Cordis expert testimony regarding the '332 patent).

Trial Transcript from Dec. 1, 2000 at 1352-54 (Cordis expert testimony regarding the '332 patent); 1364-1442 (R. Schatz testimony); 1493-1508, 1552-69 (BSC expert testimony regarding the '332 patent and the Palmaz-Schatz stent).

Trial Transcript from Dec. 4, 2000 at 1602-12, 1638-51, 1713-14, 1730-61, 1811-14, 1823-36 (BSC expert testimony regarding the alleged obviousness of the '332 patent, the prior art and the Palmaz-Schatz stent).

Trial Transcript from Dec. 6, 2000 at 2318-27, 2342-58 (BSC expert testimony regarding the '332 patent).

Trial Transcript from Dec. 7, 2000 at 2549-52 (Cordis expert testimony regarding the '332 patent); 2575-2579, 2591-92, 2630-31, 2649, 2669-71, 2684-85, 2688, 2708-10, 2725-27 (Attorney closing argument regarding '332 patent); 2742-46 Q'ury instructions as to the meaning of the limitations of the claims of the '332 patent).

Trial Transcript from Dec. 11, 2000 at 2817-22 (reading of jury verdict).

Jury verdict, dated Dec. 11, 2000.

D.I. 699, Motion by Defendant BSC and Scimed Life Systems, Inc. For Summary Judgment of Invalidity of U.S. Patent No. 5,902,332 dated Apr. 4, 2000.

D.I.896, Order Denying Motion for Summary Judgment of Invalidity and Unenforceability of Claims 1, 3, and 5 of the U.S. Patent No. 5,902,332 Denying {699-1} Motion for Summary Judgment of Invalidity of U.S. Patent No. 5,902,332 dated Oct. 12, 2000.

Wright et al., Percutaneous Endovascular Stent: An Experimental Study (Abstract), RSNA Meeting (Nov. 28, 1984).

Hearing Transcript from Feb. 10, 1998 at 122-32, 146-80 (Attorneys' opening remarks regarding '417 patent); 180-312 (R. Schatz testimony) [Portions of This Transcript Have Been Removed as Confidential].

Hearing Transcript from Feb. 11, 1998 at 427-575, 577-651 (Cordis expert testimony regarding the '417 patent, the prior art and the Palmaz-Schatz stent).

Hearing Transcript from Feb. 13, 1998 at 1121-1261 (Guidant expert testimony regarding the alleged obviousness of the '417 patent, the prior art and the Palmaz-Schatz stent). [Portions of This Transcript Have Been Removed as Confidential].

Order by J. Robinson denying Cordis' Motion for a Preliminary Injunction Against ACS dated Jul. 17, 1998.

ACS, Inc.'s and Guidant Corp.'s Opening Brief in Support of Their Motion for Summary Judgment on Invalidity of U.S. Patent No. 5,102,417 dated Aug. 27, 1998.

Plaintiffs' Answering Brief in Opposition to ACS' and BSC's Motion for Summary Judgment on Obviousness dated Sep. 24, 1998.

Order dated Mar. 31, 2000.

Schatz Deposition Testimony; May 15, 1996: 79-83, 89-92, 105-107 and 153-161.

Schatz Deposition Testimony; May 16, 1996: 555-564, 569-572.

Schatz Deposition Testimony; Jan. 8, 1998: 67-73, 108-110.

Schatz Deposition Testimony; July 14, 1998: 69-77, 108-112, 119-123.

Schatz Deposition Testimony; Jul. 12, 1999: 88-91, 132-135, 144-149, 218-223, 231-242.

Schatz Deposition Testimony; Jul. 13, 1999: 251-334, 339-345, 374-416.

Schatz Deposition Testimony; Jul. 14, 1999: 454-550.

Schatz Deposition Testimony; Jul. 15, 1999: 560-614.

Schatz Deposition Testimony; Dec. 2, 1999: 906-911, 928-942, 945-963, 976-978, 1029-1034, 1038-1042.

Palmaz Deposition Testimony, Nov. 5, 1991: 160-172.

Palmaz Deposition Testimony, Feb. 5, 1995: 710-727.

Palmaz Deposition Testimony, Jul. 16, 1998: 55-56; 81-82.

Palmaz Deposition Testimony, Jul. 28, 1999: 560-568, 570-579.

Palmaz Deposition Testimony, Jul. 29, 1999: 778-785.

Palmaz Deposition Testimony, Aug. 31, 1999: 1403-1452.

Palmaz Deposition Testimony, Sep. 2, 1999: 1953-1960.

- Palmaz Deposition Testimony, Oct. 14, 1999; 2201-2209; 2275-2342; 2371-2411.
- Palmaz Deposition Testimony, Oct. 15, 1999: 2424-2497; 2508-2589.
- Palmaz Deposition Testimony, Oct. 16, 1999; 2853-2860.
- Tobor Deposition Testimony, Jun. 17, 1999: 837-958.
- Tobor Deposition Testimony, Jun. 18, 1999: 1095-1184.
- Tobor Deposition Testimony, Dec. 1, 1999: 1217-1371.
- Tobor Deposition Testimony, Dec. 2, 1999: 1398-1414; 1444-1508; 1532-1548.
- Tobor Deposition Testimony, Dec. 3, 1999: 1652-1653; 1662-1672; 1683-1694.
- Kula Deposition Testimony, Apr. 20, 1999: 268-169.
- Kula Deposition Testimony, Nov. 16, 1999: 660-675; 680-694; 7-8-755; 774-821.
- Kula Deposition Testimony, Nov. 18, 1999; 176-223.
- Expert Report of Dr. Rodney S. Badger on Behalf of Medtronic AVE, Inc. (Jan. 31, 2000).
- Expert Report of Dr. Joseph Bonn on Behalf of Medtronic AVE, Inc. (Jan. 31, 2000).
- Deposition of Dr. Joseph Bonn dated Mar. 14, 2000.
- Rebuttal Expert Report of Nigel Buller, B.Sc., M.B., F.R.C.P. (Mar. 2000).
- Second Supplement Rebuttal Expert Report of Nigel Buller, B.Sc., M.B., F.R.C.P. (Aug. 17, 2004).
- Rebuttal Expert Report of John M. Collins, PH.D. (Feb. 2000).
- Expert Report of David C. Cumberland, M.D. (Jan. 24, 2000).
- Expert Report of John T. Goolkasian (Feb. 2000).
- Deposition of Richard R. Heuser, M.D. (Sep. 7, 2004).
- Deposition of Henry R. Piehler (Sep. 10, 2004).
- Deposition of Ronald J. Solar (Mar. 22, 2000).
- Deposition of Ronald J. Solar (Mar. 23, 2000).
- Deposition of Ronald J. Solar (Apr. 12, 2000).
- Expert Report of Dr. Arina Van Breda on Behalf of Medtronic AVE, Inc. (Jan. 31, 2000).
- Deposition of Anna Van Breda (Mar. 24, 2000).
- Deposition of Arina Van Breda (Aug. 21, 2004).
- Expert Report of John F. Witherspoon (Jan. 24, 2000).
- Supplemental Expert Report of John F. Witherspoon (Oct. 27, 2000).
- Deposition of John F. Witherspoon (Mar. 8, 2000).
- Palmaz et al., Article: "Normal and Stenotic Renal Arteries: Experimental Balloon Expandable Intraluminal Stenting", Radiology, Sep. 1987. (AVE 84).
- Julio C. Palmaz, Article: "Expandable vascular endoprosthesis." (AVE 132).
- Duprat et al., Article: Flexible Balloon-Expandable Stent for Small Vessels Duprat et. al. Radiology, vol. 162, pp. 276-278, 1987. (AVE 134).
- Coons et. al., Article: "Large-Bore, Long Biliary Endoprosthesis (Biliary Stents) for Improved Drainage," Radiology, vol. 148, pp. 89-94, 1983. (AVE 143).
- Honickman et al., Article: "Malpositioned Biliary Endoprosthesis, Technical Developments And Instrumentation," vol. 144, No. 2., 1982. (AVE 144).
- Harries-Jones, et al., Article: "Repositioning of Biliary Endoprosthesis with Gruntzig Balloon Catheters," AJR, vol. 138, pp. 771-772, 1982. (AVE 153).
- Charnsangavej et al., Article "Stenosis of the Vena Cava: Preliminary Assessment of Treatment with Expandable Metallic Stents," Radiology, vol. 161, pp. 295-298, 1986. (AVE 359).
- Wallace, M. J. et al., Article "Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications," Radiology, vol. 158, pp. 309-312, 1986. (AVE 364).
- T. Yoshioka, et al., AIR Article: "Self-Expanding Endovascular Graft: An Experimental Study in Dogs", vol. 151, pp. 673-676, 1988. (AVE 438).
- Palmaz, J. C. et al., Article: "Expandable Intraluminal Vascular Graft: A Feasibility Study," Surgery, vol. 99, pp. 199-205, 1986. (AVE 461).
- Lawrence et al., Article: "Percutaneous Endovascular Graft: Experimental Evaluation," Radiology, vol. 163, pp. 357-360, 1987. (AVE 671).
- Palmaz et al., Article: Expandable Intraluminal Graft: A Preliminary Study, Nov. 17-22, 1985, Radiology, vol. 156, pp. 73-77, 1985. (AVE 1224).
- Fallone et al., "Elastic Characteristics of the Self-Expanding Metallic Stents," Investigative Radiology, vol. 23, pp. 370-376, 1988. (AVE 1953).
- Palmaz Paper Entitled "Research Project Expandable Vascular Endoprosthesis" May 18, 1983.
- Rousseau, et al., Publication: "Percutaneous Vascular Stent: Experimental Studies & Preliminary Clinical Results in Peripheral Arterial Diseases," in Inter. Angio, vol. 6, 153-161, 1987. (AVE 3301).
- Rousseau, et al., Publication: "Self-Expanding Endovascular Prosthesis; An Experimental Study," Radiology, vol. 164, pp. 709-714, 1987. (AVE 3303).
- Wallace, et al., Article: "Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications," Radiology, vol. 58, pp. 309-312, 1986. (DBX 2938).
- Palmaz et al., Article: "Expandable Intraluminal Graft: A Preliminary Study," Radiology, vol. 156, pp. 73-77, Nov. 17-22, 1985 (DBX 4595).
- Program for the 12th Annual Course on Diagnostic Angiography and Interventional Radiology Mar. 23-26, 1987 sponsored by the Society of Cardiovascular and Interventional Radiology (DBX 6235).
- Preliminary Motion for Judgment re: Wolff claims 1, 2-8, 10, 15 and 19 (DBX6759).
- Palmaz Declaration (DBX 7069).
- Letter from Gaterud to Dr. R. Palmaz dated Jul. 5, 1988 with attached document entitled: "Segmented, balloon-expandable stents." (DBX 7160).
- Duprat et al., Article: "Flexible Balloon-Expandable Stent For Small Vessels," Radiology, vol. 168, pp. 276-278, 1987 (PX 82).
- Drawing Sent to Bodic on Mar. 17, 1986 (PX 374).
- Letter from Dr. Palmaz to R. Bowman enclosing a model of the flexible coronary graft dated Mar. 17, 1986 (PX 337).
- Lab Notebook pages dated Jul. 30, 1987 from Rodney Wolff (Cor 185596-597) (PX621A).
- Charnsangavej, et al., Article: "Stenosis of The Vena Cava Preliminary Assessment of Treatment with expandable Metallic Stents," Radiology, vol. 161, No. 2, pp. 295-298 with attached photographs, 1986. (API 72).
- J. Palmaz: The Current Status of Vascular Prostheses, published by SCIR in the Twelfth Annual Course on Diagnostic Angiography And Interventional Radiology Mar. 23-26, 1987. (API 73).
- Amendment in Response to Office Action of Oct. 18, 1998 in re: Application of Julio Palmaz S/N 174,246. (API 152).
- Article: Wallace, et al., Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications Work In Progress, Radiology, vol. 158, pp. 309-312. (API 295).
- Reply of Senior Party Schatz To Patentee Wolff's Opposition To The Belated Motion For Judgment Of Applicant Schatz With Regard To Wolff Claims 1, 2-8, 10, 11, 13-17, And 19 (COR 186450-455) (API 310).
- Brief Of Senior Party Schatz At Final Hearing (API 313).
- Letter from Ron Sickles to Ben Tobor dated Feb. 10, 1988 (Exhibit 42).
- Letter from R.O. Sickles to Mike Tatlow dated May 12, 1988 (Exhibit 43).
- Letter from R. O. Sickles to Richard Schatz dated Jun. 2, 1988 (Exhibit 44).
- Letter from Richard Schatz to Raimund Erbel dated Jun. 3, 1988 (Exhibit 45).
- Letter from Richard Schatz to Mike Schuler dated Aug. 29, 1991 (Exhibit 48).
- Minutes of J&J Stent Project Review Meeting dated Jan. 21, 1988 (Exhibit 7).
- Preliminary Motion for Judgment with Regard to Wolff Claims 1, 2-8, 10, 11, 13-17, and 19. (Exhibit 67).
- Declaration of Richard A. Schatz. (Exhibit 75).
- Belated Motion for Judgement with Regard to Wolff Claims 1, 2-8, 10, 11, 13-17 and 19. (Schatz—Exhibit 77).
- Letter from Dr. Schatz to Mr. Tobor, dated Jun. 3, 1988. (Exhibit 122).

- Letter from Dr. Schatz to Mr. Romano, dated Nov. 28, 1988. (Exhibit 131).
- Letter from Mr. Sickles to Mr. Tobor, dated Feb. 10, 1988 (Exhibit 145).
- Richard A. Schatz, Article titled: "A View of Vascular Stents" *Circulation*, vol. 79, No. 2, pp. 445-457, 1989. (Exhibit 194).
- Senior Party Schatz's reply to Patentee Wolffs Opposition to the Preliminary Motion Of Applicant Schatz for judgment with regard to Wolff Claims 1, 2-8, 10, 11, and 13-17. (Exhibit 69).
- Wallace, et al., Article: "Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications" *Work In Progress*, *Radiology*, vol. 158, pp. 309-312, 1986. (Exhibit 165).
- Charnsangavej, et al., Article: "Stenosis of The Vena Cava Preliminary Assessment of Treatment with expandable Metallic Stents," *Radiology*, vol. 161, No. 2, pp. 295-298 with attached photographs, 1986! (Exhibit 167).
- David D. Lawrence et al., Publication: Percutaneous Endovascular Graft: Experimental Evaluation¹, *Radiology* pp. 163, 357-360, 1987. (Exhibit 173).
- Charles E. Putnam, M.D., Cover and article from "Investigative Radiology", vol. 23, No. 5, May 1988. (Exhibit 177).
- Robert N. Berk, Cover and article from "American Journal of Roentology", pp. 673-676, 1988. (Exhibit 178).
- Declaration of John S. Kula Under 37 CFR § 1.672. (Kula—Exhibit 77).
- Yoshioka et al., Article: "Self-Expanding Endovascular Graft: An Experimental Study in Dogs" *AJR*, vol. 151, pp. 673-676, 1988. (PX 100).
- Palmaz, et al., Article: Expandable Intraluminal Graft: A Preliminary Study Work in Progress¹, *Radiology*, vol. 156, No. 1, pp. 73-77, 1985. (PX 101).
- Declaration of Richard Schatz Under 37 C.F.R. § 1.672. (PX 106).
- Charnsangavej et al., Article: "Stenosis of the Vena Cave: Preliminary Assessment of Treatment with Expandable Metallic Stents," *Radiology*, vol. 161, pp. 295-298, 1986. (PX 143).
- Wallace, et al., Article: Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications Work in Progress¹, *Radiology*, vol. 158, pp. 309-312, 1986. (PX 144).
- Gina Kolata, News Article: NY Times, "Devices That Opens Clogged Arteries Gets a Falling Grade in a New Study", pp. 16-18, Jan. 3, 1991. (PX 186).
- Duprat, et al., Article: "Flexible Balloon—Expanded Stent for Small Vessels Work in Progress¹", *Radiology*, vol. 62, pp. 276-278, 1987. (PX 207).
- Letter from Palmaz to Bowman dated Mar. 17, 1986. (PX 350).
- Memo re: Minutes of Stent Project Review—San Antonio—Mar. 15, 1988. (PX 651).
- Kuntz, et al., Article: *Clinical Cardiology Frontiers: "Defining Coronary Restenosis, Newer Clinical and Angiographic Paradigms"*, *Circulation*, Sep. 1993, vol. 88, No. 3, pp. 1310-1323. (PX 854).
- Belated Motion for Judgment with regard to Wolff Claims 1, 2-8, 10, 11, 13-17, and 19. (PX 1410).
- Drawing of Spiral Stent (sent to Bodic Mar. 17, 1986). (PX2933).
- Wright et al., Article: "Percutaneous Endovascular Stents: An Experimental Evaluation," *Radiology*, vol. 156, pp. 69-72, 1985. (PX 3093).
- Charnsangavej et al., Article: "A New Expandable Metallic Stent for Dilation of Stenotic Tubular Structures: Experimental and Clinical Evaluation," *Houston Medical Journal*, vol. 3, pp. 41-51, Jun. 1987. (PX 3207).
- In re Application of Wiktor, Appln. No. 69,636, Response to Office Action dated Mar. 17, 1988. (PX3236).
- Transmittal Letter of Response to First Office Action in '417 patent. (PX 3993).
- Letter from B. Tobor to R. Schatz dated Jul. 23, 1991. (PX 3996).
- Mullins et al., Article: "Implantation of balloon—expandable intravascular grafts by catheterization in pulmonary arteries and systemic veins," *Circulation*, vol. 77, No. 1, pp. 188-189, 1988. (PX4049).
- Schatz et al., Article: "Intravascular Stents for Angioplasty," *Cardio*, 1997. (PX 4050).
- Schatz et al., Article: "New Technology in Angioplasty Balloon—Expandable Intravascular Stents, New Developments in Medicine," vol. 2, No. 2 pp. 59-75, 1987. (PX4051).
- Richard A. Schatz, Article: "Introduction to Intravascular Stents," *Cardiology Clinics*, vol. 6, No. 3, pp. 357-372, 1988. (PX 4052).
- Richard A. Schatz, Article: "A View of Vascular Stents," *Circulation*, vol. 79, No. 2, pp. 445-457, 1989. (PX4053).
- Wang et al., Article: "An Update on Coronary Stents," *Cardio*, pp. 177-186, 1992. (PX 4054).
- Richard A. Schatz, Article: "New Technology in Angioplasty: Balloon-Expandable Starts," *Medicamundi*, vol. 33, No. 3, pp. 12-16, 1988. (PX 4055).
- Letter from Tobor to Schatz dated Sep. 29, 1988. (PX1395).
- Verified Statement of Facts by Unnamed Inventor R.A. Schatz document filed in U.S. Patent and Trademark Office on Sep. 8, 1989. (PX 3677).
- Declaration of John S. Kula Under 37 CFR § 1.672 (Exhibit 329).
- Letter to Mike Schular from R.A. Schatz dated Aug. 29, 1991. (Exhibit 402).
- Articulated, Balloon—Expandable Stents, (DBX 7159).
- J. Rosch et al., Experimental Intrahepatic Portacaval Anastomosis: Use of Expandable Gianturco Stents, *Radiology*, vol. 162, pp. 481-485, 1987.
- J. Rosch et al., Modified Gianturco Expandable Wire Stents In Experimental and Clinical Use, *Ann Radiol*, vol. 31, No. 2, pp. 100-103, 1987.
- J. Rosch et al., Gianturco Expandable Stents In the Treatment of Superior Vena Cava Syndrome Recurring After Vena Cava Syndrome Recurring After Maximum-Tolerance Radiation, *Cancer*, vol. 60, pp. 1243-1246, 1987.
- I.E. Gordon, Structures or Why Things Don't Fall Down, Penguin Books, pp. 45-59, 132-148, 210-244, 377-383.
- Maass et al., Radiological Follow-up of Transluminally Inserted Vascular Endoprostheses: An Experimental Study Using Expanding Spirals, *Radiology*, vol. 152, pp. 659-663, 1984.
- Argument submitted re EP 861 15473 dated Jan. 20, 1995. (AVE 2478).
- Verified Statement of Facts by Julio C. Palmaz dated Aug. 4, 1989. (PX 3662).
- Papanicolaou et al., Insertion of a Biliary Endoprosthesis Using A Balloon Dilatation Catheter, *Gastrointest Radiology*, vol. 10, pp. 394-396, 1985.
- Palmaz et al., Atherosclerotic Rabbit Aortas; Expandable Intraluminal Grafting, *Radiology*, vol. 168, pp. 723-726, 1986.
- Palmaz, The Current Status of Vascular Prostheses; Rosch et al., Gianturco, Expandable Stents in Experimental and Clinical Use, *SCIVR*, pp. 118-124, 1987.
- Rosch et al., Abstract: Modified Gianturco Expandable Wire Stents in Experimental and Clinical Use, *CIRSE, Porto Cervo, Sardinia*, May 25-29, 1987.
- Rosch et al., Gianturco Expandable Wire Stents in the Treatment of Superior Vena Cava Syndrome Recurring After Maximum-Tolerance Radiation, *Cancer*, vol. 60, pp. 1243-1246, 1987.
- Mirich et al., Percutaneously Placed Endovascular Grafts for Aortic Aneurysms: Feasibility Study, *Radiology*, vol. 170, pp. 1033-1037, 1989.
- Dotter, Transluminally-placed Coilspring Endarterial Tube Grafts, *Investigative Radiology*, vol. 4, Sep.-Oct., pp. 329-332, 1969.
- Palmaz et al., Abstract: Expandable Intraluminal Graft: A Preliminary Study, *Radiology*, vol. 153 (P), Nov. 1983: 70th Scientific Assembly and Annual Meeting.
- Cragg et al, Nonsurgical Placement of Arterial Endoprostheses: A New Technique Using Nitinol Wire, *Radiology*, vol. 147, pp. 261-263, Apr. 1983.
- J. Rosch et al., Gianturco Expandable Stents in Experimental and Clinical Use, Program: "Twelfth Annual Course on Diagnostic Angiography and Interventional Radiology" (Society of Cardiovascular and Interventional Radiology, Pittsburgh, PA), Mar. 23-26, 1987 (the second Monofilament Article).
- Uchida et al., Modifications of Gianturco Expandable Wire Stents, *AIR*, vol. 150, pp. 1185-1187, 1988.
- Palmaz, Balloon-Expandable Intravascular Stent, *AJR*, vol. 1510, pp. 1263-1269.

- Cordis Corporation v. Advanced Cardiovascular Systems, Inc., Guidant Corporation, Arterial Vascular Engineering, Inc., Boston Scientific Corporation and SCMED Life Systems, Inc.*, Plaintiffs Complaint, Oct. 23, 1997 (Case No. 97-550-SLR).
- Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership*, Plaintiffs First Amended Complaint for Declaratory Relief of Patent Validity, Unenforceability, Noninfringement, and for Antitrust Violations, Jan. 27, 1998 (Civil Action No. 97-700).
- Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership*, Cordis Corporation and Johnson & Johnson's Answer and Counterclaim, Feb. 27, 1998 (Civil Action No. 97-700-SLR).
- Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership*, Expandable-Graft Partnership's Answer, Feb. 27, 1998 (Civil Action No. 97-700-SLR).
- Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership*, Reply of Plaintiff Arterial Vascular Engineering, Inc. To Counterclaims of Defendant Cordis Corporation, Mar. 31, 1998 (Civil Action No. 97-700-SLR).
- Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership*, Reply of Plaintiff Arterial Vascular Engineering, Inc. To Counterclaims of Defendant Expandable Grafts Partnership, Mar. 31, 1998 (Civil Action No. 97-700-SLR).
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc. and Guidant Corporation*, Cordis Corporation's Motion for a Preliminary Injunction, Oct. 8, 1997 (Civil Action No. 97-550).
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc., Guidant Corporation Arterial Vascular Engineering, Inc., Boston Scientific Corporation and SCJVVIED, Inc.*, Cordis's Motion for Preliminary Injunction Against Arterial Vascular Engineering, Inc., Dec. 29, 1997 (Case No. 97-550-SLR).
- Deposition of R. Schatz, M.D. in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, taken on Jan. 8, 1998 (Civil Action No. 97-550 SLR).
- Deposition of Lee P. Bendel in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, taken on Jan. 22, 1998 (Civil Action No. 97-550 SLR).
- Deposition of Julio Cesar Palmaz in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, taken on Dec. 29, 1997 (Civil Action No. 97-550 SLR).
- Deposition of Richard A. Bowman in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, taken on Jan. 9, 1998 (Civil Action No. 97-550 SLR).
- Deposition of Gary Schneiderman in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, taken on Jan. 16, 1998 (Civil Action No. 97-550 SLR).
- Deposition of David Pearle, M.D. in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, taken on Jul. 10, 1998 (Civil Action No. 97-550 SLR).
- Preliminary Injunction hearing testimony taken on Feb. 9-13, 1998 (Civil Action No. 97-550 SLR).
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc., et al.*, (Civil Action No. 97-550 SLR) and *Cordis Corporation v. Advanced Cardiovascular Systems, Inc. Et al.* (Civil Action No. 98-65-SLR), Opening Post Hearing Brief of Plaintiff Cordis Corporation in Support of Motion for Preliminary Injunction, Mar. 6, 1998 (Portions relevant to patent claim construction and patent validity issues).
- Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc. et al.*, Post-Hearing Reply Brief of Plaintiff Cordis Corporation in Support of Its Motion for Preliminary Injunction, Apr. 10, 1998 (Case No. 97-550 SLR) (Portions relevant to patent validity issues).
- Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc. et al.*, Plaintiffs Motion for a Preliminary Injunction Against Boston Scientific Corporation and SCLMED Life Systems, Inc. And Memorandum in Support, Apr. 13, 1998 (Case No. 97-550-SLR).
- Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc., et al.*, Judge Robinson's Order Denying Plaintiffs Motion for a Preliminary Injunction, Jul. 17, 1998 (Civil Action No. 97-550 SLR).
- Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc., et al.*, Defendant Boston Scientific Corporation and SCTMED Life Systems, Inc.'s Motion for Summary Judgment of Invalidity of U.S. Patent No. 5,102,417, Aug. 27, 1998 (Civil Action No. 97-550-SLR).
- Boston Scientific Limited, et al. v. Expandable Grafts Partnership*, Plaintiffs' Statement of Claim, Mar. 13, 1997 (UK Action No. 1493).
- Boston Scientific Limited, et al. v. Expandable Grafts Partnership*, Defendant's Amended Defense and Counterclaim, Aug. 14, 1997 (UK Action No. 1493).
- Boston Scientific Limited, et al. v. Expandable Grafts Partnership*, Petition for Revocation, Mar. 13, 1997 (UK Action No. 1497).
- Boston Scientific Limited, et al. v. Expandable Grafts Partnership*, Particulars of Objections, Mar. 13, 1997 (UK Action No. 1497).
- Boston Scientific Limited, et al. v. Expandable Grafts Partnership and Boston Scientific Limited et al., v. Julio C. Palmaz*, Boston's Skeleton Argument (UK Action Nos. 1493, 1495, 1496, and 1497).
- Boston Scientific Limited, et al. v. Julio C. Palmaz and Expandable Grafts Partnership*, Skeleton Argument of Palmaz/EGP, Mar. 19, 1998 (UK Action Nos. 1493, 1495, 1496 and 1497).
- Boston Scientific Limited, et al. v. Julio C. Palmaz and Expandable Grafts Partnership*, EGP's Final Submissions, Apr. 2, 1998 (UK Action Nos. 1493, 1495, 1496 and 1497).
- Boston Scientific Limited, et al. v. Julio C. Palmaz and Expandable Grafts Partnership*, Judgment, Jun. 26, 1998 (UK Action Nos. 1493, 1495, 1496 and 1497).
- Rosch, Modified Gianturco Expandable Wire Stents in Experimental and Clinical Use, CJJR.SE 1987 Presentation: see Witness Statement of Josef Rosch from U.K. Proceeding.
- Statement of Claim By Boston Scientific et al. against *Expandable Grafts Partnership et al.*, in *EPG et al., v. Boston Scientific et al.* in Netherlands (Mar. 13, 1997).
- Motion for Joinder of Actions, Change of Claim and Statement of Claim filed by Expandable Grafts Partnership et al. in *EPG et al. v. Boston Scientific et al.* In Netherlands (Apr. 22, 1997).
- Opinion of K.J. Merman filed in *EPG et al. v. Boston Scientific et al.* in Netherlands (Aug. 29, 1997).
- Expert report of Dr. Nigel Buller in *EPG et al. v. Boston Scientific et al.* in Netherlands (Aug. 28, 1997).
- Expert report of Lee P. Bendel in *EPG et al. v. Boston Scientific et al.* in Netherlands (Aug. 28, 1997).
- Memorandum of Oral Pleading in *EPG et al. v. Boston Scientific et al.* in Netherlands (Sep. 12, 1997).
- Plea Notes of P. A.M. in *EPG et al. v. Boston Scientific et al.* in Netherlands (Mar. 10, 1998).
- Decision of Court of Appeals in *EPG et al. v. Boston Scientific et al.* in Netherlands (Apr. 23, 1998).
- Translation of Nullity Action Against EPO 0 364 787 by Biotronik in Germany.
- Translation of Nullity Action Against EPO 0 335 341 by Biotronik in Germany.
- Translation of EPG Response to Nullity Action Against EP 0 364 787 by Biotronik in Germany.
- Translation of EPG Response to Nullity Action EP 0 335 341 by Biotronik in Germany.
- Nullity Suit Against EP-B1-0 335 341 Brought by Boston Scientific in Germany.
- Translation of Opposition filed by Terumo Corp. Against Japan Patent No. 2680901.
- Translation of Decision on Opposition Against Japan Patent No. 2680901.
- Memorandum Order of the Court dated Sep. 7, 2000, concerning disputed claim construction.
- Translation of Judgment in Nullity Action Against EP 0 364 787 by Biotronik in Germany.
- Translation of Judgment in Nullity Action Against EP 0 335 341 by Biotronik in Germany.
- Trial transcript from Mar. 17, 2005 at 171-172, 191-192.
- Trial transcript from Mar. 18, 2005 at 282-285, 325-327, 349-351.
- Trial transcript from Mar. 21, 2005 at 721-726.

Trial transcript from Mar. 24, 2005 at 1387.

Trial transcript from Jul. 26, 2005.

BSC's Opening Brief in Support of Its Motion for Judgment as a Matter of Law or, in the Alternative, for a New Trial, dated Mar. 16, 2001.

Cordis' Answering Brief in Opposition to BSC's Motion for JMOL or a New Trial on the Palmaz '762 Patent and the Schatz '332 Patents, dated Apr. 17, 2001.

BSC's Reply Brief in Support of Its Motion for Judgment as a Matter of Law or, in the Alternative, for a New Trial, dated May 11, 2001.

J. Rosch et al., Abstract, Expandable Gianturco-Type Wire Stents in Experimental Intrahepatic Portacaval Shunts, Program: "72nd Scientific Assembly and Annual Meeting of the Radiological Society of North America", Nov. 30-Dec. 5, 1986, Radiology, vol. 161, pp. 40-41, 1986.

Cordis Corporation v. Boston Scientific, Order Dated Mar. 27, 2006 (97-550-SLR).

Cordis Corporation v. Boston Scientific, Judgment in a Civil Case Dated Mar. 27, 2006 (97-550-SLR).

Cordis Corporation v. Boston Scientific, Memorandum Opinion Dated Mar. 27, 2006 (97-550-SLR).

Cordis Corporation v. Boston Scientific, Memorandum Opinion Dated Mar. 27, 2006 (97-550-SLR).

Cordis Corporation v. Boston Scientific, Memorandum Opinion Dated Mar. 27, 2006 (97-550-SLR).

Cordis Corporation v. Boston Scientific, Order Dated Mar. 27, 2006 (97-550-SLR).

Cordis Corporation v. Boston Scientific, Order Dated Mar. 27, 2006 (97-550-SLR).

Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc., Guidant Corporation, Arterial Vascular Engineering, Inc., Boston Scientific Corporation and SCIMED Life Systems, Inc., Answer and Counterclaims of Defendant Advanced Cardiovascular Systems, Inc., Apr. 8, 1998 (Case No. 97-550-SLR).

Boston Scientific Limited et al. v. Expandable Grafts Partnership and Boston Scientific Limited et al. v. Julio C. Palmaz, Boston's Closing Submissions (UK Action Nos. 1493, 1495, 1496 and 1497).

Cordis Corporation v. Advanced Cardiovascular Systems, Inc., Guidant Corporation, Arterial Vascular Engineering, Inc., Boston Scientific Corporation and SCIMED Life Systems, Inc., Defendants' Answer, Nov. 12, 1997 (Case No. 97-550-SLR).

Statement of Rejoinder in the Action on the Merits, Also Including an Amendment of Defendant's Final Position in the Principal Action, as Well as the Provisional Statement of Rejoinder in the Action on the Counterclaim in *EPG et al. v. Boston Scientific et al.* in Netherlands (Feb. 10, 1998).

Statement of Answer in the Ancillary Appeal in *EPG et al. v. Boston Scientific et al.* in Netherlands (Mar. 10, 1998).

Appeal filed by Expandable Grafts Partnership et al. in *EPG et al. v. Boston Scientific et al.* in Netherlands (Nov. 12, 1997).

Title filed by Boston Scientific et al. in *EPG et al. v. Boston Scientific et al.* in Netherlands (Jan. 22, 1998).

Deposition of Richard Schatz, M.D. in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.* taken on Jul. 14, 1998 (Civil Action No. 97-550-SLR).

Jury Verdict form from the *Cordis Corporation et al. v. Boston Scientific Corporation, et al.* liability trial, undated.

Trial testimony transcripts from the *Cordis Corporation et al. v. Boston Scientific Corporation et al.* liability trial dated Nov. 21, Nov. 27-Dec. 1, Dec. 4-8 and Dec. 11, 2000.

Boston Scientific SCIMED, Inc. and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc., Opening Expert Report of Stephen R. Hanson, Ph.D. (Civil Action No. 03-283-SLR).

Boston Scientific SCIMED, Inc. and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc., Opening Expert Report of Robson F. Storey, Ph.D. (Civil Action No. 03-283-SLR).

Boston Scientific SCIMED, Inc. and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc., Rebuttal Expert Report of Kinam Park, Ph.D. (Civil Action No. 03-283-SLR).

Cordis Corporation v. Boston Scientific Corporation and SCIMED Life Systems, Inc. (C.A. No. 03-027-SLR) and *Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.* (C.A. No. 03-283-SLR) Combined Post-Hearing Brief In Support Of Cordis Corporation's Motion For Preliminary Injunction in C.A. No. 03-027-SLR, And In Opposition to Plaintiffs' Motion For Preliminary Injunction in C.A. No. 03-283-SLR.

Cordis Corporation v. Boston Scientific Corporation and SCIMED Life Systems, Inc. (C.A. No. 03-027-SLR) *Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.* (C.A. No. 03-283-SLR), Boston Scientific's Opening Post-Hearing Brief.

Cordis Corporation v. Boston Scientific Corporation and SCIMED Life Systems, Inc. (C.A. No. 03-027-SLR) *Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.* (C.A. No. 03-283-SLR), Combined Post-Hearing Answering Brief In Support of Cordis Corporation's Motion For Preliminary Injunction In C.A. No. 03-027-SLR, And In Opposition To Plaintiffs Motion For Preliminary Injunction in C.A. No. 03-283-SLR.

Wu et al., Silicone-covered self-expanding metallic stents for the palliation of malignant esophageal obstruction and esophagorespiratory fistulas: experience in 32 patients and a review of the literature, *Gastrointestinal Endoscopy*, 1994, pp. 22-33, vol. 40, No. 1, Portland Oregon.

Binmoeller, et al., Silicone-Covered Expandable Metallic Stents in the Esophagus: An Experimental Study, *Endoscopy*, 1992, pp. 416-420, vol. 24, Georg Thieme Verlag Stuttgart New York.

Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc., Answering Memorandum in Opposition to Plaintiffs Motion for a Preliminary Injunction and Appendix thereto (Civil Action No. 03-283-SLR).

Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc., Plaintiff's Reply Brief in Support of Their Motion for Preliminary Injunction. Rhine, Polymers for Sustained Macromolecule Release: Procedures to Fabricate Reproducible Delivery Systems and Control Release Kinetics, *Journal of Pharmaceutical Sciences*, 1980, pp. 265-270, vol. 69, No. 3.

Langer et al., Controlled Release of Macromolecules From Polymers, *Biomedical Polymers Polymeric Materials and Pharmaceuticals for Biomedical Use*, 1980, pp. 112-137, Academic Press, Inc., New York, NY.

Langer et al., Applications of Polymeric Delivery Systems for Macromolecules and Factors Controlling Release Kinetics.

Rhine et al., A Method to Achieve Zero-Order Release Kinetics From Polymer Matrix Drug Delivery Systems, pp. 67-72.

Langer et al., Polymers for the Sustained Release of Macromolecules: Controlled and Magnetically Modulated Systems, *Better Therapy With Existing Drugs: New Uses and Delivery Systems*, 1981, pp. 179-216, Merck Sharp & Dohme International, Rahway, NJ.

Hsieh, et al., Zero-Order Controlled-Release Polymer Matrices for Micro-and-Macromolecules, *Journal of Pharmaceutical Sciences*, 1983 pp. 17-22, vol. 72, No. 1.

Brown et al., In Vivo and In Vitro Release of Macromolecules from Polymeric Drug Delivery Systems, *Journal of Pharmaceutical Sciences*, 1983, pp. 1181-1185, vol. 72, No. 10.

Langer, Implantable Controlled Release Systems, *Pharmac. Ther.*, 1983, pp. 35-51, vol. 21, printed in Great Britain.

Kost et al., Controlled Release of Bioactive Agents, *Trends in Biotechnology*, 1984, pp. 47-51, vol. 2, No. 2, Elsevier BV Amsterdam.

Bawa et al., An Explanation for the Controlled Release of Macromolecules from Polymers, *Journal of Controlled Release*, 1985, pp. 259-267, vol. 1 Elsevier Science BV Amsterdam.

Leong et al., Polymeric controlled drug delivery, 1987, pp. 199-233, vol. 1/3, Elsevier Science Publishers BV Amsterdam.

- Langer, Polymeric Delivery Systems, *Targeting of Drugs 2 Optimization Strategies*, 1989, pp. 165-174, Plenum Press, New York and London.
- Langer, Biomaterials in Controlled Drug Delivery; New Perspectives from Biotechnological Advances; *Pharmaceutical Technology*, 1989, pp. 18, 23-24, 26, 28, 30.
- Langer, Controlled Release Systems, pp. 115-124.
- Laurencin et al., Polymeric Controlled Release Systems: New Methods for Drug Delivery, *Clinics in Laboratory Medicine*, 1987, pp. 301-323, vol. 7, No. 2, WB Saunders Company, Philadelphia.
- Langer, Biopolymers in Controlled Release Systems, *Polymeric Biomaterials*, pp. 161-169.
- Tsong-Pin Hsu et al., Polymers for the Controlled Release of Macromolecules: Effect of Molecular Weight of Ethylene-vinyl Acetate Copolymer, *Journal of Biomedical Materials Research*, 1985, pp. 445-460, vol. 19.
- Langer, Polymers and Drug Delivery Systems, *Long-Acting Contraceptive Delivery Systems*, 1983, pp. 23-32, Harper & Row, Philadelphia, PA.
- Langer, New Drug Delivery Systems: What the Clinician Can Expect, *Drug Therapy*, 1983, pp. 217-231.
- Langer, et al., Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review, *Rev. Macromol. Chem. Phys.*, 1983, pp. 61-126.
- Langer, Polymeric Delivery Systems for Controlled Drug Release, *Chem. Eng. Commun.* 1980, pp. 1-48-vol. 6, Gordon and Breach Science Publishers, Inc. USA.
- Langer, et al., Biocompatibility of Polymeric Delivery Systems for Macromolecules, *Journal of Biomedical Materials Research*, 1981, pp. 267-277, vol. 15.
- Langer, Controlled Release: A New Approach to Drug Delivery, *Technology Review*, 1981, pp. 26-34.
- Langer, et al., Sustained Release of Macromolecules from Polymers, *Polymeric Delivery Systems*, pp. 175-176, Gordon and Breach Science Publishers, New York.
- Langer, Polymers for the Sustained Release of Proteins and other Macromolecules, *Nature*, 1976, pp. 797, 263, 799-800, vol. 263, No. 5580.
- Baker, et al., Controlled Release: Mechanisms and Rates (1974).
- Hanson, et al., In Vivo Evaluation of Artificial Surfaces with a Nonhuman Primate Model of Arterial Thrombosis, *Lab Clin. Med.*, Feb. 1980, pp. 289-304.
- Baker, Controlled Release of Biologically Active Agents (1987) pp. 1-275.
- Cordis Corporation v. Boston Scientific Corporation* (CA. No. 03-27-SLR) and *Boston Scientific Scimed, Inc., v. Cordis Corporation and Johnson & Johnson, Incorporated* (CA. No. 03-283-SLR) Hearing Transcripts for Jul. 21, 2003, Jul. 22, 2003, Jul. 23, 2003.
- Cordis Corporation v. Boston Scientific Corporation et al.* (CA. No. 03-027-SLR), and *Boston Scientific Scimed, Inc. et al. v. Cordis Corporation et al.* (CA. No. 03-283-SLR), Boston Scientific's Post-Hearing Reply Brief and Exhibits Thereto, Sep. 12, 2003.
- Cordis Corporation v. Boston Scientific Corporation et al.* (CA. No. 03-027-SLR), and *Boston Scientific Scimed, Inc. et al. v. Cordis Corporation et al.* (CA. No. 03-283-SLR), Memorandum Order, Nov. 21, 2003.
- Cordis Corporation v. Boston Scientific Corporation et al.* (CA. No. 03-027-SLR), and *Boston Scientific Scimed, Inc. et al. v. Cordis Corporation et al.* (CA. No. 03-283-SLR), Deposition Transcript of Julio C. Palmaz.
- Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable Grafts Partnership*, Cordis Corporation and Johnson & Johnson's Answer and Counterclaim, Feb. 27, 1998 (Civil Action No. 97-700-SLR).
- Plea Notes in *EPG et al. v. Boston Scientific et al.* in Netherlands (Sep. 12, 1997).
- Provisional Judgment *EPG et al. v. Boston Scientific et al.* in Netherlands (Oct. 29, 1997).
- Trial testimony transcripts from the *Cordis Corporation et al. v. Medtronic AVE Inc., et al.* liability trial dated Nov. 6-9, 13-17 and 20-21, 2000.
- Jury verdict form from the *Cordis Corporation et al. v. Medtronic AVE, Inc. et al.* liability trial.
- Hearing testimony transcript from the consolidated *Cordis Corporation et al. v. Medtronic AVE, Inc. et al. and Boston Scientific Corporation et al.* inequitable conduct hearing dated Feb. 7-9 and 12, 2001.
- Cordis Corporation v. Medtronic Ave., Inc., et al.* OPINION, 97-550-SLR, dated Mar. 28, 2002.
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc. et al.* (CA. No. 97-550-SLR), *Medtronic AVE, Inc. v. Cordis Corporation et al.* (CA. No. 97-700-SLR), *Boston Scientific Corporation v. Athicon, Inc. et al.* (CA. No. 98-19-SLR), Expert Report of John T. Goolkasian, Esq.
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc. et al.* (CA. No. 97-550-SLR), *Medtronic AVE, Inc. v. Cordis Corporation et al.* (CA. No. 97-700-SLR), *Boston Scientific Corporation v. Athicon, Inc. et al.* (CA. No. 98-19-SLR), Expert Report of John F. Witherspoon.

FIG. 1




FIG. 1a




FIG. 2a




FIG. 2b




FIG. 3a





FIG. 3b



FIG. 4



1

LOCAL DELIVERY OF RAPAMYCIN FOR TREATMENT OF PROLIFERATIVE SEQUELAE ASSOCIATED WITH PTCA PROCEDURES, INCLUDING DELIVERY USING A MODIFIED STENT

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of Ser. No. 10/951,385, filed Sep. 28, 2004, now pending, which is a continuation of Ser. No. 10/408,328, filed Apr. 7, 2003, now issued as U.S. Pat. No. 6,808,536, which is a continuation of application Ser. No. 09/874,117, filed Jun. 4, 2001, now issued as U.S. Pat. No. 6,585,764, which is a continuation of application Ser. No. 09/061,568, filed Apr. 16, 1998, now issued as U.S. Pat. No. 6,273,913, which in turn claims benefit of provisional application Ser. No. 60/044,692, filed Apr. 18, 1997. The disclosures of these prior applications are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

Delivery of rapamycin locally, particularly from an intravascular stent, directly from micropores in the stent body or mixed or bound to a polymer coating applied on stent, to inhibit neointimal tissue proliferation and thereby prevent restenosis. This invention also facilitates the performance of the stent in inhibiting restenosis.

BACKGROUND OF THE INVENTION

Re-narrowing (restenosis) of an arteriosclerotic coronary artery after percutaneous transluminal coronary angioplasty (PTCA) occurs in 10–50% of patients undergoing this procedure and subsequently requires either further angioplasty or coronary artery bypass graft. While the exact hormonal and cellular processes promoting restenosis are still being determined, our present understanding is that the process of PTCA, besides opening the arteriosclerotically obstructed artery, also injures resident coronary arterial smooth muscle cells (SMC). In response to this injury, adhering platelets, infiltrating macrophages, leukocytes, or the smooth muscle cells (SMC) themselves release cell derived growth factors with subsequent proliferation and migration of medial SMC through the internal elastic lamina to the area of the vessel intima. Further proliferation and hyperplasia of intimal SMC and, most significantly, production of large amounts of extracellular matrix over a period of 3–6 months results in the filling in and narrowing of the vascular space sufficient to significantly obstruct coronary blood flow.

Several recent experimental approaches to preventing SMC proliferation have shown promise although the mechanisms for most agents employed are still unclear. Heparin is the best known and characterized agent causing inhibition of SMC proliferation both in vitro and in animal models of balloon angioplasty-mediated injury. The mechanism of SMC inhibition with heparin is still not known but may be due to any or all of the following: 1) reduced expression of the growth regulatory protooncogenes c-fos and c-myc, 2) reduced cellular production of tissue plasminogen activator; are 3) binding and sequestration of growth regulatory factors such as fibrovalent growth factor (FGF).

Other agents which have demonstrated the ability to reduce myointimal thickening in animal models of balloon vascular injury are angiopeptin (a somatostatin analog),

2

calcium channel blockers, angiotensin converting enzyme inhibitors (captopril, cilazapril), cyclosporin A, trapidil (an antianginal, antiplatelet agent), terbinafine (antifungal), colchicine and taxol (antitubulin antiproliferatives), and c-myc and c-myb antisense oligonucleotides.

Additionally, a goat antibody to the SMC mitogen platelet derived growth factor (PDGF) has been shown to be effective in reducing myointimal thickening in a rat model of balloon angioplasty injury, thereby implicating PDGF directly in the etiology of restenosis. Thus, while no therapy has as yet proven successful clinically in preventing restenosis after angioplasty, the in vivo experimental success of several agents known to inhibit SMC growth suggests that these agents as a class have the capacity to prevent clinical restenosis and deserve careful evaluation in humans.

Coronary heart disease is the major cause of death in men over the age of 40 and in women over the age of fifty in the western world. Most coronary artery-related deaths are due to atherosclerosis. Atherosclerotic lesions which limit or obstruct coronary blood flow are the major cause of ischemic heart disease related mortality and result in 500,000–600,000 deaths in the United States annually. To arrest the disease process and prevent the more advanced disease states in which the cardiac muscle itself is compromised, direct intervention has been employed via percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) PTCA is a procedure in which a small balloon-tipped catheter is passed down a narrowed coronary artery and then expanded to re-open the artery. It is currently performed in approximately 250,000–300,000 patients each year. The major advantage of this therapy is that patients in which the procedure is successful need not undergo the more invasive surgical procedure of coronary artery bypass graft. A major difficulty with PTCA is the problem of post-angioplasty closure of the vessel, both immediately after PTCA (acute reocclusion) and in the long term (restenosis).

The mechanism of acute reocclusion appears to involve several factors and may result from vascular recoil with resultant closure of the artery and/or deposition of blood platelets along the damaged length of the newly opened blood vessel followed by formation of a fibrin/red blood cell thrombus. Recently, intravascular stents have been examined as a means of preventing acute reclosure after PTCA.

Restenosis (chronic reclosure) after angioplasty is a more gradual process than acute reocclusion: 30% of patients with subtotal lesions and 50% of patients with chronic total lesions will go on to restenosis after angioplasty. While the exact mechanism for restenosis is still under active investigation, the general aspects of the restenosis process have been identified.

In the normal arterial wall, smooth muscle cells (SMC) proliferate at a low rate (<0.1%/day; ref). SMC in vessel wall exists in a contractile phenotype characterized by 80–90% of the cell cytoplasmic volume occupied with the contractile apparatus. Endoplasmic reticulum, golgi bodies, and free ribosomes are few and located in the perinuclear region. Extracellular matrix surrounds SMC and is rich in heparin-like glycosylaminoglycans which are believed to be responsible for maintaining SMC in the contractile phenotypic state.

Upon pressure expansion of an intracoronary balloon catheter during angioplasty, smooth muscle cells within the arterial wall become injured. Cell derived growth factors such as platelet derived growth factor (PDGF), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), etc. released from platelets (i.e., PDGF) adhering to the

3

damaged arterial luminal surface, invading macrophages and/or leukocytes, or directly from SMC (i.e., BFGF) provoke a proliferation and migratory response in medial SMC. These cells undergo a phenotypic change from the contractile phenotype to a synthetic phenotype characterized by only few contractile filament bundles but extensive rough endoplasmic reticulum, golgi and free ribosomes. Proliferation/migration usually begins within 1–2 days post-injury and peaks at 2 days in the media, rapidly declining thereafter (Campbell et al., In: *Vascular Smooth Muscle Cells in Culture*, Campbell, J. H. and Campbell, G. R., Eds, CRC Press, Boca. Ration, 1987, pp. 39–55); Clowes, A. W. and Schwartz, S. M., *Circ. Res.* 56:139–145, 1985).

Finally, daughter synthetic cells migrate to the intimal layer of arterial smooth muscle and continue to proliferate. Proliferation and migration continues until the damaged luminal endothelial layer regenerates at which time proliferation ceases within the intima, usually within 7–14 days postinjury. The remaining increase in intimal thickening which occurs over the next 3–6 months is due to an increase in extracellular matrix rather than cell number. Thus, SMC migration and proliferation is an acute response to vessel injury while intimal hyperplasia is a more chronic response. (Liu et al., *Circulation*, 79:1374–1387, 1989).

Patients with symptomatic reocclusion require either repeat PTCA or CABG. Because 30–50% of patients undergoing PTCA will experience restenosis, restenosis has clearly limited the success of PTCA as a therapeutic approach to coronary artery disease. Because SMC proliferation and migration are intimately involved with the pathophysiological response to arterial injury, prevention of SMC proliferation and migration represents a target for pharmacological intervention in the prevention of restenosis.

SUMMARY OF THE INVENTION

Novel Features and Applications to Stent Technology
Currently, attempts to improve the clinical performance of stents have involved some variation of either applying a coating to the metal, attaching a covering or membrane, or embedding material on the surface via ion bombardment. A stent designed to include reservoirs is a new approach which offers several important advantages over existing technologies.

Local Drug Delivery from a Stent to Inhibit Restenosis

In this application, it is desired to deliver a therapeutic agent to the site of arterial injury. The conventional approach has been to incorporate the therapeutic agent into a polymer material which is then coated on the stent. The ideal coating material must be able to adhere strongly to the metal stent both before and after expansion, be capable of retaining the drug at a sufficient load level to obtain the required dose, be able to release the drug in a controlled way over a period of several weeks, and be as thin as possible so as to minimize the increase in profile. In addition, the coating material should not contribute to any adverse response by the body (i.e., should be non-thrombogenic, non-inflammatory, etc.). To date, the ideal coating material has not been developed for this application.

An alternative would be to design the stent to contain reservoirs which could be loaded with the drug. A coating or membrane of biocompatible material could be applied over the reservoirs which would control the diffusion of the drug from the reservoirs to the artery wall.

One advantage of this system is that the properties of the coating can be optimized for achieving superior biocompatibility and adhesion properties, without the addition require-

4

ment of being able to load and release the drug. The size, shape, position, and number of reservoirs can be used to control the amount of drug, and therefore the dose delivered.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will be better understood in connection with the following figures in which

FIGS. 1 and 1A are top views and section views of a stent containing reservoirs as described in the present invention;

FIGS. 2a and 2b are similar views of an alternate embodiment of the stent with open ends;

FIGS. 3a and 3b are further alternate figures of a device containing a grooved reservoir; and

FIG. 4 is a layout view of a device containing a reservoir as in FIG. 3.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

Pharmacological attempts to prevent restenosis by pharmacologic means have thus far been unsuccessful and all involve systemic administration of the trial agents. Neither aspirin-dipyridamole, ticlopidine, acute heparin administration, chronic warfarin (6 months) nor methylprednisolone have been effective in preventing restenosis although platelet inhibitors have been effective in preventing acute reocclusion after angioplasty. The calcium antagonists have also been unsuccessful in preventing restenosis, although they are still under study. Other agents currently under study include thromboxane inhibitors, prostacyclin mimetics, platelet membrane receptor blockers, thrombin inhibitors and angiotensin converting enzyme inhibitors. These agents must be given systemically, however, and attainment of a therapeutically effective dose may not be possible; antiproliferative (or anti-restenosis) concentrations may exceed the known toxic concentrations of these agents so that levels sufficient to produce smooth muscle inhibition may not be reached (Lang et al., 42 *Ann. Rev. Med.*, 127–132 (1991); Popma et al., 84 *Circulation*, 1426–1436 (1991)).

Additional clinical trials in which the effectiveness for preventing restenosis of dietary fish oil supplements, thromboxane receptor antagonists, cholesterol lowering agents, and serotonin antagonists has been examined have shown either conflicting or negative results so that no pharmacological agents are as yet clinically available to prevent post-angioplasty restenosis (Franklin, S. M. and Faxon, D. P., 4 *Coronary Artery Disease*, 2-32-242 (1993); Serruys, P. W. et al., 88 *Circulation*, (part 1) 1588–1601, (1993).

Conversely, stents have proven useful in preventing reducing the proliferation of restenosis. Stents, such as the stent 10 seen in layout in FIG. 4, balloon-expandable slotted metal tubes (usually but not limited to stainless steel), which when expanded within the lumen of an angioplastied coronary artery, provide structural support to the arterial wall. This support is helpful in maintaining an open path for blood flow. In two randomized clinical trials, stents were shown to increase angiographic success after PTCA, increase the stenosed blood vessel lumen and to reduce the lesion recurrence at 6 months (Serruys et al., 331 *New Eng Jour. Med.*, 495, (1994); Fischman et al., 331 *New Eng Jour. Med.*, 496–501 (1994). Additionally, in a preliminary trial, heparin coated stents appear to possess the same benefit of reduction in stenosis diameter at follow-up as was observed with non-heparin coated stents. Additionally, heparin coating appears to have the added benefit of producing a reduction in sub-acute thrombosis after stent implantation (Serruys et

al., 93 *Circulation*, 412-422, (1996). Thus, 1) sustained mechanical expansion of a stenosed coronary artery has been shown to provide some measure of restenosis prevention, and 2) coating of stents with heparin has demonstrated both the feasibility and the clinical usefulness of delivering drugs to local, injured tissue off the surface of the stent.

Numerous agents are being actively studied as antiproliferative agents for use in restenosis and have shown some activity in experimental animal models. These include: heparin and heparin fragments (Clowes and Karnovsky, 265 *Nature*, 25-626, (1977); Guyton, J. R. et al. 46 *Circ. Res.*, 625-634, (1980); Clowes, A. W. and Clowes, M. M., 52 *Lab. Invest.*, 611-616, (1985); Clowes, A. W. and Clowes, M. M., 58 *Circ. Res.*, 839-845 (1986); Majesky et al., 61 *Circ Res.*, 296-300, (1987); Snow et al., 137 *Am. J. Pathol.*, 313-330 (1990); Okada, T. et al., 25 *Neurosurgery*, 92-898, (1989) colchicine (Currier, J. W. et al., 80 *Circulation*, 11-66, (1989), taxol (ref), angiotensin converting enzyme (ACE) inhibitors (Powell, J. S. et al., 245 *Science*, 186-188 (1989), angiopeptin (Lundergan, C. F. et al., 17 *Am. J. Cardiol. (Suppl. B)*; 132B-136B (1991), Cyclosporin A (Jonasson, L. et al., 85 *Proc. Natl. Acad. Sci.*, 2303 (1988), goat-anti-rabbit PDGF antibody (Ferns, G. A. A., et al., 253 *Science*, 1129-1132 (1991), terbinafine (Nemecek, G. M. et al., 248 *J. Pharmacol. Exp. Ther.*, 1167-11747 (1989), trapidil (Liu, M. W. et al., 81 *Circulation*, 1089-1093 (1990), interferon-gamma (Hansson, G. K. and Holm, 84 *J. Circulation*, 1266-1272 (1991), steroids (Colburn, M. D. et al., 15 *J. Vasc. Surg.*, 510-518 (1992), see also Berk, B. C. et al., 17 *J. Am. Coll. Cardiol.*, 111B-117B (1991), ionizing radiation (ref), fusion toxins (ref) antisense oligonucleotides (ref), gene vectors (ref), and rapamycin (see below).

Of particular interest is rapamycin. Rapamycin is a macrolide antibiotic which blocks IL-2-mediated T-cell proliferation and possesses antiinflammatory activity. While the precise mechanism of rapamycin is still under active investigation, rapamycin has been shown to prevent the G.sub.1 to S phase progression of T-cells through the cell cycle by inhibiting specific cell cyclins and cyclin-dependent protein kinases (Siekierka, *Immunol. Res.* 13: 110-116, 1994). The antiproliferative action of rapamycin is not limited to T-cells; Marx et al. (*Circ Res* 76:412-417, 1995) have demonstrated that rapamycin prevents proliferation of both rat and human SMC in vitro while Poon et al. have shown the rat, porcine, and human SMC migratin can also be inhibited by rapamycin (*J Clin Invest* 98: 2277-2283, 1996). Thus, rapamycin is capable of inhibiting both the inflammatory response known to occur after arterial injury and stent implantation, as well as the SMC hyperproliferative response. In fact, the combined effects of rapamycin have been demonstrated to result in a diminished SMC hyperproliferative response in a rat femoral artery graft model and in both rat and porcine arterial balloon injury models (Gregory et al., *Transplantation* 55:1409-1418, 1993; Gallo et al., in press, (1997)). These observations clearly support the potential use of rapamycin in the clinical setting of post-angioplasty restenosis.

Although the ideal agent for restenosis has not yet been identified, some desired properties are clear: inhibition of local thrombosis without the risk systemic bleeding complications and continuous and prevention of the dequale of arterial injury, including local inflammation and sustained prevention smooth muscle proliferation at the site of angioplasty without serious systemic complications. Inasmuch as stents prevent at least a portion of the restenosis process, an agent which prevents inflammation and the proliferation of

SMC combined with a stent may provide the most efficacious treatment for post-angioplasty restenosis.

Experiments

Agents: Rapamycin (sirolimus) structural analogs (macrocyclic lactones) and inhibitors of cell-cycle progression.

Delivery Methods: These can vary:

Local delivery of such agents (rapamycin) from the struts of a stent, from a stent graft, grafts, stent cover or sheath.

Involving comixture with polymers (both degradable and nondegrading) to hold the drug to the stent or graft or entrapping the drug into the metal of the stent or graft body which has been modified to contain micropores or channels, as will be explained further herein.

or including covalent binding of the drug to the stent via solution chemistry techniques (such as via the Carmeda process) or dry chemistry techniques (e.g. vapour deposition methods such as rf-plasma polymerization) and combinations thereof.

Catheter delivery intravascularly from a tandem balloon or a porous balloon for intramural uptake.

Extravascular delivery by the pericardial route.

Extravascular delivery by the advential application of sustained release formulations.

Uses:

for inhibition of cell proliferation to prevent neointimal proliferation and restenosis.

prevention of tumor expansion from stents.

prevent ingrowth of tissue into catheters and shunts inducing their failure.

1. Experimental Stent Delivery Method—Delivery from Polymer Matrix:

Solution of Rapamycin, prepared in a solvent miscible with polymer carrier solution, is mixed with solution of polymer at final concentration range 0.001 weight % to 30 weight % of drug. Polymers are biocompatible (i.e., not elicit any negative tissue reaction or promote mural thrombus formation) and degradable, such as lactone-based polyesters or copolyesters, e.g., polylactide, polycaprolactone-glycolide, polyorthoesters, polyanhydrides; poly-amino acids; polysaccharides; polyphosphazenes; poly(ether-ester) copolymers, e.g., PEO-PLLA, or blends thereof. Nonabsorbable biocompatible polymers are also suitable candidates. Polymers such as polydimethylsiloxane; poly(ethylene-vinylacetate); acrylate based polymers or copolymers, e.g., poly(hydroxyethyl methacrylate), polyvinyl pyrrolidinone; fluorinated polymers such as polytetrafluoroethylene; cellulose esters.

Polymer/drug mixture is applied to the surfaces of the stent by either dip-coating, or spray coating, or brush coating or dip/spin coating or combinations thereof, and the solvent allowed to evaporate to leave a film with entrapped rapamycin.

2. Experimental Stent Delivery Method—Delivery from Microporous Depots in Stent Through a Polymer Membrane Coating:

Stent, whose body has been modified to contain micropores or channels is dipped into a solution of Rapamycin, range 0.001 wt % to saturated, in organic solvent such as acetone or methylene chloride, for sufficient time to allow solution to permeate into the pores. (The dipping solution can also be compressed to improve the loading efficiency.) After solvent has been allowed to evaporate, the stent is dipped briefly in fresh solvent to remove excess surface bound drug. A solution of polymer, chosen from any

identified in the first experimental method, is applied to the stent as detailed above. This outer layer of polymer will act as diffusion-controller for release of drug.

3. Experimental Stent Delivery Method—Delivery via Lysis of a Covalent Drug Tether:

Rapamycin is modified to contain a hydrolytically or enzymatically labile covalent bond for attaching to the surface of the stent which itself has been chemically derivatized to allow covalent immobilization. Covalent bonds such as ester, amides or anhydrides may be suitable for this.

4. Experimental Method—Pericardial Delivery:

A: Polymeric Sheet

Rapamycin is combined at concentration range previously highlighted, with a degradable polymer such as poly(caprolactone-glycolid-e) or non-degradable polymer, e.g., polydimethylsiloxane, and mixture cast as a thin sheet, thickness range 10.mu. to 1000.mu. The resulting sheet can be wrapped perivascularly on the target vessel. Preference would be for the absorbable polymer.

B: Conformal Coating:

Rapamycin is combined with a polymer that has a melting temperature just above 37° C., range 40°–45° C. Mixture is applied in a molten state to the external side of the target vessel. Upon cooling to body temperature the mixture solidifies conformably to the vessel wall. Both non-degradable and absorbable biocompatible polymers are suitable.

As seen in the figures it is also possible to modify currently manufactured stents in order to adequately provide the drug dosages such as rapamycin. As seen in FIGS. 1a, 2a and 3a, any stent strut 10, 20, 30 can be modified to have a certain reservoir or channel 11, 21, 31. Each of these reservoirs can be open or closed as desired. These reservoirs can hold the drug to be delivered. FIG. 4 shows a stent 40 with a reservoir 45 created at the apex of a flexible strut. Of course, this reservoir 45 is intended to be useful to deliver rapamycin or any other drug at a specific point of flexibility of the stent. Accordingly, this concept can be useful for “second generation” type stents.

In any of the foregoing devices, however, it is useful to have the drug dosage applied with enough specificity and

enough concentration to provide an effective dosage in the lesion area. In this regard, the reservoir size in the stent struts must be kept at a size of about 0.0005" to about 0.003". Then, it should be possible to adequately apply the drug dosage at the desired location and in the desired amount.

These and other concepts will be disclosed herein. It would be apparent to the reader that modifications are possible to the stent or the drug dosage applied. In any event, however, the any obvious modifications should be perceived to fall within the scope of the invention which is to be realized from the attached claims and their equivalents.

What is claimed:

1. A metallic stent having a coating applied thereto, wherein:
 - said coating comprises a mixture of a biocompatible polymeric carrier and a therapeutic agent;
 - said polymeric carrier comprises at least one nonabsorbable polymer;
 - said therapeutic agent is rapamycin, or a macrocyclic lactone analog thereof, present in an amount effective to inhibit neointimal proliferation; and
 - said stent provides a controlled release of said therapeutic agent over a period of several weeks.
2. The metallic stent according to claim 1 wherein said therapeutic agent is a macrocyclic lactone analog of rapamycin.
3. The metallic stent according to claim 1 wherein said biocompatible polymeric carrier comprises a fluorinated polymer.
4. The metallic according to claim 3 wherein said biocompatible polymeric carrier further comprises an acrylate-based polymer or copolymer.
5. A method of inhibiting neointimal proliferation in a coronary artery resulting from percutaneous transluminal coronary angioplasty comprising implanting a metallic stent according to any one of claims 1 to 4 in the lumen of said coronary artery.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,229,473 B2
APPLICATION NO. : 11/466983
DATED : June 12, 2007
INVENTOR(S) : Robert Falotico et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title Page,

Item (56), **References Cited,**

U.S. PATENT DOCUMENTS:

Page 2, "5,195,984 A" reference, delete "Schalz" and insert -- Schatz --.

OTHER PUBLICATIONS: Item [56]

Page 6, "Vasey, C. G. et al.," reference, delete "Flow", "," and insert -- Flow", --.

Page 8, "Belated Motion For Judgment" reference, delete "1 1," and insert -- 11, --.

Page 9, "Senior Party Schatz's reply" reference, delete "1 1," and insert -- 11, --.

Page 9, "Duprat, et al.," reference, delete "vol. 62," and insert -- vol. 162, --.

Page 9, "Belated Motion for Judgment" reference, delete "Wolff Claims1," and insert -- Wolff Claims 1, --.

Column 4,

Line 50, delete "preventing" and insert -- preventing and --.

Column 5,

Line 46, delete "migratin" and insert -- migration --.

Line 61, delete "risk systemic" and insert -- risk of systemic --.

Column 8,

Line 31, claim 4, delete "metallic according" and insert -- metallic stent according --.

Signed and Sealed this

Twenty-fourth Day of June, 2008

A handwritten signature in black ink, reading "Jon W. Dudas". The signature is stylized with a large, looped initial "J" and a cursive "Dudas".

JON W. DUDAS

Director of the United States Patent and Trademark Office



US007300662B2

(12) **United States Patent**
Falotico et al.

(10) **Patent No.:** **US 7,300,662 B2**

(45) **Date of Patent:** ***Nov. 27, 2007**

(54) **DRUG/DRUG DELIVERY SYSTEMS FOR
THE PREVENTION AND TREATMENT OF
VASCULAR DISEASE**

(75) Inventors: **Robert Falotico**, Belle Mead, NJ (US);
Gregory A. Kopia, Hillsborough, NJ
(US); **Gerard H. Llanos**, Stewartsville,
NJ (US)

(73) Assignee: **Cordis Corporation**, Miami Lakes, FL
(US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 503 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **10/829,074**

(22) Filed: **Apr. 21, 2004**

(65) **Prior Publication Data**

US 2004/0260268 A1 Dec. 23, 2004

Related U.S. Application Data

(63) Continuation-in-part of application No. 09/850,293,
filed on May 7, 2001, now abandoned, which is a
continuation-in-part of application No. 09/575,480,
filed on May 19, 2000.

(60) Provisional application No. 60/263,979, filed on Jan.
25, 2001, provisional application No. 60/263,806,
filed on Jan. 24, 2001, provisional application No.
60/262,614, filed on Jan. 18, 2001, provisional appli-
cation No. 60/262,461, filed on Jan. 18, 2001, provi-
sional application No. 60/204,417, filed on May 12,
2000.

(51) **Int. Cl.**
A61F 2/00 (2006.01)
A61F 2/06 (2006.01)

(52) **U.S. Cl.** **424/424; 623/1.42; 623/1.45**

(58) **Field of Classification Search** 424/422-426;
623/1.42-1.48
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

861,659 A	7/1907	Johnston	464/147
3,051,677 A	8/1962	Rexford	522/156
3,279,996 A	10/1966	Long et al.	424/424
3,526,005 A	9/1970	Bokros	623/11.11
3,599,641 A	8/1971	Sheridan	604/256

(Continued)

FOREIGN PATENT DOCUMENTS

DE 3205942 A1 9/1983

(Continued)

OTHER PUBLICATIONS

Boston Scientific, "Measuring DES Efficacy," www.taxus-stent.com/usa/efficacy.html, pp. 1-3, copyright 2006.*

(Continued)


Primary Examiner—Sharon E. Kennedy

(74) *Attorney, Agent, or Firm*—Woodcock Washburn LLP

(57) **ABSTRACT**

A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.

25 Claims, 2 Drawing Sheets



US 7,300,662 B2

Page 2

U.S. PATENT DOCUMENTS					
3,657,744 A	4/1972	Ersek	5,047,020 A	9/1991	Hsu 604/266
3,744,596 A	7/1973	Sander 188/203	5,049,132 A	9/1991	Shaffer et al.
3,779,805 A	12/1973	Alsberg 427/105	5,049,403 A	9/1991	Larm et al. 427/2.1
3,929,992 A	12/1975	Sehgal et al. 424/122	5,053,048 A	10/1991	Pinchuk
3,932,627 A	1/1976	Margraf	5,059,166 A	10/1991	Fischell et al. 600/3
3,948,254 A	4/1976	Zaffaroni 128/833	5,061,275 A	10/1991	Wallsten et al.
3,952,334 A	4/1976	Bokros et al. 623/11.11	5,061,750 A	10/1991	Feijen et al.
3,968,800 A	7/1976	Vilasi 606/198	5,064,435 A	11/1991	Porter
4,069,307 A	1/1978	Higuchi et al. 424/432	5,092,877 A	3/1992	Pinchuk
4,076,285 A	2/1978	Martinez 285/332	5,102,417 A	4/1992	Palmaz
4,292,965 A	10/1981	Nash et al.	5,104,404 A	4/1992	Wolff
4,299,226 A	11/1981	Banka 604/509	5,116,365 A	5/1992	Hillstead
4,300,244 A	11/1981	Bokros 623/1.13	5,122,154 A	6/1992	Rhodes
4,312,920 A	1/1982	Pierce et al. 428/425.5	5,131,908 A	7/1992	Dardik et al.
4,321,711 A	3/1982	Mano 623/1.43	5,133,732 A	7/1992	Wiktor
4,323,071 A	4/1982	Simpson et al. 606/194	5,134,192 A	7/1992	Feijen et al.
4,390,599 A	6/1983	Broyles 428/597	5,135,536 A	8/1992	Hillstead
4,413,359 A	11/1983	Akiyama et al. 623/23.72	5,163,952 A	11/1992	Froix
4,423,183 A	12/1983	Close 524/546	5,163,958 A	11/1992	Pinchuk
4,441,216 A	4/1984	Ionescu et al.	5,171,217 A	12/1992	March et al. 604/507
4,503,569 A	3/1985	Dotter	5,171,262 A	12/1992	MacGregor
4,512,338 A	4/1985	Balko et al. 606/108	5,176,660 A	1/1993	Truckai
4,550,447 A	11/1985	Seiler, Jr. et al. 623/1.32	5,176,972 A	1/1993	Bloom et al. 430/14
4,553,545 A	11/1985	Maass et al.	5,178,618 A	1/1993	Kandarpa
4,560,374 A	12/1985	Hammerslag 604/509	5,180,366 A	1/1993	Woods
4,562,596 A	1/1986	Kronberg 623/1.32	5,182,317 A	1/1993	Winters et al.
4,565,740 A	1/1986	Golander et al. 428/409	5,185,408 A	2/1993	Tang et al.
4,580,568 A	4/1986	Gianturco	5,192,307 A	3/1993	Wall
4,613,665 A	9/1986	Larm	5,195,984 A	3/1993	Schalz
4,642,111 A	2/1987	Sakamoto et al. 424/492	5,202,332 A	4/1993	Hughes et al. 514/291
4,655,771 A	4/1987	Wallsten	5,213,576 A	5/1993	Abiuso et al.
4,656,083 A	4/1987	Hoffman et al. 442/123	5,213,898 A	5/1993	Larm et al. 428/422
4,676,241 A	6/1987	Webb et al. 128/207.14	5,217,483 A	6/1993	Tower
4,678,466 A	7/1987	Rosenwald 424/427	5,222,971 A	6/1993	Willard et al.
4,687,482 A	8/1987	Hanson 623/1.49	5,226,913 A	7/1993	Pinchuk
4,689,046 A	8/1987	Bokros 623/2.31	5,234,456 A	8/1993	Silvestrini
4,731,054 A	3/1988	Billeter et al. 604/93.01	5,246,445 A	9/1993	Yachia et al.
4,733,665 A	3/1988	Palmaz	5,258,020 A	11/1993	Froix
4,739,762 A	4/1988	Palmaz	5,258,021 A	11/1993	Duran
4,740,207 A	4/1988	Kreamer 623/1.15	5,262,451 A	11/1993	Winters et al.
4,749,585 A	6/1988	Greco et al. 428/422	5,266,073 A	11/1993	Wall
4,753,652 A	6/1988	Langer et al. 623/1.42	5,272,012 A	12/1993	Opolski 428/423.1
4,760,849 A	8/1988	Kropf 606/191	4,733,665 A	1/1994	Palmaz 606/108
4,768,507 A	9/1988	Fischell et al. 623/1.11	5,275,622 A	1/1994	Lazarus et al.
4,776,337 A	10/1988	Palmaz	5,282,823 A	2/1994	Schwartz et al.
4,786,500 A	11/1988	Wong 424/422	5,282,824 A	2/1994	Gianturco
4,787,899 A	11/1988	Lazarus 623/1.11	5,283,257 A	2/1994	Gregory et al.
4,800,882 A	1/1989	Gianturco	5,288,711 A	2/1994	Mitchell et al.
4,810,784 A	3/1989	Larm 536/20	5,290,305 A	3/1994	Inoue
4,856,516 A	8/1989	Hillstead	5,292,331 A	3/1994	Boneau
4,871,357 A	10/1989	Hsu et al. 604/266	5,292,802 A	3/1994	Rhee et al.
4,872,867 A	10/1989	Joh	5,304,121 A	4/1994	Sahatjian
4,876,109 A	10/1989	Mayer et al. 604/269	5,304,200 A	4/1994	Spaulding
4,886,062 A	12/1989	Wiktor	5,306,250 A	4/1994	March et al.
4,907,336 A	3/1990	Gianturco	5,308,862 A	5/1994	Ohlstein
4,916,193 A	4/1990	Tang et al.	5,308,889 A	5/1994	Rhee et al.
4,954,126 A	9/1990	Wallsten	5,314,444 A	5/1994	Gianturco
4,969,458 A	11/1990	Wiktor	5,314,472 A	5/1994	Fontaine
4,990,131 A	2/1991	Dardik	5,328,471 A	7/1994	Slepian
4,990,155 A	2/1991	Wilkoﬀ	5,334,301 A	8/1994	Heinke et al.
4,994,071 A	2/1991	MacGregor	5,336,518 A	8/1994	Pallassana et al.
4,994,298 A	2/1991	Yasuda 427/490	5,338,770 A	8/1994	Winters et al.
4,998,923 A	3/1991	Samson et al. 606/194	5,342,348 A	8/1994	Kaplan
5,015,253 A	5/1991	MacGregor	5,342,387 A	8/1994	Summers
5,019,090 A	5/1991	Pinchuk 623/1.15	5,342,621 A	8/1994	Eury
5,019,096 A	5/1991	Fox, Jr. et al. 600/36	5,354,257 A	10/1994	Roubin et al.
5,029,877 A	7/1991	Fedeli et al. 277/354	5,354,308 A	10/1994	Simon et al.
5,034,265 A	7/1991	Hoffman et al. 442/126	5,356,433 A	10/1994	Rowland et al.
5,035,706 A	7/1991	Gianturco	5,366,504 A	11/1994	Andersen et al.
5,041,100 A	8/1991	Rowland et al.	5,368,566 A	11/1994	Crocker
5,041,126 A	8/1991	Gianturco	5,370,683 A	12/1994	Fontaine
			5,370,691 A	12/1994	Samson
			5,375,612 A	12/1994	Cottenceau et al.

US 7,300,662 B2

Page 3

5,376,112 A	12/1994	Duran	5,591,224 A	1/1997	Schwartz et al.
5,378,475 A	1/1995	Smith et al. 424/473	5,591,227 A	1/1997	Dinh et al.
5,380,299 A	1/1995	Fearnot et al.	5,599,352 A	2/1997	Dinh et al.
5,382,261 A	1/1995	Palmaz	5,603,722 A	2/1997	Phan et al.
5,383,853 A	1/1995	Jung et al. 604/103.04	5,604,283 A	2/1997	Wada et al. 524/236
5,383,928 A	1/1995	Scott et al.	5,605,696 A	2/1997	Eury et al.
5,387,235 A	2/1995	Chuter	5,607,463 A	3/1997	Schwartz et al.
5,389,106 A	2/1995	Tower	5,607,475 A	3/1997	Cahalan et al.
5,391,730 A	2/1995	Skotnicki et al. 540/456	5,609,629 A	3/1997	Fearnot et al.
5,393,772 A	2/1995	Yue et al.	5,616,608 A	4/1997	Kinsella et al. 514/449
5,395,390 A	3/1995	Simon et al.	5,620,984 A	4/1997	Bianco et al.
5,397,355 A	3/1995	Marin et al.	5,621,102 A	4/1997	Bianco et al.
5,399,352 A	3/1995	Hanson 424/423	5,622,975 A	4/1997	Singh et al.
5,403,341 A	4/1995	Solar	5,624,411 A	4/1997	Tuch
5,405,377 A	4/1995	Cragg	5,628,785 A	5/1997	Schwartz et al.
5,409,696 A	4/1995	Narayanan et al.	5,629,077 A	5/1997	Turnlund et al.
5,411,549 A	5/1995	Peters	5,629,315 A	5/1997	Bianco et al.
5,415,619 A	5/1995	Lee et al.	5,632,763 A	5/1997	Glastra
5,417,969 A	5/1995	Hsu et al. 424/78.27	5,632,771 A	5/1997	Boatman et al. 623/1.15
5,419,760 A	5/1995	Narciso, Jr.	5,632,776 A	5/1997	Kurumatani et al. 424/423
D359,802 S	6/1995	Fontaine	5,632,840 A	5/1997	Campbell
5,421,955 A	6/1995	Lau	5,635,201 A	6/1997	Fabo 424/443
5,423,885 A	6/1995	Williams	5,637,113 A	6/1997	Tartaglia et al.
5,429,618 A	7/1995	Keogh	5,643,312 A	7/1997	Fischell et al.
5,429,634 A	7/1995	Narciso	5,643,939 A	7/1997	Ohlstein
5,439,446 A	8/1995	Barry	5,646,160 A	7/1997	Morris et al.
5,441,515 A	8/1995	Khosravi et al.	5,648,357 A	7/1997	Bianco et al.
5,441,516 A	8/1995	Wang et al.	5,649,952 A	7/1997	Lam
5,441,947 A	8/1995	Dodge et al.	5,649,977 A	7/1997	Campbell
5,443,458 A	8/1995	Eury	5,651,174 A	7/1997	Schwartz et al.
5,443,477 A	8/1995	Marin et al.	5,652,243 A	7/1997	Bianco et al.
5,443,496 A	8/1995	Schwartz et al.	5,653,747 A	8/1997	Dereume 623/1.54
5,443,498 A	8/1995	Fontaine	5,653,992 A	8/1997	Bezwada et al.
5,443,500 A	8/1995	Sigwart	5,662,609 A	9/1997	Slepian
5,447,724 A	9/1995	Heimus et al.	5,665,591 A	9/1997	Sonenshein et al. 435/375
5,449,372 A	9/1995	Schmaltz et al.	5,665,728 A	9/1997	Morris et al.
5,449,373 A	9/1995	Pinchasik et al.	5,667,764 A	9/1997	Kopia et al. 424/1.45
5,449,382 A	9/1995	Dayton	5,669,924 A	9/1997	Shaknovich
5,464,450 A	11/1995	Buscemi et al.	5,670,506 A	9/1997	Leigh et al.
5,464,540 A	11/1995	Friesen et al. 210/640	5,672,638 A	9/1997	Verhoeven et al. 523/112
5,464,650 A	11/1995	Berg et al.	5,674,242 A	10/1997	Phan et al. 606/198
5,474,563 A	12/1995	Myler et al. 606/108	5,679,400 A	10/1997	Tuch
5,486,357 A	1/1996	Narayanan	5,679,659 A	10/1997	Verhoeven et al.
5,496,365 A	3/1996	Sgro	5,684,061 A	11/1997	Ohnishi et al. 523/114
5,500,013 A	3/1996	Buscemi et al.	5,691,311 A	11/1997	Maraganore et al. 514/12
5,504,091 A	4/1996	Molnar-Kimber et al. .. 514/291	5,693,085 A	12/1997	Buirge et al.
5,510,077 A	4/1996	Dinh et al.	5,697,967 A	12/1997	Dinh et al.
5,512,055 A	4/1996	Domb et al. 604/265	5,697,971 A	12/1997	Fischell et al.
5,516,781 A	5/1996	Morris et al.	5,700,286 A	12/1997	Tartaglia et al.
5,519,042 A	5/1996	Morris et al. 514/378	5,707,385 A	1/1998	Williams
5,523,092 A	6/1996	Hanson et al.	5,709,874 A	1/1998	Hanson et al.
5,527,354 A	6/1996	Fontaine et al.	5,713,949 A	2/1998	Jayaraman 623/1.12
5,545,208 A	8/1996	Wolff et al.	5,716,981 A	2/1998	Hunter et al. 514/449
5,551,954 A	9/1996	Buscemi et al.	5,725,549 A	3/1998	Lam
5,554,182 A	9/1996	Dinh et al.	5,725,567 A	3/1998	Wolff et al.
5,554,954 A	9/1996	Takahashi	5,728,150 A	3/1998	McDonald et al.
5,556,413 A	9/1996	Lam	5,728,420 A	3/1998	Keogh
5,559,122 A	9/1996	Nelson et al. 514/291	5,731,326 A	3/1998	Hart et al.
5,562,922 A	10/1996	Lambert	5,733,327 A	3/1998	Igaki et al.
5,563,146 A	10/1996	Morris et al.	5,733,920 A	3/1998	Mansuri et al.
5,569,197 A	10/1996	Helmus et al.	5,733,925 A	3/1998	Kunz et al.
5,569,295 A	10/1996	Lam	5,735,897 A	4/1998	Buirge
5,569,462 A	10/1996	Martinson et al. 424/423	5,739,138 A	4/1998	Bianco et al.
5,569,463 A	10/1996	Helmus et al. 424/426	5,755,734 A	5/1998	Richter et al.
5,571,089 A	11/1996	Crocker 604/103.01	5,755,772 A	5/1998	Evans et al. 128/898
5,571,166 A	11/1996	Dinh et al.	5,759,205 A	6/1998	Valentini 433/173
5,574,059 A	11/1996	Regunathan et al.	5,769,883 A	6/1998	Buscemi et al.
5,575,818 A	11/1996	Pinchuk 623/1.15	5,776,184 A	7/1998	Tuch
5,578,075 A	11/1996	Dayton	5,780,462 A	7/1998	Lee et al. 514/183
5,580,873 A	12/1996	Bianco et al.	5,780,476 A	7/1998	Underiner et al.
5,580,874 A	12/1996	Bianco et al.	5,782,908 A	7/1998	Cahalan et al.
5,591,140 A	1/1997	Narayanan et al.	5,788,979 A	8/1998	Alt
5,591,197 A	1/1997	Orth et al.	5,792,106 A	8/1998	Mische 604/103.01

US 7,300,662 B2

Page 4

5,792,772 A	8/1998	Bianco et al.	6,179,817 B1	1/2001	Zhong	604/265
5,798,372 A	8/1998	Davies et al.	6,187,757 B1	2/2001	Clackson et al.	514/31
5,799,384 A	9/1998	Schwartz et al.	6,193,746 B1	2/2001	Strecker	623/1.13
5,800,507 A	9/1998	Schwartz	6,214,901 B1	4/2001	Chudzik et al.	
5,800,508 A	9/1998	Goicoechea et al.	6,225,346 B1	5/2001	Tang et al.	514/523
5,807,861 A	9/1998	Klein et al.	6,240,616 B1	6/2001	Yan	
5,811,447 A	9/1998	Kunz et al.	6,245,537 B1	6/2001	Williams et al.	435/135
5,820,917 A	10/1998	Tuch	6,251,920 B1	6/2001	Grainger et al.	514/319
5,820,918 A	10/1998	Ronan et al.	6,254,632 B1	7/2001	Wu et al.	
5,824,048 A	10/1998	Tuch	6,254,634 B1	7/2001	Anderson et al.	623/1.42
5,824,049 A	10/1998	Ragheb et al.	6,258,121 B1	7/2001	Yang et al.	
5,827,587 A	10/1998	Fukushi	6,268,390 B1	7/2001	Kunz	
5,833,651 A	11/1998	Donovan et al.	6,273,913 B1	8/2001	Wright et al.	
5,837,008 A	11/1998	Berg et al.	6,284,305 B1	9/2001	Ding et al.	427/2.28
5,837,313 A	11/1998	Ding et al.	6,287,320 B1	9/2001	Slepian	
5,843,120 A	12/1998	Israel et al.	6,287,628 B1	9/2001	Hossainy et al.	
5,843,166 A	12/1998	Lentz et al.	6,299,604 B1	10/2001	Ragheb et al.	
5,843,172 A	12/1998	Yan	6,306,144 B1	10/2001	Sydney et al.	606/108
5,849,034 A	12/1998	Schwartz	6,306,166 B1	10/2001	Barry et al.	
5,851,217 A	12/1998	Wolff et al.	6,306,176 B1	10/2001	Whitbourne	
5,851,231 A	12/1998	Wolff et al.	6,306,421 B1	10/2001	Kunz et al.	
5,858,990 A	1/1999	Walsh	6,309,380 B1	10/2001	Larson et al.	
5,861,027 A	1/1999	Trapp	6,309,660 B1	10/2001	Hsu et al.	
5,865,814 A	2/1999	Tuch	6,313,264 B1	11/2001	Caggiano et al.	
5,871,535 A	2/1999	Wolff et al.	6,316,018 B1	11/2001	Ding et al.	424/423
5,873,904 A	2/1999	Ragheb et al.	6,335,029 B1	1/2002	Kamath et al.	424/423
5,876,433 A	3/1999	Lunn	6,358,556 B1	3/2002	Ding et al.	427/2.24
5,877,224 A	3/1999	Brocchini et al.	6,369,039 B1	4/2002	Palasis et al.	424/93.2
5,879,697 A	3/1999	Ding et al.	6,379,382 B1	4/2002	Yang	623/1.42
5,882,335 A	3/1999	Leone et al.	6,387,121 B1	5/2002	Alt	623/1.15
5,891,108 A	4/1999	Leone et al.	6,403,635 B1	6/2002	Kinsella et al.	514/449
5,893,840 A	4/1999	Hull et al.	6,407,067 B1	6/2002	Schafer	514/19
5,897,911 A	4/1999	Loeffler	6,517,858 B1	2/2003	Le Moel et al.	424/424
5,900,246 A	5/1999	Lambert	6,517,889 B1	2/2003	Jayaraman	427/2.24
5,902,266 A	5/1999	Leone et al.	6,545,097 B2	4/2003	Pinchuk et al.	525/240
5,912,253 A	6/1999	Cottens et al.	6,585,764 B2	7/2003	Wright et al.	623/1.42
5,916,910 A	6/1999	Lai	6,620,194 B2	9/2003	Ding et al.	623/1.43
5,922,393 A	7/1999	Jayaraman	6,746,773 B2	6/2004	Llanos et al.	428/421
5,922,730 A	7/1999	Hu et al.	6,776,796 B2	8/2004	Falotico et al.	623/1.46
5,932,243 A	8/1999	Fricker et al.	6,808,536 B2	10/2004	Wright et al.	623/1.42
5,932,299 A	8/1999	Katoot	2001/0007083 A1	7/2001	Roorda	
5,932,580 A	8/1999	Levitzki et al.	2001/0029351 A1	10/2001	Falotico et al.	604/103.02
5,951,586 A	9/1999	Berg et al.	2001/0029660 A1	10/2001	Johnson	
5,957,971 A	9/1999	Schwartz	2001/0032014 A1	10/2001	Yang et al.	
5,968,091 A	10/1999	Pinchuk et al.	2001/0034363 A1	10/2001	Li et al.	
5,972,027 A	10/1999	Johnson	2001/0037145 A1	11/2001	Guruwaiya et al.	
5,976,534 A	11/1999	Hart et al.	2002/0010418 A1	1/2002	Lary et al.	604/101.04
5,977,163 A	11/1999	Li et al.	2002/0032477 A1	3/2002	Helmus et al.	623/1.2
5,980,553 A	11/1999	Gray et al.	2002/0041899 A1	4/2002	Chudzik et al.	424/487
5,980,566 A	11/1999	Alt et al.	2002/0061326 A1	5/2002	Li et al.	424/424
5,980,972 A	11/1999	Ding	2002/0068969 A1	6/2002	Shanley et al.	623/1.16
5,981,568 A	11/1999	Kunz et al.	2002/0071902 A1	6/2002	Ding et al.	427/2.24
5,985,307 A	11/1999	Hanson et al.	2002/0082680 A1	6/2002	Shanley et al.	623/1.16
5,997,468 A	12/1999	Wolff et al.	2002/0082685 A1	6/2002	Sirhan et al.	623/1.42
6,004,346 A	12/1999	Wolff et al.	2002/0091433 A1	7/2002	Ding et al.	623/1.2
6,015,432 A	1/2000	Rakos et al.	2002/0095114 A1	7/2002	Palasis	604/96.01
6,015,815 A	1/2000	Mollison	2002/0099438 A1	7/2002	Furst	623/1.16
6,039,721 A	3/2000	Johnson et al.	2002/0103526 A1	8/2002	Steinke	623/1.11
6,059,813 A	5/2000	Vrba et al.	2002/0119178 A1	8/2002	Levesque et al.	424/423
6,071,305 A	6/2000	Brown et al.	2002/0123505 A1	9/2002	Mollison et al.	514/291
6,074,659 A	6/2000	Kunz et al.	2002/0127327 A1	9/2002	Schwartz et al.	427/2.15
6,080,190 A	6/2000	Schwartz	2002/0133222 A1	9/2002	Das	623/1.16
6,096,070 A	8/2000	Ragheb et al.	2002/0133224 A1	9/2002	Bajgar et al.	623/1.39
6,120,536 A	9/2000	Dinge et al.	2002/0165608 A1	11/2002	Llanos	604/500
6,120,847 A	9/2000	Yang et al.	2002/0193475 A1	12/2002	Hossainy et al.	524/113
6,136,798 A	10/2000	Cody et al.	2003/0065377 A1	4/2003	Davila et al.	604/265
6,140,127 A	10/2000	Sprague	2003/0216699 A1	11/2003	Falotico	
6,146,358 A	11/2000	Rowe	2004/0049265 A1	3/2004	Ding et al.	623/1.42
6,153,252 A	11/2000	Hossainy et al.	2004/0243097 A1	12/2004	Falotico et al.	604/500
6,159,488 A	12/2000	Nagier et al.	2004/0260268 A1	12/2004	Falotico et al.	604/500
6,171,232 B1	1/2001	Papandreou et al.	2005/0002986 A1	1/2005	Falotico et al.	424/426
6,171,609 B1	1/2001	Kunz	2005/0004663 A1	1/2005	Llanos et al.	623/1.46
6,177,272 B1	1/2001	Nabel et al.	2005/0033261 A1	2/2005	Falotico et al.	604/500

2005/0106210	A1	5/2005	Ding et al.	424/423
2005/0187611	A1	8/2005	Ding et al.	623/1.15
2005/0208200	A1	9/2005	Ding et al.	427/2.25
2006/0088654	A1	4/2006	Ding et al.	427/2.21
2006/0089705	A1	4/2006	Ding et al.	623/1.15

FOREIGN PATENT DOCUMENTS

DE	19723723	A1	12/1998
EP	0 145 166	A2	6/1985
EP	0 177 330	A2	4/1986
EP	0 183 372	A1	6/1986
EP	0 221 570	A2	5/1987
EP	0 421 729	A2	4/1991
EP	0 540 290	A2	10/1992
EP	0 568 310	A1	11/1993
EP	0 604 022	A1	6/1994
EP	0 621 015	A1	10/1994
EP	0 623 354	A1	11/1994
EP	0 734 698	A2	3/1996
EP	0 712 615	A1	5/1996
EP	0 716 836	A1	6/1996
EP	0 800 801	A1	8/1996
EP	0 734 721	A1	10/1996
EP	0 747 069	A2	12/1996
EP	0 761 251	A1	3/1997
EP	0 830 853	A1	7/1997
EP	0 540 290	B1	1/1998
EP	0 815 803	A1	7/1998
EP	0 850 651	A2	7/1998
EP	0 938 878	A3	9/1999
EP	0950386	B1	10/1999
EP	0 968 688	A1	1/2000
EP	0 633 032	B1	2/2001
EP	1 192 957	A2	4/2002
EP	1 588 726	A1	10/2005
EP	1 588 727	A1	10/2005
FR	0 566 807	A1	4/1992
GB	1 205 743		9/1970
GB	2 135 585	A	9/1984
GB	0 662 307	A2	12/1994
SU	660689		5/1979
SU	1457921		2/1989
WO	89/03232	A1	4/1989
WO	WO 91/12779	A1	9/1991
WO	WO 92/15286	A1	9/1992
WO	WO 94/01056	A1	1/1994
WO	WO 94/21308	A1	9/1994
WO	WO 94/21309	A1	9/1994
WO	WO 94/24961	A1	11/1994
WO	WO 96/00272	A1	1/1996
WO	WO 96/26689	A1	9/1996
WO	WO 96/32907	A1	10/1996
WO	WO 96/34580	A1	11/1996
WO	96/41807	A1	12/1996
WO	WO 97/25000	A1	7/1997
WO	WO 97/33534	A1	9/1997
WO	97/35575	A1	10/1997
WO	98/08463	A1	3/1998
WO	WO 98/13344	A1	4/1998
WO	WO 98/19628	A1	5/1998
WO	98/23244	A1	6/1998
WO	WO 98/23228	A1	6/1998
WO	WO 98/34669	A1	8/1998
WO	WO 98/36784	A1	8/1998
WO	WO 98/47447	A1	10/1998
WO	WO 98/56312	A1	12/1998
WO	00/21584	A1	4/2000
WO	00/27455	A1	5/2000
WO	WO 00/27445	A1	5/2000
WO	00/32255	A1	6/2000
WO	00/38754	A1	7/2000
WO	01/87342	A2	11/2001

WO	01/87372	A1	11/2001
WO	01/87373	A1	11/2001
WO	WO 01/87376	A1	11/2001
WO	02/26139	A1	4/2002
WO	02/26271	A1	4/2002
WO	02/26280	A1	4/2002
WO	02/26281	A1	4/2002
WO	03/015664	A1	2/2003
WO	03/057218	A1	7/2003

OTHER PUBLICATIONS

U.S. Appl. No. 07/819,314, filed Jan. 9, 1992, Morris.

U.S. Appl. No. 08/424,884, filed Apr. 19, 1995, Helmus et al.

U.S. Appl. No. 08/526,273, filed Sep. 11, 1995, Ding.

U.S. Appl. No. 08/730,542, filed Oct. 11, 1996, Helmus.

U.S. Appl. No. 09/575,480, filed May 19, 2000, Kopia.

U.S. Appl. No. 10/431,059, filed May 7, 2003, Falotico.

Abraham, R. T., "Mammalian target of rapamycin: Immunosuppressive drugs offer new insight into cell growth regulation," *Progress in Inflammation Research*, 2000, Switzerland.

Alvarado, R. et al., "Evaluation of Polymer-coated Balloon-expandable Stents in Bile Ducts," *Radiology*, 1989, 170, 975-978.

Badimon, J. J. et al., "Inhibitory Effects of Rapamycin on Intimal Hyperplasia After PTCA," *JACC*, Mar. 1998.

Bailey et al., "Polymer Coating of Palmaz-Schatz Stent Attenuates Vascular Spasm after Stent Placement," *Circulation*, 82:III-541 (1990).

Berk, B. C. et al., "Pharmacologic Roles of Heparin and Glucocorticoids to Prevent Restenosis After Coronary Angioplasty," *JACC*, May 1991, 17(6), 111B-117B.

Bertram, P. G. et al., "The 14-3-3 proteins positively regulate rapamycin-sensitive signaling," *Current Biology*, 1998, 8, 1259-1267.

Biomaterials Science (B.D. Ratner, Ed.), Academic Press, New York, NY, pp. 228-238, 1996.

Campbell, G. R. et al., "Phenotypic Modulation of Smooth Muscle Cells in Primary Culture, Vascular Smooth Muscle Cells in Culture," *CRC Press*, 1987, 39-55.

Chang, M. W. et al., "Adenovirus-mediated Over-expression of the Cyclin/Cyclin-dependent Kinase inhibitor, p21 inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat Carotid Artery Model of Balloon Angioplasty," *J. Clin. Invest.*, 1995, 96, 2260-2268.

Chung, J. et al., "Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases," *Cell*, Jun. 26, 1992, 69(7), 1227-1236.

Clowes, A. W. et al., "Kinetics of cellular proliferation after arterial injury. IV. Heparin inhibits rat smooth muscle mitogenesis and migration," *Circ. Res.*, 1986, 58(6), 839-845.

Clowes, A. W. et al., Kinetics of Cellular Proliferation after Arterial Injury, *Laboratory Investigation*, 1985, 52(6), 611-616.

Clowes, A. W. et al., "Significance of quiescent smooth muscle migration in the injured rat carotid artery," *Circ. Res.* 1985, 56(1), 139-145.

Clowes, A. W., "Suppression by heparin of smooth muscle cell proliferation in injured arteries," *Nature*, 1977, 265(5595), 625-626.

Colburn, M. D. et al., "Dose responsive suppression of myointimal hyperplasia by dexamethasone," *J. Vasc. Surg.*, 1992, 15, 510-518.

Currier, J. W. et al., "Colchicine Inhibits Restenosis After Iliac Angioplasty in the Atherosclerotic Rabbit," *Circ.*, 1989, 80(4), 11-66 (Abstract No. 0263).

Encyclopedia of Polymer Science and Engineering, vol. 7, Fluococarbon Elastomers, p. 257-267, Mar. 1989.

Farb, A. et al., "Vascular smooth muscle cell cytotoxicity and sustained inhibition of neointimal formation by fibroblast growth factor 2-saporin fusion protein," *Circ. Res.*, 1997, 80, 542-550.

Ferns, G. A. A. et al., "Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF," *Science*, 1991, 253, 1129-1132.

- Fischman, D. L. et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease," *N. Eng. J. Med.*, Aug. 25, 1994, 331(8), 496-501.
- Franklin, S. M. et al., "Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials," *Coronary Artery Disease* Mar. 1993, 4(3), 232-242.
- Fukuyama, J. et al., "Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet," *Eur. J. Pharmacol.*, 1996, 318, 327-332.
- Gregory, C. R. et al., "Rapamycin Inhibits Arterial Intimal Thickening Caused by Both Alloimmune and Mechanical Injury," *Transplantation*, Jun. 1993, 55(6), 1409-1418.
- Gregory, C. R. et al., "Treatment with Rapamycin and Mycophenolic Acid Reduces Arterial Intimal Thickening Produced by Mechanical Injury and Allows Endothelial Replacement," *Transplantation*, Mar. 15, 1995, 59(5), 655-661.
- Guyton, J. R. et al., "Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin," *Circ. Res.*, 1980, 46, 625-634.
- Hansson, G. K. et al., "Interferon- γ Inhibits Arterial Stenosis After Injury," *Circ.*, 1991, 84, 1266-1272.
- Hashemolhosseini, S. et al., "Rapamycin Inhibition of the G1 to S Transition Is Mediated by Effects on Cyclin D1 mRNA and Protein Stability," *J. Biol. Chem.*, Jun. 5, 1998, 273, 14424-14429.
- Jonasson, J. et al., "Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury," *Proc. Natl. Acad. Sci.*, 1988, 85, 2303-2306.
- Kuhnt, M. et al., "Microbial Conversion of Rapamycin," *Enzyme and Microbial Technology*, 1997, 21, 405-412.
- Lange, R. A. MD et al., "Restenosis After Coronary Balloon Angioplasty," *Annu. Rev. Med.*, 1991, 42, 127-132.
- Liu, M. W. et al., "Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit," *Circ.*, 1990, 81, 1089-1093.
- Liu, M. W., MD et al., "Restenosis After Coronary Angioplasty Potential Biologic Determinants and Role of Intimal Hyperplasia," *Circulation*, 1989, 79, 1374-1387.
- Lundergan, C. F. et al., "Peptide inhibition of Myointimal Proliferation by Angiopeptin, a Somatostatin Analogue," *JACC*, May 1991, 17(6), 132B-136B.
- Majesky, M. W. et al., "Heparin regulates smooth muscle S phase entry in the injured rat carotid artery," *Circ. Res.*, 1987, 61, 296-300.
- Marx, S. O. et al., "Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells," *Circ. Res.*, 1995, 76, 412-417.
- Nemecsek, G. M. et al., "Terbinafine Inhibits the Mitogenic Response to Platelet-Derived Growth Factor in Vitro and Neoinimal Proliferation in Vivo," *J. Pharmacol. Exp. Ther.*, 1989, 248, 1167-1174.
- Okada, T. et al., "Localized Release of Perivascular Heparin Inhibits Intimal Proliferation after Endothelial Injury without Systemic Anticoagulation," *Neurosurgery*, 1989, 25, 892-898.
- Poon, M. et al., "Rapamycin Inhibits Vascular Smooth Muscle Cell Migration," *J. Clin. Invest.*, Nov. 1996, 98(10), 2277-2283.
- Popma, J. J. et al., "Clinical trials of restenosis after coronary angioplasty," *Circulation*, Sep. 1991, 84(3), 1426-1436.
- Powell, J. S. et al., "Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury," *Science*, 1989, 245, 186-188.
- Rensing, B. J. et al., "Coronary restenosis elimination with a sirolimus eluting stent," *European Heart Journal*, 2001, 22, 2125-2130.
- Rodeck, C. et al., "Methods for the Transcervical Collection of Fetal Cells During the First Trimester of Pregnancy," *Prenatal Diagnosis*, 1995, 15, 933-942.
- Serruys, P. W. et al., "A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease," *N Engl J Med*, Aug. 25, 1994; 331(8), 489-495.
- Serruys, P. W. et al., "Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial," *Circulation*. Oct. 1993; 88(4 Pt 1), 1588-1601.
- Serruys, P. W. et al., "Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study," *Circulation*, Feb. 1, 1996; 93(3), 412-422.
- Siekierka, J. J., "Probing T-Cell Signal Transduction Pathways with the Immunosuppressive Drugs, FK-506 and Rapamycin," *Immunologic Research*, 1994, 13, 110-116.
- Sigwart, et al., "Intravascular Stents to Prevent Occlusion and Restenosis After Transluminal Angioplasty," *N. Engl. J. Med.*, Mar. 19, 1987, 316, 701-706.
- Simons, M. et al., "Antisense c-myc oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo," *Nature*, 1992, 359, 67-70.
- Snow, A. D. et al., "Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells," *Am. J. Pathol.*, 1990, 137, 313-330.
- Sollott, S. J. et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat," *J. Clin. Invest.*, 1995, 95, 1869-1876.
- van Der Giessen, et al., "Self-expandable Mesh Stents: an Experimental Study Comparing Polymer Coated and Uncoated Wallstent Stents in the Coronary Circulation of Pigs," *Circulation* 1990, 82(suppl. III):III-542.
- van Der Giessen, W. J. et al., "Coronary stenting with polymer-coated and uncoated self-expanding endoprostheses in pigs," *Coron. Art. Disease* 1992; 3, 631-640.
- Vasey, C. G. et al., "Clinical Cardiology: Stress Echo and Coronary Flow", *Circulation*, Oct. 1989, 80(4) Supplement II, II-66.
- Verweire, E. et al., "Evaluation of Fluorinated Polymers As Coronary Stent Coating," *Journal of Materials Science: Materials in medicine*, Apr. 2000.
- Weinberger, J. et al., "Intracoronary irradiation: dose response for the prevention of restenosis in swine," *Int. J. Rad. Onc. Biol. Phys.*, 1996, 36, 767-775.
- Preliminary Amendment in U.S. Appl. No. 07/258,189, May 22, 1989.
- Trial Transcript from Nov. 6, 2000 at 185-90 and 235-36 (Attorney's opening remarks regarding '984 patent).
- Trial Transcript from Nov. 7, 2000 at 274-301, 307-315, 320-28 and 332 (Cordis expert testimony regarding the Palmaz-Schatz stent); 370-379, 480-496 (J. Palmaz testimony regarding the Palmaz-Schatz stent, the '984 patent and the connected z-stent art).
- Trial Transcript from Nov. 8, 2000 at 547-63, 657-63, 674-722, 782-85 (Cordis expert testimony regarding the Palmaz-Schatz stent, the '984 patent and the connected z-stent art).
- Trial Transcript from Nov. 9, 2000 at 819-23, 921 (Cordis expert testimony regarding the '984 patent); 926-941. (R. Croce testimony re Palmaz-Schatz stent); 1033-1053. (R. Schatz testimony).
- Trial Transcript from Nov. 13, 2000 at 1086-1134. (R. Schatz testimony); 1275-1305 (Cordis expert testimony regarding the '984 patent).
- Trial Transcript from Nov. 14, 2000 at 1390-1404, 1448-1454, 1486-1500 (Cordis expert testimony regarding the '984 patent).
- Trial Transcript from Nov. 15, 2000 at 1686-87, 1724-42, 1828-34, 1850-54, 1887-92 (AVE expert testimony regarding the '984 patent).
- Trial Transcript from Nov. 16, 2000 at 2077-198 (AVE expert testimony regarding the alleged obviousness of the '984 patent).
- Trial Transcript from Nov. 17, 2000 at 2331-34 (jury instructions as to the meaning of the limitations of the claims of the '984 patent).
- Trial Transcript from Nov. 20, 2000 at 2441-48, 2499-2500, 2546-50, 2552-56 (Attorney's closing arguments regarding the '984 patent).
- Trial Transcript from Nov. 21, 2000 at 2592-94 (reading of jury verdict).
- Trial Transcript from Dec. 18, 2000 at 2750-95 (Cordis expert testimony regarding the Palmaz-Schatz stent during the damages phase).
- Trial Transcript from Dec. 20, 2000 at 3421-88 (AVE expert testimony regarding the Palmaz-Schatz stent during the damages phase).
- Jury verdict, dated Nov. 21, 2000.
- District Court decisions on post-trial motions (194 F. Supp. 2d 323).
- Court of Appeal for the Federal Circuit decision (339 F.3d 1352).

Trial Transcript from Mar. 4, 2005 at 133-135, 171-173 and 192-96 (Attorney's opening remarks regarding '984 validity).

Trial Transcript from Mar. 7, 2005 at 275-311 (Cordis expert testimony regarding the Palmaz-Schatz stent); 342-46, 353-59, 416-425 (J. Palmaz testimony regarding the Palmaz-Schatz stent, the '984 patent and the connected z-stent art); 430-449, 452-58, 462-492 (R. Croce testimony regarding the Palmaz-Schatz stent); 500-507 (Cordis expert testimony regarding the '984 patent).

Trial Transcript from Mar. 8, 2005 at 609 (Cordis expert testimony regarding the '984 patent); 628-73, 724-740, 773, 801-839 (Cordis expert testimony regarding the '984 patent, the prior art and the Palmaz-Schatz stent).

Trial Transcript from Mar. 9, 2005 at 936-49, 968-69 (Cordis expert testimony regarding the '984 patent, the prior art and the Palmaz-Schatz stent).

Trial Transcript from Mar. 10, 2005 at 1427-74, 178-1509, 1514-23 (AVE expert testimony regarding the alleged obviousness of the '984 patent); 1566-93 (AVE expert testimony regarding Palmaz-Schatz stent); 1634-49 (R. Schatz testimony).

Trial Transcript from Mar. 11, 2005 at 1846-47, 1891-1900, 1919 (Attorneys' closing arguments regarding '984 obviousness).

Trial Transcript from Mar. 14, 2005 at 1964-67 (reading of jury verdict).

Jury verdict dated Mar. 14, 2005.

Medtronic Vascular Inc.'s Opening Brief in Support of Its Motion for Judgment As A Infringement Claim dated Apr. 19, 2005.

Medtronic Vascular Inc.'s Opening Brief in Support of Its Motion for a New Trial dated Apr. 19, 2005.

D.I. 1407, Cordis' Combined Answering Brief In Opposition to AVE's Motion for JMOL on Infringement of the Palmaz '762 and Schatz '984 Patents and Its Motion for a New Trial dated May 5, 2005.

D.I. 1414, Medtronic Vascular Inc.'s Combined Reply Brief In Support of Its Motion for Judgment as a Matter of Law on Cordis Corp.'s Patent Infringement Claims and Its Motion for a New Trial dated May 19, 2005.

Trial Transcript from Feb. 8, 2001 at 372-412, 449-469 (B. Tobor testimony regarding the prosecution of the '417, '984 and '332 patents); 510-13 (J. Milnamow testimony regarding the prosecution of the '332 patent); 558-604 (J. Palmaz testimony regarding the prosecution of the '417, '984 and '332 patents and the prior art).

Trial Transcript from Feb. 9, 2001 at 637-45, 662-672, 682-85 (J. Palmaz testimony regarding the prior art); 699-742 (R. Schatz testimony); 769-770, 790-95 (Cordis expert testimony regarding prior art).

D.I. 1067, Medtronic AVE, Inc.'s Post-Trial Brief Relating to the Unenforceability of the '762 and '984 Patents Due to Inequitable Conduct.

D.I. 1077, Cordis' Combined Answering Brief in Opposition to AVE's BSC's Post-Hearing Briefs on Alleged Inequitable Conduct Concerning the '762, '984 and '332 Patents.

D.I. 1089, Reply Brief In Support of Medtronic AVE, Inc.'s Contention that the '762 and '984 Patents are Unenforceable Due to Inequitable Conduct dated May 7, 2001.

C.A. No. 00-886-SLR, Answer and Counterclaims of Def. Medtronic AVE, Inc. To First Amended Complaint of Plaintiff Cordis Corp.

BSC's Opening Post-Trial Brief in Support of Its Defense That the Patents in Suit Are Unenforceable, dated Mar. 16, 2001.

Reply Brief in Support of BSC's Defense That the Patents in Suit Are Unenforceable, dated May 7, 2001.

Court's Decision on allegations of inequitable conduct (194 F. Supp. 2d 323) Mar. 28, 2002.

Trial Transcript from Nov. 21, 2000 at 155-57 and 180-84 (Attorneys' opening remarks regarding '332 patent).

Trial Transcript from Nov. 27, 2000 at 227-51, 260-300 (Cordis expert testimony regarding the Palmaz-Schatz stent); 343-60, 363-67, 424-33 (J. Palmaz testimony regarding the Palmaz-Schatz stent and the '332 patent).

Trial Transcript from Nov. 28, 2000 at 649-71.

Trial Transcript from Nov. 29, 2000 at 791-816, 859-870, 953-62 (Cordis expert testimony regarding the '332 patent and the Palmaz-Schatz stent).

Trial Transcript from Nov. 30, 2000 at 1018 (Cordis expert testimony regarding the '332 patent); 1062-80, 1108-1111 (R. Croce testimony regarding the Palmaz-Schatz stent); 1169-70, 1205-17, 1236-45 (Cordis expert testimony regarding the '332 patent).

Trial Transcript from Dec. 1, 2000 at 1352-54 (Cordis expert testimony regarding the '332 patent); 1364-1442 (R. Schatz testimony); 1493-1508, 1552-69 (BSC expert testimony regarding the '332 patent and the Palmaz-Schatz stent).

Trial Transcript from Dec. 4, 2000 at 1602-12, 1638-51, 1713-14, 1730-61, 1811-14, 1823-36 (BSC expert testimony regarding the alleged obviousness of the '332 patent, the prior art and the Palmaz-Schatz stent).

Trial Transcript from Dec. 6, 2000 at 2318-27, 2342-58 (BSC expert testimony regarding the '332 patent).

Trial Transcript from Dec. 7, 2000 at 2549-52 (Cordis expert testimony regarding the '332 patent); 2575-2579, 2591-92, 2630-31, 2649, 2669-71, 2684-85, 2688, 2708-10, 2725-27 (Attorney closing argument regarding '332 patent); 2742-46 Q'ury instructions as to the meaning of the limitations of the claims of the '332 patent).

Trial Transcript from Dec. 11, 2000 at 2817-22 (reading of jury verdict).

Jury verdict, dated Dec. 11, 2000.

D.I. 699, Motion by Defendant BSC and Scimed Life Systems, Inc. For Summary Judgment of Invalidity of U.S. Patent No. 5,902,332 dated Apr. 4, 2000.

D.I.896, Order Denying Motion for Summary Judgment of Invalidity and Unenforceability of Claims 1, 3, and 5 of the U.S. Patent No. 5,902,332 Denying {699-1} Motion for Summary Judgment of Invalidity of U.S. Patent No. 5,902,332 dated Oct. 12, 2000.

Wright et al., Percutaneous Endovascular Stent: An Experimental Study (Abstract), RSNA Meeting (Nov. 28, 1984).

Hearing Transcript from Feb. 10, 1998 at 122-32, 146-80 (Attorneys' opening remarks regarding '417 patent); 180-312 (R. Schatz testimony) [Portions of This Transcript Have Been Removed As Confidential].

Hearing Transcript from Feb. 11, 1998 at 427-575, 577-651 (Cordis expert testimony regarding the '417 patent, the prior art and the Palmaz-Schatz stent).

Hearing Transcript from Feb. 13, 1998 at 1121-1261 (Guidant expert testimony regarding the alleged obviousness of the '417 patent, the prior art and the Palmaz-Schatz stent). [Portions of This Transcript Have Been Removed As Confidential].

Order by J. Robinson denying Cordis' Motion for a Preliminary Injunction Against ACS dated Jul. 17, 1998.

ACS, Inc.'s and Guidant Corp.'s Opening Brief in Support of Their Motion for Summary Judgment of Invalidity of U.S. Patent No. 5,102,417 dated Aug. 27, 1998.

Plaintiffs' Answering Brief in Opposition to ACS' and BSC' Motion for Summary Judgment on Obviousness dated Sep. 24, 1998.

Order dated Mar. 31, 2000.

Schatz Deposition Testimony; May 15, 1996: 79-83, 89-92, 105-107 and 153-161.

Schatz Deposition Testimony; May 16, 1996: 555-564, 569-572.

Schatz Deposition Testimony; Jan. 18, 1998: 67-73, 108-110.

Schatz Deposition Testimony; Jul. 14, 1998: 69-77, 108-112, 119-123.

Schatz Deposition Testimony; Jul. 12, 1999: 88-91, 132-135, 144-149, 218-223, 231-242.

Schatz Deposition Testimony; Jul. 13, 1999: 251-334, 339-345, 374-416.

Schatz Deposition Testimony; Jul. 14, 1999: 454-550.

Schatz Deposition Testimony; Jul. 15, 1999: 560-614.

Schatz Deposition Testimony; Dec. 2, 1999: 906-911, 928-942, 945-963, 976-978, 1029-1034, 1038-1042.

Palmaz Deposition Testimony, Nov. 5, 1991: 160-172.

Palmaz Deposition Testimony, Feb. 5, 1995: 710-727.

Palmaz Deposition Testimony, Jul. 16, 1998: 55-56; 81-82.

Palmaz Deposition Testimony, Jul. 28, 1999: 560-568, 570-579.

Palmaz Deposition Testimony, Jul. 29, 1999: 778-785.

Palmaz Deposition Testimony, Aug. 31, 1999: 1403-1452.

Palmaz Deposition Testimony, Sep. 2, 1999: 1953-1960.

- Palmaz Deposition Testimony, Oct. 14, 1999: 2201-2209; 2275-2342; 2371-2411.
- Palmaz Deposition Testimony, Oct. 15, 1999: 2424-2497; 2508-2589.
- Palmaz Deposition Testimony, Oct. 16, 1999: 2853-2860.
- Tobor Deposition Testimony, Jun. 17, 1999: 837-958.
- Tobor Deposition Testimony, Jun. 18, 1999: 1095-1184.
- Tobor Deposition Testimony, Dec. 1, 1999: 1217-1371.
- Tobor Deposition Testimony, Dec. 2, 1999: 1398-1414; 1444-1508; 1532-1548.
- Tobor Deposition Testimony, Dec. 3, 1999: 1652-1653; 1662-1672; 1683-1694.
- Kula Deposition Testimony, Apr. 20, 1999: 268-169.
- Kula Deposition Testimony, Nov. 16, 1999: 660-675; 680-694; 748-755; 774-821.
- Kula Deposition Testimony, Nov. 18, 1999: 176-223.
- Expert Report of Dr. Rodney S. Badger on Behalf of Medtronic AVE, Inc. (Jan. 31, 2000).
- Expert Report of Dr. Joseph Bonn on Behalf of Medtronic AVE, Inc. (Jan. 31, 2000).
- Deposition of Dr. Joseph Bonn dated Mar. 14, 2000.
- Rebuttal Expert Report of Nigel Buller, B.Sc., M.D., F.R.C.P. (Mar. 2000).
- Second Supplemental Rebuttal Expert Report of Nigel Buller, B.Sc., M.B., F.R.C.P. (Aug. 17, 2004).
- Rebuttal Expert Report of John M. Collins, PH.D. (Feb. 2000).
- Expert Report of David C. Cumberland, M.D. (Jan. 24, 2000).
- Expert Report of John T. Goolkasian (Feb. 2000).
- Deposition of Richard R. Heuser, M.D. (Sep. 7, 2004).
- Deposition of Henry R. Piehler (Sep. 10, 2004).
- Deposition of Ronald J. Solar (Mar. 22, 2000).
- Deposition of Ronald J. Solar (Mar. 23, 2000).
- Deposition of Ronald J. Solar (Apr. 12, 2000).
- Expert Report of Dr. Arina Van Breda on Behalf of Medtronic AVE, Inc. (Jan. 31, 2000).
- Deposition of Arina Van Breda (Mar. 24, 2000).
- Deposition of Arina Van Breda (Aug. 21, 2004).
- Expert Report of John F. Witherspoon (Jan. 24, 2000).
- Supplemental Expert Report of John F. Witherspoon (Oct. 27, 2000).
- Deposition of John F. Witherspoon (Mar. 8, 2000).
- Palmaz et al., Article: Normal and Stenotic Renal Arteries: Experimental Balloon Expandable Intraluminal Stenting, Radiology, Sep. 1987. (AVE 84).
- Julio C. Palmaz, Article: "Expandable vascular endoprosthesis." (AVE 132).
- Duprat et al., Article: Flexible Balloon-Expandable Stent for Small Vessels Duprat et al. Radiology, vol. 162, pp. 276-278, 1987. (AVE 134).
- Coons et al., Article: "Large-Bore, Long Biliary Endoprosthesis (Biliary Stents) for Improved Drainage," Radiology, vol. 148, pp. 89-94, 1983. (AVE 143).
- Honickman et al., Article: "Malpositioned Biliary Endoprosthesis, Technical Developments And Instrumentation," vol. 144, No. 2., 1982. (AVE 144).
- Harries-Jones, et al., Article: "Repositioning of Biliary Endoprosthesis with Gruntzig Balloon Catheters," AJR, vol. 138, pp. 771-772, 1982. (AVE 153).
- Charnsangavej et al., Article "Stenosis of the Vena Cava: Preliminary Assessment of Treatment with Expandable Metallic Stents," Radiology, vol. 161, pp. 295-298, 1986. (AVE 359).
- Article "Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications," Radiology, vol. 158, pp. 309-312, 1986. (AVE 364).
- T. Yoshioka, et al., AIR Article: "Self-Expanding Endovascular Graft: An Experimental Study in Dogs", vol. 151, pp. 673-676, 1988. (AVE 438).
- Article: "Expandable Intraluminal Vascular Graft: A Feasibility Study," Surgery, vol. 99, pp. 199-205, 1986. (AVE 461).
- Lawrence et al., Article: "Percutaneous Endovascular Graft: Experimental Evaluation," Radiology, vol. 163, pp. 357-360, 1987. (AVE 671).
- Palmaz et al., Article: Expandable Intraluminal Graft: A Preliminary Study, Nov. 17-22, 1985, Radiology, vol. 156, pp. 73-77, 1985. (AVE 1224).
- Fallone et al., "Elastic Characteristics of the Self-Expanding Metallic Stents," Investigative Radiology, vol. 23, pp. 370-376, 1988. (AVE 1953).
- Palmaz Paper Entitled "Research Project Expandable Vascular Endoprosthesis" May 18, 1983.
- Rousseau, et al., Publication: "Percutaneous Vascular Stent: Experimental Studies & Preliminary Clinical Results in Peripheral Arterial Diseases," in Inter. Angio, vol. 6, 153-161, 1987. (AVE 3301).
- Rousseau, et al., Publication: "Self-Expanding Endovascular Prosthesis: An Experimental Study," Radiology, vol. 164, pp. 709-714, 1987. (AVE 3303).
- Wallace, et al., Article: "Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications," Radiology, vol. 58, pp. 309-312, 1986. (DBX 2938).
- Palmaz et al., Article: "Expandable Intraluminal Graft: A Preliminary Study," Radiology, vol. 156, pp. 73-77 (DBX 4595).
- Program for the 12th Annual Course on Diagnostic Angiography and Interventional Radiology Mar. 23-26, 1987 sponsored by The Society of Cardiovascular and Interventional Radiology (DBX 6235).
- Preliminary Motion for Judgment re: Wolff claims 1, 2-8, 10, 15 and 19 (DBX6759).
- Palmaz Declaration (DBX 7069).
- Letter from Gaterud to Dr. Palmaz dated Jul. 5, 1988 with attached document entitled: "Segmented, balloon-expandable stents." (DBX 7160).
- Duprat et al., Article: "Flexible Balloon-Expandable Stent For Small Vessels," Radiology, vol. 168, pp. 276-278, 1987 (PX 82).
- Drawing Sent to Bodic on Mar. 17, 1986 (PX 374).
- Letter from Dr. Palmaz to R. Bowman enclosing a model of the flexible coronary graft dated Mar. 17, 1986 (PX 337).
- Lab Notebook pages dated Jul. 30, 1987 from Rodney Wolff (COR 185596-597) (PX621A).
- Charnsangavej, et al., Article: "Stenosis of The Vena Cava Preliminary Assessment of Treatment with expandable Metallic Stents," Radiology, vol. 161, No. 2, pp. 295-298 with attached photographs, 1986. (API 72).
- J. Palmaz: The Current Status of Vascular Prostheses, published by SCIR in the Twelfth Annual Course on Diagnostic Angiography and Interventional Radiology Mar. 23-26, 1987. (API 73).
- Amendment in Response to Office Action of Oct. 18, 1988 in re: Application of Julio Palmaz S/N 174,246. (API 152).
- Article: Wallace, et al., Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications Work In Progress, Radiology, vol. 158, pp. 309-312. (API 295).
- Reply of Senior Party Schatz To Patentee Wolff's Opposition To The Belated Motion For Judgment Of Applicant Schatz With Regard To Wolff Claims 1, 2-8, 10, 11, 13-17, And 19 (COR 186450-455) (API 310).
- Brief Of Senior Party Schatz At Final Hearing (API 313).
- Letter from Ron Sickles to Ben Tobor dated Feb. 10, 1988 (Exhibit 42).
- Letter from R.O. Sickles to Mike Tatlow dated May 12, 1988 (Exhibit 43).
- Letter from R. O. Sickles to Richard Schatz dated Jun. 2, 1988 (Exhibit 44).
- Letter from Richard Schatz to Raimund Erbel dated Jun. 3, 1988 (Exhibit 45).
- Letter from Richard Schatz to Mike Schuler dated Aug. 29, 1991 (Exhibit 48).
- Minutes of J&J Stent Project Review Meeting dated Jan. 21, 1988 (Exhibit 7).
- Preliminary Motion for Judgment with Regard to Wolff Claims 1, 2-8, 10, 11, 13-17, and 19. (Exhibit 67).
- Declaration of Richard A Schatz. (Exhibit 75).
- Belated Motion for Judgement with Regard to Wolff Claims 1, 2-8, 10, 11, 13-17 and 19. (Schatz—Exhibit 77).
- Letter from Dr. Schatz to Mr. Tobor, dated Jun. 3, 1988. (Exhibit 122).

- Letter from Dr. Schatz to Mr. Romano, dated Nov. 28, 1988. (Exhibit 131).
- Letter from Mr. Sickles to Mr. Tobor, dated Feb. 10, 1988 (Exhibit 145).
- Richard A. Schatz, Article titled: "A View of Vascular Stents" *Circulation*, vol. 79, No. 2, pp. 445-457, 1989. (Exhibit 194).
- Senior Party Schatz's reply to Patente Wolffs Opposition to the Preliminary Motion Of Applicant Schatz for Judgment with regard to Wolff Claims 1, 2-8, 10, 11, and 13-17. (Exhibit 69).
- Wallace, et al., Article: "Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications" *Work In Progress*, *Radiology*, vol. 158, pp. 309-312, 1986. (Exhibit 165).
- Charnsangavej, et al., Article: "Stenosis of The Vena Cava Preliminary Assessment of Treatment with expandable Metallic Stents," *Radiology*, vol. 161, No. 2, pp. 295-298 with attached photographs, 1986. (Exhibit 167).
- David D. Lawrence et al., Publication: Percutaneous Endovascular Graft: Experimental Evaluation¹, *Radiology*, pp. 357-360, 1987. (Exhibit 173).
- Charles E. Putnam, M.D., Cover and article from "Investigative Radiology", vol. 23, No. 5, May 1988. (Exhibit 177).
- Robert N. Berk, Cover and article from "American Journal of Roentology", pp. 673-676, 1988. (Exhibit 178).
- Declaration of John S. Kula Under 37 CFR § 1.672. (Kula—Exhibit 77).
- Yoshioka et al., Article: "Self-Expanding Endovascular Graft: An Experimental Study in Dogs" *AJR*, vol. 151, pp. 673-676, 1988. (PX 100).
- Palmaz, et al., Article: Expandable Intraluminal Graft: A Preliminary Study Work in Progress¹, *Radiology*, vol. 156, No. 1, pp. 73-77, 1985. (PX 101).
- Declaration of Richard Schatz Under 37 C.F.R. § 1.672. (PX 106).
- Charnsangavej et al., Article: "Stenosis of the Vena Cave: Preliminary Assessment of Treatment with Expandable Metallic Stents," *Radiology*, vol. 161, pp. 295-298, 1986. (PX 143).
- Wallace, et al., Article: Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications Work in Progress¹, *Radiology*, vol. 158, pp. 309-312, 1986. (PX 144).
- Gina Kolata, News Article: NY Times, "Devices That Opens Clogged Arteries Gets a Falling Grade in a New Study", pp. 16-18, Jan. 3, 1991. (PX 186).
- Duprat, et al., Article: "Flexible Balloon- Expanded Stent for Small Vessels Work in Progress"¹, *Radiology*, vol. 162, pp. 276-278, 1987. (PX 207).
- Letter from Palmaz to Bowman dated Mar. 17, 1986. (PX 350).
- Memo re: Minutes of Stent Project Review- San Antonio- Mar. 15, 1988. (PX 651).
- Kuntz, et al., Article: Clinical Cardiology Frontiers: "Defining Coronary Restenosis, Newer Clinical and Angiographic Paradigms", *Circulation*, Sep. 1993, vol. 88, No. 3, pp. 1310-1323. (PX 854).
- Belated Motion for Judgment with regard to Wolff Claims¹, 2-8, 10, 11, 13-17, and 19. (PX 1410).
- Drawing of Sprial Stent (sent to Bodic Mar. 17, 1986). (PX2933).
- Wright et al., Article: "Percutaneous Endovascular Stents: An Experimental Evaluation," *Radiology*, vol. 156, pp. 69-72, 1985. (PX 3093).
- Charnsangavej et al., Article: "A New Expandable Metallic Stent for Dilation of Stenotic Tubular Structures: Experimental and Clinical Evaluation," *Houston Medical Journal*, vol. 3, pp. 41-51, Jun. 1987. (PX 3207).
- In re Application of Wiktor, Appln. No. 69,636, Response to Office Action dated Mar. 17, 1988. (PX3236).
- Transmittal Letter of Response to First Office Action in '417 patent. (PX 3993).
- Letter from B. Tobor to R. Schatz dated Jul. 23, 1991. (PX 3996).
- Mullins et al., Article: "Implantation of balloon-expandable intravascular grafts by catheterization in pulmonary arteries and systemic veins," *Circulation*, vol. 77, No. 1, pp. 188-189, 1988. (PX4049).
- Schatz et al., Article: "Intravascular Stents for Angioplasty," *Cardio*, 1997. (PX 4050).
- Schatz et al., Article: "New Technology in Angioplasty Balloon-Expandable Intravascular Stents, New Developments in Medicine," vol. 2, No. 2 pp. 59-75, 1987. (PX4051).
- Richard A. Schatz, Article: "Introduction to Intravascular Stents," *Cardiology Clinics*, vol. 6, No. 3, pp. 357-372, 1988. (PX 4052).
- Richard A. Schatz, Article: "A View of Vascular Stents," *Circulation*, vol. 79, No. 2, pp. 445-457, 1989. (PX4053).
- Wang et al., Article: "An Update on Coronary Stents," *Cardio*, pp. 177-186, 1992. (PX 4054).
- Richard A. Schatz, Article: "New Technology in Angioplasty: Balloon-Expandable Starts," *Medicamundi*, vol. 33, No. 3, pp. 112-116, 1988. (PX 4055).
- Letter from Tobor to Schatz dated Sep. 29, 1988. (PX 1395).
- Verified Statement of Facts by Unnamed Inventor R.A. Schatz document filed in U.S. Patent and Trademark Office on Sep. 8, 1989. (PX 3677).
- Declaration of John S. Kula Under 37 CFR § 1.672 (Exhibit 329).
- Letter to Mike Schular from R.A. Schatz dated Aug. 29, 1991. (Exhibit 402).
- Articulated, Balloon—Expandable Stents, (DBX 7159).
- J. Rosch et al., Experimental Intrahepatic Portacaval Anastomosis: Use of Expandable Gianturco Stents, *Radiology*, vol. 162, pp. 481-485, 1987.
- J. Rosch et al., Modified Gianturco Expandable Wire Stents In Experimental and Clinical Use, *Ann Radiol*, vol. 31, No. 2, pp. 100-103, 1987.
- J. Rosch et al., Gianturco Expandable Stents In the Treatment of Superior Vena Cava Syndrome Recurring After Vena Cava Syndrome Recurring After Maximum-Tolerance Radiation, *Cancer*, vol. 60, pp. 1243-1246, 1987.
- I.E. Gordon, Structures or Why Things Don't Fall Down, Penguin Books, pp. 45-59, 132-148, 210-244, 377-383.
- Maass et al., Radiological Follow-up of Transluminally Inserted Vascular Endoprostheses: An Experimental Study Using Expanding Spirals, *Radiology*, vol. 152, pp. 659-663, 1984.
- Argument submitted re EP 861 15473 dated Jan. 20, 1995. (AVE 2478).
- Verified Statement of Facts by Julio C. Palmaz dated Aug. 4, 1989. (PX 3662).
- Papanicolaou et al., Insertion of a Biliary Endoprosthesis Using A Balloon Dilatation Catheter, *Gastrointest Radiology*, vol. 10, pp. 394-396, 1985.
- Palmaz et al., Atherosclerotic Rabbit Aortas: Expandable Intraluminal Grafting, *Radiology*, vol. 168, pp. 723-726, 1986.
- Palmaz, The Current Status of Vascular Prostheses; Rosch et al., Gianturco, Expandable Stents in Experimental and Clinical Use, *SCIVR*, pp. 118-124, 1987.
- Rosch et al., Abstract: Modified Gianturco Expandable Wire Stents in Experimental and Clinical Use, *CIRSE*, Porto Cervo, Sardinia, May 25-29, 1987.
- Rosch et al., Gianturco Expandable Wire Stents in the Treatment of Superior Vena Cava Syndrome Recurring After Maximum-Tolerance Radiation, *Cancer*, vol. 60, pp. 1243-1246, 1987.
- Mirich et al., Percutaneously Placed Endovascular Grafts for Aortic Aneurysms: Feasibility Study, *Radiology*, vol. 170, pp. 1033-1037, 1989.
- Dotter, Transluminally-placed Coilspring Endarterial Tube Grafts, *Investigative Radiology*, vol. 4, Sept.-Oct., pp. 329-332, 1969.
- Palmaz et al., Abstract: Expandable Intraluminal Graft: A Preliminary Study, *Radiology*, vol. 153 (P), Nov. 1983: 70th Scientific Assembly and Annual Meeting.
- Cragg et al, Nonsurgical Placement of Arterial Endoprostheses: A New Technique Using Nitinol Wire, *Radiology*, vol. 147, pp. 261-263, Apr. 1983.
- J. Rosch et al., Gianturco Expandable Stents in Experimental and Clinical Use, Program: "Twelfth Annual Course on Dignostic Angiography and Interventional Radiology" (Society of Cardiovascular and Interventional Radiology, Pittsburgh, PA), Mar. 23-26, 1987 (the second Monofilament Article).
- Uchida et al., Modifications of Gianturco Expandable Wire Stents, *AIR*, vol. 150, pp. 1185-1187, 1988.
- Palmaz, Balloon-Expandable Intravascular Stent, *AJR*, vol. 1510, pp. 1263-1269.

- Cordis Corporation v. Advanced Cardiovascular Systems, Inc., Guidant Corporation, Arterial Vascular Engineering, Inc., Boston Scientific Corporation and SCMED Life System, Inc.*, Plaintiffs Complaint, Oct. 23, 1997 (Case No. 97-550-SLR).
- Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership*, Plaintiffs First Amended Complaint for Declaratory Relief of Patent Validity, Unenforceability, Noninfringement, and for Antitrust Violations, Jan. 27, 1998 (Civil Action No. 97-700).
- Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership, Cordis Corporation and Johnson & Johnson's Answer and Counterclaim*, Feb. 27, 1998 (Civil Action No. 97-700-SLR).
- Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership, Expandable-Graft Partnership's Answer*, Feb. 27, 1998 (Civil Action No. 97-700-SLR).
- Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership*, Reply of Plaintiff Arterial Vascular Engineering, Inc. To Counterclaims of Defendant Cordis Corporation, Mar. 31, 1998 (Civil Action No. 97-700-SLR).
- Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable-Grafts Partnership*, Reply of Plaintiff Arterial Vascular Engineering, Inc. To Counterclaims of Defendant Expandable Grafts Partnership, Mar. 31, 1998 (Civil Action No. 97-700-SLR).
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc. and Guidant Corporation* Cordis Corporation's Motion for a Preliminary Injunction, Oct. 8, 1997 (Civil Action No. 97-550).
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc., Guidant Corporation Arterial Vascular Engineering, Inc., Boston Scientific Corporation and SCJVVIED, Inc.*, Cordis 's Motion for Preliminary Injunction Against Arterial Vascular Engineering, Inc., Dec. 29, 1997 (Case No. 97-550-SLR).
- Deposition of R. Schatz, M.D. in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, taken on Jan. 8, 1998 (Civil Action No. 97-550 SLR).
- Deposition of Lee P. Bendel in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, taken on Jan. 22, 1998 (Civil Action No. 97-550 SLR).
- Deposition of Julio Cesar Palmaz in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, taken on Dec. 29, 1997 (Civil Action No. 97-550 SLR).
- Deposition of Richard A. Bowman in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, taken on Jan. 9, 1998 (Civil Action No. 97-550 SLR).
- Deposition of Gary Schneiderman in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, taken on Jan. 16, 1998 (Civil Action No. 97-550 SLR).
- Deposition of David Pearle, M.D. in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, taken on Jul. 10, 1998 (Civil Action No. 97-550 SLR).
- Preliminary Injunction hearing testimony taken on Feb. 9-13, 1998 (Civil Action No. 97-550 SLR).
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc.*, et al., (Civil Action No. 97-550 SLR) and *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.* Et al. (Civil Action No. 98-65-SLR), Opening Post Hearing Brief of Plaintiff Cordis Corporation in Support of Motion for Preliminary Injunction, Mar. 6, 1998 (Portions relevant to patent claim construction and patent validity issues).
- Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc.* et al., Post-Hearing Reply Brief of Plaintiff Cordis Corporation in Support of Its Motion for Preliminary Injunction, Apr. 10, 1998 (Case No. 97-550 SLR) (Portions relevant to patent validity issues).
- Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc.*, et al., Plaintiffs Motion for a Preliminary Injunction Against Boston Scientific Corporation and SCLMED Life Systems, Inc. And Memorandum in Support, Apr. 13, 1998 (Case No. 97-550-SLR).
- Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc.*, et al., Judge Robinson's Order Denying Plaintiffs Motion for a Preliminary Injunction, Jul. 17, 1998 (Civil Action No. 97-550 SLR).
- Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc.*, et al., Defendant Boston Scientific Corporation and SCTMED Life Systems, Inc.'s Motion for Summary Judgment of Invalidity of U.S. Patent No. 5,102,417, Aug. 27, 1998 (Civil Action No. 97-550-SLR).
- Boston Scientific Limited*, et al. v. *Expandable Grafts Partnership*, Plaintiff's Statement of Claim, Mar. 13, 1997 (UK Action No. 1493).
- Boston Scientific Limited*, et al. v. *Expandable Grafts Partnership*, Defendant's Amended Defense and Counterclaim, Aug. 14, 1997 (UK Action No. 1493).
- Boston Scientific Limited*, et al. v. *Expandable Grafts Partnership*, Petition for Revocation, Mar. 13, 1997 (UK Action No. 1497).
- Boston Scientific Limited*, et al. v. *Expandable Grafts Partnership*, Particulars of Objections, Mar. 13, 1997 (UK Action No. 1497).
- Boston Scientific Limited*, et al. v. *Expandable Grafts Partnership and Boston Scientific Limited* et al., v. *Julio C. Palmaz, Boston's Skeleton Argument* (UK Action Nos. 1493, 1495, 1496, and 1497).
- Boston Scientific Limited*, et al. v. *Julio C. Palmaz and Expandable Grafts Partnership*, Skeleton Argument of Palmaz/EGP, Mar. 19, 1998 (UK Action Nos. 1493, 1495, 1496 and 1497).
- Boston Scientific Limited*, et al. v. *Julio C. Palmaz and Expandable Grafts Partnership*, EGP's Final Submissions, Apr. 2, 1998 (UK Action Nos. 1493, 1495, 1496 and 1497).
- Boston Scientific Limited*, et al. v. *Julio C. Palmaz and Expandable Grafts Partnership*, Judgment, Jun. 26, 1998 (UK Action Nos. 1493, 1495, 1496 and 1497).
- Rosch, Modified Gianturco Expandable Wire Stents in Experimental and Clinical Use, CJJR.SE 1987 Presentation: see Witness Statement of Josef Rosch from U.K. Proceeding.
- Statement of Claim by Boston Scientific et al. against Expandable Grafts Partnership et al., in *EPG* et al., v. *Boston Scientific* et al. in Netherlands (Mar. 13, 1997).
- Motion for Joinder of Actions, Change of Claim and Statement of Claim filed by Expandable Grafts Partnership et al. in *EPG* et al. v. *Boston Scientific* et al. In Netherlands (Apr. 22, 1997).
- Opinion of K.J. Merman filed in *EPG* et al. v. *Boston Scientific* et al. in Netherlands (Aug. 29, 1997).
- Expert report of Dr. Nigel Buller in *EPG* et al. v. *Boston Scientific* et al. in Netherlands (Aug. 28, 1997).
- Expert report of Lee P. Bendel in *EPG* et al. v. *Boston Scientific* et al. in Netherlands (Aug. 28, 1997).
- Memorandum or Oral Pleading in *EPG* et al. v. *Boston Scientific* et al. in Netherlands (Sep. 12, 1997).
- Plea Notes of P. A.M. in *EPG* et al. v. *Boston Scientific* et al. in Netherlands (Mar. 10, 1998).
- Decision of Court of Appeals in *EPG* et al. v. *Boston Scientific* et al. In Netherlands (Apr. 23, 1998).
- Translation of Nullity Action Against EPO 0 364 787 by Biotronik in Germany.
- Translation of Nullity Action Against EPO 0 335 341 by Biotronik in Germany.
- Translation of EPG Response to Nullity Action Against EP 0 364 787 by Biotronik in Germany.
- Translation of EPG Response to Nullity Action EP 0 335 341 by Biotronik in Germany.
- Nullity Suit Against EP-B1-0 335 341 Brought by Boston Scientific in Germany.
- Translation of Opposition filed by Terumo Corp. Against Japan Patent No. 2680901.
- Translation of Decision on Opposition Against Japan Patent No. 2680901.
- Memorandum Order of the Court dated Sep. 7, 2000, concerning disputed claim construction.
- Translation of Judgment in Nullity Action Against EP 0 364 787 by Biotronik in Germany.
- Translation of Judgment in Nullity Action Against EP 0 335 341 by Biotronik in Germany.
- Trial transcript from Mar. 17, 2005 at 171-172, 191-192.
- Trial transcript from Mar. 18, 2005 at 282-285, 325-327, 349-351.
- Trial transcript from Mar. 21, 2005 at 721-726.

- Trial transcript from Mar. 24, 2005 at 1387.
- Trial transcript from Jul. 26, 2005.
- BSC's Opening Brief in Support of Its Motion for Judgment as a Matter of Law or, in the Alternative, for a New Trial, dated Mar. 16, 2001.
- Cordis' Answering Brief in Opposition to BSC's Motion for JMOL or a New Trial on the Palmaz '762 Patent and the Schatz '332 Patents, dated Apr. 17, 2001.
- BSC's Reply Brief in Support of Its Motion for Judgment as a Matter of Law or, in the Alternative, for a New Trial, dated May 11, 2001.
- J. Rosch et al., Abstract, Expandable Gianturco-Type Wire Stents in Experimental Intrahepatic Portacaval Shunts, Program: "72nd Scientific Assembly and Annual Meeting of the Radiological Society of North America", Nov. 30-Dec. 5, 1986, Radiology, vol. 161, pp. 40-41, 1986.
- Cordis Corporation v. Boston Scientific*, Order Dated Mar. 27, 2006 (97-550-SLR).
- Cordis Corporation v. Boston Scientific*, Judgment in a Civil Case Dated Mar. 27, 2006 (97-550-SLR).
- Cordis Corporation v. Boston Scientific*, Memorandum Opinion Dated Mar. 27, 2006 (97-550-SLR).
- Cordis Corporation and Expandable Grafts Partnership v. Advanced Cardiovascular Systems, Inc., Guidant Corporation, Arterial Vascular Engineering, Inc., Boston Scientific Corporation and SCIMED Life Systems, Inc.*, Answer and Counterclaims of Defendant Advanced Cardiovascular Systems, Inc., Apr. 8, 1998 (Case No. 97-550-SLR).
- Boston Scientific Limited et al. v. Expandable Grafts Partnership and Boston Scientific Limited et al. v. Julio C. Palmaz*, Boston's Closing Submissions (UK Action Nos. 1493, 1495, 1496 and 1497).
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc., Guidant Corporation, Arterial Vascular Engineering, Inc., Boston Scientific Corporation and SCIMED Life Systems, Inc.*, Defendants' Answer, Nov. 12, 1997 (Case No. 97-550-SLR).
- Statement of Rejoinder in the Action on the Merits, Also Including an Amendment of Defendant's Final Position in the Principal Action, as Well as the Provisional Statement of Rejoinder in the Action on the Counterclaim in *EPG et al. v. Boston Scientific et al.* In Netherlands (Feb. 10, 1998).
- Statement of Answer in the Ancillary Appeal in *EPG et al. v. Boston Scientific et al.* in Netherlands (Mar. 10, 1998).
- Appeal filed by Expandable Grafts Partnership et al. in *EPG et al. v. Boston Scientific et al.* in Netherlands (Nov. 12, 1997).
- Title filed by Boston Scientific et al. in *EPG et al. v. Boston Scientific et al.* in Netherlands (Jan. 22, 1998).
- Deposition of Richard Schatz, M.D. in *Cordis Corporation v. Advanced Cardiovascular Systems, Inc.* taken on Jul. 14, 1998 (Civil Action No. 97-550-SLR).
- Jury Verdict form from the *Cordis Corporation et al. v. Boston Scientific Corporation*, et al liability trial, undated.
- Trial testimony transcripts from the *Cordis Corporation et al. v. Boston Scientific Corporation et al.* liability trial dated Nov. 27-Dec. 1, Dec. 4-8 and Dec. 11, 2000.
- Boston Scientific SCIMED, Inc. and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.*, Opening Expert Report of Stephen R. Hanson, Ph.D. (Civil Action No. 03-283-SLR).
- Boston Scientific SCIMED, Inc. and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.*, Opening Expert Report of Robson F. Storey, Ph.D. (Civil Action No. 03-283-SLR).
- Boston Scientific SCIMED, Inc. and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.*, Rebuttal Expert Report of Kinam Park, Ph.D. (Civil Action No. 03-283-SLR).
- Cordis Corporation v. Boston Scientific Corporation and SCIMED Life Systems, Inc.* (C.A. No. 03-027-SLR) and *Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.* (C.A. No. 03-283-SLR) Combined Post-Hearing Brief In Support Of Cordis Corporation's Motion For Preliminary Injunction in C.A. No. 03-027-SLR, And In Opposition to Plaintiffs' Motion For Preliminary Injunction in C.A. No. 03-283-SLR.
- Cordis Corporation v. Boston Scientific Corporation and SCIMED Life Systems, Inc.* (C.A. No. 03-027-SLR) *Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.* (C.A. No. 03-283-SLR), Boston Scientific's Opening Post-Hearing Brief.
- Cordis Corporation v. Boston Scientific Corporation and SCIMED Life Systems, Inc.* (C.A. No. 03-027-SLR) *Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.* (C.A. No. 03-283-SLR), Combined Post-Hearing Answering Brief In Support of Cordis Corporation's Motion For Preliminary Injunction In C.A. No. 03-027-SLR, And In Opposition To Plaintiffs Motion For Preliminary Injunction In C.A. No. 03-283-SLR.
- Wu et al., Silicone-covered self-expanding metallic stents for the palliation of malignant esophageal obstruction and esophagorespiratory fistulas: experience in 32 patients and a review of the literature, *Gastrointestinal Endoscopy*, 1994, pp. 22-33, vol. 40, No. 1, Portland Oregon.
- Binmoeller, et al., Silicone-Covered Expandable Metallic Stents in the Esophagus: An Experimental Study, *Endoscopy*, 1992, pp. 416-420, vol. 24, Georg Thieme Verlag Stuttgart New York.
- Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.*, Answering Memorandum in Opposition to Plaintiffs Motion for a Preliminary Injunction and Appendix thereto (Civil Action No. 03-283-SLR).
- Boston Scientific SCIMED, Inc., and Boston Scientific Corporation v. Cordis Corporation and Johnson and Johnson, Inc.*, Plaintiff's Reply Brief in Support of Their Motion for Preliminary Injunction.
- Rhine, Polymers for Sustained Macromolecule Release: Procedures to Fabricate Reproducible Delivery Systems and Control Release Kinetics, *Journal of Pharmaceutical Sciences*, 1980, pp. 265-270, vol. 69, No. 3.
- Langer et al., Controlled Release of Macromolecules From Polymers, *Biomedical Polymers Polymeric Materials and Pharmaceuticals for Biomedical Use*, 1980, pp. 112-137, Academic Press, Inc., New York, NY.
- Langer et al., Applications of Polymeric Delivery Systems for Macromolecules and Factors Controlling Release Kinetics.
- Rhine et al., A Method to Achieve Zero-Order Release Kinetics From Polymer Matrix Drug Delivery Systems, pp. 67-72.
- Langer et al., Polymers for the Sustained Release of Macromolecules: Controlled and Magnetically Modulated Systems, *Better Therapy With Existing Drugs: New Uses and Delivery Systems*; 1981, pp. 179-216, Merck Sharp & Dohme International, Rahway, NJ.
- Hsieh, et al., Zero-Order Controlled-Release Polymer Matrices for Micro-and-Macromolecules, *Journal of Pharmaceutical Sciences*, 1983 pp. 17-22, vol. 72, No. 1.
- Brown et al., In Vivo and In Vitro Release of Macromolecules from Polymeric Drug Delivery Systems, *Journal of Pharmaceutical Sciences*, 1983, pp. 1181-1185, vol. 72, No. 10.
- Langer, Implantable Controlled Release Systems, *Pharmac. Ther.*, 1983, pp. 35-51, vol. 21, printed in Great Britain.
- Kost et al., Controlled Release of Bioactive Agents, *Trends in Biotechnology*, 1984, pp. 47-51, vol. 2, No. 2, Elsevier BV Amsterdam.
- Bawa et al., An Explanation for the Controlled Release of Macromolecules from Polymers, *Journal of Controlled Release*, 1985, pp. 259-267, vol. 1 Elsevier Science BV Amsterdam.
- Leong et al., Polymeric controlled drug delivery, 1987, pp. 199-233, vol. 1/3, Elsevier Science Publishers BV Amsterdam.
- Langer, Polymeric Delivery Systems, *Targeting of Drugs 2 Optimization Strategies*, 1989, pp. 165-174, Plenum Press, New York and London.
- Langer, Biomaterials in Controlled Drug Delivery; New Perspectives from Biotechnological Advances; *Pharmaceutical Technology*, 1989, pp. 18, 23-24, 26, 28, 30.
- Langer, Controlled Release Systems, pp. 115-124.
- Laurencin et al., Polymeric Controlled Release Systems: New Methods for Drug Delivery, *Clinics in Laboratory Medicine*, 1987, pp. 301-323, vol. 7, No. 2, WB Saunders Company, Philadelphia.
- Langer, Biopolymers in Controlled Release Systems, *Polymeric Biomaterials*, pp. 161-169.

- Tsong-Pin Hsu et al., Polymers for the Controlled Release of Macromolecules: Effect of Molecular Weight of Ethylene-vinyl Acetate Copolymer, *Journal of Biomedical Materials Research*, 1985, pp. 445-460, vol. 19.
- Langer, Polymers and Drug Delivery Systems, *Long-Acting Contraceptive Delivery Systems*, 1983, pp. 23-32, Harper & Row, Philadelphia, PA.
- Langer, New Drug Delivery Systems: What the Clinician Can Expect, *Drug Therapy*, 1983, pp. 217-231.
- Langer, et al., Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review, *Rev. Macromol. Chem. Phys.*, 1983, pp. 61-126.
- Langer, Polymeric Delivery Systems for Controlled Drug Release, *Chem. Eng. Commun.* 1980, pp. 1-48-vol. 6, Gordon and Breach Science Publishers, Inc. USA.
- Langer, et al., Biocompatibility of Polymeric Delivery Systems for Macromolecules, *Journal of Biomedical Materials Research*, 1981, pp. 267-277, vol. 15.
- Langer, Controlled Release: A New Approach to Drug Delivery, *Technology Review*, 1981, pp. 26-34.
- Langer, et al Sustained Release of Macromolecules from Polymers, *Polymeric Delivery Systems*, PGS. 175-176, Gordon and Breach Science Publishers, New York.
- Langer, Polymers for the Sustained Release of Proteins and other Macromolecules, *Nature*, 1976, pp. 797, 263, 799-800, vol. 263, No. 5580.
- Baker, et al., Controlled Release: Mechanisms and Rates (1974).
- Hanson, et al., In Vivo Evaluation of Artificial Surfaces with a Nonhuman Primate Model of Arterial Thrombosis, *Lab Clin. Med.*, Feb. 1980, pp. 289-304.
- Baker, Controlled Release of Biologically Active Agents (1987) pp. 1-275.
- Cordis Corporation v. Boston Scientific Corporation* (CA. No. 03-27-SLR) and *Boston Scientific Scimed, Inc., v. Cordis Corporation and Johnson & Johnson, Incorporated* (CA. No. 03-283-SLR) Hearing Transcripts for Jul. 21, 2003, Jul. 22, 2003, Jul. 23, 2003.
- Cordis Corporation v. Boston Scientific Corporation et al.* (CA. No. 03-027-SLR), and *Boston Scientific Scimed, Inc. et al. v. Cordis Corporation et al.* (CA. No. 03-283-SLR), Boston Scientific's Post-Hearing Reply Brief and Exhibits Thereto, Sep. 12, 2003.
- Cordis Corporation v. Boston Scientific Corporation et al.* (CA. No. 03-027-SLR), and *Boston Scientific Scimed, Inc. et al. v. Cordis Corporation et al.* (CA. 03-283-SLR), Memorandum Order, Nov. 21, 2003.
- Cordis Corporation v. Boston Scientific Corporation et al.* (CA. No. 03-027-SLR), and *Boston Scientific Scimed, Inc. et al. v. Cordis Corporation et al.* (CA. No. 03-283-SLR), Deposition Transcript of Julio C. Palmaz.
- Arterial Vascular Engineering, Inc. v. Cordis Corporation, Johnson & Johnson and Expandable Grafts Partnership*, Cordis Corporation and Johnson & Johnson's Answer and Counterclaim, Feb. 27, 1998 (Civil Action No. 97-700-SLR).
- Plea Notes in *EPG et al. v. Boston Scientific et al.* in Netherlands (Sep. 12, 1997).
- Provisional Judgment *EPG et al. v. Boston Scientific et al.* in Netherlands (Oct. 29, 1997).
- Trial testimony transcripts from the *Cordis Corporation et al. v. Medtronic AVE Inc., et al.* liability trial dated Nov. 6-9, 13-17 and 20-21, 2000.
- Jury verdict form from the *Cordis Corporation et al. v. Medtronic AVE, Inc. et al.* liability trial.
- Hearing testimony transcript from the consolidated *Cordis Corporation et al. v. Medtronic AVE, Inc. et al.* and *Boston Scientific Corporation et al.* inequitable conduct hearing dated Feb. 7-9 and 12, 2001.
- Cordis Corporation v. Medtronic Ave., Inc. et al.* OPINION, 97-550-SLR, dated Mar. 28, 2002.
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc. et al.* (CA. No. 97-550-SLR), *Medtronic AVE, Inc. v. Cordis Corporation et al.* (CA. No. 97-700-SLR), *Boston Scientific Corporation v. Athicon, Inc. et al.* (CA. No. 98-19-SLR), Expert Report of John T. Goolkasian, Esq.
- Cordis Corporation v. Advanced Cardiovascular Systems, Inc. et al.* (CA. No. 97-550-SLR), *Medtronic AVE, Inc. v. Cordis Corporation et al.* (CA. No. 97-700-SLR), *Boston Scientific Corporation v. Athicon, Inc. et al.* (CA. 98-19-SLR), Expert Report of John F. Witherspoon.
- Ruef, Johannes MD, et al.; "Flavopiridol Inhibits Smooth Muscle Cell Proliferation In Vitro and Neointimal Formation In Vivo After Carotid Injury In The Rat"; From the Division of Cardiology and Sealy Center for Molecular Cardiology, University of Texas Medical Branch, Galveston; Accepted Apr. 9, 1999; *Circulation* Aug. 10, 1999; pp. 659-665.
- European Search Report EP 05 25 2466 dated Jul. 26, 2005.
- European Search Report EP 05 25 2631 dated Jul. 26, 2005.
- European Search Report EP 05 25 2478 dated Jul. 26, 2005.
- Schuler, W. et al., "SDZ RAD, A New Rapamycin Derivative: Pharmacological Properties In Vitro and In Vivo," *Transplantation*, Jul. 5, 1997, 64(1), 36-42.

* cited by examiner




FIG. 1

FIG. 2**FIG. 3**

1

DRUG/DRUG DELIVERY SYSTEMS FOR THE PREVENTION AND TREATMENT OF VASCULAR DISEASE

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. application Ser. No. 09/850,293, filed May 7, 2001, now abandoned, which in turn claims priority of U.S. Provisional Application No. 60/263,979, filed Jan. 25, 2001, U.S. Provisional Application No. 60/263,806, filed January 24, 2001, U.S. Provisional Application No. 60/262,614, filed Jan. 18, 2001, U.S. Provisional Application No. 60/262,461, filed Jan. 18, 2001, and is a continuation-in-part of U.S. Application No. 09,575,480, filed May 19, 2000, now pending, which in turn claims priority of U.S. Provisional Application No. 60/204,417, filed May 12, 2000.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to drugs and drug delivery systems for the prevention and treatment of vascular disease, and more particularly to drugs and drug delivery systems for the prevention and treatment of neointimal hyperplasia.

2. Discussion of the Related Art

Many individuals suffer from circulatory disease caused by a progressive blockage of the blood vessels that perfuse the heart and other major organs with nutrients. More severe blockage of blood vessels in such individuals often leads to hypertension, ischemic injury, stroke, or myocardial infarction. Atherosclerotic lesions, which limit or obstruct coronary blood flow, are the major cause of ischemic heart disease. Percutaneous transluminal coronary angioplasty is a medical procedure whose purpose is to increase blood flow through an artery. Percutaneous transluminal coronary angioplasty is the predominant treatment for coronary vessel stenosis. The increasing use of this procedure is attributable to its relatively high success rate and its minimal invasiveness compared with coronary bypass surgery. A limitation associated with percutaneous transluminal coronary angioplasty is the abrupt closure of the vessel which may occur immediately after the procedure and restenosis which occurs gradually following the procedure. Additionally, restenosis is a chronic problem in patients who have undergone saphenous vein bypass grafting. The mechanism of acute occlusion appears to involve several factors and may result from vascular recoil with resultant closure of the artery and/or deposition of blood platelets and fibrin along the damaged length of the newly opened blood vessel.

Restenosis after percutaneous transluminal coronary angioplasty is a more gradual process initiated by vascular injury. Multiple processes, including thrombosis, inflammation, growth factor and cytokine release, cell proliferation, cell migration and extracellular matrix synthesis each contribute to the restenotic process.

While the exact mechanism of restenosis is not completely understood, the general aspects of the restenosis process have been identified. In the normal arterial wall, smooth muscle cells proliferate at a low rate, approximately less than 0.1 percent per day. Smooth muscle cells in the vessel walls exist in a contractile phenotype characterized by eighty to ninety percent of the cell cytoplasmic volume occupied with the contractile apparatus. Endoplasmic reticulum, Golgi, and free ribosomes are few and are located in the perinuclear region. Extracellular matrix surrounds the

2

smooth muscle cells and is rich in heparin-like glycosylaminoglycans which are believed to be responsible for maintaining smooth muscle cells in the contractile phenotypic state (Campbell and Campbell, 1985).

Upon pressure expansion of an intracoronary balloon catheter during angioplasty, smooth muscle cells within the vessel wall become injured, initiating a thrombotic and inflammatory response. Cell derived growth factors such as platelet derived growth factor, fibroblast growth factor, epidermal growth factor, thrombin, etc., released from platelets, invading macrophages and/or leukocytes, or directly from the smooth muscle cells provoke proliferative and migratory responses in medial smooth muscle cells. These cells undergo a change from the contractile phenotype to a synthetic phenotype characterized by only a few contractile filament bundles, extensive rough endoplasmic reticulum, Golgi and free ribosomes. Proliferation/migration usually begins within one to two days post-injury and peaks several days thereafter (Campbell and Campbell, 1987; Clowes and Schwartz, 1985).

Daughter cells migrate to the intimal layer of arterial smooth muscle and continue to proliferate and secrete significant amounts of extracellular matrix proteins. Proliferation, migration and extracellular matrix synthesis continue until the damaged endothelial layer is repaired at which time proliferation slows within the intima, usually within seven to fourteen days post-injury. The newly formed tissue is called neointima. The further vascular narrowing that occurs over the next three to six months is due primarily to negative or constrictive remodeling.

Simultaneous with local proliferation and migration, inflammatory cells invade the site of vascular injury. Within three to seven days post-injury, inflammatory cells have migrated to the deeper layers of the vessel wall. In animal models employing either balloon injury or stent implantation, inflammatory cells may persist at the site of vascular injury for at least thirty days (Tanaka et al., 1993; Edelman et al., 1998). Inflammatory cells therefore are present and may contribute to both the acute and chronic phases of restenosis.

Numerous agents have been examined for presumed anti-proliferative actions in restenosis and have shown some activity in experimental animal models. Some of the agents which have been shown to successfully reduce the extent of intimal hyperplasia in animal models include: heparin and heparin fragments (Clowes, A. W. and Karnovsky M., *Nature* 265: 25-26, 1977; Guyton, J. R. et al., *Circ. Res.*, 46: 625-634, 1980; Clowes, A. W. and Clowes, M. M., *Lab. Invest.* 52: 611-616, 1985; Clowes, A. W. and Clowes, M. M., *Circ. Res.* 58: 839-845, 1986; Majesky et al., *Circ. Res.* 61: 296-300, 1987; Snow et al., *Am. J. Pathol.* 137: 313-330, 1990; Okada, T. et al., *Neurosurgery* 25: 92-98, 1989), colchicine (Currier, J. W. et al., *Circ.* 80: 11-66, 1989), taxol (Sollot, S. J. et al., *J. Clin. Invest.* 95: 1869-1876, 1995), angiotensin converting enzyme (ACE) inhibitors (Powell, J. S. et al., *Science*, 245: 186-188, 1989), angiopeptin (Lundergan, C. F. et al. *Am. J. Cardiol.* 17(Suppl. B):132B-136B, 1991), cyclosporin A (Jonasson, L. et al., *Proc. Natl., Acad. Sci.*, 85: 2303, 1988), goat-anti-rabbit PDGF antibody (Ferns, G. A. A., et al., *Science* 253: 1129-1132, 1991), terbinafine (Nemecsek, G. M. et al., *J. Pharmacol. Exp. Thera.* 248: 1167-1174, 1989), trapidil (Liu, M. W. et al., *Circ.* 81: 1089-1093, 1990), tranilast (Fukuyama, J. et al., *Eur. J. Pharmacol.* 318: 327-332, 1996), interferon-gamma (Hansson, G. K. and Holm, J., *Circ.* 84: 1266-1272, 1991), rapamycin (Marx, S. O. et al., *Circ. Res.* 76: 412-417, 1995), corticosteroids (Colburn, M. D. et al., *J. Vasc. Surg.* 15:

510-518, 1992), see also Berk, B. C. et al., *J. Am. Coll. Cardiol.* 17: 111B-117B, 1991), ionizing radiation (Weinberger, J. et al., *Int. J. Rad. Onc. Biol. Phys.* 36: 767-775, 1996), fusion toxins (Farb, A. et al., *Circ. Res.* 80: 542-550, 1997) antisense oligonucleotides (Simons, M. et al., *Nature* 359: 67-70, 1992) and gene vectors (Chang, M. W. et al., *J. Clin. Invest.* 96: 2260-2268, 1995). Anti-proliferative effects on smooth muscle cells in vitro have been demonstrated for many of these agents, including heparin and heparin conjugates, taxol, tranilast, colchicine, ACE inhibitors, fusion toxins, antisense oligonucleotides, rapamycin and ionizing radiation. Thus, agents with diverse mechanisms of smooth muscle cell inhibition may have therapeutic utility in reducing intimal hyperplasia.

However, in contrast to animal models, attempts in human angioplasty patients to prevent restenosis by systemic pharmacologic means have thus far been unsuccessful. Neither aspirin-dipyridamole, ticlopidine, anti-coagulant therapy (acute heparin, chronic warfarin, hirudin or hirulog), thromboxane receptor antagonism nor steroids have been effective in preventing restenosis, although platelet inhibitors have been effective in preventing acute reocclusion after angioplasty (Mak and Topol, 1997; Lang et al., 1991; Popma et al., 1991). The platelet GP IIb/IIIa receptor, antagonist, Reopro is still under study but has not shown promising results for the reduction in restenosis following angioplasty and stenting. Other agents, which have also been unsuccessful in the prevention of restenosis, include the calcium channel antagonists, prostacyclin mimetics, angiotensin converting enzyme inhibitors, serotonin receptor antagonists, and anti-proliferative agents. These agents must be given systemically, however, and attainment of a therapeutically effective dose may not be possible; anti-proliferative (or anti-restenosis) concentrations may exceed the known toxic concentrations of these agents so that levels sufficient to produce smooth muscle inhibition may not be reached (Mak and Topol, 1997; Lang et al., 1991; Popma et al., 1991).

Additional clinical trials in which the effectiveness for preventing restenosis utilizing dietary fish oil supplements or cholesterol lowering agents has been examined showing either conflicting or negative results so that no pharmacological agents are as yet clinically available to prevent post-angioplasty restenosis (Mak and Topol, 1997; Franklin and Faxon, 1993; Serruys, P. W. et al., 1993). Recent observations suggest that the antilipid/antioxidant agent, probucol may be useful in preventing restenosis but this work requires confirmation (Tardif et al., 1997; Yokoi, et al., 1997). Probuco is presently not approved for use in the United States and a thirty-day pretreatment period would preclude its use in emergency angioplasty. Additionally, the application of ionizing radiation has shown significant promise in reducing or preventing restenosis after angioplasty in patients with stents (Teirstein et al., 1997). Currently, however, the most effective treatments for restenosis are repeat angioplasty, atherectomy or coronary artery bypass grafting, because no therapeutic agents currently have Food and Drug Administration approval for use for the prevention of post-angioplasty restenosis.

Unlike systemic pharmacologic therapy, stents have proven effective in significantly reducing restenosis. Typically, stents are balloon-expandable slotted metal tubes (usually, but not limited to, stainless steel), which, when expanded within the lumen of an angioplastied coronary artery, provide structural support through rigid scaffolding to the arterial wall. This support is helpful in maintaining vessel lumen patency. In two randomized clinical trials,

stents increased angiographic success after percutaneous transluminal coronary angioplasty, by increasing minimal lumen diameter and reducing, but not eliminating, the incidence of restenosis at six months (Serruys et al., 1994; Fischman et al., 1994).

Additionally, the heparin coating of stents appears to have the added benefit of producing a reduction in sub-acute thrombosis after stent implantation (Serruys et al., 1996). Thus, sustained mechanical expansion of a stenosed coronary artery with a stent has been shown to provide some measure of restenosis prevention, and the coating of stents with heparin has demonstrated both the feasibility and the clinical usefulness of delivering drugs locally, at the site of injured tissue.

Accordingly, there exists a need for effective drugs and drug delivery systems for the effective prevention and treatment of neointimal thickening that occurs after percutaneous transluminal coronary angioplasty and stent implantation.

SUMMARY OF THE INVENTION

The drugs and drug delivery systems of the present invention provide a means for overcoming the difficulties associated with the methods and devices currently in use as briefly described above.

In accordance with one aspect, the present invention is directed to a method for the prevention of constrictive remodeling. The method comprises the controlled delivery, by release from an intraluminal medical device, of a compound in therapeutic dosage amounts.

In accordance with another aspect, the present invention is directed to a drug delivery device. The drug delivery device comprises an intraluminal medical device and a therapeutic dosage of an agent releasably affixed to the intraluminal medical device for the treatment of constrictive vascular remodeling.

The drugs and drug delivery systems of the present invention utilize a stent or graft in combination with rapamycin or other drugs/agents/compounds to prevent and treat neointimal hyperplasia, i.e. restenosis, following percutaneous transluminal coronary angioplasty and stent implantation. It has been determined that rapamycin functions to inhibit smooth muscle cell proliferation through a number of mechanisms. It has also been determined that rapamycin eluting stent coatings produce superior effects in humans, when compared to animals, with respect to the magnitude and duration of the reduction in neointimal hyperplasia. Rapamycin administration from a local delivery platform also produces an anti-inflammatory effect in the vessel wall that is distinct from and complimentary to its smooth muscle cell anti-proliferative effect. In addition, it has also been demonstrated that rapamycin inhibits constrictive vascular remodeling in humans.

Other drugs, agents or compounds which mimic certain actions of rapamycin may also be utilized in combination with local delivery systems or platforms.

The local administration of drugs, agents or compounds to stented vessels have the additional therapeutic benefit of higher tissue concentration than that which would be achievable through the systemic administration of the same drugs, agents or compounds. Other benefits include reduced systemic toxicity, single treatment, and ease of administration. An additional benefit of a local delivery device and drug, agent or compound therapy may be to reduce the dose of the therapeutic drugs, agents or compounds and thus limit their toxicity, while still achieving a reduction in restenosis.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other features and advantages of the invention will be apparent from the following, more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings.

FIG. 1 is a chart indicating the effectiveness of rapamycin as an anti-inflammatory relative to other anti-inflammatories.

FIG. 2 is a view along the length of a stent (ends not shown) prior to expansion showing the exterior surface of the stent and the characteristic banding pattern.

FIG. 3 is a perspective view of the stent of FIG. 1 having reservoirs in accordance with the present invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

As stated above, the proliferation of vascular smooth muscle cells in response to mitogenic stimuli that are released during balloon angioplasty and stent implantation is the primary cause of neointimal hyperplasia. Excessive neointimal hyperplasia can often lead to impairment of blood flow, cardiac ischemia and the need for a repeat intervention in selected patients in high risk treatment groups. Yet repeat revascularization incurs risk of patient morbidity and mortality while adding significantly to the cost of health care. Given the widespread use of stents in interventional practice, there is a clear need for safe and effective inhibitors of neointimal hyperplasia.

Rapamycin is a macrocyclic triene antibiotic produced by *streptomyces hygroscopicus* as disclosed in U.S. Pat. No. 3,929,992. It has been found that rapamycin inhibits the proliferation of vascular smooth muscle cells in vivo. Accordingly, rapamycin may be utilized in treating intimal smooth muscle cell hyperplasia, restenosis and vascular occlusion in a mammal, particularly following either biologically or mechanically mediated vascular injury, or under conditions that would predispose a mammal to suffering such a vascular injury. Rapamycin functions to inhibit smooth muscle cell proliferation and does not interfere with the re-endothelialization of the vessel walls.

Rapamycin functions to inhibit smooth muscle cell proliferation through a number of mechanisms. In addition, rapamycin reduces the other effects caused by vascular injury, for example, inflammation. The operation and various functions of rapamycin are described in detail below. Rapamycin as used throughout this application shall include rapamycin, rapamycin analogs, derivatives and congeners that bind FKBP12 and possess the same pharmacologic properties as rapamycin.

Rapamycin reduces vascular hyperplasia by antagonizing smooth muscle proliferation in response to mitogenic signals that are released during angioplasty. Inhibition of growth factor and cytokine mediated smooth muscle proliferation at the late G1 phase of the cell cycle is believed to be the dominant mechanism of action of rapamycin. However, rapamycin is also known to prevent T-cell proliferation and differentiation when administered systemically. This is the basis for its immunosuppressive activity and its ability to prevent graft rejection.

The molecular events that are responsible for the actions of rapamycin, a known anti-proliferative, which acts to reduce the magnitude and duration of neointimal hyperplasia, are still being elucidated. It is known, however, that rapamycin enters cells and binds to a high-affinity cytosolic protein called FKBP12. The complex of rapamycin and

FKBP12 in turn binds to and inhibits a phosphoinositide (PI)-3 kinase called the "mammalian Target of Rapamycin" or TOR. TOR is a protein kinase that plays a key role in mediating the downstream signaling events associated with mitogenic growth factors and cytokines in smooth muscle cells and T lymphocytes. These events include phosphorylation of p27, phosphorylation of p70 s6 kinase and phosphorylation of 4BP-1, an important regulator of protein translation.

It is recognized that rapamycin reduces restenosis by inhibiting neointimal hyperplasia. However, there is evidence that rapamycin may also inhibit the other major component of restenosis, namely, negative remodeling. Remodeling is a process whose mechanism is not clearly understood but which results in shrinkage of the external elastic lamina and reduction in luminal area over time, generally a period of approximately three to six months in humans.

Negative or constrictive vascular remodeling may be quantified angiographically as the percent diameter stenosis at the lesion site where there is no stent to obstruct the process. If late lumen loss is abolished in-lesion, it may be inferred that negative remodeling has been inhibited. Another method of determining the degree of remodeling involves measuring in-lesion external elastic lamina area using intravascular ultrasound (IVUS). Intravascular ultrasound is a technique that can image the external elastic lamina as well as the vascular lumen. Changes in the external elastic lamina proximal and distal to the stent from the post-procedural timepoint to four-month and twelve-month follow-ups are reflective of remodeling changes.

Evidence that rapamycin exerts an effect on remodeling comes from human implant studies with rapamycin coated stents showing a very low degree of restenosis in-lesion as well as in-stent. In-lesion parameters are usually measured approximately five millimeters on either side of the stent i.e. proximal and distal. Since the stent is not present to control remodeling in these zones which are still affected by balloon expansion, it may be inferred that rapamycin is preventing vascular remodeling.

The data in Table 1 below illustrate that in-lesion percent diameter stenosis remains low in the rapamycin treated groups, even at twelve months. Accordingly, these results support the hypothesis that rapamycin reduces remodeling.

TABLE 1.0

Angiographic In-Lesion Percent Diameter Stenosis (%, mean \pm SD and "n=") In Patients Who Received a Rapamycin-Coated Stent			
Coating Group	Post Placement	4-6 month Follow Up	12 month Follow Up
Brazil	10.6 \pm 5.7 (30)	13.6 \pm 8.6 (30)	22.3 \pm 7.2 (15)
Netherlands	14.7 \pm 8.8	22.4 \pm 6.4	—

Additional evidence supporting a reduction in negative remodeling with rapamycin comes from intravascular ultrasound data that was obtained from a first-in-man clinical program as illustrated in Table 2 below.

TABLE 2.0

Matched IVUS data in Patients Who Received a Rapamycin-Coated Stent			
IVUS Parameter	Post (n=)	4-Month Follow-Up (n=)	12-Month Follow-Up (n=)
Mean proximal vessel area (mm ²)	16.53 ± 3.53 (27)	16.31 ± 4.36 (28)	13.96 ± 2.26 (13)
Mean distal vessel area (mm ²)	13.12 ± 3.68 (26)	13.53 ± 4.17 (26)	12.49 ± 3.25 (14)

The data illustrated that there is minimal loss of vessel area proximally or distally which indicates that inhibition of negative remodeling has occurred in vessels treated with rapamycin-coated stents.

Other than the stent itself, there have been no effective solutions to the problem of vascular remodeling. Accordingly, rapamycin may represent a biological approach to controlling the vascular remodeling phenomenon.

It may be hypothesized that rapamycin acts to reduce negative remodeling in several ways. By specifically blocking the proliferation of fibroblasts in the vascular wall in response to injury, rapamycin may reduce the formation of vascular scar tissue. Rapamycin may also affect the translation of key proteins involved in collagen formation or metabolism.

Rapamycin used in this context includes rapamycin and all analogs, derivatives and congeners that bind FKBP12 and possess the same pharmacologic properties as rapamycin.

In a preferred embodiment, the rapamycin is delivered by a local delivery device to control negative remodeling of an arterial segment after balloon angioplasty as a means of reducing or preventing restenosis. While any delivery device may be utilized, it is preferred that the delivery device comprises a stent that includes a coating or sheath which elutes or releases rapamycin. The delivery system for such a device may comprise a local infusion catheter that delivers rapamycin at a rate controlled by the administrator.

Rapamycin may also be delivered systemically using an oral dosage form or a chronic injectible depot form or a patch to deliver rapamycin for a period ranging from about seven to forty-five days to achieve vascular tissue levels that are sufficient to inhibit negative remodeling. Such treatment is to be used to reduce or prevent restenosis when administered several days prior to elective angioplasty with or without a stent.

Data generated in porcine and rabbit models show that the release of rapamycin into the vascular wall from a non-erodible polymeric stent coating in a range of doses (35-430 ug/5-18 mm coronary stent) produces a peak fifty to fifty-five percent reduction in neointimal hyperplasia as set forth in Table 3 below. This reduction, which is maximal at about twenty-eight to thirty days, is typically not sustained in the range of ninety to one hundred eighty days in the porcine model as set forth in Table 4 below.

TABLE 3.0

Animal Studies with Rapamycin-coated stents. Values are mean ± Standard Error of Mean							
Study	Duration	Stent ¹	Rapamycin	N	Neointimal Area	% Change From	
					(mm ²)	Polyme	Metal
Porcine							
98009	14 days	Metal		8	2.04 ± 0.17		
		1X + rapamycin	153 µg	8	1.66 ± 0.17*	-42%	-19%
99005	28 days	1X + TC300 + rapamycin	155 µg	8	1.51 ± 0.19*	-47%	-26%
		Metal		10	2.29 ± 0.21		
99006	28 days			9	3.91 ± 0.60**		
		1X + TC30 + rapamycin	130 µg	8	2.81 ± 0.34		+23%
		1X + TC100 + rapamycin	120 µg	9	2.62 ± 0.21		+14%
		Metal		12	4.57 ± 0.46		
		EVA/BMA 3X		12	5.02 ± 0.62		+10%
99011	28 days	1X + rapamycin	125 µg	11	2.84 ± 0.31* **	-43%	-38%
		3X + rapamycin	430 µg	12	3.06 ± 0.17* **	-39%	-33%
		3X + rapamycin	157 µg	12	2.77 ± 0.41* **	-45%	-39%
		Metal		11	3.09 ± 0.27		
99021	60 days			11	4.52 ± 0.37		
		1X + rapamycin	189 µg	14	3.05 ± 0.35		-1%
		3X + rapamycin/dex	182/363 µg	14	2.72 ± 0.71		-12%
99034	28 days	Metal		12	2.14 ± 0.25		
		1X + rapamycin	181 µg	12	2.95 ± 0.38		+38%
		Metal		8	5.24 ± 0.58		
20001	28 days	1X + rapamycin	186 µg	8	2.47 ± 0.33**	-53%	
		3X + rapamycin/dex	185/369 µg	6	2.42 ± 0.64**	-54%	
		Metal		6	1.81 ± 0.09		
20007	30 days	1X + rapamycin	172 µg	5	1.66 ± 0.44	-8%	
		Metal		9	2.94 ± 0.43		
Rabbit							
99019	28 days	1XTC + rapamycin	155 µg	10	1.40 ± 0.11*	-52%*	
99019	28 days	Metal		8	1.20 ± 0.07		

TABLE 3.0-continued

Animal Studies with Rapamycin-coated stents. Values are mean \pm Standard Error of Mean						
Study	Duration	Stent ¹	Rapamycin	Neointimal Area		% Change From
				N	(mm ²)	
99020	28 days	EVA/BMA 1X		10	1.26 \pm 0.16	+5%
		1X + rapamycin	64 μ g	9	0.92 \pm 0.14	-27%
		1X + rapamycin	196 μ g	10	0.66 \pm 0.12* **	-48%
		Metal		12	1.18 \pm 0.10	-45%
		EVA/BMA 1X + rapamycin	197 μ g	8	0.81 \pm 0.16	-32%

¹Stent nomenclature: EVA/BMA 1X, 2X, and 3X signifies approx. 500 μ g, 1000 μ g, and 1500 μ g total mass (polymer + drug), respectively. TC, top coat of 30 μ g, 100 μ g, or 300 μ g drug-free BMA; Biphasic; 2 \times 1X layers of rapamycin in EVA/BMA separated by a 100 μ g drug-free BMA layer.

²0.25 mg/kg/d \times 14 d preceded by a loading dose of 0.5 mg/kg/d \times 3 d prior to stent implantation.

*p < 0.05 from EVA/BMA control.

**p < 0.05 from Metal;

[#]Inflammation score: (0 = essentially no intimal involvement; 1 = <25% intima involved; 2 = \geq 25% intima involved; 3 = >50% intima involved).

TABLE 4.0

180 day Porcine Study with Rapamycin-coated stents. Values are mean \pm Standard Error of Mean								
Study	Duration	Stent ¹	Rapamycin	N	Neointimal Area		% Change From	Inflammation
					(mm ²)	Polyme		
20007 (ETP-2-002233-P)	3 days	Metal		10	0.38 \pm 0.06			1.05 \pm 0.06
		1XTC + rapamycin	155 μ g	10	0.29 \pm 0.03		-24%	1.08 \pm 0.04
	30 days	Metal		9	2.94 \pm 0.43			0.11 \pm 0.08
		1XTC + rapamycin	155 μ g	10	1.40 \pm 0.11*		-52%*	0.25 \pm 0.10
	90 days	Metal		10	3.45 \pm 0.34			0.20 \pm 0.08
		1XTC + rapamycin	155 μ g	10	3.03 \pm 0.29		-12%	0.80 \pm 0.23
		1X + rapamycin	171 μ g	10	2.86 \pm 0.35		-17%	0.60 \pm 0.23
	180 days	Metal		10	3.65 \pm 0.39			0.65 \pm 0.21
		1XTC + rapamycin	155 μ g	10	3.34 \pm 0.31		-8%	1.50 \pm 0.34
		1X + rapamycin	171 μ g	10	3.87 \pm 0.28		+6%	1.68 \pm 0.37

The release of rapamycin into the vascular wall of a human from a nonerodible polymeric stent coating provides superior results with respect to the magnitude and duration of the reduction in neointimal hyperplasia within the stent as compared to the vascular walls of animals as set forth above.

Humans implanted with a rapamycin coated stent comprising rapamycin in the same dose range as studied in animal models using the same polymeric matrix, as

described above, reveal a much more profound reduction in neointimal hyperplasia than observed in animal models, based on the magnitude and duration of reduction in neointima. The human clinical response to rapamycin reveals essentially total abolition of neointimal hyperplasia inside the stent using both angiographic and intravascular ultrasound measurements. These results are sustained for at least one year as set forth in Table 5 below.

TABLE 5.0

Patients Treated (N = 45 patients) with a Rapamycin-coated Stent		
Effectiveness Measures	Sirolimus FIM (N = 45 Patients, 45 Lesions)	95% Confidence Limit
Procedure Success (QCA)	100.0% (45/45)	[92.1%, 100.0%]
4-month In-Stent Diameter Stenosis (%)		
Mean \pm SD (N)	4.8% \pm 6.1% (30)	[2.6%, 7.0%]
Range (min, max)	(-8.2%, 14.9%)	
6-month In-Stent Diameter Stenosis (%)		
Mean \pm SD (N)	8.9% \pm 7.6% (13)	[4.8%, 13.0%]
Range (min, max)	(-2.9%, 20.4%)	
12-month In-Stent Diameter Stenosis (%)		
Mean \pm SD (N)	8.9% \pm 6.1% (15)	[5.8%, 12.0%]
Range (min, max)	(-3.0%, 22.0%)	

TABLE 5.0-continued

Patients Treated (N = 45 patients) with a Rapamycin-coated Stent		
Effectiveness Measures	Sirolimus FIM (N = 45 Patients, 45 Lesions)	95% Confidence Limit
<u>4-month In-Stent Late Loss (mm)</u>		
Mean \pm SD (N)	0.00 \pm 0.29 (30)	[-0.10, 0.10]
Range (min, max)	(-0.51, 0.45)	
<u>6-month In-Stent Late Loss (mm)</u>		
Mean \pm SD (N)	0.25 \pm 0.27 (13)	[0.10, 0.39]
Range (min, max)	(-0.51, 0.91)	
<u>12-month In-Stent Late Loss (mm)</u>		
Mean \pm SD (N)	0.11 \pm 0.36 (15)	[-0.08, 0.29]
Range (min, max)	(-0.51, 0.82)	
<u>4-month Obstruction Volume (%) (IVUS)</u>		
Mean \pm SD (N)	10.48% \pm 2.78% (28)	[9.45%, 11.51%]
Range (min, max)	(4.60%, 16.35%)	
<u>6-month Obstruction Volume (%) (IVUS)</u>		
Mean \pm SD (N)	7.22% \pm 4.60% (13)	[4.72%, 9.72%],
Range (min, max)	(3.82%, 19.88%)	
<u>12-month Obstruction Volume (%) (IVUS)</u>		
Mean \pm SD (N)	2.11% \pm 5.28% (15)	[0.00%, 4.78%],
Range (min, max)	(0.00%, 19.89%)	
6-month Target Lesion Revascularization (TLR)	0.0% (0/30)	[0.0%, 9.5%]
12-month Target Lesion Revascularization (TLR)	0.0% (0/15)	[0.0%, 18.1%]

QCA = Quantitative Coronary Angiography

SD = Standard Deviation

IVUS = Intravascular Ultrasound

Rapamycin produces an unexpected benefit in humans when delivered from a stent by causing a profound reduction in in-stent neointimal hyperplasia that is sustained for at least one year. The magnitude and duration of this benefit in humans is not predicted from animal model data. Rapamycin used in this context includes rapamycin and all analogs, derivatives and congeners that bind FKBP12 and possess the same pharmacologic properties as rapamycin.

These results may be due to a number of factors. For example, the greater effectiveness of rapamycin in humans is due to greater sensitivity of its mechanism(s) of action toward the pathophysiology of human vascular lesions compared to the pathophysiology of animal models of angioplasty. In addition, the combination of the dose applied to the stent and the polymer coating that controls the release of the drug is important in the effectiveness of the drug.

As stated above, rapamycin reduces vascular hyperplasia by antagonizing smooth muscle proliferation in response to mitogenic signals that are released during angioplasty injury. Also, it is known that rapamycin prevents T-cell proliferation and differentiation when administered systemically. It has also been determined that rapamycin exerts a local inflammatory effect in the vessel wall when administered from a stent in low doses for a sustained period of time (approximately two to six weeks). The local anti-inflammatory benefit is profound and unexpected. In combination with the smooth muscle anti-proliferative effect, this dual mode of action of rapamycin may be responsible for its exceptional efficacy.

Accordingly, rapamycin delivered from a local device platform, reduces neointimal hyperplasia by a combination of anti-inflammatory and smooth muscle anti-proliferative effects. Rapamycin used in this context means rapamycin

and all analogs, derivatives and congeners that bind FKBP12 and possess the same pharmacologic properties as rapamycin. Local device platforms include stent coatings, stent sheaths, grafts and local drug infusion catheters or porous balloons or any other suitable means for the in situ or local delivery of drugs, agents or compounds.

The anti-inflammatory effect of rapamycin is evident in data from an experiment, illustrated in Table 6, in which rapamycin delivered from a stent was compared with dexamethasone delivered from a stent. Dexamethasone, a potent steroidal anti-inflammatory agent, was used as a reference standard. Although dexamethasone is able to reduce inflammation scores, rapamycin is far more effective than dexamethasone in reducing inflammation scores. In addition, rapamycin significantly reduces neointimal hyperplasia, unlike dexamethasone.

TABLE 6.0

Group	N=	Neointimal Area (mm ²)	% Area Stenosis	Inflammation Score
Rapamycin				
Uncoated	8	5.24 \pm 1.65	54 \pm 19	0.97 \pm 1.00
Dexamethasone	8	4.31 \pm 3.02	45 \pm 31	0.39 \pm 0.24
(Dex)				
Rapamycin	7	2.47 \pm 0.94*	26 \pm 10*	0.13 \pm 0.19*
(Rap)				
Rap + Dex	6	2.42 \pm 1.58*	26 \pm 18*	0.17 \pm 0.30*

* = significance level P < 0.05

Rapamycin has also been found to reduce cytokine levels in vascular tissue when delivered from a stent. The data in FIG. 1 illustrates that rapamycin is highly effective in reducing monocyte chemotactic protein (MCP-1) levels in

the vascular wall. MCP-1 is an example of a proinflammatory/chemotactic cytokine that is elaborated during vessel injury. Reduction in MCP-1 illustrates the beneficial effect of rapamycin in reducing the expression of proinflammatory mediators and contributing to the anti-inflammatory effect of rapamycin delivered locally from a stent. It is recognized that vascular inflammation in response to injury is a major contributor to the development of neointimal hyperplasia.

Since rapamycin may be shown to inhibit local inflammatory events in the vessel it is believed that this could explain the unexpected superiority of rapamycin in inhibiting neointima.

As set forth above, rapamycin functions on a number of levels to produce such desired effects as the prevention of T-cell proliferation, the inhibition of negative remodeling, the reduction of inflammation, and the prevention of smooth muscle cell proliferation. While the exact mechanisms of these functions are not completely known, the mechanisms that have been identified may be expanded upon.

Studies with rapamycin suggest that the prevention of smooth muscle cell proliferation by blockade of the cell cycle is a valid strategy for reducing neointimal hyperplasia. Dramatic and sustained reductions in late lumen loss and neointimal plaque volume have been observed in patients receiving rapamycin delivered locally from a stent. The present invention expands upon the mechanism of rapamycin to include additional approaches to inhibit the cell cycle and reduce neointimal hyperplasia without producing toxicity.

The cell cycle is a tightly controlled biochemical cascade of events that regulate the process of cell replication. When cells are stimulated by appropriate growth factors, they move from G₀ (quiescence) to the G1 phase of the cell cycle. Selective inhibition of the cell cycle in the G1 phase, prior to DNA replication (S phase), may offer therapeutic advantages of cell preservation and viability while retaining anti-proliferative efficacy when compared to therapeutics that act later in the cell cycle i.e. at S, G2 or M phase.

Accordingly, the prevention of intimal hyperplasia in blood vessels and other conduit vessels in the body may be achieved using cell cycle inhibitors that act selectively at the G1 phase of the cell cycle. These inhibitors of the G1 phase of the cell cycle may be small molecules, peptides, proteins, oligonucleotides or DNA sequences. More specifically, these drugs or agents include inhibitors of cyclin dependent kinases (cdk's) involved with the progression of the cell cycle through the G1 phase, in particular cdk2 and cdk4.

Examples of drugs, agents or compounds that act selectively at the G1 phase of the cell cycle include small molecules such as flavopiridol and its structural analogs that have been found to inhibit cell cycle in the late G1 phase by antagonism of cyclin dependent kinases. Therapeutic agents that elevate an endogenous kinase inhibitory protein^{k_{ip}} called P27, sometimes referred to as P27^{k_{ip}1}, that selectively inhibits cyclin dependent kinases may be utilized. This includes small molecules, peptides and proteins that either block the degradation of P27 or enhance the cellular production of P27, including gene vectors that can transfect the gene to produce P27. Staurosporin and related small molecules that block the cell cycle by inhibiting protein kinases may be utilized. Protein kinase inhibitors, including the class of tyrphostins that selectively inhibit protein kinases to antagonize signal transduction in smooth muscle in response to a broad range of growth factors such as PDGF and FGF may also be utilized.

Any of the drugs, agents or compounds discussed above may be administered either systemically, for example,

orally, intravenously, intramuscularly, subcutaneously, nasally or intradermally, or locally, for example, stent coating, stent covering or local delivery catheter. In addition, the drugs or agents discussed above may be formulated for fast-release or slow release with the objective of maintaining the drugs or agents in contact with target tissues for a period ranging from three days to eight weeks.

As set forth above, the complex of rapamycin and FKBP12 binds to and inhibits a phosphoinositide (PI)-3 kinase called the mammalian Target of Rapamycin or TOR. An antagonist of the catalytic activity of TOR, functioning as either an active site inhibitor or as an allosteric modulator, i.e. an indirect inhibitor that allosterically modulates, would mimic the actions of rapamycin but bypass the requirement for FKBP12. The potential advantages of a direct inhibitor of TOR include better tissue penetration and better physical/chemical stability. In addition, other potential advantages include greater selectivity and specificity of action due to the specificity of an antagonist for one of multiple isoforms of TOR that may exist in different tissues, and a potentially different spectrum of downstream effects leading to greater drug efficacy and/or safety.

The inhibitor may be a small organic molecule (approximate mw<1000), which is either a synthetic or naturally derived product. Wortmanin may be an agent which inhibits the function of this class of proteins. It may also be a peptide or an oligonucleotide sequence. The inhibitor may be administered either systemically (orally, intravenously, intramuscularly, subcutaneously, nasally, or intradermally) or locally (stent coating, stent covering, local drug delivery catheter). For example, the inhibitor may be released into the vascular wall of a human from a nonerodible polymeric stent coating. In addition, the inhibitor may be formulated for fast-release or slow release with the objective of maintaining the rapamycin or other drug, agent or compound in contact with target tissues for a period ranging from three days to eight weeks.

As stated previously, the implantation of a coronary stent in conjunction with balloon angioplasty is highly effective in treating acute vessel closure and may reduce the risk of restenosis. Intravascular ultrasound studies (Mintz et al., 1996) suggest that coronary stenting effectively prevents vessel constriction and that most of the late luminal loss after stent implantation is due to plaque growth, probably related to neointimal hyperplasia. The late luminal loss after coronary stenting is almost two times higher than that observed after conventional balloon angioplasty. Thus, inasmuch as stents prevent at least a portion of the restenosis process, the use of drugs, agents or compounds which prevent inflammation and proliferation, or prevent proliferation by multiple mechanisms, combined with a stent may provide the most efficacious treatment for post-angioplasty restenosis.

The local delivery of drugs, agents or compounds from a stent has the following advantages; namely, the prevention of vessel recoil and remodeling through the scaffolding action of the stent and the drugs, agents or compounds and the prevention of multiple components of neointimal hyperplasia. This local administration of drugs, agents or compounds to stented coronary arteries may also have additional therapeutic benefit. For example, higher tissue concentrations would be achievable than that which would occur with systemic administration, reduced systemic toxicity, and single treatment and ease of administration. An additional benefit of drug therapy may be to reduce the dose of the therapeutic compounds, thereby limiting their toxicity, while still achieving a reduction in restenosis.

15

There are a multiplicity of different stents that may be utilized following percutaneous transluminal coronary angioplasty. Although any number of stents may be utilized in accordance with the present invention, for simplicity, one particular stent will be described in exemplary embodiments of the present invention. The skilled artisan will recognize that any number of stents may be utilized in connection with the present invention.

A stent is commonly used as a tubular structure left inside the lumen of a duct to relieve an obstruction. Commonly, stents are inserted into the lumen in a non-expanded form and are then expanded autonomously, or with the aid of a second device in situ. A typical method of expansion occurs through the use of a catheter-mounted angioplasty balloon which is inflated within the stenosed vessel or body passageway in order to shear and disrupt the obstructions associated with the wall components of the vessel and to obtain an enlarged lumen. As set forth below, self-expanding stents may also be utilized.

FIG. 2 illustrates an exemplary stent 100 which may be utilized in accordance with an exemplary embodiment of the present invention. The expandable cylindrical stent 100 comprises a fenestrated structure for placement in a blood vessel, duct or lumen to hold the vessel, duct or lumen open, more particularly for protecting a segment of artery from restenosis after angioplasty. The stent 100 may be expanded circumferentially and maintained in an expanded configuration, that is circumferentially or radially rigid. The stent 100 is axially flexible and when flexed at a band, the stent 100 avoids any externally-protruding component parts.

The stent 100 generally comprises first and second ends with an intermediate section therebetween. The stent 100 has a longitudinal axis and comprises a plurality of longitudinally disposed bands 102, wherein each band 102 defines a generally continuous wave along a line segment parallel to the longitudinal axis. A plurality of circumferentially arranged links 104 maintain the bands 102 in a substantially tubular structure. Essentially, each longitudinally disposed band 102 is connected at a plurality of periodic locations, by a short circumferentially arranged link 104 to an adjacent band 102. The wave associated with each of the bands 102 has approximately the same fundamental spatial frequency in the intermediate section, and the bands 102 are so disposed that the wave associated with them are generally aligned so as to be generally in phase with one another. As illustrated in the figure, each longitudinally arranged band 102 undulates through approximately two cycles before there is a link to an adjacent band.

The stent 100 may be fabricated utilizing any number of methods. For example, the stent 100 may be fabricated from a hollow or formed stainless steel tube that may be machined using lasers, electric discharge milling, chemical etching or other means. The stent 100 is inserted into the body and placed at the desired site in an unexpanded form. In one embodiment, expansion may be effected in a blood vessel by a balloon catheter, where the final diameter of the stent 100 is a function of the diameter of the balloon catheter used.

It should be appreciated that a stent 100 in accordance with the present invention may be embodied in a shape-memory material, including, for example, an appropriate alloy of nickel and titanium. In this embodiment, after the stent 100 has been formed it may be compressed so as to occupy a space sufficiently small as to permit its insertion in a blood vessel or other tissue by insertion means, wherein the insertion means include a suitable catheter, or flexible rod. On emerging from the catheter, the stent 100 may be configured to expand into the desired configuration where

16

the expansion is automatic or triggered by a change in pressure, temperature or electrical stimulation.

FIG. 3 illustrates an exemplary embodiment of the present invention utilizing the stent 100 illustrated in FIG. 2. As illustrated, the stent 100 may be modified to comprise a reservoir 106. Each of the reservoirs may be opened or closed as desired. These reservoirs 106 may be specifically designed to hold the drug, agent, compound or combinations thereof to be delivered. Regardless of the design of the stent 100, it is preferable to have the drug, agent, compound or combinations thereof dosage applied with enough specificity and a sufficient concentration to provide an effective dosage in the lesion area. In this regard, the reservoir size in the bands 102 is preferably sized to adequately apply the drug/drug combination dosage at the desired location and in the desired amount.

In an alternate exemplary embodiment, the entire inner and outer surface of the stent 100 may be coated with various drug and drug combinations in therapeutic dosage amounts. A detailed description of exemplary coating techniques is described below.

Rapamycin or any of the drugs, agents or compounds described above may be incorporated into or affixed to the stent in a number of ways and utilizing any number of biocompatible materials. In the exemplary embodiment, the rapamycin is directly incorporated into a polymeric matrix and sprayed onto the outer surface of the stent. The rapamycin elutes from the polymeric matrix over time and enters the surrounding tissue. The rapamycin preferably remains on the stent for at least three days up to approximately six months and more preferably between seven and thirty days.

Any number of non-erodible polymers may be utilized in conjunction with rapamycin. In the exemplary embodiment, the polymeric matrix comprises two layers. The base layer comprises a solution of ethylene-co-vinylacetate and polybutylmethacrylate. The rapamycin is incorporated into this layer. The outer layer comprises only polybutylmethacrylate and acts as a diffusion barrier to prevent the rapamycin from eluting too quickly and entering the surrounding tissues. The thickness of the outer layer or top coat determines the rate at which the rapamycin elutes from the matrix. Essentially, the rapamycin elutes from the matrix by diffusion through the polymer molecules. Polymers tend to move, thereby allowing solids, liquids and gases to escape therefrom. The total thickness of the polymeric matrix is in the range from about 1 micron to about 20 microns or greater. In a preferred exemplary embodiment, the base layer, including the polymer and drug, has a thickness in the range from about 8 microns to about 12 microns and the outer layer has a thickness in the range from about 1 micron to about 2 microns.

The ethylene-co-vinylacetate, polybutylmethacrylate and rapamycin solution may be incorporated into or onto the stent in a number of ways. For example, the solution may be sprayed onto the stent or the stent may be dipped into the solution. In a preferred embodiment, the solution is sprayed onto the stent and then allowed to dry. In another exemplary embodiment, the solution may be electrically charged to one polarity and the stent electrically changed to the opposite polarity. In this manner, the solution and stent will be attracted to one another. In using this type of spraying process, waste may be reduced and more control over the thickness of the coat may be achieved.

Since rapamycin works by entering the surrounding tissue, it is preferably only affixed to the surface of the stent making contact with one tissue. Typically, only the outer surface of the stent makes contact with the tissue. Accord-

ingly, in a preferred embodiment, only the outer surface of the stent is coated with rapamycin. For other drugs, agents or compounds, the entire stent may be coated.

It is important to note that different polymers may be utilized for different stents. For example, in the above-described embodiment, ethylene-co-vinylacetate and polybutylmethacrylate are utilized to form the polymeric matrix. This matrix works well with stainless steel stents. Other polymers may be utilized more effectively with stents formed from other materials, including materials that exhibit superelastic properties such as alloys of nickel and titanium.

Although shown and described is what is believed to be the most practical and preferred embodiments, it is apparent that departures from specific designs and methods described and shown will suggest themselves to those skilled in the art and may be used without departing from the spirit and scope of the invention. The present invention is not restricted to the particular constructions described and illustrated, but should be constructed to cohere with all modifications that may fall within the scope of the appended claims.

What is claimed is:

1. A drug delivery device comprising: an intraluminal stent; a biocompatible, nonerodible polymeric coating affixed to the intraluminal stent; and from about 64 μ g to about 197 μ g of rapamycin or a macrocyclic triene analog thereof that binds FKBP12 incorporated into the polymeric coating, wherein said device provides an in-stent late loss in diameter at 12 months following implantation in a human of less than about 0.5 mm, as measured by quantitative coronary angiography.

2. A drug delivery device according to claim 1 that provides an in-stent late loss in diameter at 12 months following implantation in a human of less than about 0.3 mm, as measured by quantitative coronary angiography.

3. A drug delivery device according to claim 1 or 2 that provides an in-stent diameter stenosis at 12 months following implantation in a human of less than about 22%, as measured by quantitative coronary angiography.

4. A drug delivery device according to claim 3 that provides an in-stent diameter stenosis at 12 months following implantation in a human of less than about 15%, as measured by quantitative coronary angiography.

5. A drug delivery device comprising: an intraluminal stent; a biocompatible, nonerodible polymeric coating affixed to the intraluminal stent; and from about 64 μ g to about 197 μ g of rapamycin or a macrocyclic triene analog thereof that binds FKBP12 incorporated into the polymeric coating, wherein said device provides a mean in-stent late loss in diameter in a human population at 12 months following implantation of less than about 0.5 mm, as measured by quantitative coronary angiography.

6. A drug delivery device according to claim 5 that provides a mean in-stent late loss in diameter in a human population at 12 months following implantation of less than about 0.3 mm, as measured by quantitative coronary angiography.

7. A drug delivery device according to claim 5 or 6 that provides a mean in-stent diameter stenosis in a human population at 12 months following implantation of less than about 22%, as measured by quantitative coronary angiography.

8. A drug delivery device according to claim 7 that provides a mean in-stent diameter stenosis in a human population at 12 months following implantation of less than about 15%, as measured by quantitative coronary angiography.

9. A method of inhibiting neointimal proliferation in a human coronary artery resulting from percutaneous transluminal coronary angioplasty comprising implanting in the lumen of said coronary artery a drug delivery device comprising: an intraluminal stent; a biocompatible, nonerodible polymeric coating affixed to the intraluminal stent; and from about 64 μ g to about 197 μ g of rapamycin or a macrocyclic triene analog thereof that binds FKBP12 incorporated into the polymeric coating, wherein said method provides an in-stent late loss in diameter at 12 months following implantation of less than about 0.5 mm, as measured by quantitative coronary angiography.

10. A method according to claim 9 that provides an in-stent late loss in diameter at 12 months following implantation of less than about 0.3 mm, as measured by quantitative coronary angiography.

11. A method according to claim 9 or 10 that provides an in-stent diameter stenosis at 12 months following implantation of less than about 22%, as measured by quantitative coronary angiography.

12. A method according to claim 11 that provides an in-stent diameter stenosis at 12 months following implantation of less than about 15%, as measured by quantitative coronary angiography.

13. A method of inhibiting neointimal proliferation in a coronary artery resulting from percutaneous transluminal coronary angioplasty comprising implanting in the lumen of said coronary artery a drug delivery device comprising: an intraluminal stent; a biocompatible, nonerodible polymeric coating affixed to the intraluminal stent; and from about 64 μ g to about 197 μ g of rapamycin or a macrocyclic triene analog thereof that binds FKBP12 incorporated into the polymeric coating, wherein said method provides a mean in-stent late loss in diameter in a human population at 12 months following implantation of less than about 0.5 mm, as measured by quantitative coronary angiography.

14. A method according to claim 13 that provides a mean in-stent late loss in diameter in a human population at 12 months following implantation of less than about 0.3 mm, as measured by quantitative coronary angiography.

15. A method according to claim 13 or 14 that provides a mean in-stent diameter stenosis in a human population at 12 months following implantation of less than about 22%, as measured by quantitative coronary angiography.

16. A method according to claim 15 that provides a mean in-stent diameter stenosis in a human population at 12 months following implantation of less than about 15%, as measured by quantitative coronary angiography.

17. The drug delivery device according to any one of claims 1, 2, 4 or 5 wherein said rapamycin or macrocyclic triene analog thereof is incorporated into the polymeric coating at a dose of from about 64 μ g to about 125 μ g.

18. The drug delivery device according to any one of claims 1, 2, 4 or 5 that releases a portion of said dose of rapamycin or a macrocyclic triene analog thereof at about six weeks following intraluminal implantation.

19. The drug delivery device according to any one of claims 1, 2, 4 or 5 wherein said rapamycin or macrocyclic triene analog thereof is incorporated into the polymeric coating at a dose of from about 2 μ g to about 30 μ g per millimeter of stent length.

20. The drug delivery device according to claim 19 wherein said rapamycin or macrocyclic triene analog thereof is incorporated into the polymeric coating at a dose of from about 3 μ g to about 13 μ g per millimeter of stent length.

19

21. The drug delivery device according to claim **19** that releases a portion of said dose of rapamycin or a macrocyclic triene analog thereof at about six weeks following intraluminal implantation.

22. The method according to any one of claims **9, 10, 13** or **14**, wherein said rapamycin or macrocyclic triene analog thereof is incorporated into the polymeric coating at a dose of from about 64 μg to about 125 μg .

23. The method according to any one of claims **9, 10, 13** or **14**, wherein said rapamycin or macrocyclic triene analog thereof is incorporated into the polymeric coating at a dose of from about 2 μg to about 30 μg per millimeter of stent length.

20

24. The method according to any one of claims **9, 10, 13** or **14**, wherein said rapamycin or macrocyclic triene analog thereof is incorporated into the polymeric coating at a dose of from about 3 μg to about 13 μg per millimeter of stent length.

25. The method according to any one of claims **9, 10, 13** or **14**, wherein said drug delivery device releases a portion of said dose of rapamycin or a macrocyclic triene analog thereof at about six weeks following intraluminal implantation.

* * * * *